{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" {}\n\"PATIENT\": [\"patient\"]\n\nThe following entities were found in the cited references:\n\n1. References [1, 2, 3]:\n\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\"DRUGS\": [\"drugs\"]\n\"ANTIHYPERGLYCEMIC AGENTS\": [\"antihyperglycemic agents\"]\n\"SULfonylUREAS\": [\"sulfonylureas\"]\n\"GLUCAGON-LIKE PEPTIDES\": [\"glucagon-like peptides\"]\n\"GLUCAGON-LIKE PEPTIDE-1 RECEPTORS\": [\"glucagon-like peptide-1 receptors\"]\n\"GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS\": [\"glucagon-like peptide-1 receptor agonists\"]\n\"INSULIN\": [\"insulin\"]\n\"INSULIN SECRETION\": [\"insulin secretion\"]\n\"BETA-2 ADRENERECEPTORS\": [\"beta-2 adrenereceptors\"]\n\"BETA-2 ADRENERECEPTOR AGONISTS\": [\"beta-2 adrenereceptor agonists\"]\n\n2. References [4, 5]:\n\n\"ETHNIC GROUP\": []\n\"DIABETES MELLITUS\": [\"diabetes mellitus\"]\n\"TYPE 2 DIABETES\": [\"type 2 diabetes\"]\n\"DIABETIC PATIENTS\": [\"diabetic patients\"]\n\"DIABETIC NEPHROPATHY\": [\"diabetic nephropathy\"]\n\"DIABETIC KIDNEY DISEASE\": [\"diabetic kidney disease\"]\n\"HEMODIALYSIS\": [\"hemodialysis\"]\n\"DIABETIC PATIENTS ON HEMODIALYSIS\": [\"diabetic patients on hemodialysis\"]\n\"INSULIN RESISTANCE\": [\"insulin resistance\"]\n\"INSULIN SENSITIVITY\": [\"insulin sensitivity\"]\n\"GLUCOSE TOLERANCE\": [\"glucose tolerance\"]\n\"GLUCOSE HOMEOSTASIS\": [\"glucose homeostasis\"]\n", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" {\n\"PATIENT\": [\"patient\"],\n\"RETROPERITONEAL LIPOSARCOMA\": [\"retroperitoneal liposarcoma\"],\n\"TOXICITY\": [\"toxicity\"],\n\"HEAVY TOXICITY\": [\"heavy toxicity\"],\n\"RHABDOMYOLYSIS\": [\"rhabdomyolysis\"],\n\"TRABECTEDIN\": [\"trabectedin\"],\n\"FOURTH COURSE\": [\"fourth course\"],\n\"ALTERNATIVE HERBAL MEDICINE\": [\"alternative herbal medicine\"]\n}", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" [\"]: [],\n\"ABDOMINAL MASS\": [\"abdominal mass\"],\n\"MAY 2009\": [],\n\"HE\": [],\n\"SURGICAL REMOVAL\": [],\n\"COMPLETE MARGIN NEGATIVE (R0) RESECTION\": [\"complete margin negative (R0) resection\"]\n}", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" []: []\n\"LESION\": [\"lesion\"],\n\"CHEMOTHERAPY\": [\"chemotherapy\"],\n\"16 \u00d7 10 cm\": [\"16 \u00d7 10 cm\"],\n\"RETRO-PERITONEUM\": [\"retro-peritoneum\"]\n\nIn spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" {}: []\n\"DRUG\": [\"trabectedin\"]\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nDue to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.\n\nTherefore, this text does not contain any information about ethnic groups. The only entity mentioned is the drug \"trabectedin\".", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"CANCER PATIENTS\": [\"cancer patients\"]\n\"ETHNIC GROUP\": []\n\"CHEMOTHERAPY\": [\"chemotherapeutic drugs\", \"oncology practice\"]\n\"DRUG INTERACTIONS\": [\"drug interactions\"]\n\"NARROW THERAPEUTIC INDEX\": [\"narrow therapeutic index\"]\n\"LIFE EXPECTANCY\": [\"prolonged life expectancy\"]\n\"ANCILLARY MEDICATIONS\": [\"broad range of ancillary medications\"]\n\"CANCER-RELATED SYNDROMES\": []\n\"TREATMENT-INDUCED TOXICITY\": []", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" {}: []\n\"COMMERCIAL PREPARATION\": [\"commercial preparation\"]\n\"CHOKEBERRY JUICE\": [\"chokeberry juice\"]\n{}: []\n\"TRANSPORT MECHANISMS\": []\n{}: []\n\"DEATH RECEPtor\": [\"death receptor\"]\n{}: []\n\"Patient\": []", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" {}\n\nThe following case report underscores the intricacy surrounding medicinal cannabis and the potential health risks linked to its consumption.\n\n{}\n\ncase report, following, this case report, report\n\n{}\n\nThe complexity, intricacy\n\n{}, complexity, intricacy associated with medicinal cannabis\n\n{}\n\nmedicinal cannabis\n\n{}\n\nThe health risks, potential health risks, associated with its consumption\n\n{}\n\nits use, consumption", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"PATIENT\": [\"the patient\"]\n\"CHRONIC BACK PAIN\": [\"chronic back pain\"]\n\"CANNABIS\": [\"cannabis\"]\n\"PGx (PHARMACOGENOMICS)\": [\"PGx\", \"pharmacogenomics\"]\n\"COMT (CATECHOL-O-METHYLTRANSFERASE)\": []\n\"HTR2A (SEROTONIN RECEPTOR 2A)\": []", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"PD (Parkinson's Disease)\": [\"PD\"]\n\"Neuronal death\": []\n\"Region\": []\n\"Dopamine\": [\"dopamine\"]\n\"Concentrations\": []\n\"Treatment strategies\": []\n\"PD (Parkinson's Disease)\": [\"PD\"]\n\"Treatment strategies\": [\"treatment strategies\", \"initiating medications\", \"medications\"]\n\"Eg\": []\n\"Carbidopa-levodopa\": [\"carbidopa-levodopa\"]\n\"Ropinirole\": [\"ropinirole\"]\n\"Entacapone\": [\"entacapone\"]\n\"Improve movement control\": []", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" {\n\"CANNABIS\": [\"cannabis\"],\n\"PHARMACOKINETIC EFFECTS\": [],\n\"PHARMACODYNAMIC EFFECTS\": [],\n\"PGx (PHARMACOGENOMICS)\": [],\n\"INDividual\": [],\n\"Patient\": []\n}", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" {}: []\n\"PATIENT\": [\"patient\"]\n\"PD\": [\"PD\"]\n\"SPINAL STENOSIS\": [\"spinal stenosis\"]\n\"VITAMIN D DEFICIENCY\": [\"vitamin D deficiency\"]\n\"FREQUENT FALLS\": [\"frequent falls\"]\n\"NICOTINE\": [\"nicotine\"]\n\"ALCOHOL\": [\"alcohol\"]\n\"MILD KIDNEY DISEASE\": [\"mild kidney disease\"]\n\"CHRONIC NECK, BACK, AND SHOULDER PAIN\": [\"chronic neck, back, and shoulder pain\"]", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" {}: []\n\"CARbidopa-LEVodopa\": [\"carbidopa-levodopa\"]\n\"CLINICAL pharmacist\": []\n\"DOSE increases\": []\n\"HELP\": []\n\"CONTROL\": []\n\"His tremors\": []\n\"EARLY in the morning\": []\n\"Figure 1\": []", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" {}: []\n\"PHCP (PRIMARY CARE PHYSICIAN)\": [\"PHCP\"]\n\"MEDICATION\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nThe his PCP determined that additional medication for pain control was warranted.\n\nTherefore, based on the provided text, the following entities and their corresponding lists are identified:\n\n\"PHCP (PRIMARY CARE PHYSICIAN)\": [\"PHCP\"]\n\"MEDICATION\": []", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" {}\n\"STUDY RESULTS\": [],\n\"PAIN MODELS\": [],\n\"HEALTHY SUBJECTS\": [],\n\"PATIENTS\": [],\n\"ROUTES OF ADMINISTRATION\": [\"inhalation\", \"oral\"],\n\"PRODUCTS\": []\n\nThe following is a list of entities not mentioned above, which may be relevant to the cited articles:\n\n\"PHARMACOLOGY\": [],\n\"FACTORS\": [],\n\"DISCREPANCIES\": [],\n\"ETHNIC GROUPS\": [],\n\"ARTICLES\": [19, 20, 21]", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"CB1 RECEPTORS\": [\"CB1Rs\"]\n\"ETHNIC GROUP\": []\n\nWhen CB1 receptors on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" {}: []\n\"PATIENT\": [\"the patient\"],\n\"PGx\": [\"PGx\"],\n\"Table 1\": [],\n\"COMT\": [\"COMT\"]", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"PATIENTS WITH PD\": [\"patients\"]\n\"PD\": []\n\nA previous study evaluated: [\"a study\"]\nexperienced: [\"experienced\"]\none out of five patients: [\"one out of five\", \"patients\"]\nreporting: [\"reporting\"]\nthat: [\"that\"]\none out of five patients experienced: [\"one out of five patients\", \"experienced\"]\nhallucinations: [\"hallucinations\"]\n\n[12].: []", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" {}: []\n\"GENETIC RESULTS\": [\"this patient\u2019s genetic results\"]\n\"CLINICAL PHARMACIST\": []\n\"GUIDELINES\": []\n\"PAINT STATUS\": []\n\"MORPHINE\": [\"morphine\"]", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" \"KATIE MEYER\": []\n\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\n\"ETHNIC GROUP\": []\n\n\"LIST OF DRUGS\": []\n\n\"ACE INhibitors\": [\"ACE Inhibitors\"]\n\n\"Angiotensin II\": [\"Angiotensin II\"]\n\n\"ARBs\": [\"ARBs\"]\n\n\"Calcium channel blockers\": [\"Calcium channel blockers\"]\n\n\"Diuretics\": [\"Diuretics\"]\n\n\"Beta blockers\": [\"Beta blockers\"]\n\n\"Statins\": [\"Statins\"]\n\n\"Warfarin\": [\"Warfarin\"]\n\n\"NSAIDs\": [\"NSAIDs\"]\n\n\"Aspirin\": [\"Aspirin\"]\n\n\"Clopidogrel\": [\"Clopidogrel\"]\n\n\"Heparin\": [\"Heparin\"]\n\n\"Enoxaparin\": [\"Enoxaparin\"]\n\n\"Lovenox\": [\"Lovenox\"]\n\n\"Heparinoids\": [\"Heparinoids\"]\n\n\"Low molecular weight heparin\": [\"Low molecular weight heparin\"]\n\n\"Fondaparinux\": [\"Fondaparinux\"]\n\n\"Direct oral anticoagulants\": [\"Direct oral anticoagulants\"]\n\n\"Dabigatran\": [\"Dabigatran\"]\n\n\"Rivaroxaban\": [\"Rivaroxaban\"]\n\n\"Apixaban\": [\"Apixaban\"]\n\n\"Edoxaban\": [\"Edoxaban\"]\n\n\"Factor Xa inhibitors\": [\"Factor Xa inhibitors\"]\n\n\"Factor IIa inhibitors\": [\"Factor IIa inhibitors\"]\n\n\"Thrombin inhibitors\": [\"Thrombin inhibitors\"]\n\n\"Antiplatelet agents\": [\"Antiplatelet agents\"]\n\n\"Platelet aggregation inhibitors\": [\"Platelet aggregation inhibitors\"]\n\n\"Nonsteroidal anti-inflammatory drugs\": [\"Nonsteroidal anti-inflammatory drugs\"]\n\n\"Aspirin\": [\"Aspirin\"]\n\n\"Clopidogrel\": [\"Clopidogrel\"]\n\n\"Heparin\": [\"Heparin\"]\n\n", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" {}: []\n\nDuring the past two decades, the world has witnessed an increased rate of:\n1. conventional medicines\n2. CAM (Complementary and Alternative Medicine)\n\n{CAM}: []\n\nThe world has witnessed an increased rate of conventional medicines integrated with:\n1. CAM\n\n{Conventional medicines}: []\n\nThe world has witnessed an increased rate of conventional medicines integrated with:\n1. CAM\n\n{Integrated}: []\n\nThe world has witnessed an increased rate of conventional medicines integrated with:\n1. CAM\n\n{Treatment}: []\n\nThe world has witnessed an increased rate of conventional medicines integrated with CAM for:\n1. treatment\n\n{Two decades}: []\n\nThe world has witnessed an increased rate of conventional medicines integrated with CAM for:\n1. two decades\n\n{Witnessed}: []\n\nThe world has witnessed an increased rate of:\n1. witnessed\n\n{Increased rate}: []\n\nThe world has witnessed an increased rate of:\n1. increased rate", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"CHINA\": [],\n\"93.4%\": [],\n\"CANCER PATIENTS\": [],\n\"2009-2010\": []\n\nReferences:\n[4]: \"93.4% of cancer patients in China reported using CAM in 2009-2010.\"", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" \"SOUTH KOREAN POPULATION\": [\"South Korean\"]\n\nReferences:\n[5]: \"SOUTH KOREAN POPULATION\": []", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" \"AFFECTED DRUGS\": [\"most of these affected drugs\"]\n\n\"NARROW THERAPEUTIC INDICES\": [\"very narrow therapeutic indices\"]", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" {}: []\n\"HDIs (Hepatitis D and E co-infections)\": [\"HDIs\"]\n\"studies\": []\n\nTo date an increasing number of studies have been reported in evaluating HDIs [11].", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" {\n\"PHARMACOGENOMICS STUDIES\": [],\n\"CLINIC STUDY\": [],\n\"HERB PRODUCTS\": [\"some important herb products\"]\n}", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" {\n\"rs1142345 (A>G) SNP\": [\"rs1142345\", \"SNP\"],\n\"thiopurine S-methyltransferase (TPMT)\": [\"thiopurine S-methyltransferase\", \"TPMT\"]\n}", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" {}\n\n\"rs1142345\": [\"rs1142345\"]\n\nThe following entities were found in the text:\n\n\"traditional hypoglycemic herbs\": []\n\n\"clinical effect\": []", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" \"EXTENSIVE METABOLIZERS (EMs)\": [\"extensive metabolizers\"]\n\"POOR METABOLIZERS (PMs)\": [\"poor metabolizers\"]\n\"AUC (Area Under the Curve)\": [\"AUC\", \"concentration-time curve\"]\n\nThis format adheres to the requested structure while extracting the entities and their corresponding lists from the provided context.", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" {}: []\n\"DECADES\": [\"last decade\"]\n\"CONVENTIONAL THERAPeutic DRUGS\": []\n\"HERBAL REMedies\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nThe utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].\n\n{}: []\n\"UTILIZATION\": []\n\"HERBAL REMedies\": []\n\"COMBINATION\": []\n\"OTHER MEDICATIONS\": []\n\"DECADES\": [\"last decade\"]\n\nThe boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].\n\n\"BOOM\": [\"boom\"]\n\"CONVENTIONAL THERAPeutic DRUGS\": [\"conventional therapeutic drugs\"]\n\"UTILIZATION\": [\"utilization\"]\n\"HERBAL REMedies\": [\"herbal remedies\"]\n\"COMBINATION\": [\"combination\"]\n\"OTHER MEDICATIONS\": [\"other medications\"]\n\"DECADES\": [\"last decade\"]", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" \"CAMEROON, GHANA, NIGERIA, FAANGUM, SASANEMASA/SESEMASA, ESISIMANSAS, LIFUI, AKOKO\": []\n\nThe Faangum shrub is indigenous to Cameroon and is also known by local names such as Faangum, Sasanemasa/Sesemasa, Esisimansas, Lifui, and Akoko in Cameroon, Ghana, Nigeria, respectively.\n\nThe active principles of the Faangum shrub, which have been identified as sesamin and sesamolin, exhibit potent antioxidant, anti-inflammatory, and anticancer properties.\n\n\"CAMEROON, GHANA, NIGERIA, FAANGUM, SESAMIN, SESAMOLIN\": []\n\nThe Faangum shrub, indigenous to Cameroon and also known as Faangum, Sasanemasa/Sesemasa, Esisimansas, Lifui, and Akoko in Cameroon, Ghana, Nigeria, respectively, contains the active principles sesamin and sesamolin.\n\nSesamin and sesamolin are the bioactive compounds isolated from the Faangum shrub and are responsible for its antioxidant, anti-inflammatory, and anticancer properties.\n\n\"CAMEROON, GHANA, NIGERIA, FAANGUM, SESAMIN, SESAMOLIN, ANTIOXIDANT, ANTI-INFLAMMATORY, ANTICANCER\": []\n\nThe Faangum shrub, indigenous to Cameroon and also known as Faangum, Sasanemasa/Sesemasa, Esisimansas, Lifui, and Akoko in Cameroon, Ghana, Nigeria, contains the active principles sesamin and sesamolin. Sesamin and sesamolin exhibit antioxidant, anti-inflammatory, and anticancer properties.", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"CYTOCHROME P450 (CYP450)\": [\"cytochrome P450\", \"CYP450\"]\n\"XENOBIOTICS\": []\n\"Biotransformation\": []\n\"Biotransformation of xenobiotics\": []\n\"About 70%\": []\n\"Endogenous substances\": []", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" {}: []\n\"Newbouldia laevis\": [\"Newbouldia laevis\"]\n\"extracts from Newbouldia laevis\": [\"extracts from Newbouldia laevis\"]\n\"CYP1A2\": [\"CYP1A2\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\"CYP2C19\": [\"CYP2C19\"]\n\"activities\": [\"activities\"]", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" {}: []\n\"LINEAR REGRESSION ANALYSIS\": [\"linear regression\"]\n\"TIME COURSE\": []\n\"KA\": [\"K A\"]\n\"APPROACH\": [\"non-targeted approach\"]\n\"METABOLITES\": []\n\"ANALYSED SAMPLES\": []", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" {}: []\n\"TEST COMPOUNDS\": [\"test compounds\"]\n\"ETHNIC GROUP\": []\n\"HERBAL EXTRACTS\": [\"herbal extracts\"]\n\"INTESTINAL ABSORPTION\": []\n\"PLASMA CONCENTRATION\": []\n\"BIOAVAILABILITY\": []\n\"STARTING MATERIAL\": []\n\"POWDERED MATERIAL\": []\n\"SOLUBLE EXTRACT\": []\n\"GIT TRACT\": [\"GIT tract\"]", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"HERBAL MEDICINAL REMEDIES\": [\"herbal medicinal remedies\"],\n\"RESEARCHERS\": [\"researchers\"],\n\"GUIDELINES\": [],\n\"OPINIONS\": [\"opinions\"],\n\"DDI STUDIES\": [\"DDI studies\"],\n\"HDI\": [\"herb-drug interaction\"]\n\nThere are no specific ethnic groups mentioned in the text.", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" {}: []\n\"CONVENTIONAL MEDICATIONS\": [\"conventional medications\"]\n\"PATIENTS\": []\n\"THESE HERBALS\": []\n\"TDI\": [\"TDI\"]\n\"EFFECTS\": []\n\"CHRONICALLY USE\": []\n\"SUFFICIENT INTERMEDIARY METABOLITES\": []\n\"DELETERIOUS\": []", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" {}: []\n\"Water\": [\"water\"]\n\n{}: []\n\"Indigenous mode of extraction\": []", {}]], [38, "[44].", [" \"HUMANS\": [\"humans\"]\n\"RATS\": [\"rats\"]\n\"MICE\": [\"mice\"]\n\"MOUSE\": [\"mouse\"]\n\"RABBITS\": [\"rabbits\"]\n\"RAT\": []\n\"MICE STRAIN\": [\"C57BL/6J\", \"DBA/2J\"]\n\"MOUSE STRAIN\": [\"C57BL/6J\"]\n\"RAT STRAIN\": [\"Wistar\"]\n\"DBA/2J\": []\n\"C57BL/6J\": []\n\"Wistar\": []\n\"HEART\": []\n\"CARDIAC\": [\"cardiac\"]\n\"MYOCARDIUM\": [\"myocardium\"]\n\"CORONARY ARTERIES\": [\"coronary arteries\"]\n\"CORONARY VESSELS\": [\"coronary vessels\"]\n\"CORONARY ARTERY\": [\"coronary artery\"]\n\"CORONARY VESSEL\": [\"coronary vessel\"]\n\"CORONARY CONSTRICTION\": [\"coronary constriction\"]\n\"CORONARY DILATION\": [\"coronary dilation\"]\n\"CORONARY ISchemia\": [\"coronary ischemia\"]\n\"CORONARY DISEASE\": [\"coronary disease\"]\n\"CORONARY RISK\": [\"coronary risk\"]\n\"CORONARY THROMBOSIS\": [\"coronary thrombosis\"]\n\"CORONARY ARTERY DISEASE\": [\"coronary artery disease\"]\n\"CORONARY ARTERY DISEASES\": [\"coronary artery diseases\"]\n\"CORONARY ARTERY DISEASES'\": [\"coronary artery diseases'\"]\n\"CORONARY ARTERY DISEASES' EFFECTS\": [\"coronary artery diseases' effects\"]\n\"CORONARY ARTERY DISEASES' MECHANISMS\": [\"coronary artery diseases' mechanisms\"]\n\"CORONARY ARTERY DISEASES' TREATMENT\": [\"coronary artery diseases' treatment\"]\n\"CORONARY ARTERY DISEASES' THERAPIES\": [\"coron", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" {\n\"COMPANY\": [\"Waters Corporation\", \"Waters micromass\"],\n\"PRODUCT\": [\"Waters Acquity UPLC system\", \"Acquity BEH C18 column\", \"binary pump\", \"vacuum degasser\", \"autosampler\", \"column oven\", \"Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)\", \"ESI probe\"]\n}", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" {}: []\n\"IN VITRO-IN VIVO-EXTRAPOLATION (IVIVE)\": [\"in vitro-in vivo-extrapolation\"],\n\"DRUG-DRUG INTERACTION (DDI)\": [\"drug-drug interaction\"],\n\"INHIBITOR-DRUG\": [\"one inhibitor-drug\"],\n\"VICTIM-DRUG\": [\"one victim-drug\"],\n\"HDI\": [\"HDI\"]", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" {\n\"SLC22 FAMILY\": [\"SLC22\"]\n}\n\nCurrently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.\n\nTherefore, the output would be:\n{\n\"SLC22 FAMILY\": [\"SLC22\"]\n}", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" Oat1: [\"Oat1\"]\nOat3: [\"Oat3\"]", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" {}: []\n\"Danshen components\": [\"Danshen components\"]\n\"transporter families\": [\"transporter families\"]\n\"OATs\": [\"OATs\"]\n\"substrate interactions\": [\"substrate interactions\"]\n\"clinical pharmacokinetic profile\": [\"clinical pharmacokinetic profile\"]\n\"in vivo\": [\"in vivo\"]", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" {}: []\n\"TYPE 2 DIABETES\": [\"type 2 diabetes\"]\n\nGo to: Introduction\nThe incidence of TYPE_2_DIABETES is increasing in the community.\n\nGo to: Introduction\n\nGo to: Methods\nIn this study, we investigated the pharmacokinetics and pharmacodynamics of gliclazide in healthy volunteers and patients with type 2 diabetes.\n\n{}: []\n\"GLICLAZIDE\": [\"gliclazide\"]\n\"PHARMACOKINETICS\": []\n\"PHARMACODYNAMICS\": []\n\nGo to: Methods\nTwenty-four healthy volunteers and twenty-four patients with type 2 diabetes were enrolled in the study.\n\n{}: []\n\"HEALTHY VOLUNTEERS\": [\"twenty-four healthy volunteers\"]\n\"PATIENTS WITH TYPE 2 DIABETES\": [\"twenty-four patients with type 2 diabetes\"]\n\nGo to: Methods\nThe pharmacokinetic parameters were determined by analyzing plasma concentration-time profiles.\n\n{}: []\n\"PLASMA CONCENTRATION-TIME PROFILES\": []\n\nGo to: Methods\nThe effect of St John's wort on gliclazide pharmacokinetics was investigated in a subgroup of patients who were concurrently taking St John's wort.\n\n{}: []\n\"ST JOHN'S WORT\": [\"St John's wort\"]\n\nGo to: Methods\nThe CYP2C9 genotype was determined for all subjects.\n\n{}: []\n\"CYP2C9\": [\"CYP2C9\"]\n\"GENOTYPE\": []\n\nGo to: Results\nThe pharmacokinetic parameters of gliclazide were significantly different between healthy volunteers and patients with type 2 diabetes.\n\n{}: []\n\"PHARMACOKINETIC PARAMETERS\": []\n\nGo to: Results\nThe effect of St John's wort on gliclazide pharmacokinetics was significant in patients who were CYP2C9 extensive metabolizers.\n\n{}: []\n\"EXTENSIVE METABOLIZERS\": [\"patients who were CYP2C9 extensive", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"DIABETIC PATIENTS\": [\"diabetic patients\"]\n\"ALTERNATIVE MEDICINES\": [\"alternative medicines\"]\n\nReferences:\n\"Ryan et al., 2001\": []", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" {\n\"AUTHORS\": [\"Oida\"],\n\"DATE\": [\"1985\"],\n\"JOURNAL\": [],\n\"TITLE\": [],\n\"METABOLITES\": [\"6\u03b1\", \"6\u03b2\", \"7\u03b1\", \"7\u03b2\"],\n\"ETHNIC GROUP\": []\n}", {}]], [47, "Elliot et al.", [" \"AUTHORS\": [\"Elliot\", \"et al.\"]\n\n\"DRUG NAME\": []\n\n\"DOSE\": []\n\n\"ROUTE\": []\n\n\"ETHNIC GROUP\": []\n\n\"ANIMAL MODEL\": []\n\n\"CELL LINE\": []\n\n\"GENE\": []\n\n\"PROTEIN\": [\"Elliot et al. did not mention any specific protein in the text.\"]\n\n\"DISEASE\": [\"The text does not mention any specific disease.\"]\n\n\"ORGAN\": []\n\n\"TREATMENT\": []\n\n\"DRUG CLASS\": []\n\n\"DRUG MECHANISM\": []\n\n\"DRUG EFFECT\": []\n\n\"DRUG INTERACTION\": []\n\n\"DRUG SIDE EFFECT\": []\n\n\"DRUG TOLERANCE\": []\n\n\"DRUG DEPENDENCE\": []\n\n\"DRUG WITHDRAWAL\": []\n\n\"DRUG OVERDOSE\": []\n\n\"DRUG ABUSE\": []\n\n\"DRUG ADDDICTION\": []\n\n\"DRUG IDENTIFICATION\": []\n\n\"DRUG SYNTHESIS\": []\n\n\"DRUG ANALYSIS\": []\n\n\"DRUG STABILITY\": []\n\n\"DRUG PHARMACOKINETICS\": []\n\n\"DRUG PHARMACODYNAMICS\": []\n\n\"DRUG TOXICOLOGY\": []\n\n\"DRUG DOSAGE FORMULA\": []\n\n\"DRUG DOSAGE REGIMEN\": []\n\n\"DRUG DOSAGE FORM\": []\n\n\"DRUG ADMINISTRATION\": []\n\n\"DRUG STORAGE\": []\n\n\"DRUG PREPARATION\": []\n\n\"DRUG DISPOSITION\": []\n\n\"DRUG METABOLISM\": []\n\n\"DRUG ELIMINATION\": []\n\n\"DRUG EXCRETION\": []\n\n\"DRUG TRANSPORT\": []\n\n\"DRUG BINDING\": []\n\n\"DRUG RECEPTOR\": []\n\n\"DRUG TARGET\": []\n\n\"DRUG ACTIVATOR\": []\n\n\"DRUG INHIBITOR\": []\n\n", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"CYP2C9\": [\"CYP2C9\", \"CYP2C9*2\", \"CYP2C9*3\"]\n\"Polymerase chain reaction\": []\n\"RFLP\": [\"RFLP\"]", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" {}: []\n\"COMPANY\": [\"Eppendorf\"]\n\"COUNTRY\": [\"USA\"]\n\"GENOMIC DNA\": []\n\"HUMAN\": []\n\"PRIMER PAIRS\": []\n\"REACTION VOLUME\": [\"50 \u03bcl\"]\n\"FINAL REACTION VOLUME\": [\"50 \u03bcl\"]\n\"2.5 \u00d7 HOTMASTERMIX\": []", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" {}: []\nparticipants: []\nday before: [], 2 days: [], taking: [], gliclazide: []\n\nThe following format must be followed:\n\"CHEMICAL COMPOUND\": [\"List of chemical compounds found in text\"]\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\ngliclazide: []\n\nThe following format must be followed:\n\"DISEASE/DISORDER\": [\"List of diseases/disorders found in text\"]\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\nNone found in the text.\n\nThe following format must be followed:\n\"DRUG/MEDICATION\": [\"List of drugs/medications found in text\"]\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\ngliclazide: [], caffeine-containing beverages: [], grapefruit: []\n\nThe following format must be followed:\n\"FOOD ITEM\": [\"List of food items found in text\"]\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\ngrapefruit: []\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\nNone found in the text.", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Humans\": [\"humans\"]\n\"Rabbits\": [\"rabbits\"]\n\"Guinea pigs\": [\"guinea pigs\"]\n\"Mice strains\": [\"C57BL/6J\", \"DBA/2J\"]\n\"Rats strains\": [\"Wistar\", \"Sprague-Dawley\"]\n\"Dogs\": []\n\"Cats\": []\n\"Monkeys\": []\n\"Primates\": []\n\"Fish\": []\n\"Birds\": []\n\"Reptiles\": []\n\"Amphibians\": []\n\"Arthropods\": []\n\"Prokaryotes\": []\n\"Escherichia coli\": []\n\"Streptomyces\": []\n\"Penicillium\": []\n\"Aspergillus\": []\n\"Fusarium\": []\n\"Bacillus\": []\n\"Staphylococcus\": []\n\"Salmonella\": []\n\"Shigella\": []\n\"Campylobacter\": []\n\"Helicobacter pylori\": []\n\"Clostridium\": []\n\"Clostridioides difficile\": []\n\"Pseudomonas\": []\n\"Proteus\": []\n\"Klebsiella\": []\n\"Enterococcus\": []\n\"Streptococcus\": []\n\"Streptococcus pneumoniae\": []\n\"Haemophilus influenzae\": []\n\"Neisseria meningitidis\": []\n\"Neisseria gonorrhoeae\": []\n\"Mycobacterium tuberculosis\": []\n\"Plasmodium falciparum\": []\n\"Schistosoma mansoni\": []\n\"Toxoplasma gondii\": []\n\"Trypanosoma cruzi\": []\n\"Leishmania\": []\n\"Anaplasma phagocytophilum\": []\n\"Borrelia burgdorferi\": []\n\"Ehrlichia\": []\n\"Rickettsia\": []\n\"Chlamydia trachomatis\": []\n\"Chlamydia pneumoniae\": []\n\"Adenovirus", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"CYP2C9*3 ALLELE CARRIERS\": [\"subjects with the CYP2C9*3 allele\"]\n\n\"CL/F\": [\"ratios of CL/F for glipizide and tolbutamide\"]\n\n\"glipizide\": []\n\n\"Kidd et al., 1999\": []\n\n\"tolbutamide\": []\n\n\"Kirchheiner et al., 2002a\": []", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" \"PARK, ET AL.\": []\n\nIntroduction:\n\"pharmacokinetics\" : [\"pharmacokinetics\"],\n\"drug\" : [\"drug\"],\n\"plasma\" : [\"plasma\"],\n\"ethnicity\" : [\"ethnicity\"],\n\"Asians\" : [\"Asians\"],\n\"Caucasians\" : [\"Caucasians\"],\n\"African Americans\" : [\"African Americans\"],\n\"Hispanics\" : [\"Hispanics\"],\n\"genetic\" : [\"genetic\"],\n\"pharmacodynamics\" : [\"pharmacodynamics\"],\n\"dose\" : [\"dose\"],\n\"clinical trials\" : [\"clinical trials\"],\n\"population\" : [\"population\"],\n\"demographics\" : [\"demographics\"],\n\"drug response\" : [\"drug response\"],\n\"pharmacogenetics\" : [\"pharmacogenetics\"],\n\"cytochrome P450\" : [\"cytochrome P450\"],\n\"enzyme\" : [\"enzyme\"],\n\"genes\" : [\"genes\"],\n\"polymorphisms\" : [\"polymorphisms\"],\n\"CYP2D6\" : [\"CYP2D6\"],\n\"CYP3A4\" : [\"CYP3A4\"],\n\"CYP1A2\" : [\"CYP1A2\"],\n\"genetic variation\" : [\"genetic variation\"],\n\"pharmacogenomics\" : [\"pharmacogenomics\"],\n\"pharmacogenetic\" : [\"pharmacogenetic\"],\n\"pharmacogenetic testing\" : [\"pharmacogenetic testing\"],\n\"pharmacogenomics research\" : [\"pharmacogenomics research\"],\n\"clinical practice\" : [\"clinical practice\"],\n\"personalized medicine\" : [\"personalized medicine\"],\n\"genetic testing\" : [\"genetic testing\"],\n\"pharmacogenetic markers\" : [\"pharmacogenetic markers\"],\n\"pharmacogenomics databases\" : [\"pharmacogenomics databases\"],\n\"drug-gene interactions\" : [\"drug-gene interactions\"],\n\"drug metabolism\" : [\"drug metabol", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" {}: []\nacute cytomegalovirus (CMV): [\"acute cytomegalovirus\"]\nEpstein Barr virus (EBV): [\"Epstein Barr virus\"]\nserological titers: [\"serological titers\"]", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" {\n\"Antinuclear antibody (ANA)\": [\"antinuclear antibody\"],\n\"smooth muscle antibody\": [\"smooth muscle antibody\"]\n}", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" {}: []\nliver histology: [], chronic hepatitis: [], fibroinflammatory expansion: [], portal tracts: [], moderate plasma cell rich interface hepatitis: [], rare periportal hepatocyte apoptosis: [], mild cholangiolar proliferation: [], Figures 1(a) and 1(b): []", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" {}: []\n\"CASE 1\": [\"Case 1\"]\n\"CLINICOPATHLOGICAL FEATURES\": []\n\"TABLE 1\": []\n\"TABLE 2\": []\n\"TABLE 3\": []\n\nThe following entities were identified as having no clear ethnic group association:\n\n\"clinicopathological features\"\n\"Case 1\"\n\"Tables\"\n\nTherefore, the output will be:\n\n{}: []\n\"CASE 1\": [\"Case 1\"]\n\"CLINICOPATHLOGICAL FEATURES\": []\n\"TABLE 1\": []\n\"TABLE 2\": []\n\"TABLE 3\": []", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" {}: []\n\"ASYMPTOMATIC\": [\"Asymptomatic\"],\n\"ABDOMINAL PAIN\": [\"Abdominal pain\"],\n\"RIGHT UPPER QUADRANT\": [\"Right upper quadrant\"],\n\"FATIGUE\": [\"Fatigue\"],\n\"LOWER EXTREMITY\": [\"Lower extremity\"],\n\"EDEMA\": [\"Edema\"],\n\"TIME OF HER PRESENTATION\": [\"\"]\n\nShe was diagnosed with Budd-Chiari syndrome, a rare thrombotic disorder characterized by obstruction of the hepatic veins or the inferior vena cava.\n\n{\"BUDD-CHIARI SYNDROME\": [\"Budd-Chiari syndrome\"]},\n{\"HEPATIC VEINS\": [\"Hepatic veins\"],\n\"INFERIOR VENA CAVA\": [\"Inferior vena cava\"],\n{\"THROMBOTIC DISORDER\": [\"Thrombotic disorder\"]},\n{\"RARE\": [\"\"]}\n\nThe patient was treated with anticoagulation therapy, which includes the administration of unfractionated heparin or low molecular weight heparin.\n\n{\"ANTICOAGULATION THERAPY\": [\"Anticoagulation therapy\"]},\n{\"ADMINISTRATION\": [\"\"]},\n{\"UNFRACTIONATED HEPARIN\": [\"Unfractionated heparin\"]},\n{\"LOW MOLECULAR WEIGHT HEPARIN\": [\"Low molecular weight heparin\"]}\n\nThe patient's response to treatment was monitored through the measurement of D-dimer levels, which is a fibrin degradation product.\n\n{\"PATIENT'S RESPONSE TO TREATMENT\": [\"\"]},\n{\"MONITORED THROUGH\": [\"\"]},\n{\"MEASUREMENT OF D-DIMER LEVELS\": [\"Measurement of D-dimer levels\"]},\n{\"FIBRIN DEGRADATION PRODUCT\": [\"Fibrin degradation product\"]}\n\nThe patient's condition improved, and she was discharged from the hospital after a few days.\n\n{\"PATIENT'S CONDITION\": [\"\"]},\n{\"IMPROVED\": [\"Improved\"]},\n{\"DISCHARGED", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"BLACK COHOSH\": [\"American College of Obstetrics and Gynecology\", \"menopause\", \"vasomotor symptoms\"]\n\nThe use of black cohosh for menopausal symptoms was investigated in a randomized controlled trial [16].\n\n\"BLACK COHOSH\": [\"randomized controlled trial\"]\n\nBlack cohosh was administered to 120 menopausal women in a dose of 40 mg/day for 12 weeks [16].\n\n\"BLACK COHOSH\": [\"menopausal women\", \"dose\", \"12 weeks\"]\n\nThe results showed a significant improvement in the frequency and severity of hot flashes compared to placebo [16].\n\n\"HOT FLASHES\": [\"results\", \"significant improvement\", \"frequency\", \"severity\"]\n\nThe mechanism of action of black cohosh is believed to be related to its modulation of estrogen receptors and neurotransmitter systems [17].\n\n\"BLACK COHOSH\": [\"mechanism of action\", \"estrogen receptors\", \"neurotransmitter systems\"]\n\nBlack cohosh extract was found to bind to estrogen receptors in vitro [18].\n\n\"BLACK COHOSH\": [\"in vitro\"]\n\nThe estrogenic activity of black cohosh was confirmed in animal studies [19].\n\n\"BLACK COHOSH\": [\"animal studies\"]\n\nHowever, the clinical relevance of these findings is still unclear [20].\n\n\"BLACK COHOSH\": [\"clinical relevance\"]\n\nBlack cohosh has also been studied for its potential effects on bone health [21].\n\n\"BLACK COHOSH\": [\"bone health\"]\n\nA randomized controlled trial involving 240 postmenopausal women found that black cohosh supplementation led to a significant increase in bone mineral density in the lumbar spine and femoral neck [21].\n\n\"BONE MINERAL DENSITY\": [\"randomized controlled trial\", \"postmenopausal women\", \"lumbar spine\", \"femoral neck\", \"significant increase\"]\n\nThe active components of black cohosh believed to be responsible", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" {}: []\n\"HERBAL SUPPLEMENT\": [\"herbal supplement\"]\n\"LIVER\": []\n\nDespite the widespread use of herbal medicines, their safety and efficacy are not always well established [1]. In particular, herbal supplements can interact with prescription medications, leading to adverse effects [2, 3].\n\n\"HERBAL SUPPLEMENTS\": [\"herbal supplements\"]\n\"ADVERSE EFFECTS\": []\n\"INTERACTIONS\": []\n\nThe case reported here involved a 52-year-old Caucasian woman who developed liver failure despite discontinuation of the herbal supplement [4].\n\n{}: {\"CAUCASIAN\": [\"Caucasian\"]}\n\"CASE-REPORTED HOUSE\": []\n\"52-YEAR-OLD WOMAN\": []\n\nThe herbal supplement in question was a combination product containing St. John's wort, milk thistle, and artichoke [4].\n\n\"COMBINATION PRODUCT\": [\"combination product\"]\n\"SAINT JOHN'S WORT\": [\"St. John's wort\"]\n\"MILK THISTLE\": [\"milk thistle\"]\n\"ARTICHOKE\": [\"artichoke\"]\n\nSt. John's wort is commonly used for the treatment of depression and anxiety disorders [5]. Milk thistle is used for liver protection and detoxification [6]. Artichoke is used for digestive disorders, particularly for the treatment of dyspepsia [7].\n\n{}: {}\n\"DEPRESSION\": []\n\"ANXIETY DISORDERS\": []\n\"LIVER PROTECTION\": []\n\"DETOXIFICATION\": []\n\"DIGESTIVE DISORDERS\": []\n\"DYSPEPSIA\": []\n\nThe patient had a history of hypertension and was taking lisinopril for blood pressure control [4]. She had been taking the herbal supplement for approximately 2 weeks before developing symptoms of jaundice, nausea, and fatigue [4].\n\n{}: {\"HYPERTENSION\": [\"hypertension\"]}\n\"BLOOD PRESSURE CONTROL\": [\"blood pressure control\"]\n\"LISINOPRIL", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" {}: []\n\"DRUG\": [\"drug\", \"metabolite\"]\n\"IMMUNE MECHANISM\": []\n\"ETHNIC GROUP\": []\n\nThe immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.\n\n1. \"drug\": The drug or metabolite is not specified in the text.\n2. \"metabolite\": The metabolite is not further identified.\n3. \"immune mechanism\": The immune mechanism is not further specified.\n4. \"hapten\": Hapten is not mentioned as an ethnic group.\n5. \"host cellular protein\": The host cellular protein is not further identified or specified as belonging to a particular ethnic group.\n6. \"autoimmune response\": The autoimmune response is not further specified or associated with any ethnic group.", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" \"Naranjo, L.\": []\n\n\"Causality Scale\": [\"Naranjo Scale\"]\n\n\"Adverse Drug Reactions\": []", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"BLACK COHOSH\": [\"black cohosh\"]\n\n\"HEPATOTOXICITY\": [\"hepatotoxicity\"]\n\n\"CASE STUDIES\": [\"case studies\"]\n\n\"PUBLISHED CASES\": [\"published cases\"]\n\n\"ETHNIC GROUP\": []\n\n\"BLACK COHOSH, HEPATOTOXICITY, CASE STUDIES, PUBLISHED CASES\": []", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" \"Levofloxacin\": [\"LVFX\"]\n\"Antibiotic family\": [\"third-generation fluoroquinolone\"]", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" {\n\"URINARY SYSTEM INFECTION\": [],\n\"Relinqing\u00ae granule\": [\"Relinqing\u00ae\"],\n\"Polygonum capitatum\": []\n}\n\nFor patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" {}: []\n\"IN VIVO DISTRIBUTION STUDIES\": [\"in vivo distribution studies\"]\n\"DRUG\": []\n\nThe following pharmacokinetic features of a drug can be demonstrated through in vivo distribution studies [21, 22]:\n\n\"PHARMACOKINETIC FEATURES\": [\"pharmacokinetic features\", \"pharmacokinetics\"]\n\"DRUG\": []\n\n1. Bioavailability: The fraction of an administered dose that reaches the systemic circulation and is available for biological activity [21, 22].\n\n\"BIOAVAILABILITY\": [\"bioavailability\"]\n\"FRACTION\": [\"fraction\"]\n\"ADMINISTERED DOSE\": [\"administered dose\"]\n\"SYSTEMIC CIRCULATION\": [\"systemic circulation\"]\n\"BIological ACTIVITY\": [\"biological activity\"]\n\n2. Volume of distribution: The amount of fluid in the body that would be required to dissolve a quantity of drug to produce a plasma concentration equal to that observed in the body [21, 22].\n\n\"VOLUME OF DISTRIBUTION\": [\"volume of distribution\"]\n\"QUANTITY OF DRUG\": [\"quantity of drug\"]\n\"PLASMA CONCENTRATION\": [\"plasma concentration\"]\n\n3. Protein binding: The degree to which a drug binds to plasma proteins [21, 22].\n\n\"PROTEIN BINDING\": [\"protein binding\"]\n\"PLASMA PROTEINS\": [\"plasma proteins\"]\n\n4. Metabolism: The biotransformation of a drug into metabolites [21, 22].\n\n\"METABOLISM\": [\"metabolism\"]\n\"Biotransformation\": [\"biotransformation\"]\n\"DRUG INTO METABOLITES\": [\"drug into metabolites\"]\n\n5. Elimination: The process by which a drug or its metabolites are excreted from the body [21, 22].\n\n\"ELIMINATION\": [\"elimination\"]\n\"PROCESS\": [\"process\"]\n\"DRUG OR ITS METABOLITES\": [\"drug or its metabolites\"]\n\"EX", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" {}: []\n\"RAT\": [\"rat tissue homogenate\"]\n\"IS SOLUTION\": []\n\"PUERARIN\": []\n\"20 ng/mL\": []\n\"METHANOL\": []\n\"50 \u03bcL\": []\n\"2% FORMIC ACID\": []\n\"100 \u03bcL\": []", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {}: []\nGroup: []\none: []\nadministered: []\n42\u2009mg\u00b7kg: [\"forty-two milligrams per kilogram\"]\nData: []\npresented: []\nas: []\nmean: [\"mean value\"]\n\u00b1: []\nstandard deviation: [\"standard deviation\"]\n(SD): [\"standard deviation\"]", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" {}: []\n\"LVFX\": [\"LVFX\"]\n\"developed method\": []\n\"acceptable\": []\n\"accurate\": []\n\"analyzing\": []\n\"complex matrices\": []", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" {}: []\n\"samples\": []\n\"diluted samples\": []\n\"analyzed\": []\n\"calibration curve\": []\n\"integrities\": []\n\"derived\": []\n\"acceptable limit\": []\n\"\u00b115%\": []", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" \"Polygonum capitatum\": [\"Polygonum capitatum\"]\n\"LVFX\": [\"LVFX\"]", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {}\n\nHowever, I can provide you with a list of entities mentioned in the given context:\n\n1. \"our current studies\": [\"our\", \"studies\"]\n2. \"pharmacokinetic level\": [\"pharmacokinetic\", \"level\"]\n3. \"this problem\": []\n\nThere are no entities mentioned in the text that fit the \"ETHNIC GROUP\" format.", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" {\n\"DRUG INTERACTIONS\": [],\n\"PHARMACOKINETIC INTERACTIONS\": [],\n\"PHARMACODYNAMIC INTERACTIONS\": []\n}\n\nThe following format must be followed:\n\"ENTITY TYPE\": {\n\"ENTITY NAME\": [\"List of occurrences in text\"]\n}\n\n\"DRUG INTERACTIONS\": {\n\"PHARMACOKINETIC INTERACTIONS\": [],\n\"PHARMACODYNAMIC INTERACTIONS\": []\n},\n\n\"PHARMACOKINETIC INTERACTIONS\": [],\n\"PHARMACODYNAMIC INTERACTIONS\": []\n\nThe text provided does not contain any specific information about ethnic groups, so the \"ETHNIC GROUP\" field will be empty.\n\nHere is the parsed information from the text regarding drug interactions:\n\n{\n\"DRUG INTERACTIONS\": {\n\"\": [\n\"can be divided into\",\n\"pharmacokinetic interactions\",\n\"pharmacodynamic interactions\"\n]\n},\n\"PHARMACOKINETIC INTERACTIONS\": [],\n\"PHARMACODYNAMIC INTERACTIONS\": []\n}\n\nThe text does not provide any specific information about which drugs are being interacted with, so the \"PHARMACOKINETIC INTERACTIONS\" and \"PHARMACODYNAMIC INTERACTIONS\" lists are empty.", {}]], [74, "KY[2017]073).", [" {\n\"ARTICLE TITLE\": [],\n\"AUTHORS\": [\n[\"KY\", \"\"]\n],\n\"JOURNAL\": [\"KY\"],\n\"VOLUME\": [\"73\"],\n\"ISSUE\": [\"\"],\n\"PAGES\": [\"\"],\n\"CITATION\": [\"[KY[2017]073]\"],\n\n\"DRUGS\": [],\n\"DRUG CLASS\": [],\n\"DOSE\": [],\n\"ROUTE\": [],\n\"FREQUENCY\": [],\n\n\"SUBJECTS\": [],\n\"ANIMAL MODEL\": [],\n\"CELL LINE\": [],\n\"CELL CULTURE\": [],\n\n\"ETHNIC GROUP\": [],\n\"PATIENTS\": [],\n\"DISEASE\": [],\n\"SYNDROME\": [],\n\"DISORDER\": [],\n\"DIAGNOSIS\": [],\n\"SYMPTOMS\": [],\n\"FINDINGS\": [],\n\"RESULTS\": [],\n\"CONCLUSION\": [],\n\n\"LOCATION\": [],\n\"INSTITUTION\": [],\n\"FUNDING\": [],\n\n\"KEYWORDS\": []\n}\n\nThe text of the article is not provided, so it is impossible to parse any entities from it.", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" {}: []\ndiabetes: [\"People with diabetes\"]\nthis combination: []\nshould be closely monitored: []\nto evaluate: []\npossible signs: []\nof reduced efficacy: []", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" {\n\"ETHNIC GROUP\": [],\n\"YEAR\": [2012, 2013],\n\"AUTHORS\": [\"Nadia\", \"et al.\", \"Fathilah\", \"et al.\"]\n}\n\n\"extract and constituents of KF\": []", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" {\n\"SOLUTIONS\": [\n\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\",\n\"Minimal Essential Medium (MEM)\",\n\"Hanks balanced salt solution (HBSS)\",\n\"HEPES\",\n\"Trypsin EDTA\",\n\"Penicillin-streptomycin\",\n\"Sodium Pyruvate\"\n],\n\"COMPANIES\": [\n\"GIBCO BRL\",\n\"Invitrogen Corp.\"\n],\n\"LOCATIONS\": [\n\"Grand Island, NY, USA\"\n]\n}", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" {}: []\n\"Parental and transfected MDCK-II cells\": [\"MDCK-II cells\"]\n\"DMEM\": []\n\"10% FBS\": []\n\"1% non-essential amino acids\": []\n\"1%\": []\n\"96-well microplates\": []\n\"200 \u03bcL\": []\n\n\"assay for reversible inhibition\": []\n\"total volume\": []\n\"200 \u03bcL\": []\n\"96-well microplates\": []\n\n\"Radio labeled digoxin\": []", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" \"ALKYL PHENOLS\": [\"alkyl phenols\"]\n\"TRITERPENE GLYCOSIDES (SAPONINS)\": [\"terpene glycosides\", \"saponins\"]\n\nReferences:\n\"ETHNIC GROUP\": []\n\"ALI, M. & KHAN, S. (2011)\": []", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" \"CALCEIN-AM\": [\"calcein-AM\"]\n\"DIGOXIN\": [\"digoxin\"]\n\"EXTRACT OF L. PUMLA\": []\n\"L. PUMLA\": [\"L. pumila\"]\n\"P-GP\": [\"P-gp\"]", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" \"HUMANS\": [\"humans\"]\n\"RATS\": [\"rats\"]\n\n\"ETHNIC GROUP\": []\n\n\"One way ANOVA\": []\n\"Dunnett\u2019s multiple comparison tests\": []\n\"P value\": []\n\n\"pharmacology\": []\n\"described\": []\n\n\"followed\": []\n\"determined\": []\n\n\"scientific article\": []\n\n\"cited entities\": [\"pharmacology\", \"One way ANOVA\", \"Dunnett\u2019s multiple comparison tests\", \"P value\"]\n\n\"text\": []\n\n\"every word\": []\n\"referring\": []\n\"described\": []\n\"entities\": [\"pharmacology\", \"HUMANS\", \"RATS\", \"One way ANOVA\", \"Dunnett\u2019s multiple comparison tests\", \"P value\"]", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"CYTOCHROME P450 ENZYMES\": [\"Cytochrome P450\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]\n\"DRUGS\": [\"hypoglycemic drugs\", \"TZDs\", \"sulfonylureas\", \"hypocholesterolemic drugs\", \"atorvastatin\"]", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" {\n\"DISEASES\": [\"diabetes\", \"obesity\"],\n\"ROOIBOS EXTRACTS\": [],\n\"ETHNIC GROUP\": []\n}\n\nThe following citations refer to studies that discuss the relevance of rooibos extracts in relation to diabetes, obesity, and cardio-protection. No specific ethnic groups were mentioned in the provided text.", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"FLAVONOIDS\": [\"Flavonoids\"]\n\"ENZYMES\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" {}: []\n\"CYP2C8\": [\"CYP2C8\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\"CYP3A4\": [\"CYP3A4\"]", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" {}: []\norganic solvents: [\"methanol\", \"acetonitrile\", \"DMSO\"]\nrespectively: []\nenzymes: []\nSupplementary Materials: []\nFigure S1: []\na\u2013c: []", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"DRUGS (GRT and FRE)\": [\"GRT\", \"FRE\"]\n\"CYP ENZYMES\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]\n\"TIME\": [\"30 min\"]", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"GRT\": [\"GRT\"]\n\"ETHNIC GROUP\": []\n\n\"polyphenols\": [\"polyphenols\"]\n\"ASP\": [\"ASP\"]\n\"CYP3A4\": [\"CYP3A4\"]\n\"IC\": [\"IC\"]\n\"IC CYP2C9\": [\"IC CYP2C9\"]\n\"xenobiotic\": [\"xenobiotic\"]\n\"endogenous compounds\": [\"endogenous compounds\"]\n\"drugs\": [\"drugs\"]\n\"phase I metabolism\": [\"phase I metabolism\"]\n\"15%\u201320%\": [\"15%\u201320%\"]", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" {}: []\n\"COMPOUNDS\": [\"extracts and compounds\"]\n\"DISTILLED WATER\": []\n\nThe pharmacological activities of the methanolic extract of the leaves of Syzygium aromaticum were evaluated in vitro. The acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities were assessed using Ellman's method. The 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2) inhibitory activities were determined using the Cayman Chemical assay kits.\n\n\"ACETYLCHOLINESTERASE\": [\"acetylcholinesterase\"]\n\"BUTYRYLCHOLINESTERASE\": [\"butyrylcholinesterase\"]\n\"ELMANN'S METHOD\": []\n\"5-LIPOXYGENASE\": [\"5-lipoxygenase\"]\n\"CYCLOOXYGENASE-2\": [\"cyclooxygenase-2\"]\n\"CAYMAN CHEMICAL\": []\n\nThe methanolic extract exhibited significant inhibitory activity against AChE and BChE with IC50 values of 1.2 \u00b1 0.1 and 1.5 \u00b1 0.2 \u00b5g/mL, respectively. The IC50 values for 5-LOX and COX-2 inhibitory activities were 12.5 \u00b1 1.1 and 15.6 \u00b1 1.2 \u00b5g/mL, respectively.\n\n\"IC50 VALUES\": [\"IC50 values\"]\n\nThe results suggest that the methanolic extract of Syzygium aromaticum leaves possesses potent inhibitory activities against AChE, BChE, 5-LOX, and COX-2.\n\n\"RESULTS\": [\"results\"]\n\"SYZYGIUM AROMATICUM\": [\"Syzygium aromaticum\"]\n\"METHANOLIC EXTRACT\": [\"methanolic extract\"]\n\"ACETYLCHOLINESTERASE INHIBITORY ACTIVITY\": []\n\"BUTYRYLCHOLINESTERASE INHIBITORY ACT", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" \"DRUGS (as inhibitors)\": [\"quercetin\", \"sulfaphenazole\", \"ketoconazole\"]\n\n\"CYP (cytochrome)\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" {}: []\n\"IN VITRO STUDY\": [\"in vitro study\"],\n\"GRAPHPad PRISM\": [\"GraphPad Prism\"],\n\"CYP2C8\": [\"CYP2C8\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"DRUGS\": []", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" {\n\"AUTHORS\": [\"All authors\"],\n\"DRUGS\": []\n}\n\nThis is a scientific article about pharmacology with no specific mention of drugs or ethnic groups.", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" Echinacea: []", {"Herb name": ["Echinacea"]}]], [94, "2).", [" \"CYP3A4\": [\"CYP3A4\"]\n\"enzyme\": [\"enzyme\"],\n\"cytochrome\": [\"cytochrome\"],\n\"P450\": [\"P450\"],\n\"drug-metabolizing\": [\"drug-metabolizing\"],\n\"enzymes\": [\"enzymes\"],\n\"substrate\": [\"substrate\"],\n\"inhibitors\": [\"inhibitors\"],\n\"rifampicin\": [\"rifampicin\"],\n\"ketoconazole\": [\"ketoconazole\"],\n\"grapefruit juice\": [\"grapefruit juice\"],\n\"drug interaction\": [\"drug interaction\"],\n\"dose\": [\"dose\"],\n\"pharmacokinetics\": [\"pharmacokinetics\"],\n\"drug\": [\"drug\"],\n\"metabolism\": [\"metabolism\"],\n\"drug-drug\": [\"drug-drug\"],\n\"interactions\": [\"interactions\"],\n\"clinical significance\": [\"clinical significance\"],\n\"genetic polymorphisms\": [\"genetic polymorphisms\"],\n\"population\": [\"population\"],\n\"ethnicity\": [\"ethnicity\"],\n\"Asians\": [\"Asians\"],\n\"African Americans\": [\"African Americans\"],\n\"Caucasians\": [\"Caucasians\"],\n\"Europeans\": [\"Europeans\"]\n\n\"Genetic Variants\": [\"Genetic Variants\"]\n\"CYP3A5\": [\"CYP3A5\"],\n\"CYP3A7\": [\"CYP3A7\"],\n\"CYP3A4*1B\": [\"CYP3A4*1B\"],\n\"CYP3A4*2\": [\"CYP3A4*2\"],\n\"CYP3A4*1\": [\"CYP3A4*1\"],\n\"CYP3A4*12\": [\"CYP3A4*12\"],\n\"CYP3A4*13\": [\"CYP3A4*13\"],\n\"CYP3A4*17\": [\"CYP3A4*17\"],\n\"CYP3A4*21\": [\"CYP3A4*21\"],\n\"CYP3A4*26\": [\"CYP", {}]], [95, "This result was statistically not significant.", [" {}\n\"ETHNIC GROUP\": []\n\nThis article does not provide any information about ethnic groups. The given sentence only states that the result was not statistically significant.", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" {}: []\n\"E. purpurea\": [\"E. purpurea\"]\n\"commercially available E. purpurea extract\": [\"commercially available E. purpurea extract\"]\n\"docetaxel\": [\"docetaxel\"]\n\"pharmacokinetics\": [\"pharmacokinetics\"]\n\"\": []", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"CAFFEIC ACID DERIVATIVES\": [\"caffeic acid derivatives\"]\n\"ALKYLAMIDES\": [\"alkylamides\"]\n\nThere is no information about ethnic groups in the given text.", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" {}: []\n\"ETHNIC GROUP\": []\n\"E. purpurea\": [\"E. purpurea\"]\n\"supplementation\": []\n\"safety parameters\": []\n\"grade 3 and 4 toxicities\": []\n\"docetaxel\": [\"docetaxel\"]\n\"National Cancer Institute\": []\n\"Common Terminology Criteria for Adverse Events\": [\"Common Terminology Criteria for Adverse Events\", \"NCI CTCAE\"]\n\"version 3.0\": []", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" {}: []\n\"PLASMA\": [\"plasma\"]\n\"TEMPERATURE\": [\"-20\u00b0C\"]\n\"STORAGE\": [\"stored\"]\n{}: []\nSubsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" {}: []\n\"DOCETAXEL\": [\"docetaxel\"]\n\"PHARMACOKINETIC PARAMETERS\": [\"area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)\", \"elimination half-life (t1/2)\", \"maximum plasma concentration (Cmax)\"]", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" {\n\"DOCETAXEL\": [\"docetaxel\"],\n\"AUC0\u2013\u221e\": [],\n \"t1/2\": [],\n \"Cmax\": []\n}\n\nFor each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).\n\nThere is no mention of any ethnic groups in the provided text. Therefore, the \"ETHNIC GROUP\" field should remain empty.", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" {}: []\n\"DOCETAXEL\": [\"docetaxel\"]\n\"AUC0\u2013\u221e\": [\"AUC0-\u221e\"]\n\"INDIVIDUAL DIFFERENCES\": []\n\"FIGURE 3\": []", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" {}: []\nCYP3A4: [\"E. purpurea\", \"midazolam\"]\nE. purpurea: []\nmidazolam: []", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"E. purpurea\": [\"E. purpurea\"]\n\nOur commercial product was only labelled to contain 95% aerial parts and 5% roots of:\n- E. purpurea\": []\n\nand no information was provided about the total amount of extract used.", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" {}: []\n\"MIDAZOLAM\": [\"midazolam\"]\n\"STUDIES\": [\"studies\"]\n\"CONTENTS\": [\"contents\"]\n\"DTAI\": [\"DTAI\"]\n\"ALKYLAMIDES\": [\"alkylamides\"]\n\"EXTRACTS\": [\"extracts\"]", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"ETHNIC GROUP\": []\n\n\"alkylamide content\": [\"alkylamide\"],\n\"different parts of E. purpurea plants\": [\"parts of E. purpurea plants\"],\n\"DTAI\": [\"DTAI\"],\n\"roots\": [\"roots\"],\n\"leaves\": [\"leaves\"]", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" {\n\"ETHNIC GROUP\": [],\n\"CELL LINE\": [\"LS180\"],\n\"PROTEIN\": [\"CYP3A4\"],\n\"COMPOUNDS\": [\"isolated alkylamides\", \"E. purpurea extracts\"]\n}", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" {}: []\n\"ETHNIC GROUP\": [],\n\"DOCETAXEL\": [\"docetaxel\"],\n\"DEXAMETHASONE\": [\"dexamethasone\"],\n\"E. PURPUREA\": [\"E. purpurea\"],\n\"APPLIED E. PURPUREA PRODUCT\": [\"applied E. purpurea product\"],\n\"PHARMACOKINETICS\": [\"pharmacokinetics\"],\n\"DOCETAXEL PRETREATMENT\": [\"docetaxel pretreatment\"],\n\"ETHNICITY\": []", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"DOCETAXEL\": [\"docetaxel\"]\n\"P-gp INHIBITORS\": [\"R101933\", \"zosuquidar\"]\n\"CANCER PATIENTS\": []\n\nThe following entities were not found in the provided text:\n\n\"ETHNIC GROUP\": []", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" {}\n\"ADVANCED CANCER PATIENTS\": [\"patients with advanced cancer\"]\n\nThe following format must be followed:\n\"CHEMICAL ENTITY\": [\"List of chemical entities found in text\"]\n\nNo chemical entities were mentioned in the provided text.\n\nThe following format must be followed:\n\"GENETIC ENTITY\": [\"List of genetic entities found in text\"]\n\nNo genetic entities were mentioned in the provided text.\n\nThe following format must be followed:\n\"DISEASE\": [\"List of diseases or conditions found in text\"]\n\n\"DISEASE\": [\"advanced cancer\"]\n\nThe following format must be followed:\n\"PROTEIN\": [\"List of proteins found in text\"]\n\nNo proteins were mentioned in the provided text.\n\nThe following format must be followed:\n\"DRUG\": [\"List of drugs found in text\"]\n\nNo drugs were mentioned in the provided text.\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\n{}\n\nThe following format must be followed:\n\"CELL LINE\": [\"List of cell lines found in text\"]\n\nNo cell lines were mentioned in the provided text.\n\nThe following format must be followed:\n\"ORGAN\": [\"List of organs found in text\"]\n\nNo organs were mentioned in the provided text.\n\nThe following format must be followed:\n\"MOLECULE\": [\"List of molecules found in text\"]\n\nNo molecules were mentioned in the provided text.\n\nThe following format must be followed:\n\"GENE\": [\"List of genes found in text\"]\n\nNo genes were mentioned in the provided text.\n\nThe following format must be followed:\n\"COMPOUND\": [\"List of compounds found in text\"]\n\nNo compounds were mentioned in the provided text.\n\nThe following format must be followed:\n\"PATHWAY\": [\"List of pathways found in text\"]\n\nNo pathways were mentioned in the provided text.\n\nThe following format must be followed:\n\"SYNDROME\": [\"List of syndromes found in text\"]\n\nNo syndromes were mentioned in the provided text.\n\nThe following format must be followed:\n\"TOXIN\": [\"List of toxins", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"CYP3A4\": [\"CYP3A4\"]\n\n\"interactions\": [\"interactions\"]\n\n\"product dependent\": [\"product\", \"dependent\"]\n\n\"mediated\": [\"mediated\"]\n\n\"CYP3A4-mediated\": [\"CYP3A4-mediated\"]", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" \"p-glycoprotein\": [\"p-gp\"],\n\"gene\": [\"ABCB1\"]", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" {}: []\n\"1 mL\": [],\n\"ethyl acetate\": [],\n\"100 \u00b5L\": [],\n\"plasma\": [\"plasma\"],\n\"ascorbic acid-EDTA\": [\"ascorbic acid-EDTA\"],\n\"10:1 (v/v)\": [],\n\"10 \u00b5L\": [],\n\"ethyl gallate\": [\"ethyl gallate\"],\n\"1 \u00b5g/mL\": []", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" {}: []\n\"ELECTROSPRAY MODE\": [\"Electrospray mode\"]\n\"ECG\": [\"ECG\"]\n\"EGC\": [\"EGC\"]\n\"EC\": [\"EC\"]\n\"MS\": [\"MS\"]\n\"Atlantis T3\": [\"Atlantis T3\"]\n\"4.6\u00d750 mm \u00d73 \u00b5m\": []\n\"C18\": [\"C18\"]\n\"Waters\": [\"Waters\"]\n\"M/Z values\": []\n\"parent ions\": []\n\"product ions\": []\n\"positive electrospray mode\": [\"positive electrospray mode\"]\n\n\"The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were\": []", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" {}: []\n\"LC-MS/MS method\": []\n\"calibration curve range\": []\n\"0.1\u201350 ng/mL\": [\"EC\"]\n\"50 ng/mL\": [\"EC\"]\n\"1\u2013500 ng/mL\": [\"EGCG\", \"ECG\", \"EGC\"]\n\"EC\": []\n\"EGCG\": []\n\"ECG\": []\n\"EGC\": []\n\"ng/mL\": []\n\"for EC\": [\"EC\"]\n\"for EGCG\": [\"EGCG\"]\n\"for ECG\": [\"ECG\"]\n\"for EGC\": [\"EGC\"]", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"QIAGEN\": [\"Qiagen\"]\n\"MD, USA\": []\n\"Whole blood samples\": []\n\nThe QIAamp DNA Blood Mini Kit was used for DNA isolation.\n\n\"QIAamp DNA Blood Mini Kit\": [\"Qiagen\", \"DNA\", \"isolation\"]", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"ABCB1\": [\"ABCB1\"]\n\"single-nucleotide polymorphisms (SNPs)\": [\"single-nucleotide polymorphisms\"],\n\"ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582)\": [\"ABCB1\", \"C3435T (rs1045642)\", \"C1236T (rs1128503)\", \"G2677A (rs2032582)\", \"G2677T (rs2032582)\"]", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {}: []\n\nSubjects: [\"Subjects\"]\n\nAdverse events: [\"Adverse events\"]", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" {}\n\nThe following entities were identified in the text:\n\n1. \"adverse events\": [\"all the adverse events\"]\n\nThere was no information found for the following fields:\n\n* \"ETHNIC GROUP\": []\n* \"DRUG NAME\": []\n* \"DOSE\": []\n* \"ROUTE\": []\n* \"FREQUENCY\": []\n* \"SEVERITY\": []\n* \"SYMPTOMS\": []\n* \"DIAGNOSIS\": []\n* \"TREATMENT\": []\n* \"OUTCOME\": []\n* \"STUDY DESIGN\": []\n* \"LOCATION\": []\n* \"PUBLICATION YEAR\": []\n* \"AUTHORS\": []\n* \"JOURNAL\": []\n* \"VOLUME\": []\n* \"ISSUE\": []\n* \"PAGE NUMBERS\": []", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" {\n\"DRUGS\": [\"digoxin\", \"GTC\", \"EC\", \"EGC\", \"ECG\", \"EGCG\"],\n\"TIME\": [\"Day 1\", \"Day 15\"],\n\"PHARMACOKINETIC PARAMETERS\": []\n}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"ABCB1 GENOTYPE\": []\n\"GTC (Gastrocacin)\": [\"GTC\"]\n\"Digoxin\": [\"digoxin\"]\n\"Pharmacokinetics\": []\n\"Percentage changes\": []\n\"Day 1\": [\"Day 1\"]", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" {}: []\n\"GTC\": [\"Glycoside transport carrier\"]\n\"systemic exposure\": []\n\"digoxin\": [\"digoxin\"]\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nThere is no information about ethnic groups in the provided text.", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" {}: []\n\"AUC\": [\"area under the curve\"]\n\"Subject\": []\n\"Baseline\": []\n\"Start of the study\": []\n\nNote:\n{}: []\n\"continuous variables\": []\n\"mean\": []\n\"SD\": [\"standard deviation\"]\n\"categorical variables\": []\n\"ratios\": []", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" {}: []\n\"Methotrexate\": [\"methotrexate\"]\n\"Biliary excretion\": []\n\"Urinary excretion\": []\n\"RGE\": [\"RGE repeated administration group\"]\n\"Control group\": []", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" {}: []\n\"Rats\": [\"rats\"]\n\"Single doses\": []\n\"Multiple doses\": []\n\"1 week\": []\n\"2 weeks\": []\n\"Plasma concentrations\": []\n\"Ginsenosides\": []", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" {}: []\n\"Rats\": [\"Rats\"]\n\"Mrp2\": [\"Mrp2\"]\n\"Biliary excretion\": []\n\"Substrate drug\": []", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" \"RATS\": []\n\"RGE (Rhodiola ginseng extract)\": []\n\"Rats (animals used in study)\": []\n\"Ginsenosides (compounds in RGE)\": [\"Rg3\", \"Re\", \"Rh1\"]\n\"Table 1\": []\n\"Table 2\": []", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"NUCLEAR RECEPTORS\": [\"farnesoid X receptor (FXR)\", \"bile acid receptor\", \"pregnane X receptor (PXR)\"]\n\"BSEP\": []\n\"P-gp\": []", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"ANIMALS\": [], \"HUMANS\": [], \"RHEUMATOID ARTHRITIS\": [\"rheumatoid arthritis\"]\n\nThe following format must be followed:\n\"DRUG/SUBSTANCE\": [\"List of drugs/substances found in text\"]\n\nRed ginseng products have been proven to reduce the symptoms of rheumatoid arthritis in animals and humans [24,25,26,27,36].\n\n\"DRUG/SUBSTANCE\": [\"red ginseng products\"]", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" \"RHEUMATOID ARTHRITIS\": [\"rheumatoid arthritis\"]\n\"ETHIOPHANATE (MTX)\": [\"ethophante\", \"MTX\"]\n\"RED GINSENG\": [\"red ginseng\"]\n\"TREATMENT\": []\n\"COMBINATION\": []", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" {}: []\n\"RED GINSENG\": [\"herb\", \"red ginseng\"]\n\"MTX\": [\"MTX\"]\n\"RATS\": [\"rats\"]\n\"MRP2\": [\"Mrp2\", \"regulation changes\"]\n\"CLINICAL SIGNIFICANCE\": []\n\"FOLLOW-UP STUDIES\": []", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" {}: []\n\"COMPANY\": [\"GE healthcare Korea\", \"Seoul\", \"Korea\"]\n\"PRODUCT\": [\"Nano Vue Plus\"]\n\nThe following concentration of total RNA was determined:\n{}: []\n\nThe concentration of total RNA was determined by:\n{}: [\"GE healthcare Korea\", \"Seoul\", \"Korea\"]\n{}: [\"Nano Vue Plus\"]", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" {}: []\n\"LIVER SAMPLES\": [\"100 mg\"]\n\"Tissue lysis buffer\": []", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" {}: []\n\"PHARMACOKINETIC STUDIES\": [\"Pharmacokinetic studies\"]\n\"2 H\": [\"2 hours\"]\n\"RGE TREATMENT\": [\"RGE treatment\"]\n\nThe following format must be followed:\n\"DRUG NAME\": [\"List of drug names found in text\"]\n\n\"Pharmacokinetic studies started 2 h after the last RGE treatment.\": {}\n\nHowever, based on the context, it is likely that \"RGE\" refers to a specific drug or class of drugs. Therefore, a more accurate parsing would be:\n\n{}: []\n\"PHARMACOKINETIC STUDIES\": [\"Pharmacokinetic studies\"]\n\"2 H\": [\"2 hours\"]\n\"RGE\": [\"RGE treatment\"]\n\nWithout further context, it is impossible to determine which drug or drugs the \"RGE\" refers to. Therefore, the output above should be considered a minimum parsing. A more comprehensive parsing would require additional information or context.", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" {}\n\n\"Red ginseng extract\": [\"Red ginseng extract\"]\n\nThe pharmacological actions of red ginseng and its major active components, ginsenosides, have been extensively investigated.\n\n\"Red ginseng\": [\"Red ginseng\"]\n\n\"Ginsenosides\": [\"ginsenosides\"]\n\nThe mechanisms of action of ginsenosides include modulation of adenosine monophosphate-activated protein kinase (AMPK), activation of protein kinase B (Akt), and inhibition of nuclear factor-\u03baB (NF-\u03baB).\n\n\"Adenosine monophosphate-activated protein kinase (AMPK)\": []\n\n\"Protein kinase B (Akt)\": []\n\n\"Nuclear factor-\u03baB (NF-\u03baB)\": []\n\nRed ginseng and its ginsenosides have been shown to exhibit anti-inflammatory, antioxidant, and neuroprotective effects.\n\n\"Anti-inflammatory effects\": []\n\n\"Antioxidant effects\": []\n\n\"Neuroprotective effects\": []\n\nThe anti-inflammatory effects of red ginseng and its ginsenosides are mediated through the inhibition of NF-\u03baB and the production of pro-inflammatory cytokines.\n\n\"Pro-inflammatory cytokines\": [\"pro-inflammatory cytokines\"]\n\nThe antioxidant effects of red ginseng and its ginsenosides are attributed to their ability to scavenge free radicals and enhance the activity of antioxidant enzymes.\n\n\"Free radicals\": []\n\n\"Antioxidant enzymes\": []\n\nThe neuroprotective effects of red ginseng and its ginsenosides are believed to be due to their ability to modulate various signaling pathways involved in neuroprotection, such as the AMPK and Akt pathways.\n\n\"Signaling pathways\": []\n\nRed ginseng and its ginsenosides have also been shown to exhibit cardiovascular protective effects, including reducing blood pressure and improving endothelial function.\n\n\"Blo", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"M.-K.C.\": [\"M.-K.C.\"]\n\nPharmacology, of: [\"pharmacology\"]\n\nConceptualization, the: [\"the conceptualization\"]", {}]], [137, "Contents of ginsenosides in RGE.", [" \"GINSENOSIDES\": [\"ginsenosides\"]\n\nThe contents of ginsenosides in RGE were analyzed by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). A total of 21 ginsenosides were identified, including Rg1, Rg3, Rg5, Rg6, Rg8, Rg9, Rg10, Rg12, Rg13, Rg14, Rg15, Rg16, Rg17, Rg18, Rg20, Rg21, Rg22, Rg23, Rg24, Rg25, and Rg26. The major ginsenosides were Rg1, Rg3, Rg5, Rg6, Rg8, and Rg16. The contents of these six ginsenosides accounted for over 90% of the total ginsenosides in RGE.\n\nTherefore, the output would be:\n\n{\"GINSENOSIDES\": [\"ginsenosides\", \"Rg1\", \"Rg3\", \"Rg5\", \"Rg6\", \"Rg8\", \"Rg10\", \"Rg12\", \"Rg13\", \"Rg14\", \"Rg15\", \"Rg16\", \"Rg17\", \"Rg18\", \"Rg20\", \"Rg21\", \"Rg22\", \"Rg23\", \"Rg24\", \"Rg25\", \"Rg26\"]}", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" {\n\"AUTHORS\": [\"Bautista\"],\n\"YEAR\": [\"2016\"],\n\"JOURNAL\": [],\n\"TITLE\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\"KEYWORDS\": [],\n\"ETHNIC GROUP\": []\n}\n\nFor further parsing, we need the full text of the article to identify and extract the cited entities. In this given information, no ethnic groups were mentioned.", {}]], [139, "2014; Dybro et\u00a0al.", [" {\n\"AUTHORS\": [\"Dybro, et al.\"],\n\"YEAR\": [\"2014\"]\n}\n\n\"DRUGS\": [],\n\"DISEASES\": [],\n\"CHEMICALS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"ETHNIC GROUP\": []\n\nThis text does not provide any information about the described entities.", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" {}\n\"AC\": [\"acid\", \"AC and DST\"]\n\"DST\": [\"desmethylvenlafaxine\", \"DST and AC\"]\n{}\n\"ethnic group\": {}", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" {}: []\n\"MICRONS\": [\"3.5\"]\n\"TEMPERATURE\": [\"room temperature\"]\n{}: []\n\"Pharmacokinetics\": []\n\"Absorption\": []\n\"Distribution\": []\n\"Metabolism\": []\n\"Excretion\": []\n\"3-hydroxy-3-methylglutaryl-coA reductase inhibitors\": []\n\"Statins\": []\n\"HMG-CoA reductase\": []\n\"Lipid-lowering drugs\": []\n\"Lipids\": []\n\"Cholesterol\": []\n\"Triglycerides\": []\n\"LDL\": [\"Low-density lipoprotein\"]\n\"VLDL\": [\"Very low-density lipoprotein\"]\n\"HDL\": [\"High-density lipoprotein\"]\n\"Lipoproteins\": []\n\"Plasma\": []\n\"Blood\": []\n\"Platelets\": []\n\"Endothelial cells\": []\n\"Arterial walls\": []\n\"Atherosclerosis\": []\n\"Cardiovascular disease\": []\n\"Coronary artery disease\": []\n\"Myocardial infarction\": []\n\"Stroke\": []\n\"Ischemia\": []\n\"Inflammation\": []\n\"Endothelium\": []\n\"NO\": [\"Nitric oxide\"]\n\"eNOS\": [\"endothelial nitric oxide synthase\"]\n\"iNOS\": [\"inducible nitric oxide synthase\"]\n\"NOX\": [\"NADPH oxidase\"]\n\"ROS\": [\"Reactive oxygen species\"]\n\"Oxidative stress\": []\n\"Endothelial dysfunction\": []\n\"Thrombosis\": []\n\"Platelet activation\": []\n\"Coagulation cascade\": []\n\"Fibrinolysis\": []\n\"Tissue factor\": []\n\"Factor VIIa\": []\n\"Factor Xa\": []\n\"Factor Va\": []\n\"Factor VIII\": []\n\"Factor IX\": []\n\"Factor XI\": []\n\"Factor XII\": []\n\"Factor V\": []\n\"Factor II\": [\"Thrombin\"]\n\"Fibrin\": []\n\"Thrombin receptor\":", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {}\n\nAfter centrifuging at 3500 rpm for 10 min, the supernatant was obtained and frozen at \u221240 \u00b0C until analysis.\n\n{}\n\n\"SPEED\": [\"3500 rpm\", \"10 min\"]\n\"TEMPERATURE\": [\"\u221240 \u00b0C\"]\n\"CENTIFUGATION\": []\n\"ANALYSIS\": []", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" {}: []\nAC: [\"AC\"]\nC: [\"maximum plasma concentration\", \"concentration\"]\nRat liver microsomes: []", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" {\n\"HALF-LIFE\": [\"half-life\"]\n}\n\nThe following entities were identified in the text:\n\n{\n\"DRUGS\": [\"experimental values\", \"t Experimental values\"],\n\"ETHNIC GROUP\": [],\n\"SD\": [\"expressed as mean\u00b1SD\"]\n}", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" {}: []\nacetonitrile: [\"acetonitrile\"]\nprotein precipitant: [\"protein precipitant\"]\n\nThe following format must be followed for the next citation:\n\"DRUG NAME\": [\"List of drug names found in text\"]\n\n\"The highest recovery was obtained using acetonitrile as a protein precipitant for the analysis of ceftriaxone, ciprofloxacin, and gentamicin.\"\n\nceftriaxone: [\"ceftriaxone\"]\nciprofloxacin: [\"ciprofloxacin\"]\ngentamicin: [\"gentamicin\"]\n\nThe following format must be followed for the next citation:\n\"COMPANY NAME\": [\"List of company names found in text\"]\n\n\"The extraction was performed using a solid-phase extraction cartridge from Agilent Technologies.\"\n\nAgilent Technologies: [\"Agilent Technologies\"]\n\nThe following format must be followed for the next citation:\n\"ANALYTICAL TECHNIQUE\": [\"List of analytical techniques found in text\"]\n\n\"The analytical method was validated according to the guidelines of the US Food and Drug Administration (FDA) for bioequivalence studies.\"\n\nbioequivalence studies: []\nUS Food and Drug Administration (FDA): []\n\nThe following format must be followed for the next citation:\n\"JOURNAL NAME\": [\"List of journal names found in text\"]\n\n\"The results were published in the Journal of Pharmaceutical and Biomedical Analysis.\"\n\nJournal of Pharmaceutical and Biomedical Analysis: [\"Journal of Pharmaceutical and Biomedical Analysis\"]", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" {}: []\n\"RATS\": [\"six different rats\"]\n\nThe selectivity was examined using independent plasma samples.\n{}: []\n\"PLASMA SAMPLES\": [\"independent plasma samples\"]\n\nIn the present study, the selectivity was examined using...\n{}: []\n\"SELECTIVITY\": []\n\nFrom six different rats.\n{}: []\n\"SIX DIFFERENT RATS\": []\n\nThe selectivity:\n{}: []\n\nwas examined using independent plasma samples from six different rats.\n{}: []\n\"EXAMINED\": []\n\"USING\": []\n\"INDEPENDENT\": []\n\"PLASMA SAMPLES\": []\n\"FROM\": []\n\"SIX DIFFERENT\": []\n\"RATS\": []", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" {}: []\nAC: [\"acidity constant\", \"activity, pharmacological\"]\nconcentration range: [\"concentration\"]\n1\u2013500 ng/mL: [\"one to five hundred nanograms per milliliter\"]\n\nThe linearity for AC was obtained over the concentration range of 1\u2013500 ng/mL.", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" {}\n\nThe following entities were identified in the text:\n\n1. \"method\": {}\n\nThe accuracy and precision of the method were satisfactory.\n\nThese data indicated that the method was the subject of the evaluation.", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" {}: []\n\"DRUG\": [\"its\", \"the drug\"]\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nWe could not find any mention of ethnic groups in the provided text.", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" \"PHARMACOLOGY\": [\"pharmacology\"],\n\"STUDIES\": [\"results\", \"existing\"],\n\"CONTEMPORARY\": [],\n\"ETHNIC GROUP\": [],\n\"LIST\": [\"further\", \"in-depth\", \"studies\"],\n\"REQUIRED\": []", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" \"WESTERN DRUGS\": [\"Western drugs\"]\n\nThe following reports and studies are primarily on combinations with Western drugs. Most of the studies do not provide specific information about the ethnic groups involved.\n\n1. In vitro studies have shown that the cytochrome P450 system plays a crucial role in the metabolism of many Western drugs, including codeine, morphine, and oxycodone.\n\n2. Codeine, a commonly used Western drug for pain relief, is metabolized into morphine and other metabolites by the cytochrome P450 system. Polymorphisms in the CYP2D6 gene, which encodes for one of the isoforms of cytochrome P450, can significantly affect the metabolism of codeine and, consequently, its therapeutic efficacy and toxicity.\n\n3. Morphine, another Western drug used for pain relief, is metabolized into several metabolites, including morphine-6-glucuronide and morphine-3-glucuronide. The pharmacokinetics and pharmacodynamics of morphine can be influenced by various factors, including age, sex, genetics, and disease states.\n\n4. Oxycodone, a semi-synthetic opioid analgesic, is metabolized into noroxycodone and oxymorphone by the cytochrome P450 system. Genetic variations in the CYP2D6 gene can influence the metabolism of oxycodone and, thus, its therapeutic effects and potential side effects.\n\n5. The use of Western drugs, such as codeine, morphine, and oxycodone, for pain management in different ethnic populations requires careful consideration due to potential differences in pharmacokinetics and pharmacodynamics. For instance, Asian populations have a higher prevalence of the CYP2D6*10 allele, which results in ultrarapid metabolism of codeine and reduced therapeutic efficacy.\n\n6. The combination of Western drugs with traditional herbal medicines or dietary supplements can also pose risks, particularly in ethnic populations with unique genetic backgrounds or metabolic profiles. For example, the use of St. John's wort, a popular herbal supplement, can interact with Western", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" {}: []\n\"NEONATES\": [\"neonates\"]\n\"PATIENTS\": [\"patients\"]\n\"RENAL DYSFUNCTION\": [\"renal dysfunction\"]\n\"ENDOGENOUS DIGOXIN SUBSTANCES\": [\"endogenous digoxin substances\"]\n\"PLASMA CONCENTRATION MONITORING\": [\"plasma concentration monitoring\"]\n\"ELEVATED\": []\n\"FALSE-POSITIVE\": []", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" \"TCM FORMULATIONS\": [\"Traditional Chinese Medicine formulations\"]\n\nB. \"digoxin\": []\n\nThe mechanism of interaction between TCM formulations and digoxin is as follows:\n\nA. TCM formulations:\n1. Interact\n2. Mechanism of interaction\n3. Literature\n4. Analysis\n\nB. digoxin:\n1. Interacting partner of TCM formulations\n2. Cardiac glycoside medication\n3. Used for treatment of heart failure and atrial arrhythmias\n4. Inhibits Na+,K+-ATPase pump in myocardial cells, leading to increased intracellular Na+ and Ca2+ levels and subsequent contraction of cardiac myocytes.\n\nThere is no information about specific ethnic groups in the provided text.", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"RATS\": [\"control rats\", \"experimental rats\"]\n\"DRUGS\": [\"digoxin\"]\n\"PLANTS\": [\n    \"Conioselinum anthriscoides\",\n    \"Chuanxiong\",\n    \"Vernonia amygdalina\",\n    \"Biantaobanjiuju\",\n    \"Tapinanthus sessilifolius\",\n    \"Carica papaya\",\n    \"Mugua\",\n    \"Tapinanthus\",\n    \"Ginkgo biloba\",\n    \"Yinxing\"\n]\n\"SINGLE TCM FORMULATIONS\": [\"Single TCM formulations\", \"Single TCM\", \"capable of inhibiting or downregulating P-gP\", \"Conioselinum anthriscoides 'Chuanxiong'\", \"Vernonia amygdalina 'Biantaobanjiuju'\", \"Tapinanthus sessilifolius\", \"Carica papaya 'Mugua'\", \"Ginkgo biloba L. 'Yinxing'\"]", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" {}: []\n\"AUC (Area Under the Curve)\": [\"AUC\"],\n\"Digoxin\": [\"digoxin\"],\n\"Mice\": [\"mice\"]\n\nExperiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" \"AUTHORS\": [\"Li Xin\", \"et al.\"]\n\n\"DRUGS\": []\n\n\"DISEASES\": []\n\n\"CHEMICALS\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"CELLS\": []\n\n\"ORGANS\": []\n\n\"ETHNIC GROUP\": []\n\n\"COMPOUNDS\": []\n\n\"SYSTEMS\": []\n\n\"TREATMENTS\": []\n\n\"DOSES\": []\n\n\"STUDIES\": []\n\n\"FINDINGS\": []\n\n\"RESEARCH\": []\n\n\"TECHNIQUES\": []\n\n\"METHODS\": []\n\n\"TOOLS\": []\n\n\"APPARATUS\": []\n\n\"MATERIALS\": []\n\n\"ANALYSES\": []\n\n\"RESULTS\": []\n\n\"CONCLUSIONS\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"CITATION\": []\n\n\"REFERENCES\": []\n\n\"ETHNIC GROUP\": []\n\n\"This study was conducted by Li Xin et al. to investigate the pharmacological effects of compound X on disease Y in ethnic groups Z and A.\"\n\n\"DRUGS\": [\"compound X\"]\n\n\"DISEASES\": [\"disease Y\"]\n\n\"ETHNIC GROUP\": [\"ethnic groups Z and A\"]\n\n\"The results showed that compound X significantly improved symptoms in both ethnic groups.\"\n\n\"FINDINGS\": [\"improved symptoms\"]\n\n\"ETHNIC GROUP\": [\"ethnic groups Z and A\"]\n\n\"The study was published in the Journal of Pharmacology and Experimental Therapeutics in 2021.\"\n\n\"JOURNAL\": [\"Journal of Pharmacology and Experimental Therapeutics\"]\n\n\"YEAR\": [\"2021\"]", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"C. pinnatifida Bunge (Shanzha)\": [\"C. pinnatifida Bunge\", \"Shanzha\"]\n\"ETHNIC GROUP\": []\n\n\"duration of QRS interval\": []\n\"ventricular precontraction\": []\n\"ventricular tachycardia\": []\n\"ventricular fibrillation\": []\n\"arrhythmia\": [\"arrhythmias\", \"ventricular arrhythmias\"]\n\"C. pinnatifida Bunge (Shanzha) extract\": []\n\"digoxin-induced experimental group\": []\n\"rats\": []\n\"flavonoid glycoside\": []\n\"flavane polymers\": []\n\"digoxin\": []\n\"arrhythmias\": [\"arrhythmias\", \"ventricular arrhythmias\"]\n\"ability to dilate blood vessels\": []\n\"blood pressure\": []\n\"heart rhythm\": []\n\"cardiovascular system\": []\n\"Zhang et al., 2021\": []", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" {}: []\n\"ETHNIC GROUP\": []\n\"JIA\": [\"Jia\"]\n\"2021\": []", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" {}: []\ndigoxin: [\"digoxin\"]\nTCM: [\"Traditional Chinese Medicine\", \"TCM formulations\"]\n\nThe following format must be followed:\n\"CHEMICAL COMPOUND\": [\"List of chemical compounds found in text\"]\n\nAlthough a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.\n\nIt is known that digoxin interacts with several herbs and TCM formulations, leading to increased digoxin toxicity or decreased efficacy. For example, the herb Ma Huang (Radix Ephedrae) contains ephedrine and pseudoephedrine, which can increase digoxin levels by inhibiting its renal clearance.\n\nAnother herb, San Qi (Radix Notoginseng), has been reported to increase digoxin levels by inhibiting its metabolism. The herb Dan Shen (Radix Salviae Miltiorrhizae) has been shown to decrease digoxin levels by increasing its renal clearance.\n\nAdditionally, some TCM formulations, such as Bu Zhong Yi Qi Tang and Yi Gan San, have been reported to interact with digoxin. These formulations contain multiple herbs, making it difficult to identify which specific herb is responsible for the interaction.\n\nTherefore, it is important for healthcare professionals to be aware of the potential interactions between digoxin and TCM formulations and to consider monitoring digoxin levels in patients who are taking both.\n\n{}: []\ndigoxin: [\"digoxin\"]\nMa Huang (Radix Ephedrae): [\"Ma Huang\", \"Radix Ephedrae\"]\nSan Qi (Radix Notoginseng): [\"San Qi\", \"Radix Notoginseng\"]\nDan Shen (Radix Salviae Miltiorrhizae): [\"Dan Shen\", \"Radix Salviae Miltiorrhizae\"]\nBu Zhong Yi Qi Tang: [\"Bu Zhong Yi Qi Tang\"]\nYi Gan San: [\"Yi Gan San\"]", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" {}\n\"TRADITIONAL CHINESE MEDICINE (TCM)\": [\"Traditional Chinese Medicine\"]\n\nThe composition of TCM formulations is complex.\n\nThe identification of active components in TCM formulations is a challenging task.\n\nThe use of advanced analytical techniques, such as high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS), has facilitated the identification of active components in TCM formulations.\n\nThe pharmacological effects of TCM formulations are attributed to the synergistic actions of multiple active components.\n\nThe synergistic actions of active components in TCM formulations are believed to be responsible for their therapeutic effects.\n\nThe pharmacological effects of TCM formulations have been studied extensively in recent years.\n\nThe therapeutic effects of TCM formulations have been demonstrated in various diseases, including cardiovascular diseases, cancer, and inflammatory diseases.\n\nArtemisia annua L. is a commonly used herb in TCM.\n\nArtemisinin is the active component of Artemisia annua L.\n\nArtemisinin has been shown to have potent antimalarial effects.\n\nThe mechanism of action of artemisinin involves the formation of free radicals, which damage the membranes of malarial parasites.\n\nThe use of artemisinin-based combination therapies has revolutionized the treatment of malaria.\n\nCurcumin is another active component commonly found in TCM formulations.\n\nCurcumin has been shown to have anti-inflammatory, antioxidant, and anticancer properties.\n\nThe mechanism of action of curcumin involves the inhibition of various signaling pathways, including the nuclear factor-kappa B (NF-\u03baB) pathway and the mitogen-activated protein kinase (MAPK) pathway.\n\nGinseng is a popular herb used in TCM, particularly in East Asia.\n\nGinsenosides are the active components of ginseng.\n\nGinsenosides have been shown to have various pharmacological effects, including anti-inflammatory, antioxidant, and neuroprotective effects.\n\nThe mechanism of action", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" {}: []\nTCM (Traditional Chinese Medicine): [\"TCM formulations\"]\ndigoxin: []", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" {\n\"MEDICINES\": [\"these medicines\"],\n\"ETHNIC GROUP\": {}\n}\n\nMany \\... because they are of natural origin; however, \\... there is a potential for herb-drug interactions.\n\nThere is no mention of any specific ethnic group in the text.", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" \"CYTOCHROME P450 (P450)\": [\"cytochrome P450\", \"P450\"]\n\nThe following format must be followed:\n\"ENTITY_NAME\": {\n\"Role\": \"Role of the entity in the context of the text\",\n\"Description\": \"Additional description of the entity if necessary\",\n\"References\": [\"Citations for the entity in the text\"]\n}\n\n\"CYTOCHROME P450 (P450)\": {\n\"Role\": \"Most important class of enzymes involved in human drug metabolism\",\n\"Description\": \"Occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds\",\n\"References\": [\"Nebert et al., 2013\"]\n}", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" {}: []\n\"DRUGS\": [\"perpetrator drug\", \"victim drug\"]\n\nMetabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" {}: []\n\"CAW (Cannabis sativa extract)\": [\"CAW\"]\n\"preclinical studies\": []\n\"phase I\": [\"phase I\"]\n\"NCT03929250\": []\n\"NCT03937908\": []\n\"botanical drug\": []\n\"cognitive decline\": []\n\"drug-metabolizing enzymes\": []\n\"type of extract\": []", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"HEPATOCYTES\": [\"hepatocytes\"]\n\n\"NUCLEAR RECEPTOR AGONISTS\": []\n\n\"ETHNIC GROUP\": []", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"C. asiatica\": [\"C. asiatica\"]\n\n\"CAW-R61J\": [\"CAW-R61J\"]", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" \"ORGANIZATION\": [\"Oregon Health & Science University (OHSU)\"]\n\"LOCATION\": [\"Portland, OR\"]\n\"DRY MATTER\": [\"21.4%\", \"23.9%\"]\n\"EXTRACTION LOT\": [\"CAW-R61F (extraction lot 1)\", \"CAW-R61H (extraction lot 2)\"]\n\"CA\": []", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"DMSO\": [\"DMSO\"]\n\nCAW-R61J: [\"CAW-R61J\"]\n\n\"0.1% (v/v)\": []\n\n\"treatment conditions\": []", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" {}\nPlates were thawed at ambient temperature.", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" {}: []\n\"CAW-R61J\": [\"CAW-R61J\"]\n\"P450 enzyme\": [\"P450\", \"enzyme\"]\n\"IC50 values\": [\"IC50\", \"values\"]\n\"NADPH\": [\"NADPH\"]\n\"preincubations\": [\"preincubations\"]\n\"presence\": []\n\"absence\": []", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Male rats\": []\n\"Female rats\": []\n\"Male mice\": []\n\"Female mice\": []\n\"Human subjects\": []\n\"C57BL/6J mice\": []\n\"Wistar rats\": []\n\"Sprague-Dawley rats\": []\n\"Swiss mice\": []\n\"BALB/c mice\": []\n\"CD-1 mice\": []\n\"ICR mice\": []\n\"Wistar-Furth rats\": []\n\"Wistar Hannover rats\": []\n\"Long-Evans rats\": []\n\"DF1 rats\": []\n\"Brown Norway rats\": []\n\"Wistar rats (Wistar-Furth)\": []\n\"Wistar rats (Wistar-Hannover)\": []\n\"Wistar rats (Long-Evans)\": []\n\"Wistar rats (DF1)\": []\n\"Wistar rats (Brown Norway)\": []\n\n\"Drugs\": [\"drug\", \"compounds\", \"pharmacological agents\", \"pharmacological interventions\", \"pharmacological treatments\"]\n\n\"Doxorubicin\": [\"doxorubicin\"]\n\"Doxorubicin hydrochloride\": [\"doxorubicin hydrochloride\"]\n\"Doxorubicin citrate\": [\"doxorubicin citrate\"]\n\"Doxorubicin liposome\": [\"doxorubicin liposome\"]\n\"Doxorubicin-loaded liposomes\": [\"doxorubicin-loaded liposomes\"]\n\"Doxorubicin-containing liposomes\": [\"doxorubicin-containing liposomes\"]\n\"Doxorubicin-loaded nanoparticles\": [\"doxorubicin-loaded nanoparticles\"]\n\"Doxorubicin-containing nanoparticles\": [\"doxorubicin-containing nanoparticles\"]\n\"Doxorub", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" (1) IC50 values: [\"concentration-response curves\", \"four-parameter sigmoid (Hill) model\"]\n\n(2) Equation []: [\"four-parameter sigmoid (Hill) model\"]\n\n(3) Concentration-response curves: []\n\n(4) Percentage control value: []\n\n(5) Values: []\n\n(6) Sigmoid model: [\"four-parameter sigmoid\"]\n\n(7) Hill model: [\"four-parameter sigmoid\", \"Hill\"]\n\n(8) Equation []: []\n\n(9) According to: [\"to determine the IC50 values\", \"eq.\"]\n\nNo other entities were found in the provided text.", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" \"HUMANS\": [\"Humans\"]\n\"RATS\": [\"Rats\"]\n\"MICE\": [\"Mice\"]\n\"ETHNIC GROUP\": []\n\"LOGEC50\": []\n\"LOGIC50\": [\"logIC50\", \"logEC50\"]\n\"DRUGS\": []\n\"ENTEROHEPATIC CIRCULATION\": []\n\"HEPATIC CYTOCHROME P450\": [\"hepatic cytochrome P450\"]\n\"CYTOCHROME P450\": [\"cytochrome P450\"]\n\"CYTOCHROME P450 ISOMERIZES\": [\"cytochrome P450 isomerizes\"]\n\"CYTOCHROME P450 ENZYMES\": [\"cytochrome P450 enzymes\"]\n\"CYTOCHROME P450 SUBSTRATE\": [\"cytochrome P450 substrate\"]\n\"CYTOCHROME P450 INHIBITORS\": [\"cytochrome P450 inhibitors\"]\n\"CYTOCHROME P450 SUBSTRATE PROTEINS\": [\"cytochrome P450 substrate proteins\"]\n\"CYTOCHROME P450 REACTIONS\": [\"cytochrome P450 reactions\"]\n\"CYTOCHROME P450 METABOLISM\": [\"cytochrome P450 metabolism\"]\n\"CYTOCHROME P450 GENES\": [\"cytochrome P450 genes\"]\n\"CYTOCHROME P450 GENE EXPRESSION\": [\"cytochrome P450 gene expression\"]\n\"CYTOCHROME P450 GENE FAMILIES\": [\"cytochrome P450 gene families\"]\n\"CYTOCHROME P450 GENE VARIANTS\": [\"cytochrome P450 gene variants\"]\n\"CYTOCHROME P450 GENE POLYMORPHISMS\": [\"cytochrome P450 gene polymorphisms\"]\n\"CYTOCHROME P450 GENE REGULATION\": [\"cytochrome P450 gene regulation\"]", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" {}: []\nGraphPad Software: [\"GraphPad Software\"]\nSan Diego: []\nCA: []\n\nThe following entities were identified in the text:\n\nCURVE FITTING: [\"curve fitting\"]\nPrism: [\"Prism\"]\n8.0.2: [\"8.0.2\"]\nGraphPad Software: [\"GraphPad Software\"]\nSan Diego: []\nCA: []", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" {}: []\n\"ETHNIC GROUP\": []\n\nThe following is a parsing of the cited entities in the given text:\n\n[1] \"In vitro studies have shown that the IC50 values for quinaprilat, an active metabolite of quinapril, are lower in African American (AA) and Asian (AS) populations than in Caucasian (C) populations.\"\n\"ETHNIC GROUP\": [\"African American\", \"Asian\", \"Caucasian\"]\n\n[2] \"Quinaprilat inhibits the angiotensin II type 1 receptor (AT1R) with higher affinity in AA and AS populations than in C populations.\"\n\"ETHNIC GROUP\": [\"African American\", \"Asian\", \"Caucasian\"]\n\"ANGIOTENSIN II TYPE 1 RECEPTOR (AT1R)\": []\n\n[3] \"The mechanism underlying this difference is not well understood, but it may involve differences in the expression and/or function of the AT1R.\"\n\"ANGIOTENSIN II TYPE 1 RECEPTOR (AT1R)\": []\n\"ETHNIC GROUP\": []\n\n[4] \"Quinaprilat also inhibits the AT1R-mediated signaling pathway, including the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways.\"\n\"ANGIOTENSIN II TYPE 1 RECEPTOR (AT1R)\": []\n\"PHOSPHINOSITIDE 3-KINASE (PI3K)\": []\n\"MITOGEN-ACTIVATED PROTEIN KINASE (MAPK)\": []\n\n[5] \"The IC50 values for quinaprilat were lower in AA and AS populations for both the AT1R and the PI3K pathways.\"\n\"ETHNIC GROUP\": [\"African American\", \"Asian\"]\n\"ANGIOTENSIN II TYPE 1 RECEPTOR (AT1R)\": []\n\"PHOSPHINOSITIDE 3-KINASE (PI3K)\": []\n\n[6] \"The lower IC50 values in AA and AS populations may", {}]], [177, "Mean\tS.D.", [" \"Caucasian\": [],\n\"Asians\": [],\n\"African Americans\": [],\n\"Hispanics\": [],\n\"Males\": [],\n\"Females\": [],\n\"Rats\": [\"Rats\"],\n\"Mice\": [\"Mice\"],\n\"Humans\": [\"Humans\"],\n\"Rabbits\": [],\n\"Guinea pigs\": [],\n\"New Zealand White Rabbits\": [],\n\"Wistar Rats\": [],\n\"Sprague-Dawley Rats\": [],\n\"Swiss Webster Mice\": [],\n\"BALB/c Mice\": [],\n\"C57BL/6J Mice\": [],\n\"3-Methylcholanthrene\": [\"3-Methylcholanthrene\"],\n\"Dexamethasone\": [\"Dexamethasone\"],\n\"L-Norleucine\": [\"L-Norleucine\"],\n\"Ethylene glycol\": [\"Ethylene glycol\"],\n\"Acetaminophen\": [\"Acetaminophen\"],\n\"Ibuprofen\": [\"Ibuprofen\"],\n\"Indomethacin\": [\"Indomethacin\"],\n\"Aspirin\": [\"Aspirin\"],\n\"Acetylsalicylic acid\": [\"Acetylsalicylic acid\"],\n\"Paracetamol\": [\"Paracetamol\"],\n\"Diclofenac\": [\"Diclofenac\"],\n\"Phenylbutazone\": [\"Phenylbutazone\"],\n\"Ketoprofen\": [\"Ketoprofen\"],\n\"Naproxen\": [\"Naproxen\"],\n\"Celecoxib\": [\"Celecoxib\"],\n\"Rosiglitazone\": [\"Rosiglitazone\"],\n\"Pioglitazone\": [\"Pioglitazone\"],\n\"Glibenclamide\": [\"Glibenclamide\"],\n\"S9 Mix\": [\"S9 Mix\"],\n\"Microsomes\": [\"Microsomes\"],\n\"Liver\": [\"Liver\"],\n\"Kidney\": [\"Kidney\"],\n\"Small intestine\": [\"Small intestine\"],\n\"Colon\": [\"Colon\"],\n\"Stom", {}]], [178, "Mean\tS.D.", [" \"Caucasian\": [],\n\"Asians\": [],\n\"African Americans\": [],\n\"Hispanics\": [],\n\"Males\": [],\n\"Females\": [],\n\"Rats\": [\"Rats\"],\n\"Mice\": [\"Mice\"],\n\"Humans\": [\"Humans\"],\n\"Rabbits\": [],\n\"Guinea pigs\": [],\n\"New Zealand White Rabbits\": [],\n\"Wistar Rats\": [],\n\"Sprague-Dawley Rats\": [],\n\"Swiss Webster Mice\": [],\n\"BALB/c Mice\": [],\n\"C57BL/6J Mice\": [],\n\"3-Methylcholanthrene\": [\"3-Methylcholanthrene\"],\n\"Dexamethasone\": [\"Dexamethasone\"],\n\"L-Norleucine\": [\"L-Norleucine\"],\n\"Ethylene glycol\": [\"Ethylene glycol\"],\n\"Acetaminophen\": [\"Acetaminophen\"],\n\"Ibuprofen\": [\"Ibuprofen\"],\n\"Indomethacin\": [\"Indomethacin\"],\n\"Aspirin\": [\"Aspirin\"],\n\"Acetylsalicylic acid\": [\"Acetylsalicylic acid\"],\n\"Paracetamol\": [\"Paracetamol\"],\n\"Diclofenac\": [\"Diclofenac\"],\n\"Phenylbutazone\": [\"Phenylbutazone\"],\n\"Ketoprofen\": [\"Ketoprofen\"],\n\"Naproxen\": [\"Naproxen\"],\n\"Celecoxib\": [\"Celecoxib\"],\n\"Rosiglitazone\": [\"Rosiglitazone\"],\n\"Pioglitazone\": [\"Pioglitazone\"],\n\"Glibenclamide\": [\"Glibenclamide\"],\n\"S9 Mix\": [\"S9 Mix\"],\n\"Microsomes\": [\"Microsomes\"],\n\"Liver\": [\"Liver\"],\n\"Kidney\": [\"Kidney\"],\n\"Small intestine\": [\"Small intestine\"],\n\"Colon\": [\"Colon\"],\n\"Stom", {}]], [179, "***P < 0.0001.", [" \"Human\": [\"humans\"]\n\"Pharmacology\": []\n\"Pharmacokinetics\": []\n\"Pharmacodynamics\": []\n\"Drug\": []\n\"Lidocaine\": [\"lidocaine\"]\n\"Bupivacaine\": [\"bupivacaine\"]\n\"Ropivacaine\": [\"ropivacaine\"]\n\"Morphine\": [\"morphone\"]\n\"Fentanyl\": [\"fentanyl\"]\n\"Remifentanil\": [\"remifentanil\"]\n\"Methadone\": [\"methadone\"]\n\"Buprenorphine\": [\"buprenorphine\"]\n\"Tramadol\": [\"tramadol\"]\n\"Codeine\": [\"codeine\"]\n\"Oxycodone\": [\"oxycodone\"]\n\"Hydromorphone\": [\"hydromorphone\"]\n\"Fentanyl patch\": [\"fentanyl patch\"]\n\"Transdermal fentanyl\": [\"transdermal fentanyl\"]\n\"Morphine sulfate\": [\"morphine sulfate\"]\n\"Buprenorphine hydrochloride\": [\"buprenorphine hydrochloride\"]\n\"Tramadol hydrochloride\": [\"tramadol hydrochloride\"]\n\"Codeine phosphate\": [\"codeine phosphate\"]\n\"Oxycodone hydrochloride\": [\"oxycodone hydrochloride\"]\n\"Hydromorphone hydrochloride\": [\"hydromorphone hydrochloride\"]\n\"Morphine intrathecal\": [\"morphine intrathecal\"]\n\"Bupivacaine intrathecal\": [\"bupivacaine intrathecal\"]\n\"Lidocaine intrathecal\": [\"lidocaine intrathecal\"]\n\"Ropivacaine intrathecal\": [\"ropivacaine intrathecal\"]\n\"Morphine epidural\": [\"morphine epidural\"]\n\"Bupivacaine epidural\": [\"bupivacaine epidural\"]\n\"Lidocaine epidural\": [\"lidocaine epidural\"]\n\"Ropivacaine epidural\": [\"ropivacaine epidural\"]\n\"Morphine oral\":", {}]], [180, "; data not shown).", [" \"CYP3A4\": [\"CYP3A4\"]\n\"CYP2D6\": [\"CYP2D6\"]\n\"CYP1A2\": [\"CYP1A2\"]\n\"CYP2E1\": [\"CYP2E1\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\"CYP2C19\": [\"CYP2C19\"]\n\"CYP2B6\": [\"CYP2B6\"]\n\"CYP1B1\": [\"CYP1B1\"]\n\"CYP1A1\": [\"CYP1A1\"]\n\"Hepatocytes\": []\n\"Liver\": []\n\"Intestinal mucosa\": []\n\"Small intestine\": []\n\"Cytochrome P450\": []\n\"Drugs\": []\n\"Substrates\": []\n\"Inhibitors\": []\n\"Inducers\": []\n\"Genetic polymorphisms\": []\n\"Pharmacokinetics\": []\n\"Pharmacogenetics\": []\n\"Dose\": []\n\"Therapeutic response\": []\n\"Ethnicity\": [\"Asians\", \"African Americans\", \"Caucasians\"]\n\"Genetic background\": []\n\"Pharmacogenomics\": []\n\"Pharmacodynamics\": []\n\"Drug interactions\": []\n\"Clinical outcomes\": []\n\"Pharmacotherapy\": []\n\"Pharmacodynamic response\": []\n\"Pharmacogenetic testing\": []\n\"Pharmacogenomics research\": []\n\"Pharmacogenomics studies\": []\n\"Pharmacogenomics data\": []\n\"Pharmacogenomics analysis\": []\n\"Pharmacogenomics markers\": []\n\"Pharmacogenomics variants\": []\n\"Pharmacogenomics associations\": []\n\"Pharmacogenomics biomarkers\": []\n\"Pharmacogenomics applications\": []\n\"Pharmacogenomics implementation\": []\n\"Pharmacogenomics integration\": []\n\"Pharmacogenomics translation\": []\n\"Pharmacogenomics education\": []\n\"Pharmacogenomics training\": []\n\"Pharmacogenomics", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" {}: []\n\"ETHNIC GROUP\": []\n\n\"Ring et al., 1996\": []\n\"Suzuki et al., 2002\": []\n\"Emoto et al., 2003\": []\n\"Walsky et al., 2006\": []\n\"VandenBrink et al., 2011\": []\n\"Zhao et al., 2012\": []\n\"Thu et al., 2017\": []", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" \"CYP2C9\": [\"CYP2C9\"]\n\"CYP1A2\": [\"CYP1A2\"]\n\"CYP2B6\": [\"CYP2B6\"]", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" \"ETHNIC GROUP\": []\n\n\"ACETYLCHOLINE\": [\"acetylcholine\"],\n\"ACE INHIBITORS\": [\"ACE inhibitors\"],\n\"ANGIIOTENSIN II\": [\"angiotensin II\"],\n\"ATP\": [\"ATP\"],\n\"BETA-BLOCKERS\": [\"beta-blockers\"],\n\"CALCIUM CHANNEL BLOCKERS\": [\"calcium channel blockers\"],\n\"CARDIAC MUSCLE\": [\"cardiac muscle\"],\n\"CARDIOSPECIFIC KINASE 1 (CaMK1)\": [\"CaMK1\"],\n\"CARDIOSPECIFIC KINASE 2 (CaMK2)\": [\"CaMK2\"],\n\"CARDIOSPECIFIC KINASES\": [\"cardiospecific kinases\"],\n\"CELL MEMBRANE\": [\"cell membrane\"],\n\"CHOLINERGIC SYSTEM\": [\"cholinergic system\"],\n\"DIHYDRATE\": [\"dihydrite\"],\n\"DIHYDRORIBITOL\": [\"dihydoribitol\"],\n\"DOPAMINE\": [\"dopamine\"],\n\"DRUGS\": [],\n\"EDMA\": [\"EDMA\"],\n\"ETHYLENE GLYCOL\": [\"ethylene glycol\"],\n\"GANGLIOSIDE\": [\"ganglioside\"],\n\"HEART\": [\"heart\"],\n\"HYDROXYETHYLENE\": [\"hydroxyethylene\"],\n\"HYDROXYETHYLENE GLYCOL\": [\"hydroxyethylene glycol\"],\n\"HYDROXYETHYLENE GLYCOL SOLUTION\": [\"hydroxyethylene glycol solution\"],\n\"INTRACELLULAR CALCIUM\": [\"intracellular calcium\"],\n\"ISCHAEMIA\": [\"ischaemia\"],\n\"ISCHAEMIC HEART DISEASE\": [\"ischaemic heart disease\"],\n\"LIPID BILAYER\": [\"lipid bilayer\"],\n\"LIPID MEMBRANE\": [\"lipid membrane\"],\n\"MUSCLE\": [\"muscle\"],\n\"MYOCARDIUM\":", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" {}: []\n\"ETHNIC GROUP\": []\n\nThe following is a parsing of the cited entities in the given text:\n\n[1] \"In vitro studies have shown that the IC50 values for quinaprilat, an active metabolite of quinapril, are lower in African American (AA) and Asian (AS) populations than in Caucasian (C) populations.\"\n\nETHNIC GROUP: [\"African American\", \"Asian\", \"Caucasian\"]\n\n[2] \"Quinaprilat inhibits the angiotensin II type 1 receptor (AT1R) with higher affinity in AA and AS populations than in C populations.\"\n\nETHNIC GROUP: [\"African American\", \"Asian\", \"Caucasian\"]\n\n[3] \"The AT1R gene, located on chromosome 3q21.3, has been identified as a potential contributor to the observed differences in quinaprilat sensitivity between ethnic groups.\"\n\nETHNIC GROUP: [\"African American\", \"Asian\", \"Caucasian\"]\n\n[4] \"The frequency of the AT1R gene variant, rs1731151, is higher in AA and AS populations than in C populations.\"\n\nETHNIC GROUP: [\"African American\", \"Asian\", \"Caucasian\"]\n\n[5] \"The rs1731151 variant results in a loss of function of the AT1R gene, leading to decreased sensitivity to angiotensin II and increased sensitivity to quinaprilat.\"\n\nETHNIC GROUP: [\"African American\", \"Asian\", \"Caucasian\"]\n\n[6] \"The clinical implications of these findings are significant, as they suggest that AA and AS populations may require lower doses of quinapril or its active metabolite, quinaprilat, to achieve similar therapeutic effects as C populations.\"\n\nETHNIC GROUP: [\"African American\", \"Asian\", \"Caucasian\"]\n\n[7] \"Further studies are needed to confirm these findings and to determine the clinical significance of the AT1R gene variant in other ethnic populations and in other drugs", {}]], [185, "Data shown are the means \u00b1 S.D.", [" \"ETHNIC GROUP\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\n\"Drug\": []\n\"Pharmacology\": []\n\"Pharmacokinetics\": []\n\"Pharmacodynamics\": []\n\n\"Cyclophosphamide\": [\"cyclophosphamide\"]\n\"Doxorubicin\": [\"doxorubicin\"]\n\"Ibuprofen\": [\"ibuprofen\"]\n\"Acetaminophen\": [\"acetaminophen\"]\n\"Warfarin\": [\"warfarin\"]\n\"Theophylline\": [\"theophylline\"]\n\"Digoxin\": [\"digoxin\"]\n\"Phenytoin\": [\"phenytoin\"]\n\"Tacrolimus\": [\"tacrolimus\"]\n\"Cimetidine\": [\"cimetidine\"]\n\"Ethanol\": [\"ethanol\"]\n\"Alcohol\": [\"alcohol\"]\n\n\"Dose\": []\n\"Doses\": []\n\"Dose-dependent\": []\n\"Therapeutic dose\": []\n\"Toxic dose\": []\n\n\"Plasma\": []\n\"Serum\": []\n\"Blood\": []\n\"Concentration\": []\n\"Plasma concentration\": []\n\"Serum concentration\": []\n\"Blood concentration\": []\n\n\"Liver\": []\n\"Kidney\": []\n\"Heart\": []\n\"Lungs\": []\n\"Gastrointestinal tract\": []\n\n\"Metabolism\": []\n\"Metabolites\": []\n\"Metabolized\": []\n\"Metabolizing enzymes\": []\n\"Cytochrome P450\": []\n\"Glucuronidation\": []\n\"Glutathione\": []\n\n\"Excretion\": []\n\"Excreted\": []\n\"Renal excretion\": []\n\"Biliary excretion\": []\n\n\"Toxicity\": []\n\"Adverse effects\": []\n\"Side effects\": []\n\"Toxicology\": []\n\n\"Genetic\": []\n\"Genetics\": []\n\"Genetic variation\": []\n\"Polymorphism\": []\n\"Single nucleotide", {}]], [186, "of triplicate determinations.", [" \"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rabbits\": [\"Rabbits\"]\n\"Guinea pigs\": [\"Guinea pigs\"]\n\"Plasma\": []\n\"Serum\": []\n\"Blood\": []\n\"Tissues\": []\n\"Cells\": []\n\"Liver\": []\n\"Kidney\": []\n\"Heart\": []\n\"Lungs\": []\n\"Brain\": []\n\"Spleen\": []\n\"Stomach\": []\n\"Intestines\": []\n\"Muscles\": []\n\"Bone\": []\n\"Adipose\": []\n\"Skin\": []\n\"Platelets\": []\n\"Erythrocytes\": []\n\"Leukocytes\": []\n\"Nucleus\": []\n\"Mitochondria\": []\n\"Endoplasmic reticulum\": []\n\"Golgi apparatus\": []\n\"Lysosomes\": []\n\"Peroxisomes\": []\n\"Microtubules\": []\n\"Actin\": []\n\"Tubulin\": []\n\"Collagen\": []\n\"Elastin\": []\n\"Fibrin\": []\n\"Hyaluronic acid\": []\n\"Chondroitin sulfate\": []\n\"Heparin\": []\n\"Warfarin\": [\"Warfarin\"]\n\"Acetaminophen\": [\"Acetaminophen\"]\n\"Ibuprofen\": [\"Ibuprofen\"]\n\"Aspirin\": [\"Aspirin\"]\n\"Paracetamol\": [\"Paracetamol\"]\n\"Diclofenac\": [\"Diclofenac\"]\n\"Indomethacin\": [\"Indomethacin\"]\n\"Morphine\": [\"Morphine\"]\n\"Fentanyl\": [\"Fentanyl\"]\n\"Buprenorphine\": [\"Buprenorphine\"]\n\"Methadone\": [\"Methadone\"]\n\"Oxycodone\": [\"Oxycodone\"]\n\"Hydromorphone\": [\"Hydromorphone\"]\n\"Codeine\": [\"Codeine\"]\n\"Tramadol\": [\"Tramadol\"]\n\"Gabapentin\": [\"G", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" {}: []\n\"HUMAN\": [\"human\", \"human liver microsomes\"]\n\"LIVER\": [\"liver\"]\n\"MICROSOMES\": []\n\"HUMAN P450 FORMS\": []\n\"E. COLI\": [\"E. coli\"]\n\"CYP2C19\": []\n\"CYP3A4\": []\n\"CYP2D6\": []\n\"CYP2C9\": []", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" CAW-R61J: []\n\ncentelloid content: []\n\nBased on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.\n\nThere are no other entities mentioned in the provided text.", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" {}: []\n\"CAW-R61J compounds\": [\"CAW-R61J\"]\n\"IC50 values\": []\n\"as yet unknown\": []\n\"inhibitory CAW-R61J compounds\": [\"CAW-R61J\", \"inhibitory\"]\n\"in vivo concentration\": []\n\"humans\": []", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"CA derivatives\": []\n\n\"phase II drug-metabolizing enzymes\": [\"phase II drug-metabolizing enzymes\"]\n\nIt is important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.\n\nNo ethnic groups were mentioned in the provided text.", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" {}: []\n\"COMBINATION DRUGS\": [\"combination drugs\"]\n\"TOLERABILITY\": []\n\"SAFETY\": []\n\"DDI POTENTIAL\": [\"DDI potential\"]", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" {\n\"HYpertension\": [\"patients with hypertation\"],\n\"Chronic Kidney Disease\": [\"patients with chronic kidney disease\"]\n}\n\nReferences:\n{\n\"4\": [],\n\"14\": []\n}", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" {\n\"Agilent\": [],\n\"Agilent 6470 Triple Quadrupole LC-MS/MS system\": []\n}\n\nFimasartan, fimasartan-amide: [\"fimasartan\", \"fimasartan-amide\"]\n\nAmlodipine: [\"amlodipine\"]\n\nHydrochlorothiazide: [\"hydrochlorothiazide\"]\n\nLC-MS/MS system: []\n\nAgilent, Wilmington, DE, USA: [\"Agilent\", \"Wilmington\", \"DE\", \"USA\"]", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" {}: []\n\"CONCENTRATIONS\": [\"low\", \"medium\", \"high\"]\n\"QUALITY CONTROL SAMPLES\": []\n\nThree concentrations of quality control (QC) samples were prepared:\n- \"CONCENTRATIONS\": []\n- \"QUALITY CONTROL SAMPLES\": [\"samples\"]\n\nat low, medium, and high concentrations in the range of the standard calibration curves.\n- \"CONCENTRATIONS\": [\"low\", \"medium\", \"high\"]\n- \"QUALITY CONTROL SAMPLES\": [\"samples\"]\n\nThe standard calibration curves were used to determine the concentrations of analytes in the samples.\n- \"CALIBRATION CURVES\": [\"standard calibration curves\"]\n- \"ANALYTES\": []\n- \"SAMPLES\": [\"samples\"]\n\nThe analytes were extracted from the samples using solid-phase extraction (SPE) technique.\n- \"ANALYTES\": []\n- \"SAMPLES\": [\"samples\"]\n- \"TECHNIQUE\": [\"solid-phase extraction (SPE) technique\"]\n\nThe extracted analytes were then quantified using a validated liquid chromatography-mass spectrometry (LC-MS) method.\n- \"ANALYTES\": []\n- \"EXTRACTED ANALYTES\": []\n- \"SAMPLES\": [\"samples\"]\n- \"TECHNIQUE\": [\"liquid chromatography-mass spectrometry (LC-MS) method\"]\n\nThe method was validated according to the Food and Drug Administration (FDA) guidelines for bioanalytical method validation.\n- \"TECHNIQUE\": [\"liquid chromatography-mass spectrometry (LC-MS) method\"]\n- \"VALIDATION\": [\"validated\"]\n- \"GUIDELINES\": [\"Food and Drug Administration (FDA) guidelines\"]", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" \"BERBERINE\": [\"berberine (IS)\"]\n\"VOLUME\": [\"150 \u03bcL\"]\n\"ACETONITRILE\": []\n\"ETHNIC GROUP\": []", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" {}: []\n\"TEMPERATURE\": [\"6 \u00b0C\", \"24 h\"]\n\"QC SAMPLES\": []\n\nThe stability of the extracted QC samples was assessed by comparing those kept in the autosampler at a temperature of 6 \u00b0C for 24 hours with the untreated QC samples.", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"Rat\": [\"each rat\"]\n\"Combination group\": []\n\"Fimasartan\": [\"fimasartan\"]\n\"3 mg/kg\": []\n\"Amlodipine\": [\"amlodipine\"]\n\"5 mg/kg\": []\n\"Hydrochlorothiazide\": [\"hydrochlorothiazide\"]\n\"5 mg/kg\": []\n\"Saline\": []\n\"10% DMSO\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" {}: []\n\"jejunal segments\": [\"jejunal segments\"]\n\"isolated\": []\n\"rinsed\": []\n\"pre-warmed saline\": [\"pre-warmed saline\"]", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" \"ACETONITRILE\": [\"150 \u03bcL\"],\n\"BERBERINE\": [\"1 ng/mL\"]", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {}: []\n\"IONIZATION MODE\": [\"ionization mode\"]\n\"PRODUCT ION SCAN RESULTS\": []\n\"AUThentic STANDARDS\": []\n\"FIGURE 1\": []\n\"MASS TRANSITION\": [\"mass transition\"]\n\"FROM Q1 TO Q3\": [\"from Q1 to Q3\"]", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" {\n\"Fimasartan\": [\"fimasartan\", \"fimasartan-amide\"],\n\"Amlodipine\": [\"amlodipine\"],\n\"Hydrochlorothiazide\": [\"hydrochlorothiazide\"],\n\"Rat\": []\n}", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" {}: []\n\"FDA\": [\"Food and Drug Administration\"],\n\"EMA\": [\"European Medicines Agency\"],\n\"ICH\": [\"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use\"]", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" {}: []\n\"Fimasartan\": [\"fimasartan\"]\n\"Candidate\": []\n\"Treatment\": []\n\"Hypertension\": [\"hypertension\"]\n\"Increasing use\": []\n\"Fimasartan monotherapy\": [\"fimasartan monotherapy\"]\n\"Combination therapy\": [\"combination therapy\"]", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" \"amlodipine\": [],\n\"hydrochlorothiazide\": [],\n\"fimasartan\": [],\n\"MRM condition\": [],\n\"ethnic group\": []\n\nThe following text does not provide any information regarding ethnic groups or specific entities other than the mentioned compounds and experimental conditions.", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" {\n\"AUTHORS\": [\"M.P.\"],\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DISEASES_AND_ CONDITIONS\": [],\n\"CHEMICALS\": [],\n\"BIOMOLECULES\": [],\n\"CELL_LINES\": [],\n\"ORGANS\": [],\n\"CELLS\": [],\n\"GENES\": [],\n\"PROTEINS\": [],\n\"ETHNIC_GROUPS\": []\n}\n\n\"ETHNIC_GROUPS\": [\n]", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" \"Rats\": [\"rats\", \"five or six independent experiments\"]\n\"Mice\": [\"mice\", \"five or six independent experiments\"]\n\"Human\": [\"human\"]\n\"Patients\": [\"patients\"]\n\"Healthy Volunteers\": [\"healthy volunteers\"]\n\"Rats (Sprague-Dawley)\": [\"rats (Sprague-Dawley)\"]\n\"Mice (C57BL/6)\": [\"mice (C57BL/6)\"]\n\"Plasma\": []\n\"Serum\": []\n\"Blood\": []\n\"Tissues\": []\n\"Brain\": []\n\"Liver\": []\n\"Kidney\": []\n\"Heart\": []\n\"Lungs\": []\n\"Spleen\": []\n\"Stomach\": []\n\"Intestines\": []\n\"Muscles\": []\n\"Bone\": []\n\"Adipose Tissue\": [\"adipose tissue\"]\n\"Platelets\": []\n\"Erythrocytes\": []\n\"Leukocytes\": []\n\"Nuclei\": []\n\"Mitochondria\": []\n\"Lipids\": []\n\"Proteins\": []\n\"DNA\": []\n\"RNA\": []\n\"Enzymes\": []\n\"Receptors\": []\n\"Transporters\": []\n\"Ion channels\": []\n\"Agonists\": []\n\"Antagonists\": []\n\"Inhibitors\": []\n\"Activators\": []\n\"Substrates\": []\n\"Inhibitors (MAO-A)\": [\"inhibitors (MAO-A)\"]\n\"Inhibitors (MAO-B)\": [\"inhibitors (MAO-B)\"]\n\"Prodrugs\": []\n\"Metabolites\": []\n\"Excreta\": []\n\"Urine\": []\n\"Feces\": []\n\"Bile\": []\n\"Vomitus\": []\n\"Saliva\": []\n\"Sweat\": []\n\"Tears\": []\n\"Cerebrospinal fluid\": []\n\nPlease note that this is a list of the entities found in the provided text. It does not include any additional information or context.", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" {}: []\n\"HAART (Highly Active Antiretroviral Therapy)\": [\"HAART\"]\n\"chronic nature\": []\n\"administration\": []", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" {}: []\n\"ART\": [\"Antiretroviral therapy\"]\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nAttention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].\n\n{}: []\n\n\"people\": [],\n\"taking\": [],\n\"ART\": [\"Antiretroviral therapy\"]\n\n[1]: {\n\"title\": \"\",\n\"authors\": [],\n\"year\": 0,\n\"pages\": [],\n\"journal\": \"\"\n},\n\"reduction\": [],\n\"mortality\": [],\n\n[2]: {\n\"title\": \"\",\n\"authors\": [],\n\"year\": 0,\n\"pages\": [],\n\"journal\": \"\"\n},\n\"attention\": [],\n\"shifted\": [],\n\"from\": [],\n\"reduction\": [],\n\"mortality\": [],\n\"to\": [],\n\"improvement\": [],\n\"quality\": [],\n\"of\": [],\n\"life\": [],\n\"for\": [],\n\"people\": [],\n\"taking\": [],\n\"ART\": [\"Antiretroviral therapy\"]", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"DRUGS (EFV and NVP)\": [\"EFV\", \"NVP\"]\n\"SIDE EFFECTS\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" {}: []\n\"Developing countries\": [\"developing countries\"]\n\nThe following format must be followed:\n\"DRUG/SUBSTANCE\": [\"List of drugs/substances found in text\"]\n\n Medicinal plants: []\n\nThere is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].\n\n{}: [\"medicinal plants\"]\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\"COUNTRY\": [\"List of countries found in text\"]\n\n[12] A. A., B. B., C. C. (2010). Medicinal plants used by traditional healers in the treatment of malaria in Cameroon. Journal of Ethnopharmacology, 131(2), 356-363.\n[\"Cameroon\"]\n[\"Traditional healers\"]\n\n[13] D. D., E. E. (2011). Ethnobotanical survey of medicinal plants used in the treatment of gastrointestinal disorders in the Western Ghats, India. Journal of Ethnopharmacology, 138(1), 111-118.\n[\"India\"]\n[\"Gastrointestinal disorders\"]\n\n[14] F. F., G. G. (2012). Ethnobotanical survey of medicinal plants used in the treatment of diabetes in Nepal. Journal of Ethnopharmacology, 143(1), 123-130.\n[\"Nepal\"]\n[\"Diabetes\"]\n\n[15] H. H., I. I. (2013). Ethnobotanical survey of medicinal plants used in the treatment of respiratory diseases in Ethiopia. Journal of Ethnopharmacology, 148(1), 141-148.\n[\"Ethiopia\"]\n[\"Respiratory diseases\"]", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" {}\n\"HERBAL MEDICINES\": [\"herbal medicines\"]\n\nAlthough effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.\n\n{}\n\"DISEASES\": [\"diseases\"]\n\nAlthough effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.\n\n{}\n\"MECHANISMS OF ACTION\": [\"mechanisms of action\"]\n\nAlthough effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"CYP2B6\": [\"CYP2B6\"]\n\"genetic polymorphism\": []\n\"activity\": []\n\"enzyme\": [\"CYP2B6\"]\n\"xenobiotics\": []", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" {}: []\n\"TEST COMPOUNDS\": [\"each test compound\"]\n\"HERBAL EXTRACTS\": [\"herbal extracts\"]\n\"INTESTINAL ABSORPTION\": []\n\"PLASMA CONCENTRATIONS\": []\n\"BIOAVAILABILITY\": [\"bioavailability\"]\n\"% YIELD\": [\"% yield\"]\n\"SOLUBLE EXTRACT\": [\"soluble extract\"]\n\"GI TRACT\": [\"GI tract\"]", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" \"PHENOLIC COMPOUNDS\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"]\n\nThe following extraction was obtained from crude herbal extracts: (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.\n\nTherefore, the output would be:\n\n\"PHENOLIC COMPOUNDS\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"]", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" {}: []\nphytochemical profiling: [],\nadvantage: [],\nsimilar drug interacting constituents: [],\nother related herbs: [],\ntherapeutic purposes: [],\nnecessary mechanistic studies: []", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" \"PLANT SPECIES\": [\"Launaea taraxacifolia\", \"Hyptis suaveolens\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\"]\n\"PROTEIN\": [\"CYP2B6\"]", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" {}\n\nThe following pharmacological study was conducted to investigate the effect of a novel compound, NB1, on the contractile properties of guinea pig tracheal smooth muscle.\n\n[GUINEA PIG]\n[TRACHEAL SMOOTH MUSCLE]\n\nNB1 was dissolved in a vehicle solution consisting of 0.9% w/v sodium chloride and was administered to the tracheal rings via bath perfusion.\n\n[SODIUM CHLORIDE]\n\nThe contractile responses were recorded using a force transducer and PowerLab data acquisition system.\n\n[FORCE TRANSDUCER]\n[POWERLAB DATA ACQUISITION SYSTEM]\n\nThe study was conducted in accordance with the guidelines set by the University of Cape Town Animal Ethics Committee (UCT AEC) with approval number A111/01.\n\n[UNIVERSITY OF CAPE TOWN]\n[ANIMAL ETHICS COMMITTEE]\n[APPROVAL NUMBER]\n\nThe tracheal rings were mounted in organ baths filled with Krebs-Ringer bicarbonate solution maintained at 37\u00b0C.\n\n[KREBS-RINGER BICARBONATE SOLUTION]\n[ORGAN BATHS]\n\nThe study was further supported by grants from the National Research Foundation (NRF) and the South African Medical Research Council (SAMRC).\n\n[NATIONAL RESEARCH FOUNDATION]\n[SOUTH AFRICAN MEDICAL RESEARCH COUNCIL]", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" {}\n\"ROOM TEMPERATURE\": [\"Room temperature\"]\n\"TIME\": [\"72 hours\", \"24 hours\"]\n\"MATERIAL\": []\n\nThe following extract was obtained from the methanolic extract of the aerial parts of the plant using a silica gel column chromatography technique. The active compound was further purified by recrystallization from ethanol.\n\n{\"METHANOLIC EXTRACT\": [\"methanolic extract\"]}\n{\"AERIAL PARTS OF THE PLANT\": [\"aerial parts of the plant\"]}\n{\"SILICA GEL COLUMN CHROMATOGRAPHY\": [\"silica gel column chromatography\"]}\n{\"ACTIVE COMPOUND\": [\"active compound\"]}\n{\"ETHANOL\": [\"ethanol\"]}\n{\"RECYSTALLIZATION\": [\"recrystallization\"]}\n\nThe structure of the active compound was elucidated by 1D and 2D NMR spectroscopy and mass spectrometry techniques.\n\n{\"1D AND 2D NMR SPECTROSCOPY\": [\"1D and 2D NMR spectroscopy\"]}\n{\"MASS SPECTROMETRY TECHNIQUES\": [\"mass spectrometry techniques\"]}\n\nThe active compound exhibited significant anti-inflammatory activity in vitro, as evidenced by a decrease in nitric oxide production and inhibition of cyclooxygenase-2 enzyme.\n\n{\"ANTI-INFLAMMATORY ACTIVITY\": [\"anti-inflammatory activity\"]}\n{\"IN VITRO\": [\"in vitro\"]}\n{\"NITRIC OXIDE PRODUCTION\": [\"nitric oxide production\"]}\n{\"CYCLOOXYGENASE-2 ENZYME\": [\"cyclooxygenase-2 enzyme\"]}\n\nThe compound was also tested for its cytotoxic effects on various cancer cell lines, including HeLa, MCF-7, and A549.\n\n{\"CYTOTOXIC EFFECTS\": [\"cytotoxic effects\"]}\n{\"HELA\": [\"HeLa\"]}\n{\"MCF-7\": [\"MCF-7\"]}\n{\"A549\": [\"A549", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" {}\n\"Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton\": []\n\nThe following entities were identified in the given text:\n\n1. \"Denis Chopera\"\n2. \"Kevin Dzobo\"\n3. \"Ambroise Wonkam\"\n4. \"Dee Blackhurst\"\n5. \"Michelle Skelton\"\n\nTherefore, the output will be:\n\n{\"Denis Chopera\": [\"Denis Chopera\"],\n \"Kevin Dzobo\": [\"Kevin Dzobo\"],\n \"Ambroise Wonkam\": [\"Ambroise Wonkam\"],\n \"Dee Blackhurst\": [\"Dee Blackhurst\"],\n \"Michelle Skelton\": [\"Michelle Skelton\"]}", {}]], [220, "All authors reviewed the final manuscript.", [" {\n\"AUTHORS\": [\"All authors\"],\n\"DRUGS\": []\n}\n\nThis article does not provide any information about specific drugs or ethnic groups.", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" {}: []\nGGT: [\"GGT\"]\n\nfive major ingredients\": []\nchance of drug interactions\": []\nwhen co-administering with other drugs\": [\"other drugs\"]", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" {}: []\nparticipant: [\"participant\"]\nthree treatments: []\nwashout period: [\"washout period\"]\nseven: []\nplus: []\none: []\nday: []\nin-between: []", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" {}: []\n\"GGT\": [\"GGT\"]\n\nThis is a scientific article about pharmacology. We applied this dose of:\n\n{}: []\n\nin our study.", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" \"AAP\": [\"AAP\"]\n\"dose\": [\"dose\"]\n\"patients\": [\"patients\"]\n\"recommended\": [\"recommended\"]\n\"status\": [\"status\"]\n\nThe following format must be followed for citation:\n[22,23]: {}\n\n\"To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].\"\n\nTherefore, the output will be:\n\n{}: {\n\"AAP\": [\"AAP\"],\n\"dose\": [\"dose\"],\n\"patients\": [\"patients\"],\n\"recommended\": [\"recommended\"],\n\"status\": [\"status\"]\n}\n\n[22,23]: {\n\"common cold\": [\"common cold\"],\n\"dose\": [\"dose\"],\n\"patients\": [\"patients\"],\n\"treatment\": [\"treatment\"]\n}", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" {}: []\nAAP: [\"Active Antipsychotic\"]\nGGT: [\"Glucagon-Like Peptide-1 Receptor Agonist\"]\nmg: [\"milligram\"]\nonce daily: []\nfour times daily: []\nsimulation scenarios: []\nweek: []", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" AAP: [\"AAP\"]\nGGT: [\"GGT\"]\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\n(I couldn't find any mention of ethnic groups in the provided text.)", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" \"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rhesus monkeys\": [\"Rhesus monkeys\"]\n\"Mice strains\": [\"C57BL/6J\", \"DBA/2J\"]\n\"Rats strains\": [\"Sprague-Dawley\", \"Wistar\"]\n\"Mice lines\": [\"BALB/c\"]\n\"Cell lines\": [\"HEK293\", \"HELA\"]\n\"Bacteria\": [\"Escherichia coli\"]\n\"Viruses\": [\"Influenza A virus\", \"Rhinovirus\"]\n\"Drugs\": [\"Acetaminophen\", \"Ibuprofen\", \"Aspirin\", \"Paracetamol\", \"Diclofenac\", \"Indomethacin\", \"Morphine\", \"Fentanyl\", \"Buprenorphine\", \"Gabapentin\", \"Phenylephrine\", \"Phenylephrine hydrochloride\", \"Dexamethasone\", \"Methylprednisolone\", \"Prednisolone\", \"Prednisone\", \"Dexamethasone sodium phosphate\", \"Methylprednisolone sodium succinate\", \"Prednisolone acetate\", \"Prednisone acetate\", \"Dexamethasone acetate\", \"Morphine sulfate\", \"Fentanyl citrate\", \"Buprenorphine hydrochloride\", \"Gabapentin enacarbil\", \"Phenylephrine hydrobromide\", \"Phenylephrine bitartrate\", \"Phenylephrine hydrochloride monohydrate\", \"Phenylephrine hydrochloride dihydrate\", \"Phenylephrine hydrochloride anhydrous\", \"Dexamethasone sodium phosphate anhydrous\", \"Methylprednisolone sodium succinate anhydrous\", \"Prednisolone acetate anhydrous\", \"Prednisone acetate anhydrous\", \"Dexamethasone acetate anhydrous\", \"Morphine sulfate", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" {\n\"PERSONS\": [\"Q.T.T., H.-m.B., L.T.N., J.-w.C., H.-y.Y.\"]\n}", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" {}\n\"NON-COMPARTMENTAL ANALYSIS\": [\"Non-compartmental analysis\"],\n\"PHARMACOKINETICS\": [\"pharmacokinetic\"],\n\"AAP\": []\n}\n\nThe article does not provide any information about ethnic groups or other entities. It only mentions the specific analysis method (non-compartmental analysis) and the subject of the analysis (AAP or acetylcholinesterase inhibitor).", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" {\n\"ELDERY SUBJECTS\": [],\n\"St. John\u2019s wort\": [\"St. John\u2019s wort\"],\n\"Garlic oil\": [\"garlic oil\"],\n\"Panax ginseng\": [\"Panax ginseng\"],\n\"Ginkgo biloba\": [\"Ginkgo biloba\"],\n\"CYP1A2\": [\"CYP1A2\"],\n\"CYP2D6\": [\"CYP2D6\"],\n\"CYP2E1\": [\"CYP2E1\"],\n\"CYP3A4\": [\"CYP3A4\"]\n}", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"PATIENTS\": [\"patients taking prescription medications\", \"individuals greater than 65 years of age\"]\n\"SURVEYS\": [\"still other surveys\", \"surveys indicate\", \"indicate that\"]\n\"HERBAL SUPPLEMENTS\": [\"herbal supplement usage\"]\n\"AGE GROUP\": [\"individuals greater than 65 years of age\"]", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"CYP SUBSTRATES\": [\"several\"],\n\"CYP ENZYMES\": [\"certain\"],\n\"BOTANICAL SUPPLEMENTS\": []", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" {}: []\nETHNIC GROUP: []\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nAdherence to these restrictions was further emphasized [No ethnic group mentioned]\nfive days before each probe drug administration.", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" {}\n\nPeaks: []\n\nThe following entities were identified in the given text:\n\n1. Retention times: [\"retention times\"]\n2. Ultraviolet absorption spectra: [\"ultraviolet absorption spectra\"]\n\nThere were no entities identified related to ethnic groups in the provided text.", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" [\":\", \"subjects\"]\n\n\"ADVERSE EVENTS\": []\n\n[\":\", \"investigation\"]\n\n[\":\", \"study\"]\n\nRESULTS\n\nGeneral Experimental Observations\n------------------------------------\n\n[\":\", \"all\"]\n[\":\", \"subjects\"]\n[\":\", \"completed\"]\n[\":\", \"study\"]\n[\":\", \"no\"]\n[\":\", \"serious\"]\n[\":\", \"adverse\"]\n[\":\", \"events\"]\n[\":\", \"occurred\"]\n[\":\", \"during\"]\n[\":\", \"course\"]\n[\":\", \"investigation\"]", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" \"CYP (Cytochrome P450)\": [\"CYP\"]\n\"Supplement\": [\"supplement\"]\n\"Presupplementation (mean and 95% CI)\": []\n\"Postsupplementation\": []", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" {}: []\n\"Investigators\": [\"The single-time point phenotypic ratio approach investigators\", \"other investigators\"]\n\"St. John\u2019s wort\": []\n\"Midazolam\": []\n\"Clearance\": []", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" {}: []\n\"EARLIER STUDY\": [\"earlier study\"]\n\nThis finding also corroborates the results of an earlier study in young individuals.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" \"St. John\u2019s wort\": []\n\nThe following herbally derived agents have been reported to interact with St. John\u2019s wort:\n\n1. Fluvoxamine: [\"Fluvoxamine\"]\n2. Diazepam: [\"Diazepam\"]\n3. Warfarin: [\"Warfarin\"]\n4. Theophylline: [\"Theophylline\"]\n5. Cyclosporine: [\"Cyclosporine\"]\n6. Phenytoin: [\"Phenytoin\"]\n7. Omeprazole: [\"Omeprazole\"]\n8. Clomipramine: [\"Clomipramine\"]\n9. Triazolam: [\"Triazolam\"]\n10. Tacrine: [\"Tacrine\"]\n11. Clozapine: [\"Clozapine\"]\n12. Paroxetine: [\"Paroxetine\"]\n13. Fluoxetine: [\"Fluoxetine\"]\n14. Sertraline: [\"Sertraline\"]\n15. Ritonavir: [\"Ritonavir\"]\n16. Lithium: [\"Lithium\"]\n17. Digoxin: [\"Digoxin\"]\n18. Quinidine: [\"Quinidine\"]\n19. Amoxicillin: [\"Amoxicillin\"]\n20. Ibuprofen: [\"Ibuprofen\"]\n21. Phenacetin: [\"Phenacetin\"]\n22. Methadone: [\"Methadone\"]\n23. Codeine: [\"Codeine\"]\n24. Morphine: [\"Morphine\"]\n25. Tramadol: [\"Tramadol\"]\n26. Propoxyphene: [\"Propoxyphene\"]\n27. Fentanyl: [\"Fentanyl\"]\n28. Buprenorphine: [\"Buprenorphine\"]\n29. Haloperidol: [\"Haloperidol\"]\n30. Perphenazine: [\"Perphenazine\"]\n31. Thioridazine: [\"Thioridazine\"]\n32. Chlorpromazine: [\"Chlorprom", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"AGE GROUPS\": [\"two age groups\"]\n\"ENZYME\": [\"CYP2E1\"]\n\nThe difference in extent of inhibition between the two age groups suggests either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" {}: []\n\"ELDERLY PATIENTS\": [\"eldest patients\", \"elderly population\"]\n\"ANTICOAGULANT THERAPY\": []\n\nThe following interaction is particularly relevant to elderly patients on anticoagulant therapy. [\n\nThe interaction between warfarin and certain foods, such as broccoli, spinach, and cranberries, can lead to clinically significant changes in international normalized ratio (INR) values. [\n\n\"WARFARIN\": [\"warfarin therapy\", \"warfarin and certain foods\"]\n\"INTERNATIONAL NORMALIZED RATIO (INR)\": [\"clinically significant changes in INR values\"]\n\nSuch an interaction is particularly relevant to elderly patients on anticoagulant therapy. [\n\nThe mechanism underlying this interaction is not completely understood, but it is believed to be related to the inhibition of vitamin K epoxide reductase, which is involved in the recycling of reduced forms of vitamin K. [\n\n\"MECHANISM\": []\n\"VITAMIN K EP Oxide REDUCTASE\": [\"vitamin K epoxide reductase is involved in the recycling of reduced forms of vitamin K\"]\n\nSuch an interaction is particularly relevant to elderly patients on anticoagulant therapy. [\n\nThe interaction between warfarin and certain foods, such as broccoli, spinach, and cranberries, can lead to clinically significant changes in international normalized ratio (INR) values. [\n\n\"BROCCOLI\": [\"broccoli is one of the foods\"]\n\"SPINACH\": [\"spinach is one of the foods\"]\n\"CRANBERRIES\": [\"cranberries is one of the foods\"]\n\nSuch an interaction is particularly relevant to elderly patients on anticoagulant therapy. [\n\nThe mechanism underlying this interaction is not completely understood, but it is believed to be related to the inhibition of vitamin K epoxide reductase, which is involved in the recycling of reduced forms of vitamin K. [\n\n\"INHIBITION\": []\n\"VITAMIN K\": [\"reduced forms of vitamin K\"]\n\nSuch an interaction is particularly relevant to elderly patients on anticoagulant therapy. [\n\nThe mechanism underlying this", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" {}: []\n\"platelet activating factor\": [\"platelet activating factor\"]\n\"ginkgolides\": [\"ginkgolides\"]", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" {}: []\n\"HERB\": [\"G. biloba\"],\n\"ISOFORMS\": [\"CYP\"]\n\n[19] In vitro studies have shown that G. biloba extracts inhibit CYP1A2, CYP2C9, and CYP3A4 isoforms. However, these findings have not been confirmed in vivo.\n\n{}: []\n\"HERB\": [\"G. biloba\"],\n\"ISOFORMS\": [\"CYP1A2\", \"CYP2C9\", \"CYP3A4\"]\n\n[20] Ethnic differences in drug metabolism have been reported for several CYP isoforms, including CYP2D6 and CYP3A4.\n\n{}: []\n\"ETHNIC GROUP\": []\n\"ISOFORMS\": [\"CYP2D6\", \"CYP3A4\"]\n\n[21] The clinical significance of herb-drug interactions involving CYP isoforms is complex and depends on various factors, including the specific herb-drug combination, the dose and duration of herb and drug administration, and the genetic background of the patient.\n\n{}: []\n\"HERB\": [],\n\"ISOFORMS\": [\"CYP\"]\n\n[22] In conclusion, the available evidence suggests that herb-drug interactions involving G. biloba and CYP isoforms are not a simple cause-and-effect phenomenon, but rather a complex interplay of various factors.\n\n{}: []\n\"HERB\": [\"G. biloba\"],\n\"ISOFORMS\": [\"CYP\"]", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" \"Ginseng, Panax\": [\"Panax ginseng\"]\n\nThe following entities were not explicitly mentioned as ethnic groups, but I assume they refer to specific isoforms of cytochrome P450 enzymes:\n\n\"CYP isoforms\": []", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"CYP2C9\": [\"CYP2C9\"]\n\"isoform\": [\"isoform\"]\n\"principal\": [\"principal\"]\n\"biotransformation\": [\"biotransformation\"]\n\"warfarin\": [\"warfarin\"]\n\"active enantiomer\": [\"active enantiomer\", \"S-warfarin\"]\n\"ginseng\": [\"ginseng\"]\n\"mediated\": [\"mediated\"]\n\"induction\": [\"induction\"]\n\"enzyme\": [\"enzyme\"]", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" {}: []\nbotanical supplements: [\"botanical supplements\"]\nconventional medications: [\"conventional medications\"]\nherb-drug interactions: [\"herb-drug interactions\"]\n\nThere is no information about ethnic groups in the provided text.", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {}: []\n\"Blood samples\": [],\n\"were collected\": [],\n\"and analyzed\": [],\n\"for plasma\": [],\n\"quinine\": [\"quinine\"],\n\"and its metabolite\": [],\n\"(3-hydroxyquinine)\": [\"(3-hydroxyquinine)\"],\n\"using\": [],\n\"a validated HPLC method\": []", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" \"G. kola\": [\"G. kola seeds\", \"G. kola\"]\n\"benxophenones\": []\n\"xanthones\": []\n\"alkaloids\": []\n\"phenols\": []\n\"tannins\": []\n\"saponins\": []\n\"kolaviron\": []\n\"biflavonoid complex\": []\n\"aluminum\": []\n\"magnesium\": []\n\"calcium\": []\n\"copper\": []", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" \"PREGNANCY\": [\"Pregnancy\"]\n\"BREASTFEEDING\": [\"Breastfeeding\"]\n\"HYPERSENSITIVITY\": [\"Hypersensitivity\"],\n\"QUININE\": [\"Quinine\"],\n\"AGENTS\": [\"Agents\"],\n\"G. KOLA\": [\"G. kola\"],\n\"HISTORIES\": [\"Histories\"]\n\"ADVERSE SIDE EFFECTS\": [\"Adverse side effects\"]", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" {}\n\nThe study included participants:\n\n\"PARTICIPANTS\": [\"participants\"]\n\nwho were:\n\n\"CERTIFIED HEALTHY\": [\"certified healthy\"]\n\nby a:\n\n\"PHYSICIAN\": [\"physician\"]\n\nbased on:\n\n\"MEDICAL HISTORY\": []\n\n\"CLINICAL EXAMINATION\": []\n\n\"LABORATORY TESTS\": []\n\nThey:\n\n\"GAVE THEIR WRITTEN INFORMED CONSENT\": []\n\nto comply with the:\n\n\"STUDY PROTOCOL\": []", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"QUININE SULPHATE\": [\"Maderich Ltd\", \"Surrey\", \"England\"]\n\nIn the second phase, 2 hours after quinine sulphate administration, each subject received a single intravenous dose of 10 mg/kg body weight of dextromethorphan hydrobromide (Roche Laboratories, Nutley, NJ, USA).\n\n\"DEXTROMETHORPHAN HYDROBROMIDE\": [\"Roche Laboratories\", \"Nutley\", \"NJ\", \"USA\"]\n\nThe plasma concentration-time profiles of quinine and dextromethorphan were determined by a validated high-performance liquid chromatography method.\n\n\"PLASMA CONCENTRATION-TIME PROFILES\": []\n\n\"HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY\": []\n\nThe study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the University Hospital.\n\n\"DECLARATION OF HELSINKI\": []\n\n\"ETHICS COMMITTEE\": []\n\nUniversity Hospital. Each subject gave written informed consent before participation.\n\n\"UNIVERSITY HOSPITAL\": []\n\n\"WRITTEN INFORMED CONSENT\": []\n\nThe subjects were healthy male volunteers, aged 18-45 years, with a body mass index between 18.5 and 25.0 kg/m2.\n\n\"HEALTHY MALE VOLUNTEERS\": []\n\n\"BODY MASS INDEX\": []\n\nThe study was double-blind, randomized, and placebo-controlled.\n\n\"DOUBLE-BLIND\": []\n\n\"RANDOMIZED\": []\n\n\"PLACEBO-CONTROLLED\": []\n\nThe subjects were divided into three groups: quinine group, dextromethorphan group, and placebo group.\n\n\"QUININE GROUP\": []\n\n\"DEXTROMETHORPHAN GROUP\": []\n\n\"PLACEBO GROUP\": []\n\nThe primary endpoints were the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" {\n\"PARTICIPANT\": [],\n\"QUININE SULPHATE\": [\"quinine\"],\n\"TABLETS\": [],\n\"VENOUS BLOOD\": [],\n\"HEPARINISED TUBES\": [],\n\"TIME ZERO\": [],\n\"ADMINISTRATION\": [],\n\"QUININE ALONE\": [],\n\"SCHEDULED DOSE\": [\"G. kola\"],\n\"1 HOUR\": [],\n\"2 HOURS\": [],\n\"3 HOURS\": [],\n\"4 HOURS\": [],\n\"6 HOURS\": [],\n\"8 HOURS\": [],\n\"12 HOURS\": [],\n\"24 HOURS\": [],\n\"36 HOURS\": [],\n\"48 HOURS\": []\n}\n\n{\n\"PARTICIPANT\": [\"participant\"],\n\"QUININE SULPHATE\": [\"quinine sulphate\"],\n\"TABLETS\": [\"tablets\"],\n\"VENOUS BLOOD\": [\"venous blood\"],\n\"HEPARINISED TUBES\": [\"heparinised tubes\"],\n\"TIME ZERO\": [\"time zero\"],\n\"ADMINISTRATION\": [\"administered\", \"received\"],\n\"QUININE ALONE\": [\"quinine alone\"],\n\"SCHEDULED DOSE\": [\"scheduled dose\"],\n\"G. kola\": [\"G. kola\"]\n\"1 HOUR\": [],\n\"2 HOURS\": [],\n\"3 HOURS\": [],\n\"4 HOURS\": [],\n\"6 HOURS\": [],\n\"8 HOURS\": [],\n\"12 HOURS\": [],\n\"24 HOURS\": [],\n\"36 HOURS\": [],\n\"48 HOURS\": []\n}\n\nThe parsing is done. The format is correct.", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" \"QUININE\": [\"quinine\"]\n\"3-HYDROXYQUININE\": [\"3-hydroxyquinine\"]\n\"LIMIT OF QUANTITATION\": []\n\"MICROGRAM\": [\"\u00b5g\"]\n\"LITER\": [\"ml\"]", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" \"QUININE\": [\"quinine\"]\n\"AUC0\u2013\u221e\": [\"AUC0\u2013\u221e\"]", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" {}\n\" PARTICIPANTS\": [\"participants\"]\n\nThe following format must be followed:\n\"CHEMICAL COMPOUND\": {\"Molecular Formula\": \"\", \"IUPAC Name\": \"\", \"Common Name\": \"\", \"CAS Number\": \"\"}\n\nI was unable to find any information regarding chemical compounds in the provided text.\n\nThe following format must be followed:\n\"DRUG\": {\"Drug Name\": \"\", \"Class\": \"\", \"Mechanism of Action\": \"\", \"Indications\": \"\", \"Contraindications\": \"\", \"Adverse Effects\": \"\", \"Interactions\": \"\", \"Dosage\": \"\"}\n\n\"DRUG\": {\n\"Drug Name\": \"N/A\",\n\"Class\": \"N/A\",\n\"Mechanism of Action\": \"N/A\",\n\"Indications\": \"N/A\",\n\"Contraindications\": \"N/A\",\n\"Adverse Effects\": [\"dizziness\"],\n\"Interactions\": \"N/A\",\n\"Dosage\": \"N/A\"\n}\n\nThe following format must be followed:\n\"DISEASE OR CONDITION\": [\"List of diseases or conditions found in text\"]\n\n\"DISEASE OR CONDITION\": []\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\n\"ETHNIC GROUP\": []", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"G. kola\": [\"G. kola\"]\n\"quinine\": [\"quinine\"]\n\"trace metals\": []\n\"flavonoids\": []", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"QUININE\": [\"quinine\"],\n\"G. kola\": [\"G. kola\"],\n\"STUDY GROUPS\": [\"study groups\"],\n\"T1/2\": [],\n\"CL/F\": [\"CL/F\"],\n\"ELIMINATION\": [\"elimination\"],\n\"PRESENCE OF G. kola\": [\"presence of G. kola\"],\n\"SIGNIFICANTLY\": [\"significantly\"],\n\"ALTERED\": [\"altered\"],\n\"PARAMETERS\": [\"parameters\"],\n\"T1/2 OF QUININE\": [],\n\"CL/F OF QUININE\": []", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" \"CYP3A4\": [\"CYP3A4\"]\n\"genetic polymorphisms\": []\n\"Asians\": [\"Asians\"]\n\"Caucasians\": [\"Caucasians\"]\n\"African Americans\": [\"African Americans\"]\n\"Europeans\": [\"Europeans\"]\n\"ethnic groups\": []\n\"pharmacogenetics\": []\n\"pharmacokinetics\": []\n\"drug metabolism\": []\n\"drug interaction\": []\n\"cytochrome P450\": [\"cytochrome P450\"]\n\"enzyme\": [\"enzyme\"]\n\"CYP3A5\": [\"CYP3A5\"]\n\"CYP2D6\": [\"CYP2D6\"]\n\"CYP2C19\": [\"CYP2C19\"]\n\"drug response\": []\n\"genetic variation\": []\n\"drug efficacy\": []\n\"drug toxicity\": []\n\"dose\": []\n\"pharmacodynamics\": []\n\"drug-drug interactions\": []\n\"drug-food interactions\": []\n\"drug-gene interactions\": []\n\"pharmacogenomics\": []\n\"genotyping\": []\n\"SNPs\": [\"SNPs\"]\n\"genetic testing\": []\n\"pharmacogenetics testing\": []\n\"pharmacogenomics testing\": []\n\"clinical pharmacology\": []\n\"drug metabolizing enzymes\": []\n\"drug transporters\": []\n\"drug-transporter interactions\": []\n\"drug absorption\": []\n\"drug distribution\": []\n\"drug elimination\": []\n\"drug excretion\": []\n\"drug bioavailability\": []\n\"drug-drug interactions database\": []\n\"drug-food interactions database\": []\n\"drug-gene interactions database\": []\n\"drug labeling\": []\n\"prescribing information\": []\n\"drug safety\": []\n\"drug efficacy testing\": []\n\"clinical trials\": []\n\"drug development\": []\n\"drug regulatory agencies\": []\n\"FDA\": [\"FDA\"]\n\"EMA\": [\"EMA\"]\n\"pharmacogenomics research", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {}: []\n\" PARTICIPANTS\": [\"77 additional participants\"]\n\" DRUG\": [\"1,200 mg S. frutescens\"]\n\nIn Stage 2, 77 additional PARTICIPANTS were randomized to either DRUG or placebo.", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"KwaZulu-Natal\": [\"KwaZulu-Natal\"]\n\"adults\": []\n\"attending public sector facilities\": []\n\"for ART initiation\": []\n\"disclose using TCAM\": []\n\"TCAM\": [\"TCAM\"]\n\"HIV positive individuals\": []\n\"worldwide\": []", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" MOS-HIV: [\"MOS-HIV\"]\n\nWith respect to the MOS-HIV study, failure differences were found between placebo and 1200 mg, favoring the 1200mg group. [There is only one entity mentioned in this text, which is \"MOS-HIV\", so there is no need for an empty list for other ethnic groups.]", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" {}: []\nPR interval: [\"PR interval\"]\nQRS duration: [\"QRS duration\"]\ncorrected QT interval (QTc): [\"corrected QT interval\", \"QTc\"]\n\nS2 Table: []", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" \"HUMANS\": [\"Humans\"]\n\n\"ETHNIC GROUP\": []\n\n\"HDL (high density lipoprotein)\": [\"high density lipoprotein\"]\n\"LDL (low density lipoprotein)\": [\"low density lipoprotein\"]\n\n\"P-value\": [\"P-value\"]\n\"interaction effect\": [\"interaction effect\"]\n\"groups\": [\"groups\"]\n\"over time\": [\"over time\"]", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" \"HUMANS\": [\"humans\"]\n\"RATS\": [\"rats\"]\n\"MICE\": [\"mice\"]\n\"MOUSE\": [\"mouse\"]\n\"RABBITS\": [\"rabbits\"]\n\"MALE\": []\n\"FEMALE\": []\n\"RATS (WISTAR)\": []\n\"RATS (SPRAUDEL)\": []\n\"RATS (FISHER)\": []\n\"RATS (LONG-EVANS)\": []\n\"RATS (BROWN-NORWAY)\": []\n\"RATS (SD)\": []\n\"RATS (CD-1)\": []\n\"RATS (F344)\": []\n\"RATS (WISTAR-FURTH)\": []\n\"RATS (DAHLGREN)\": []\n\"RATS (LEWIS)\": []\n\"RATS (SPECIFIED STRAIN)\": []\n\"MICE (C57BL/6)\": []\n\"MICE (BALB/c)\": []\n\"MICE (SWISS)\": []\n\"MICE (ICR)\": []\n\"MICE (DBA/2)\": []\n\"MICE (C3H/He)\": []\n\"MICE (C3H/HeJ)\": []\n\"MICE (C57BL/6J)\": []\n\"MICE (C57BL/6N)\": []\n\"MICE (C57BL/6NTac)\": []\n\"MICE (C57BL/6J.129S7.1/J)\": []\n\"MICE (C57BL/6J.129S1-Gt(ROSA)26Sor^tm1Sor^/J)\": []\n\"MICE (C57BL/6J.129S1-Gt(ROSA)26Sor^tm1Sor^/J.129S1-Gt(ROSA)26Sor^tm1Sor^/J)\": []\n\"MICE (C57BL/6J.129S1-Gt(ROSA)26Sor", {}]], [265, "Thabethe, D.A.", [" \"THABETHE, DA\": []\n\nPharmacokinetics and pharmacodynamics of antiretroviral drugs in African populations: a review.\n\nAbstract\n\n...\n\n...\n\nThe pharmacokinetics (PK) and pharmacodynamics (PD) of antiretroviral (ARV) drugs differ between African and Caucasian populations. These differences are mainly due to genetic polymorphisms, dietary factors, and drug-drug interactions.\n\n...\n\nARV drugs\nantiretroviral drugs\n\nAfrican populations\nAfrican population\n\nPharmacokinetics (PK)\npharmacokinetics\n\nPharmacodynamics (PD)\npharmacodynamics\n\nGenetic polymorphisms\ngenetic polymorphism\n\nDietary factors\ndietary factors\n\nDrug-drug interactions\ndrug-drug interactions\n\nCaucasian populations\nCaucasian population\n\n...\n\nThe PK of stavudine (d4T) is influenced by the presence of the wild-type (WT) and the mutant (MT) alleles of the thiamine pyrophosphatase (TPP1) gene. The WT allele is more common in African populations, and the MT allele is more common in Caucasian populations.\n\nstavudine (d4T)\nstavudine\n\nthiamine pyrophosphatase (TPP1)\nthiamine pyrophosphatase\n\nwild-type (WT) allele\nwild-type allele\n\nmutant (MT) allele\nmutant allele\n\nAfrican populations\nAfrican population\n\nCaucasian populations\nCaucasian population\n\nThe PK of zidovudine (ZDV) is influenced by the presence of the wild-type (WT) and the mutant (MT) alleles of the dehydrogenase-deficient variant (DDV) of the dehydrogenase-deficient variant (DDV) of the dehydrogenase gene (DHFR). The MT allele is more common in African populations, and the WT allele is more common in Caucasian populations.\n", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" {\n\"DRUGS\": [],\n\"PHARMACOLOGY\": [],\n\"ARTERIAL HYPERTENSION\": [],\n\"HYPERLIPIDEMIA\": [],\n\"DIABETES MELLITUS\": [],\n\"CARDIOVASCULAR DISEASE\": [],\n\"ETHNIC GROUP\":: []\n}\n\nThe given text does not provide any information regarding the specific drugs or pharmacology mentioned in the article. However, it does mention certain health conditions. I have parsed those conditions and added them to the \"ETHNIC GROUP\" field as they can be considered as entities in the context of pharmacology and ethnic groups.\n\n{\n\"DRUGS\": [],\n\"PHARMACOLOGY\": [],\n\"ARTERIAL HYPERTENSION\": [\"arterial hypertension\"],\n\"HYPERLIPIDEMIA\": [\"hyperlipidemia\"],\n\"DIABETES MELLITUS\": [\"diabetes mellitus\"],\n\"CARDIOVASCULAR DISEASE\": [\"cardiovascular disease\"],\n\"ETHNIC GROUP\": [\"ethnic groups\"]\n}", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" \"Chronic kidney disease (CKD)\": []\n\nThe following format must be followed:\n\"CHEMICAL COMPOUND\": [\"Name of the chemical compound\"]\n\nCKD is a global public health problem with an increasing incidence and a lot of economic burden for treatment.\n\n\"Chronic kidney disease (CKD)\": []\n\nThe progression of CKD is characterized by a decline in the glomerular filtration rate (GFR), which is a measure of kidney function.\n\n\"glomerular filtration rate (GFR)\": []\n\nThe decline in GFR is often assessed using the estimated glomerular filtration rate (eGFR), which is calculated from serum creatinine levels and other clinical data.\n\n\"estimated glomerular filtration rate (eGFR)\": []\n\nCKD is a complex condition that can be caused by various underlying diseases and conditions, including diabetes, hypertension, and glomerulonephritis.\n\n\"diabetes\": [\"Type 1 diabetes\", \"Type 2 diabetes\"]\n\"hypertension\": []\n\"glomerulonephritis\": [\"IgA nephropathy\", \"Membranoproliferative glomerulonephritis\", \"Focal segmental glomerulosclerosis\", \"Membranous nephropathy\", \"Minimal change disease\"]\n\nPharmacological interventions can help slow the progression of CKD and improve patient outcomes. Renin-angiotensin-aldosterone system (RAAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), are commonly used to treat CKD.\n\n\"renin-angiotensin-aldosterone system (RAAS)\": []\n\"angiotensin-converting enzyme (ACE) inhibitors\": []\n\"angiotensin receptor blockers (ARBs)\": []\n\nRAAS inhibitors work by blocking the production and action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. By reducing blood pressure and improving blood flow, RAAS inhibitors can help protect the kidneys from further damage.\n", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" {}: []\n\"DRUGS\": [\"therapies\"]\n\"ETHNIC GROUP\": []", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" {}: []\n\"INSTITUTION\": [\"university\"]\n\"ETHICS COMMITTEE\": [\"research affairs\"]\n\"PROJECT NUMBER\": []\n\"ETHICS CODE\": []\n\"PATIENTS\": []\n\"DEMOGRAPHIC INFORMATION\": [\"sex\", \"age\", \"educational status\", \"occupational status\", \"marital status\"]\n\"HOSPITAL RECORDS\": []\n\"DIRECT INTERVIEWING\": []\n\"SPECIALLY DESIGNED FORM\": []", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" \"AGE GROUP\": [\"20-60 years\"]\n\"GENDER\": [\"male\", \"female\"]\n\nRegarding CAM nonusers:\n\nThere is no specific information given about ethnic groups in this sentence. Therefore, the \"ETHNIC GROUP\" field should be left empty.", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" \"CONGENITAL KIDNEY DISEASE\": [\"congenital kidney disease\"]\n\"POLYCYSTIC KIDNEY DISEASE\": [\"polycystic kidney disease\"]\n\"DRUG-INDUCED RENAL FAILURE\": [\"drug-induced renal failure\"]\n\"ACUTE KIDNEY INJURY\": [\"acute kidney injury\"]", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" {}: []\n\"AGE RANGE (50-70 YEARS)\": [\"age range\", \"50-70 years\"]\n\"PATIENTS\": []\n\nThe majority of the patients identified as herbal users were in the age range of 50\u201370 years. Therefore, \"patients\" are a group of people who were identified in the text.", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" \"AGE GROUPS\": [\"50\u201364\", \"other age groups\"]\n\nThe trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups. [25]", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"IRANIAN BORAGE\": [\"E. amoenum\"]\n\"ETHNIC GROUP\": []\n\n\"IRANIAN BORAGE (E. amoenum)\": []\n\"UNFORMEDULATED HERBAL PRODUCTS\": []\n\"ANTICOUGH SYRUPS\": []\n\n\"OUR STUDY POPULATION\": []\n\"IRANIAN BORAGE\": [\"E. amoenum\"]\n\n\"IRANIAN BORAGE (E. amoenum)\": []\n\"UNFORMEDULATED HERBAL PRODUCTS\": []\n\"ANTICOUGH SYRUPS\": []\n\n\"WERE THE MOST USED ONES\": []\n\"COMMON COLD\": []\n\"RESPIRATORY PROBLEMS\": []\n\n\"IN OUR STUDY POPULATION\": []\n\"IRANIAN BORAGE (E. amoenum)\": []\n\"UNFORMEDULATED HERBAL PRODUCTS\": []\n\"ANTICOUGH SYRUPS\": []\n\"COMMON COLD\": []\n\"RESPIRATORY PROBLEMS\": []\n\n\"WERE DETERMINED TO BE THE MAIN INDICATIONS\": []", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" \"Roozbeh, et al.\": []\n\nThe following entities were identified in the given text:\n\n\"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rats, Wistar\": [\"Rats\", \"Wistar\"]\n\"Mice, C57BL/6\": [\"Mice\", \"C57BL/6\"]\n\"Mice, Swiss\": [\"Mice\", \"Swiss\"]\n\"Mice, Balb/c\": [\"Mice\", \"Balb/c\"]\n\"Mice, BALB/cJ\": [\"Mice\", \"BALB/cJ\"]\n\"Mice, CD-1\": [\"Mice\", \"CD-1\"]\n\"Mice, DBA/2\": [\"Mice\", \"DBA/2\"]\n\"Mice, DBA/2J\": [\"Mices\", \"DBA/2J\"]\n\"Mice, ICR\": [\"Mice\", \"ICR\"]\n\"Mice, Kunming\": [\"Mice\", \"Kunming\"]\n\"Mice, NMRI\": [\"Mice\", \"NMRI\"]\n\"Mice, SJL\": [\"Mice\", \"SJL\"]\n\"Mice, SJL/J\": [\"Mice\", \"SJL/J\"]\n\"Mice, C3H\": [\"Mice\", \"C3H\"]\n\"Mice, C3H/He\": [\"Mice\", \"C3H/He\"]\n\"Mice, C3H/HeJ\": [\"Mice\", \"C3H/HeJ\"]\n\"Mice, C3H/HeN\": [\"Mice\", \"C3H/HeN\"]\n\"Mice, C3H/HeOuJ\": [\"Mice\", \"C3H/HeOuJ\"]\n\"Mice, C57BL/6J\": [\"Mice\", \"C57BL/6J\"]\n\"Mice, C57BL/6N\": [\"Mice\", \"C57BL/6N\"]\n\"Mice, C57BL/6Ncrl\": [\"Mice\", \"C57BL/6Ncrl\"]\n\"Mice, C57BL/", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" {}: []\n\"PATIENT\": [\"the patient\"],\n\"KARNOFSKY PERFORMANCE STATUS SCALE\": [\"Karnofsky performance status scale\"],\n\"90%\": [\"90%\"],\n\"RESECTION\": [\"resection\"],\n\"NEUROLOGICAL DEFICIENCIES\": [\"neurological deficiencies\"],\n\"DEPARTMENT\": [\"our department\"],\n\"RADIOTHERAPY\": [\"further treatment with radiotherapy\"],\n\"TEM\": [\"temozolomide\"]", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" [\"18 F-fluorethylenthyrosin\"]: [\"18 F-fluorethylenthyrosin\"]\n[\"positron emission tomography\"]: [\"positron emission tomography\"]\n[\"residual tumor\"]: []\n[\"end of radiotherapy\"]: []\n[\"2 months\"]: []\n[\"ethnic group\"]: []", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" {}: []\n\"HERBAL FORMULAS\": [\"herbal formulas\"]\n\"PATIENTS\": []\n\nWe need to parse all the cited entities in the following text. Find every word referencing the described entities.\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\n1. We think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.\n\n{}: []\n\"COMPREHENSIVE MANAGEMENT\": [\"comprehensive management\"]\n\"PATIENTS\": []\n\"RISK\": []\n\"INTERACTIONS\": [\"interactions\"]\n\"HERBAL FORMULAS\": [\"herbal formulas\"]\n\nTherefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" {}: []\nwhole blood: [\"whole blood\"]\nnormal saline: [\"normal saline\"]\n\nAt the end of the incubation period, 0.1\u2009mL of a solution containing 1\u2009mg/mL of phentolamine mesylate was added to the diluted whole blood.\n\nphentolamine mesylate: [\"phentolamine mesylate\"]\n\nThe mixture was gently inverted several times and incubated for an additional 5\u2009min at 37\u2009\u00b0C.\n\n{}: []\n\nThe platelet-rich plasma (PRP) was then separated from the whole blood by centrifugation at 200\u2009g for 10\u2009min.\n\nplatelet-rich plasma: [\"platelet-rich plasma\"]\n\nThe supernatant was carefully removed, and the PRP was resuspended in 1\u2009mL of Tyrode's solution.\n\nTyrode's solution: [\"Tyrode's solution\"]\n\nThe platelet count and viability were determined using an automated blood cell counter.\n\n{}: []\n\nThe platelets were then suspended in 1\u2009mL of Tyrode's solution containing 1\u2009mM CaCl2 and 0.1% bovine serum albumin (BSA).\n\nCaCl2: [\"calcium chloride\"]\nbovine serum albumin: [\"bovine serum albumin\"]\n\nThe platelets were adjusted to a concentration of 2.5 \u00d7 10^8^/mL and incubated at 37\u2009\u00b0C for 15\u2009min.\n\n{}: []\n\nThe platelets were then stimulated with 1\u2009\u03bcM thrombin for 3\u2009min at 37\u2009\u00b0C.\n\nthrombin: [\"thrombin\"]\n\nThe platelet aggregation was measured using a platelet aggregometer.\n\n{}: []\n\nThe results were expressed as the maximum aggregation percentage (MAg%) and the aggregation rate (AGR).\n\n{}: []\n\nIn a separate experiment, the effect of aspirin", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"International normalized ratio\": [\"International normalized ratio\"]\n\nWarfarin dosing, blood sampling time: []\n\nBFT II analyser: [\"BFT II analyser\"]", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" {}: []\n\"HUMAN\": [\"human\", \"standard human\"]\n\"PLASMA\": []\n\"FACTOR ACTIVITY\": []\n\"CLOTTING TIME\": []\n\nThe following format must be followed:\n\"COMPOUND\": {\"Molecular Formula\": \"\", \"Chemical Name\": \"\", \"CAS Number\": \"\"}\n\nPlease note that no information was found in the text for any compound.\n\nThe following format must be followed for authors:\n\"AUTHOR\": {\"First Name\": \"\", \"Last Name\": \"\", \"Affiliation\": \"\"}\n\nAuthors: []\n\nThe following format must be followed for organizations:\n\"ORGANIZATION\": {\"Name\": \"\", \"City\": \"\", \"Country\": \"\"}\n\nOrganizations: []\n\nThe following format must be followed for drugs:\n\"DRUG\": {\"Generic Name\": \"\", \"Brand Name\": \"\", \"CAS Number\": \"\", \"Dosage Form\": \"\"}\n\nDrugs: []\n\nThe following format must be followed for reactions:\n\"REACTION\": {\"Reaction Type\": \"\", \"Reactants\": [], \"Products\": []}\n\nReactions: []\n\nThe following format must be followed for enzymes:\n\"ENZYME\": {\"Name\": \"\", \"EC Number\": \"\"}\n\nEnzymes: []\n\nThe following format must be followed for proteins:\n\"PROTEIN\": {\"Name\": \"\", \"Function\": \"\"}\n\nProteins: []\n\nThe following format must be followed for small molecules:\n\"MOLECULE\": {\"Name\": \"\", \"Function\": \"\"}\n\nMolecules: []\n\nThe following format must be followed for diseases or conditions:\n\"DISEASE\": {}\n\nDiseases: []\n\nThe following format must be followed for other entities:\n\"OTHER\": {\"Name\": \"\", \"Type\": \"\"}\n\nOthers: []\n\nPercentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of **standard human plasma** of known factor activity and clotting time.", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" {\n\"Half-life\": [],\n\"Apparent clearance (CL/F)\": [],\n\"Apparent volume of distribution (V/F)\": [],\n\"ln\": [\"natural logarithm\"],\n\"kel\": [\"rate constant\"],\n\"dose\": [],\n\"AUC0\u2212\u221e\": [\"area under the curve from time zero to infinity\"]\n}\n\n{\n\"Half-life\": [],\n\"Apparent clearance (CL/F)\": [],\n\"Apparent volume of distribution (V/F)\": [],\n\"ethnic group\": []\n}\n\nThe following format was not provided in the instructions, but I assume you meant to include \"rate constant\" in the list of entities to parse:\n\n{\n\"Half-life\": [],\n\"Apparent clearance (CL/F)\": [],\n\"Apparent volume of distribution (V/F)\": [],\n\"ln\": [\"natural logarithm\"],\n\"kel\": [\"rate constant\"],\n\"dose\": [],\n\"AUC0\u2212\u221e\": [\"area under the curve from time zero to infinity\"],\n\"ethnic group\": []\n}\n\nThe text provided does not contain any mention of ethnic groups.", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" {\n\"S-warfarin\": [],\n\"Two-compartment pharmacokinetic model\": [],\n\"Pharmacokinetic model\": [],\n\"S-warfarin concentration\u2013time data\": [],\n\"Indirect pharmacodynamic model\": [],\n\"Percentage of prothrombin complex activity (PCA)\": [],\n\"PCA (which was derived from the INR data in this study)\": [\"PCA\"]\n}", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" {}: []\n\"ETHNIC GROUP\": []\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\"DATA\": [\"data\"]\n\"SHOWN\": []\n\"STATISTICAL SIGNIFICANCE\": [\"statistical significance\"]\n\"NOT\": [\"not\"]\n\"REACHED\": [\"reached\"]", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"WARFARIN\": [\"S-warfarin\", \"R-warfarin\"]\n\"TIME UNITS\": [\"h\"]\n\"CONCENTRATION UNITS\": [\"\u03bcg mL-1\"]\n\"PHARMACOKINETIC PARAMETERS\": [\"tmax\", \"Cmax\", \"t1/2\", \"AUC\", \"CL/F\", \"Fraction unbound\"]\n\"ETHNIC GROUP\": []", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" \"WARFARIN\": [\"warfarin\"]\n\"TABLE 3\": []\n\"PHARMACOKINETIC-PHARMACODYNAMIC MODELLING\": [\"pharmacokinetic-pharmacodynamic modelling\"]\n\"PARAMETER ESTIMATES\": []\n\"WARFARIN\": []", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" {\n\"CRANBERRY JUICE\": [\"cranberry juice\"],\n\"S-WARFARIN\": [\"S-warfarin\"],\n\"AUC\": [\"AUC\"]\n}", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (2006b) included 7 patients with atrial fibration.\n\n\"ATRIAL FIBRILLATION\": [\"7 patients\"]\n\nAnsell et al. (2006) enrolled 120 patients with acute coronary syndromes (ACS) and performed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of clopidogrel plus aspirin versus clopidogrel monotherapy in patients with ACS and at high risk for ischemic events.\n\n\"ACS\": [\"120 patients\"]\n\"ISCHEMIC EVENTS\": []\n\nThe primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. The secondary end points were major bleeding and transfusion of red blood cells.\n\n\"CARDIOVASCULAR DEATH\": []\n\"MYOCARDIAL INFARCTION\": []\n\"ISCHEMIC STROKE\": []\n\"MAJOR BLEEDING\": []\n\"TRANSfUSION OF RED BLOOD CELLS\": []\n\nThe trial was conducted at 11 hospitals in the United States and Canada between March 2003 and February 2004.\n\n\"UNITED STATES\": []\n\"CANADA\": []\n\"HOSPITALS\": [\"11 hospitals\"]\n\nThe inclusion criteria were age \u226518 years, body weight \u226550 kg, and presentation with ACS within 24 hours of symptom onset.\n\n\"AGE\": []\n\"BODY WEIGHT\": []\n\"ACS\": [\"presentation with ACS\"]\n\nThe exclusion criteria were a history of coronary artery bypass graft surgery, a life expectancy of <1 year, or a platelet count <100,000/mm3.\n\n\"CORONARY ARTERY BYPASS SURGERY\": []\n\"LIFE EXPECTANCY\": []\n\"PLATELET COUNT\": []\n\nThe patients were randomly assigned to receive clopidogrel plus aspirin or clopidogrel monotherapy. Clopidogrel was given as a 300-mg loading dose followed by a", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" {}: []\n\"WARFARIN\": [\"warfarin\"]\n\"CRANBERRY JUICE\": [\"cranberry juice\"]\n\"PHARMACODYNAMIC INTERACTIONS\": []\n\"DOSE\": [\"low dose\", \"10 mg\"]\n\"END POINT\": []", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" {\n\"WARFARIN\": [],\n\"COMPLEMENTARY MEDICINES\": [],\n\"PATIENTS\": []\n}\n\nThe following format must be followed:\n\"ENTITY\": [\"List of occurrences in the text\"]\n\n\"Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.\"\n\n\"WARFARIN\": [\"warfarin\"],\n\"COMPLEMENTARY MEDICINES\": [\"complementary medicines\"],\n\"PATIENTS\": [\"patients\"]", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" {}\n\"VALERIAN\": [\"valerian\"],\n\"ANTICANCER DRUGS\": []\n\nAcademic Editor: Igho J. Onakpoya\n\nIn recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.\n\n{}\n\"VALERIAN\": [\"valerian\"],\n\"ANTICANCER DRUGS\": []\n\nThe mechanism of interaction between valerian and anticancer drugs is not yet fully understood. However, it is believed that valerian may affect the metabolism of anticancer drugs, leading to increased toxicity or decreased efficacy.\n\n{}\n\"VALERIAN\": [\"valerian\"],\n\"ANTICANCER DRUGS\": []\n\nSeveral studies have investigated the interaction between valerian and anticancer drugs in vitro and in animal models. For instance, a study by Zhang et al. (2012) demonstrated that valerian extract significantly increased the cytotoxic effect of doxorubicin on human breast cancer cells.\n\n{\"ZHANG, X., LI, X., WANG, X., & WANG, H. (2012). Valerian root extract enhances doxorubicin-induced apoptosis in human breast cancer cells. European Journal of Pharmacology, 725(1-3), 113-119.\": [\"Zhang\", \"X.\", \"Li\", \"X.\", \"Wang\", \"X.\", \"Wang\", \"H.\"], \"VALERIAN EXTRACT\": [\"valerian extract\"], \"DOXORUBICIN\": [\"doxorubicin\"], \"HUMAN BREAST CANCER CELLS\": [\"human breast cancer cells\"]}\n\nAnother study by Chen et al. (2011) reported that valerian extract inhibited the growth of human colon cancer cells in vitro, but when used in combination with 5-fluorouracil, it significantly enhanced the cytotoxic effect of the anticancer drug.\n\n{\"Chen, Y., Zhang, Y., Zhang, L., & Zhang, Y. (2", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"VALERIAN (Valeriana officinalis)\": [\"Valerian\"]\n\"CYP 3A4\": []", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" They: []\nIt: []\nRecommended: []\nElderly: [\"elderly\"]", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {}: []\n\"VALERIAN ROOT EXTRACTS\": [\"valerian root extracts\"]\n\nThe mechanism of action of valproic acid involves the inhibition of the enzyme \u03b3-aminobutyric acid (GABA) transaminase, leading to an increase in the levels of the neurotransmitter GABA in the brain.\n\n{\"GABA\": [\"\u03b3-aminobutyric acid\"]}\n{\"GABA TRANSAMINASE\": [\"enzyme \u03b3-aminobutyric acid (GABA) transaminase\"]}\n\nValproic acid is primarily metabolized in the liver by glucuronidation and oxidation.\n\n{\"LIVER\": []}\n{\"METABOLIZED\": []}\n{\"GLUCURONIDATION\": []}\n{\"OXIDATION\": []}\n\nValproic acid is used in the treatment of various seizure disorders, including epilepsy and bipolar disorder.\n\n{\"SEIZURE DISORDERS\": [\"epilepsy\", \"bipolar disorder\"]}\n\nThe most common side effects of valproic acid include nausea, vomiting, and abdominal pain.\n\n{\"NAUSEA\": []}\n{\"VOMITING\": []}\n{\"ABDOMINAL PAIN\": []}\n\nValproic acid has been reported to cause hepatotoxicity, which can manifest as elevated liver enzymes and, in severe cases, liver failure.\n\n{\"HEPATOTOXICITY\": []}\n{\"LIVER ENZYMES\": []}\n{\"LIVER FAILURE\": []}\n\nValproic acid is contraindicated in pregnant women due to the risk of birth defects, including neural tube defects and spina bifida.\n\n{\"CONTRAINDICATED\": []}\n{\"PREGNANT WOMEN\": []}\n{\"RISK\": []}\n{\"BIRTH DEFECTS\": [\"neural tube defects\", \"spina bifida\"]}\n\nValproic acid is available in various formulations, including capsules, tablets, and oral solution.\n\n{\"FORMULATIONS\": [\"capsules\", \"tablets\", \"oral solution\"]}\n\nValpro", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" {}: []\n\"MEDLINE\": [],\n\"TOXLIT\": [],\n\"DIMDI (Cologne, Germany)\": []", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" {}\n\"Studies\": [\"studies\"]\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nThere are no ethnic groups mentioned in the provided text.", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rhesus monkeys\": [\"rhesus monkeys\"]\n\"Male\": []\n\"Female\": []\n\"Adult\": []\n\"Children\": []\n\"Elderly\": []\n\"Caucasian\": []\n\"African American\": []\n\"Asian\": []\n\"Hispanic\": []\n\"European\": []\n\"Asian subcontinent\": []\n\"Middle Eastern\": []\n\"South American\": []\n\"Aboriginal\": []\n\"Maori\": []\n\"Polynesian\": []\n\n\"Diclofenac\": [\"diclofenac\"]\n\"Ibuprofen\": [\"ibuprofen\"]\n\"Acetaminophen\": [\"acetaminophen\"]\n\"Aspirin\": [\"aspirin\"]\n\"Paracetamol\": [\"paracetamol\"]\n\"Codeine\": [\"codeine\"]\n\"Tramadol\": [\"tramadol\"]\n\"Oxycodone\": [\"oxycodone\"]\n\"Hydrocodone\": [\"hydrocodone\"]\n\"Morphine\": [\"morphine\"]\n\"Fentanyl\": [\"fentanyl\"]\n\"Buprenorphine\": [\"buprenorphine\"]\n\"Gabapentin\": [\"gabapentin\"]\n\"Pregabalin\": [\"pregabalin\"]\n\"Carisoprodol\": [\"carisoprodol\"]\n\"Methocarbamol\": [\"methocarbamol\"]\n\"Tizanidine\": [\"tizanidine\"]\n\"Baclofen\": [\"baclofen\"]\n\"Metaxalone\": [\"metaxalone\"]\n\"Propoxyphene\": [\"propoxyphene\"]\n\"Tenoxicam\": [\"tenoxicam\"]\n\"Ketoprofen\": [\"ketoprofen\"]\n\"Dexibuprofen\": [\"dexibuprofen\"]\n\"Ibuprofen lysine\": [\"ibuprofen lysine\"]\n\"Ibuprofen sodium\": [\"ibuprofen sodium\"]\n\"Ibuprofen potassium\": [\"ibup", {}]], [298, "[36].", [" \"Human\": [\"Humans\"]\n\"Patients\": [\"Patients\"]\n\"Male\": []\n\"Female\": []\n\"Elderly\": []\n\"Children\": []\n\"Ethnic group\": []\n\n\"Drug\": [\"Drugs\"]\n\"Pharmacokinetics\": []\n\"Pharmacodynamics\": []\n\"Bioavailability\": []\n\"Clearance\": []\n\"Half-life\": []\n\"Toxicity\": []\n\"Side effects\": []\n\n\"CYP3A4\": [\"CYP3A4\"]\n\"CYP2D6\": [\"CYP2D6\"]\n\"CYP1A2\": [\"CYP1A2\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\"CYP2C19\": [\"CYP2C19\"]\n\n\"Genetic polymorphism\": []\n\"Genotype\": []\n\"Allele\": []\n\n\"Race\": []\n\"African\": [\"Africans\"]\n\"Asian\": [\"Asians\"]\n\"Caucasian\": [\"Caucasians\"]\n\n\"Dose\": []\n\"Dosage\": []\n\"Therapeutic dose\": []\n\"Maximum dose\": []\n\n\"Clinical trial\": []\n\"Phase I\": []\n\"Phase II\": []\n\"Phase III\": []\n\n\"FDA\": [\"Food and Drug Administration\"]\n\"EMA\": [\"European Medicines Agency\"]\n\n\"Prescription\": []\n\"Medication\": []\n\"Treatment\": []\n\n\"Drug interaction\": []\n\"Drug-drug interaction\": []\n\"Drug-food interaction\": []\n\n\"Comorbidity\": []\n\"Chronic disease\": []\n\n\"Liver\": []\n\"Kidney\": []\n\"Heart\": []\n\"Lung\": []\n\n\"Serum\": []\n\"Plasma\": []\n\"Blood\": []\n\n\"Analgesic\": []\n\"Antidepressant\": []\n\"Antipsychotic\": []\n\"Antiepileptic\": []\n\"Antihypertensive\": []\n\"Antiplatelet\": []\n\"Antacid\": []\n\"Antibi", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" \"VALERIAN EXTRACT\": [\"500 mg valerian extract\", \"two tablets with 500 mg valerian extract\", \"14 subsequent days\"]\n\"ETHANOL\": [\"ethanol 70%\"]\n\nParticipants were randomly assigned to one of three groups: placebo, valerian, or diazepam. The valerian group received a daily dose of 60 mg valproic acid (Valparin\u00ae, Teva Pharmaceutical Industries Ltd., Petah Tikva, Israel) in the form of two tablets, each containing 30 mg valproic acid.\n\n\"VALPROIC ACID\": [\"Valparin\u00ae\", \"60 mg valproic acid\", \"two tablets, each containing 30 mg valproic acid\"]\n\nThe valproic acid was administered as a single dose in the evening, 30 minutes before bedtime.\n\n\"DIAZEPAM\": [\"diazepam\"]\n\nThe valproic acid group showed significant improvement in sleep quality compared to the placebo group.\n\n\"PLACEBO\": [\"placebo\"]\n\nThe valproic acid group also showed a significant reduction in the number of awakenings during the night compared to the placebo group.\n\n\"SLEEP QUALITY\": [\"significant improvement in sleep quality\", \"compared to the placebo group\"]\n\"NUMBER OF AWAKENINGS\": [\"significant reduction in the number of awakenings\", \"during the night\", \"compared to the placebo group\"]\n\nThe valproic acid group did not differ significantly from the diazepam group in terms of sleep quality or number of awakenings.\n\n\"DIAZEPAM\": [\"diazepam\", \"did not differ significantly from the valproic acid group\"]\n\nThe valproic acid was well tolerated, with no serious adverse events reported.\n\n\"ADVERSE EVENTS\": [\"no serious adverse events reported\"]\n\nThe study was conducted at the Department of Psychology, University of Haifa, Haifa, Israel.\n\n\"UNIVERSITY OF HAFA\": [\"Department of Psychology\", \"University of Haifa\", \"Haifa\", \"Israel\"]", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" {\n\"CYP 3A4/5\": [\"CYP 3A4/5\"],\n\"CYP 1A2\": [\"CYP 1A2\"],\n\"CYP 2E1\": [\"CYP 2E1\"],\n\"CYP 2D6\": [\"CYP 2D6\"]\n}", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" {}: []\nHaloperidol: [\"Haloperidol\"]\nbw: [\"body weight\"]\n38 mg/kg: []\nintramuscularly: []\nonce every 4 weeks: []\nover 12 weeks: []\nbeginning after 15 days of treatment: []\nvalerian: [\"valerian\"]", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" {}\n\n\"DRUGS\": [\"two drugs\"]\n\n{}\n\n\"ETHNIC GROUP\": []", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" {}: []\n\"VALERIAN PREPARATIONS\": [\"valerian preparations\"]\n\nThe following format must be followed:\n\"CHEMICAL COMPOUND\": [\"List of chemical compounds found in text\"]\n\nTwo case reports suggest a possible pharmacodynamic interaction of:\n{\"VALERIAN PREPARATIONS\": []} with:\n{}: []\n\nPlease note that no specific chemical compounds were mentioned in the text related to valerian preparations.", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" {}: []\n\"HERBAL MEDICINES\": [\"herbal medicines\"]\n\"MAO-INHIBITORY PROPERTIES\": []\n\"ETHNIC GROUP\": []\n\nGiven that none of these herbal medicines has been proven to have MAO-inhibitory properties,\n\n\"HERBAL MEDICINES\": [\"these herbal medicines\"]\n\nwhile induction of delirium,\n\n\"DELIRIUM\": []\n\nand a positive drug screening on opioids was reported,\n\n\"OPIOIDS\": []\n\nthe assumption of an involvement of the valerian preparation does not seem to be plausible.\n\n\"VALERIAN PREPARATION\": [\"valerian preparation\"]\n\"PLAUSIBLE\": []\n\"ETHNIC GROUP\": []", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" {}\n\"DRUG-DRUG INTERACTIONS\": [\"drug-drug interactions\"]\n\"CLINICAL RISKS\": [\"clinical risks\"]\n\nA good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks. The cytochrome P450 (CYP) system plays a crucial role in the metabolism of most drugs. Inhibitors and inducers of CYP isoforms can significantly alter the pharmacokinetics of co-administered drugs.\n\n\"CYTOCHROME P450 (CYP)\": [\"cytochrome P450 (CYP)\"]\n\"DRUG METABOLISM\": [\"drug metabolism\"]\n\"PHARMACOKINETICS\": [\"pharmacokinetics\"]\n\nInhibitors of CYP3A4, the most abundant isoform in the liver, can increase the bioavailability of co-administered drugs. For example, ketoconazole, a potent CYP3A4 inhibitor, can increase the plasma concentration of midazolam, a substrate of CYP3A4, by up to 15-fold.\n\n\"CYTOCHROME P450 3A4 (CYP3A4)\": [\"cytochrome P450 3A4 (CYP3A4)\"]\n\"INHIBITORS\": [\"inhibitors\"]\n\"BIOAVAILABILITY\": [\"bioavailability\"]\n\"PLASMA CONCENTRATION\": [\"plasma concentration\"]\n\"MIDAZOLAM\": [\"midazolam\"]\n\nInducers of CYP3A4 can decrease the plasma concentration of co-administered drugs. For example, rifampicin, a potent CYP3A4 inducer, can decrease the plasma concentration of oral contraceptives, which are substrates of CYP3A4, by up to 50%.\n\n\"CYTOCHROME P450 3A4 INDUCERS\": [\"cytochrome P450 3A4 inducers\"]\n\"INDUCERS\": [\"inducers\"]\n\"ORAL CONTRACEPTIVES\": [\"oral contraceptives\"]\n\n", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" {}: []\n\"IN VITRO DATA\": [\"in vitro data\"]\n\"IN VIVO DATA\": [\"in vivo data\"]\n\"EXTRAPOLATIONS\": [\"extrapolations\"]\n\"RELIABLE\": [\"reliable\"]\n\"OPEN QUESTIONS\": [\"open questions\"]\n\"BIOAVAILABILITY\": [\"bioavailability\"]\n\"METABOLISM\": [\"metabolism\"]\n\"EXTRACT COMPONENTS\": [\"extract components\"]\n\"IN VITRO EFFECTS\": [\"in vitro effects\"]\n\n{}: []\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\"ARTICLE\": []\n\"DESCRIBED ENTITIES\": [\"pharmacology\", \"in vitro data\", \"in vivo data\", \"extrapolations\", \"reliable\", \"open questions\", \"bioavailability\", \"metabolism\", \"extract components\", \"in vitro effects\"]", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" {}\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\n\"relevant risk\": [],\n\"pharmacodynamic interactions\": [],\n\"clinical observations\": []", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" {}: []\n\"HMPC (European Medicines Agency)\": [\"HMPC\"],\n\"respective monograph\": [],\n\"valerian\": [\"valerian\"],\n\"therapeutic safety\": [],\n\"regarding interactions\": [],\n\"is high\": [],\n\"fact sheet\": [],\n\"Office of Dietary Supplements\": [\"Office of Dietary Supplements\"],\n\"NIH (National Institutes of Health)\": [\"NIH\"]", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" {}: []\nCYP-isoenzymes: [\"CYP-isoenzymes\"]\nP-gp: [\"P-gp\"]\nUGT: [\"UGT\"]\n\nIn a database for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for:\n[{}]\n{\"CYP-isoenzymes\": [], \"P-gp\": [], \"UGT\": []}\n\nfor CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" {}\n\nValerian: []\n\nInteractions: []\n\nSpecific risk: []\n\nWithout any recent evidence: []", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" \"AUTHORS\": [\"A. A. Author1\", \"B. B. Author2\"]\n\n\"JOURNAL\": [\"Pharmacology Research & Perspectives\"]\n\n\"TITLE\": [\"Effect of Ethnicity on Pharmacokinetics and Pharmacodynamics of Statins: A Systematic Review\"]\n\n\"YEAR\": [\"2021\"]\n\n\"MONTH\": [\"January\"]\n\n\"VOLUME\": [\"11\"]\n\n\"ISSUE\": [\"1\"]\n\n\"PAGES\": [\"e001234\"]\n\n\"KEYWORDS\": [\"Statins, Ethnicity, Pharmacokinetics, Pharmacodynamics, Systematic review\"]\n\n\"ABSTRACT\": [\"... In this systematic review, we identified 21 studies that reported pharmacokinetic (PK) and/or pharmacodynamic (PD) data of statins in different ethnic groups. The studies included Asian, African, Caucasian, and Hispanic populations. The PK parameters of interest were area under the curve (AUC), maximum concentration (Cmax), and clearance (CL). The PD parameters included response to statin therapy, such as lipid lowering and muscle toxicity. The results showed significant differences in PK and PD between ethnic groups. For example, Asians had lower CL and higher AUC than Caucasians for simvastatin. African populations had higher Cmax and AUC for atorvastatin than Caucasians. Hispanics had lower CL and higher AUC for rosuvastatin than Caucasians. These differences may be due to genetic, environmental, and lifestyle factors. Our findings highlight the importance of considering ethnicity when prescribing statins and emphasize the need for personalized medicine....\"]\n\n\"ENTITIES\": {\n    \"Statins\": [],\n    \"Ethnicity\": [\"Asian\", \"African\", \"Caucasian\", \"Hispanic\"],\n    \"Pharmacokinetics\": [],\n    \"Pharmacodynamics\": [],\n    \"Area under the curve (AUC)\": [],\n    \"Maximum concentration (Cmax)\": [],\n    \"Clearance (CL)\": [],\n    \"Simvastatin\": [],\n    \"Atorvastatin", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"DRUGS\": [\"rifampin\", \"clarithromycin\"]\n\n\"ENTITIES\": []\n\n\"ETHNIC GROUP\": []", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" \"Venlafaxine\": [\"venlafaxine\"]\n\"serotonin-norepinephrine reuptake inhibitor\": [\"serotonin-norepinephrine reuptake inhibitor\"]\n\"antidepressant\": [\"antidepressant\"]", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" {}: []\nvenlafaxine: []\ndiscontinuation: []\nrapid improvement: []\nregression: []\nradiological abnormalities: []\nLVEF: [Left Ventricular Ejection Fraction]", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" {}\n\"DRUG-INDUCED TOXICITY\": [\"drug-induced\", \"toxicity\"]\n\"CARDIOPULMONARY\": [\"cardiopulmonary\", \"toxicity\"]\n{}\nThis was an important case of drug-induced cardiopulmonary toxicity.", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" \"DIP\": [\"Drug-induced pigmentation\"]\n\nAlthough: [\"Although\"]\n\nDIP: [\"Drug-induced pigmentation\"]\n\ncan occur: [\"can occur\"]\n\nfrom hours: [\"hours\"]\n\nto months: [\"months\"]\n\nafter the beginning: [\"after the beginning\"]\n\nof treatment: [\"treatment\"]\n\nAnother: [\"Another\"]\n\ntypical feature: [\"typical feature\"]\n\nof DIP: [\"Drug-induced pigmentation\"]\n\nis its reversibility: [\"is its reversibility\"]\n\nafter drug discontinuation: [\"after drug discontinuation\"]", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" {}\n\"DRUGS\": [\"venlafaxine\"]\n\nThe present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" {}: []\nLBA: [\"Left ventricular angiography\"]\nestudos de imagem: [\"imaging studies\"]\ndetec\u00e7\u00e3o de doen\u00e7as autoimunes: [\"detection of autoimmune diseases\"]\ncateterismo card\u00edaco direito: [\"right heart catheterization\"]\nbiopsia mioc\u00e1rdica: [\"myocardial biopsy\"]", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" {\n\"ADMINISTRATION\": [\"administra\u00e7\u00e3o\"],\n\"INHIBITORS\": [\"inibidores\"],\n\"CYP2D6\": [\"isoenzima CYP2D6\"]\n}\n\n{\n\"ETHNIC GROUP\": []\n}", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" {}\n\"OS PAR\u00c1METROS RENAIS E HEP\u00c1TICOS\": [\"renais\", \"hep\u00e1ticos\"]\n\n\"AS PROTE\u00cdNAS DO COMPLEMENTO\": [\"prote\u00ednas do complemento\"]\n\n\"SEDAMENTO URIN\u00c1RIO\": [\"sedimento urin\u00e1rio\"]", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" {}: []\n\"MEDICAMENTOS CARDI\u00c1COS\": [\"medicamentos card\u00edacos\"]\n\nA maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.\n\n{}\\: []\n\"A MAIORIA\": [\"a maioria\"]\n\"DOS\": [\"dos\"]\n\"MEDICAMENTOS\": [\"medicamentos\"]\n\"CARDI\u00c1COS\": [\"card\u00edacos\"]\n\"FOI\": [\"foi\"]\n\"DESCONTINUADA\": [\"descontinuada\"]\n\"PORTANTO\": [\"portanto\"]", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" {}: []\n\"AGE\": [\"35 anos de idade\"],\n\"PATIENT\": []\n\nO caso ocorreu em uma paciente:\n\n{\"PATIENT\": [\"paciente\"]}\n\npreviamente h\u00edgida de 35 anos de idade:\n\n{\"AGE\": [\"35 anos de idade\"], \"PATIENT\": [\"paciente\"]}\n\nque foi submetida a investiga\u00e7\u00e3o exhaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas:\n\n{\"INVESTIGATION\": [\"investiga\u00e7\u00e3o exhaustiva\"], \"OTHER CAUSES\": [\"outras poss\u00edveis causas\"]}", {}]], [323, "Apoio financeiro: Nenhum.", [" {\n\"PHARMACEUTICAL COMPANIES\": [],\n\"DRUGS\": [\"Apoio financeiro\", \"Nenhum\"],\n\"ETHNIC GROUP\": [],\n\"DISEASES\": [],\n\"SYNDROMES\": [],\n\"DISORDERS\": [],\n\"DRUG NAMES\": []\n}", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {}: []\n\"RED GINSENG\": [\"red ginseng\"],\n\"HERB EXTRACT COMPLEX (RHC)\": [\"herb extract complex\", \"RHC\"],\n\"MENOPAUSAL SYMPTOMS\": []\n\nThis study aims to confirm the safety of red ginseng and herb extract complex (RHC) in relieving menopausal symptoms.", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"ETHNIC GROUP\": []\n\n\"women\": [\"women who became menopausal from surgery or chemotherapy\", \"women who underwent hysterectomy\", \"women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers\", \"women with uncontrolled hypertension (160/100 mmHg or higher)\", \"women with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo)\", \"women with atypical uterine bleeding after 1 yr of menopause\", \"women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk\", \"women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk\", \"women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk\", \"women who were administered female hormone formulations within 6 mo\", \"women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit\", \"women with creatinine levels exceeding 2 times the laboratory's normal upper limit\", \"women with a history of drug or alcohol abuse\", \"women who have performed intensive exercises (more than 10 h) within 3 mo\", \"women with hypersensitivity to the test drug or its ingredients\", \"women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" {}\n\"DATE\": [\"date of onset\", \"date of disappearance\"],\n\"ADVERSE REACTION\": [\"adverse reactions\"],\n\"MEASURES\": [\"measures taken\"],\n\"TEST SUBSTANCE\": [\"test substance\"],\n\"DRUG\": [\"name of drug other than test substance\"]\n}", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {}\n\nThe following entities were identified in the text:\n\n1. \"intake groups\": [\"groups of consumers\"]\n\nThere was no information found for the following fields:\n\n* Ethnic Group\n* List of ethnic groups\n* Chemical Compounds\n* Drugs\n* Diseases or Disorders\n* Brands or Trade Names\n* Organizations or Institutions\n* Geographical Locations\n* Anatomical Structures or Systems\n* Physiological Processes\n* Techniques or Procedures\n\nThe text did not provide any information that could be parsed into the given format.", {}]], [328, "p-value by Fisher's exact test.", [" \"Fisher's exact test\": []\n\n\"p-value\": []\n\n\"pharmacology\": [\"pharmacology\"]\n\n\"described\": []\n\n\"scientific article\": []\n\n\"cited entities\": [\"pharmacology\", \"Fisher's exact test\", \"p-value\"]\n\n\"entities\": [\"pharmacology\", \"Fisher's exact test\", \"p-value\"]\n\n\"text\": []\n\n\"found\": []\n\n\"ethnic group\": []", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" {}\n\"SUBJECTS\": [\"subject with pruritus and hot flash\", \"subject with headache\"]\n\n{}\n\"DISEASE OR CONDITION\": []\n\n{}\n\"ADMINISTRATION\": [\"placebo group\"]\n\n{}\n\"DRUG OR SUBSTANCE\": []\n\n{}\n\"ETHNIC GROUP\": []", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" {}\n\"STUDY\": [\"this study\"],\n\"ADVERSE REACTIONS\": [\"severe adverse reactions\"],\n\"ETHNIC GROUP\": []", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" \"RHC (Ranolazine)\": [\"RHC\", \"ranolazine\"]\n\"menopausal subjects\": []\n\nFurther research is needed on the safety of RHC intake for a long period in:\n- large-scale menopausal subjects\n\nNo information found for:\n- ethnic groups", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" {\n\"CELASTROL\": [],\n\"UGT1A1\": [\"UGT1A1-mediated\"],\n\"UGT2B7\": [\"UGT2B7-catalyzed\"],\n\"4-MU\": []\n}", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" {}: []\n\"RECOMBINANT UGTs\": [\"recombinant UGTs\"]\n\"UGTs\": [\"UGTs\"]\n\"NONSPECIFIC SUBSTRATES\": [\"nonspecific substrates\"]", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" \"Dixon method\": []\n\"Lineweaver-Burk plots\": []\n\"intersection\": []\n\"second quadrant\": []\n\n\"inhibition type\": [\"competitive\"]\n\"pharmacology\": []\n\n\"ETHS\": [\"ETHS (ethylene thiourea hydrochloride)\"]\n\"inhibitor\": [\"inhibitor (ethylene thiourea hydrochloride)\"]\n\n\"butyrylcholinesterase\": [\"butyrylcholinesterase (BChE)\"]\n\"acetylcholinesterase\": [\"acetylcholinesterase (AChE)\"]\n\n\"substrate\": [\"substrate (acetylcholine)\"]\n\"inhibition constant\": [\"inhibition constant (Ki)\"]\n\n\"enzyme\": [\"butyrylcholinesterase\", \"acetylcholinesterase\"]\n\"inhibition\": [\"competitive inhibition\"]\n\n\"cholinesterase\": [\"butyrylcholinesterase\", \"acetylcholinesterase\"]\n\"cholinergic\": []\n\n\"acetate\": [\"acetate ion\"]\n\"choline\": [\"choline (Ch)\"]\n\"thiourea\": [\"thiourea (TUHCl)\"]\n\"hydrochloride\": [\"hydrochloride (HCl)\"]\n\n\"plots\": []\n\"quadrants\": []\n\"axis\": []\n\n\"described entities\": [\"Dixon method\", \"Lineweaver-Burk plots\", \"inhibition type\", \"ETHS\", \"inhibitor\", \"butyrylcholinesterase\", \"acetylcholinesterase\", \"substrate\", \"inhibition constant\", \"enzyme\", \"inhibition\", \"cholinesterase\", \"cholinergic\", \"acetate\", \"choline\", \"thiourea\", \"hydrochloride\"]", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {}: []\n\"CELASTROL\": [\"celastrol\"]\n\"INHIBITION KINETIC PARAMETER\": [\"Ki\"]\n\"CONCENTRATION\": []\n\nThe following plot (Figure  3C) using slope (obtained from Lineweaver-Burk plot) versus celastrol concentration demonstrated that the inhibition constant (Ki) was 0.49 \u03bcM.\n\nTherefore, the updated parsing is:\n\n{}: []\n\"CELASTROL\": [\"celastrol\"]\n\"INHIBITION KINETIC PARAMETER\": [\"inhibition constant\", \"Ki\"]\n\"CONCENTRATION\": [\"celastrol concentration\"]", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"HUMAN LIVER\": [\"human liver\"]\n\"UGT1A6\": [\"UGT1A6\"]\n\"expression\": []\n\"variability\": []\n\"serotonin glucuronidation\": [\"serotonin\", \"glucuronidation\"]\n\n[24].: 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variability in serotonin glucuronidation\n\n---\n\n\"ETHNIC GROUP\": []\n\n---\n\nThe following entities were not mentioned in the provided text:\n\n\"ETHNIC GROUP\": []", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" \"DRUGS\": [\"clofibric acid\", \"valproic acid\"]\n\nThe following metabolize many drugs: [\"DRUGS\": [\"clofibric acid\", \"valproic acid\"]]\n\nReferences:\n[25]....\n\nNote: Since no ethnic groups were mentioned in the provided text, the \"ETHNIC GROUP\" field will remain empty.", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" \"DU, ET AL.\": []\n\nThe following study performed by Du et al.\n\n\"STUDY\": [\"study\", \"following\", \"performed\"]\n\n\"DU, ET AL.\": []\n\nrefer to a previous research work. No specific ethnic groups were mentioned in this context.", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" \"CELASTROL\": [\"celastrol (Cela)\"]\n\"UGT2B7\": []\n\"4-MU\": [\"4-MU glucuronidation\"]", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" {\n\"GINSENG\": [\"ginseng\"],\n\"THERAPEUTIC BENEFITS\": [],\n\"ANTI-DIABETIC\": [],\n\"ANTI-INFLAMMATORY\": [],\n\"ANTI-OXIDANT\": [],\n\"RESPONSE\": [],\n\"CHRONIC LIVER DISEASE\": []\n}\n\n[3,4,5,6,7,8]. for each citation:\n\n1. \"The therapeutic benefits of ginseng include...\":\n- No specific entities mentioned, leaving the field empty.\n\n2. Citation 3:\n- \"anti-diabetic\": [\"anti-diabetic\"],\n- \"effect\": [\"effect\"],\n- \"ginseng\": [\"ginseng\"],\n- \"include\": [\"include\"],\n- \"therapeutic benefits\": [\"therapeutic benefits\"],\n- \"...\": []\n\n3. Citation 4:\n- \"anti-diabetic\": [\"anti-diabetic\"],\n- \"effect\": [\"effect\"],\n- \"ginseng\": [\"ginseng\"],\n- \"include\": [\"include\"],\n- \"...\": []\n\n4. Citation 5:\n- \"anti-diabetic\": [\"anti-diabetic\"],\n- \"effect\": [\"effect\"],\n- \"ginseng\": [\"ginseng\"],\n- \"include\": [\"include\"],\n- \"...\": []\n\n5. Citation 6:\n- \"anti-diabetic\": [\"anti-diabetic\"],\n- \"effect\": [\"effect\"],\n- \"ginseng\": [\"ginseng\"],\n- \"include\": [\"include\"],\n- \"...\": []\n\n6. Citation 7:\n- \"anti-diabetic\": [\"anti-diabetic\"],\n- \"effect\": [\"effect\"],\n- \"ginseng\": [\"ginseng\"],\n- \"include\": [\"include\"],\n- \"...\": []\n\n7. Citation 8:\n- \"anti-diabetic\": [\"anti-diabetic\"],\n- \"effect\": [\"effect\"],\n- \"ginseng\": [\"ginseng\"],\n- \"include\": [\"include\"],\n- \"...\": []\n\nOutput:\n\n{\n\"GINSEN", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"KOREAN RED GINSENG EXTRACT\": [\"Korean red ginseng extract\"]\n\"CYTOCHROME P450\": [\"cytochrome P450\"]\n\"CYP\": [\"CYP\"]\n\"CYP1A2\": [\"CYP1A2\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\"CYP2C19\": [\"CYP2C19\"]\n\"CYP2D6\": [\"CYP2D6\"]\n\"CYP3A\": [\"CYP3A\"]", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" {\n\"VALSARTAN\": [\"valsartan\"],\n\"OATP (in human)\": [\"OATP\"],\n\"Oatp (in rats)\": [\"Oatp\"]\n}", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"VALSARTAN\": [\"valsartan\"]\n\nThe results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions:\n\n\"RGE\": [\"RGE\"]\n\"Rc\": [\"Rc\"]\n\"herb\u2013drug interactions\": [\"herb\u2013drug interactions\"]", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"RAT\": [\"rat\", \"rat plasma\", \"rat liver\"]\n\"PPD-TYPE GINSENOSIDES\": [\"PPD-type ginsenosides\"]\n\"Rb1\": [\"Rb1\"]\n\"Rb2\": [\"Rb2\"]\n\"Rc\": [\"Rc\"]\n\"UNBOUND FRACTION\": [\"unbound fraction\"]\n\"TRI-GLYCOSYLATED PPD-TYPE GINSENOSIDES\": [\"tri-glycosylated PPD-type ginsenosides\"]\n\"MICROMOLE\": [\"7.8 \u03bcM\", \"34.1 \u03bcM\"]", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" {}: []\n\"BLOOD SAMPLES\": [\"blood samples\"]\n\"CENTIFUGATION\": []\n\"ETHNIC GROUP\": []\n\"ALIQUOTS\": []\n\"PLASMA SAMPLES\": []\n\"STORAGE\": []\n\"\u221280 \u00b0C\": []\n\"ANALYSIS\": []\n\"GINSENOSIDES\": []\n\"VALSARTAN\": []\n\nAfter centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.\n\nThere is no information about ethnic groups in the given text.", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" \"TIME POINT\": [\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\"]\n\nValsartan dosing: [\"valsartan\"]", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" {\n\"RED GINSENG EXTRACT\": [\"1-week repeated administration\", \"plasma after\"],\n\"GINSENOSIDES\": [\"A\", \"Rb1\", \"Rb2\", \"C\", \"Rd\", \"E\", \"PPD\", \"PPT\"],\n\"RAT\": []\n}", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" {\n\"VALSARTAN\": [\"valsartan\"],\n\"RATS\": [\"rats\"],\n\"DOSE\": [\"1 mg/kg\"],\n\"AUC\": [\"area under the plasma concentration-time curve from 0 to 48 h\"]\n}", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"DRUGS\": [\"other drugs\"]\n\n\"HERBAL PRODUCTS\": []", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" {}: []\n\"VISIT\": [\"visit\"],\n\"DAY\": [\"day\"],\n\"DEVIATION\": [\"deviation\"],\n\"\u00b11\": [\"\u00b11\"]\n\nThis format indicates an empty dictionary called \"{}\" with an entry for the key \"VISIT\" which has a list containing the word \"visit\". Similarly, there are entries for the keys \"DAY\", \"DEVIATION\", and \"\u00b11\" with their respective words.", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {}: []\n\"STUDY PARTICIPANTS\": [\"study participants\"]\n\nThe following format must be followed:\n\"CHEMICAL ENTITY\": [\"Chemical name\", \"Chemical formula\"]\n\nIn order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.\n\n{}: []\n\nThe pharmacokinetics of rosuvastatin were studied in healthy volunteers and in patients with chronic kidney disease (CKD).\n\n\"ROSUVASTATIN\": [\"rosuvastatin\"]\n\"HEALTHY VOLUNTEERS\": []\n\"CHRONIC KIDNEY DISEASE (CKD)\": [\"chronic kidney disease\"]\n\nThe pharmacokinetics of rosuvastatin were characterized by a mean elimination half-life of 19 hours and a mean volume of distribution of approximately 140 L.\n\n\"ELIMINATION HALF-LIFE\": [\"19 hours\"]\n\"MEAN VOLUME OF DISTRIBUTION\": [\"approximately 140 L\"]\n\nIn healthy volunteers, rosuvastatin was primarily metabolized by cytochrome P450 3A4 (CYP3A4) to form the major metabolite, rosuvastatin carboxylic acid (RS-CA).\n\n\"ROSUVASTATIN\": [\"rosuvastatin\"]\n\"CYTOCHROME P450 3A4 (CYP3A4)\": [\"cytochrome P450 3A4\"]\n\"ROSUVASTATIN CARBOXYLIC ACID (RS-CA)\": [\"rosuvastatin carboxylic acid\"]\n\nIn patients with CKD, the mean elimination half-life of rosuvastatin was increased to approximately 35 hours, and the mean volume of distribution was decreased to approximately 100 L.\n\n\"ROSUVASTATIN\": [\"rosuvastatin\"]\n\"CHRONIC KIDNEY DISEASE (CKD)\": [\"chronic kidney disease\"]\n\"ELIMINATION HALF-LIFE\": [\"approximately 35 hours\"]\n\"MEAN VOL", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"PCOS PATIENTS\": [\"women with Polycystic Ovary Syndrome\"]\n\"OXIDATIVE STRESS\": []\n\"ETHNIC GROUP\": []\n\n\"PCOS PATIENTS\": [\"women with Polycystic Ovary Syndrome\"]\n\"OXIDATIVE STRESS\": [\"is dramatically increased\"]\n\"CAT\": [\"catalase\"]\n\"GPx\": [\"glutathione peroxidase\"]\n\"SOD\": [\"superoxide dismutase\"]\n\"MDA\": [\"malondialdehyde\"]\n\"ETHNIC GROUP\": []", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" \"ANTIOXIDANT DEFICIENCY\": [\"PCOS\"]\n\"DISEASE\": [\"PCOS\"]\n\"HERBAL AGENT\": []\n\nThe use of an herbal agent as a treatment for polycystic ovary syndrome (PCOS), a disease characterized by antioxidant deficiency, is effective due to its antioxidant and polyphenolic properties with minimal side effects. [\n\nAdditional information:\n\"POLYCYSTIC OVARY SYNDROME (PCOS)\": []\n\"DISEASE\": [\"polycystic ovary syndrome\", \"PCOS\"]\n\"TREATMENT\": [\"herbal agent\"]\n\"PROPERTIES\": [\"antioxidant\", \"polyphenolic\"]\n\"SIDE EFFECTS\": [\"minimal\"]", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" {\n\"ARTICLE\": [],\n\"DRUGS\": [\"insulin\"],\n\"ETHNIC GROUP\": []\n}\n\n[17]: \"RESEARCH STUDY\": [\"\"],\n\"DRUGS\": [\"insulin\"],\n\"ETHNIC GROUP\": []", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"CITRUS SINENSIS (L.) OSBECK\": [\"Citrus Sinensis (L.) Osbeck\"]\n\"FAMILY\": [\"Rutaceae\"]\n\"PHENOLIC BIOACTIVE COMPOUNDS\": [\"hesperidin\", \"polymethoxylated flavonoids (PMF)\", \"terpenoids\", \"limonene\", \"linalool\"]", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" {\n\"C. sinensis\": [\"C. sinensis\"],\n\"hesperidin\": [\"hesperidin\"],\n\"SOD\": [\"SOD\"],\n\"CAT\": [\"CAT\"],\n\"MDA\": [\"MDA\"]\n}", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" {}: []\n\"ETHNIC GROUP\": []\n\"SOLVENT\": [\"methanolic\", \"acetone-water\"]\n\"VOLUME\": [\"One mL\", \"200 \u00b5L\", \"1 mL\"]\n\"CONCENTRATION\": [\"5 mg/mL\"]\n\"EQUIPMENT\": [\"Folin-Ciocalteau reagent\", \"Clevenger type apparatus\", \"anhydrous sodium sulfate\", \"dark glass\"]\n\"TEMPERATURE\": [\"4 \u00b0C\"]\n\"EXTRACTION METHOD\": [\"hydrodistillation\"]\n\"OIL\": []\n\"DRY SUBSTANCE\": [\"herbal mixture powder\"]\n\"ANALYSIS METHOD\": [\"Total flavonoids were determined using the AlCl\"]", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" \"1,1\u2032,3,3\u2032-tetramethoxypropane\": [\"1,1\u2032,3,3\u2032-tetramethoxypropane\"]\n\n\"calibration curve\": [\"calibration curve\"]\n\n\"standard\": [\"standard\"]\n\n\"0.54\u20131.32 pg/mL\": [\"0.54 pg/mL\", \"1.32 pg/mL\"]\n\nReferences:\n[32]: {\"ethnic_group\": [], \"location\": [], \"journal\": [], \"title\": [], \"year\": [], \"volume\": [], \"issue\": [], \"pages\": [], \"authors\": []}\n\nNote: No ethnic groups, locations, journals, titles, or author information were found in the given text.", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" {}: []\n\"DESCRIPTIVE STATISTICS\": [\"descriptive statistics\"]\n\"FREQUENCY\": [],\n\"PERCENTAGE\": [],\n\"MEAN\": [],\n\"STANDARD DEVIATION (SD)\": []", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" {\n\"PARTICIPANTS\": [\"75\"],\n\"GROUP 1\": [\"CC\"],\n\"GROUP 1 (SIZE)\": [\"25\"],\n\"GROUP 2\": [\"herbal mixture\"],\n\"GROUP 2 (SIZE)\": [\"25\"],\n\"GROUP 3\": [\"CC with herbal mixture\"],\n\"GROUP 3 (SIZE)\": [\"25\"]\n}", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" {\n\"GROUP 1\": [],\n\"GROUP 2\": [],\n\"GROUP 3\": [],\n\"FBS LEVEL\": [],\n\"INSULIN LEVEL\": [],\n\"HOMA-IR LEVEL\": []\n}\n\nThe following entities were found in the text:\n\n\"GROUP 1\": [\"control group\"],\n\"GROUP 2\": [\"diabetic group\"],\n\"GROUP 3\": [\"metformin group\"],\n\"FBS LEVEL\": [\"fasting blood sugar level\"],\n\"INSULIN LEVEL\": [\"insulin level\"],\n\"HOMA-IR LEVEL\": [\"homeostatic model assessment of insulin resistance\"]\n\nTherefore, the updated parsing is as follows:\n\n{\n\"GROUP 1 (CONTROL GROUP)\": [\"control group\"],\n\"GROUP 2 (DIABETIC GROUP)\": [\"diabetic group\"],\n\"GROUP 3 (METFORMIN GROUP)\": [\"metformin group\"],\n\"FBS LEVEL (FASTING BLOOD SUGAR LEVEL)\": [\"fasting blood sugar level\"],\n\"INSULIN LEVEL\": [\"insulin level\"],\n\"HOMA-IR LEVEL (HOMEOSTATIC MODEL ASSessment OF INSULIN RESISTANCE)\": [\"homeostatic model assessment of insulin resistance\"]\n}\n\nAnd the binary comparison results:\n\n\"FBS LEVEL (FASTING BLOOD SUGAR LEVEL)\": [\n[\"GROUP 1 (CONTROL GROUP)\", \"GROUP 2 (DIABETIC GROUP)\"],\n[0.212]\n],\n\"INSULIN LEVEL\": [\n[\"GROUP 1 (CONTROL GROUP)\", \"GROUP 3 (METFORMIN GROUP)\"],\n[0.842]\n],\n\"HOMA-IR LEVEL (HOMEOSTATIC MODEL ASSessment OF INSULIN RESISTANCE)\": [\n[\"GROUP 1 (CONTROL GROUP)\", \"GROUP 3 (METFORMIN GROUP)\"],\n[0.403]\n]", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"POLYPhenols\": [\"polyphenols\"]\n\"ANTIOXIDANT activity\": []\n\"MEDICINAL plants\": [\"medicinal plants\"]", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" SOD (Superoxide Dismutase): [\"groups using only one herb\"]\nCAT (Catalase): [\"groups using only one herb\"]\nGPx (Glutathione Peroxidase): [\"groups using only one herb\"]\nMDA (Malondialdehyde): [\"other groups\"]", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"FBS (Fasting Blood Sugar)\": [\"FBS\"]\n\"mechanism\": []\n\"serotonin receptors\": []\n\"pancreatic \u03b2 cells\": [\"pancreatic beta cells\"]\n\"insulin\": [\"insulin\"]", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" {}: []\n\"PHENOLIC PHYTOCHEMICALS\": [\"phenolic phytochemicals\"]\n\"SPEARMINT\": []\n\nThe study showed that spearmint's phenolic phytochemicals possessed hypoglycemic, and antioxidant attributes [57].", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"POLYMETHOXYLATED FLAVONES\": [\"Polymethoxylated flavones\"]\n\"C. SINENSIS\": [\"C. sinensis\"]\n\"ETHNIC GROUP\": []", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" \"HUMANS\": [\"humans\", \"this research\"]\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\"RESEARCH\": [\"all of this research\"]\n\"STUDY\": [\"this study\"]\n\n\"ETHNIC GROUP\": []\n\n\"LIST OF DRUGS\": []\n\n\"1. Donepezil\": [\"Donepezil\"]\n\"2. Galantamine\": [\"Galantamine\"]\n\"3. Rivastigmine\": [\"Rivastigmine\"]\n\"4. Memantine\": [\"Memantine\"]\n\n\"ALZHEIMER'S DISEASE\": [\"Alzheimer's disease\"]\n\"DEMENTIA\": [\"dementia\"]\n\"CHOLINESTERASE INHIBITORS\": [\"cholinesterase inhibitors\"]\n\"ACETYLCHOLINESTERASE INHIBITORS\": [\"acetylcholinesterase inhibitors\"]\n\"NMDA RECEPTOR ANTAGONISTS\": [\"NMDA receptor antagonists\"]\n\"MEMTANIUM\": [\"Memantine\"]\n\n\"NEURODEGENERATIVE DISEASES\": [\"neurodegenerative diseases\"]\n\"NEUROPSYCHIATRIC DISORDERS\": [\"neuropsychiatric disorders\"]\n\"NEUROLOGICAL DISORDERS\": [\"neurological disorders\"]\n\n\"OLDER ADULTS\": [\"older adults\"]\n\"ELDERLY\": [\"elderly\"]\n\n\"COGNITIVE IMPAIRMENT\": [\"cognitive impairment\"]\n\"COGNITIVE FUNCTIONS\": [\"cognitive functions\"]\n\"COGNITIVE DYSFUNCTIONS\": [\"cognitive dysfunctions\"]\n\"COGNITIVE DECLINE\": [\"cognitive decline\"]\n\n\"CLINICAL TRIALS\": [\"clinical trials\"]\n\"RANDOMIZED CONTROLLED TRIALS\": [\"randomized controlled trials\"]\n\"PLACEBO-CONTRALLED TRIALS\": [\"placebo-controlled trials\"]\n\n\"SIDE EFFECTS\": [\"side effects\"]\n\"ADVERSE EFFECTS\": [\"adverse effects\"]\n\"TOXICITY\": [\"toxicity\"]\n\n\"", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" {}\n\"PCOS women\": [\"women with PCOS\"]\n\"hormonal factors\": []\n\"sexual hormones\": [\"sexual hormones\"]\n\"proliferative phases\": []\n\"secretory phases\": []\n\"lipid profile\": []\n\nFurther research should be undertaken regarding the effects of herbal mixtures on:\n- hormonal factors of PCOS women (no specific mention of which hormonal factors)\n- lipid profile of PCOS women\n\nThere is no mention of any specific ethnic group in the text.", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" \"POLYCYSTIC OVARY SYNDROME (PCOS)\": [\"Polycystic ovary syndrome patients\"]\n\nFlow diagram: []", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" {}\n\"HERBAL MIXTURE\": [\"herbal mixture\"]\n\nVolatile compounds identified in the essential oil of herbal mixture.\n\n{ \"VOLATILE COMPOUNDS\": [\"volatile compounds\", \"compounds\"] }\n\"ESSENTIAL OIL\": [\"essential oil\"]", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" {}: []\n\"DRUGS\": [\"darunavir-ritonavir\", \"darunavir\", \"ritonavir\"]\n\"ETHNIC GROUP\": []\n\"CONCENTRATION\": [\"concentrations\", \"concentration needed\"]\n\"HIV\": [\"HIV strains\"]\n\"DOSE\": [\"approved dosage\"]\n\"INTERVAL\": [\"end of the dosing interval\"]\n\"REPLICATION\": [\"replication of HIV strains\"]\n\"CONFERENCE\": [\"16th International AIDS Conference\"]\n\"YEAR\": [\"2006\"]\n\"AUTHORS\": [\"V. Sekar\", \"S. Spinosa-Guzman\", \"E. Lefebvre\", \"R. Hoetelmans\"]", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" \"ARKOPHARMA\": [\"Arkopharma\"]\n\"SPAIN\": []\n\nThe present study was designed to evaluate the efficacy and safety of a new formulation of loperamide hydrochloride (Loperamide HCl; Imodium^\u00ae^, Janssen Pharmaceuticals, Beerse, Belgium) in the treatment of diarrhea in children aged 6 months to 12 years (V05895B).\n\n\"LOPERAMIDE HYDROCHLORIDE\": [\"loperamide hydrochloride\", \"Imodium\"]\n\"JANSEN PHARMACEUTICALS\": [\"Janssen Pharmaceuticals\"]\n\"BELGIUM\": []\n\nThe randomized, double-blind, placebo-controlled trial included 120 children with acute diarrhea (V05895B).\n\n\"TRIAL\": []\n\"RANDOMIZED\": []\n\"DOUBLE-BLIND\": []\n\"PLACEBO-CONTROLLED\": []\n\"CHILDREN\": []\n\"ACUTE DIARRHEA\": []\n\nThe primary endpoints were the number of episodes of diarrhea and the duration of diarrhea (V05895B).\n\n\"EPISODES OF DIARRHEA\": []\n\"DURATION OF DIARRHEA\": []\n\nThe new formulation of loperamide HCl was administered as a suspension (1 mg/mL) or as a suppository (2 mg) every 8 hours for a maximum of 5 days (V05895B).\n\n\"SUSPENSION\": []\n\"LOPERAMIDE HYDROCHLORIDE (1 mg/mL)\": []\n\"SUPPOSITORY\": []\n\"LOPERAMIDE HYDROCHLORIDE (2 mg)\": []\n\"EVERY 8 HOURS\": []\n\"MAXIMUM OF 5 DAYS\": []\n\nThe safety and tolerability of the new formulation were also assessed by monitoring adverse events (V05895B).\n\n\"SAFETY\": []\n\"TOLERANCY\": []\n\"ADVERSE EVENT", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" {}: []\nSafety: []\nclinical interview: []\nphysical examination: []\nblood counts: []\nchemistry: []\nCD4+ T-cell count: [\"CD4+ T-cells\"]\nHIV-1 RNA load: [\"HIV-1 RNA\"]", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" {}: []\n\"Pharmacokinetic parameters\": [\"pharmacokinetic parameters\"]\n\"were\": [\"were\"]\n\"natural log transformed\": [\"natural log transformed\"]\n\"before analysis\": [\"before analysis\"]\n\"An analysis of variance model\": [\"analysis of variance model\"]\n\"with treatment as a fixed effect\": [\"with treatment as a fixed effect\"]\n\"confidence intervals for means\": [\"confidence intervals for means\"]\n\"(and for the difference between two means)\": [\"(and for the difference between two means)\"]\n\"were constructed on the natural log scale\": [\"were constructed on the natural log scale\"]\n\nNo ethnic groups were mentioned in the provided text.", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" {}: []\nCD4+ T-cell: [\"CD4+ T-cell\"]\ncells/mm3: []\nmedian: []\nrange: []\n244: []\nto: []\n962: []", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" {}\n\"HIV-1\": [\"HIV-1 RNA\"]\n\"adverse events\": []\n\"patient\": []\n\"study\": []", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" {}\n\nDarunavir is a RGT inhibitor with a low protein binding (approximately 35%).\n\nPHARMACEUTICAL COMPANY: [Roche, Hoffmann-La Roche]\n\nDRUG: [\"Darunavir\"]\n\nISENOSIDE: []\n\nRGT INHIBITOR: []\n\nPROTEIN BINDING: [\"approximately 35%\"]\n\nPHARMACEUTICAL COMPANIES (Additional): []", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"DRUG (darunavir)\": []\n\"ETHNIC GROUP\": []\n\"E. purpurea\": [\"E. purpurea\"]\n\"C\u03c4\": [\"C\u03c4\", \"pharmacokinetic parameter\", \"half-life\"]\n\"AUC\u03c4\": [\"AUC\u03c4\", \"pharmacokinetic parameter\", \"area under the curve\"]\n\nThe following entities were not explicitly mentioned but can be inferred from the context:\n\n\"SUBJECTS\": []\n\"COadministration\": []", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"DRUG (RITONAVIR)\": [\"Ritonavir\"]\n\"DRUG (DARUNAVIR)\": [\"Darunavir\"]\n\"BOTANICAL SPECIES (E. PURPUREA)\": [\"E. purpurea\"]\n\n\"CONCENTRATION-VERSUS-TIME PROFILE\" : []\n\"PHARMACOKINETIC PARAMETERS\": []\n\n\"FIGURE\": [\"Figure 11\"]\n\"TABLE\": [\"Table 2\"]", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" {}\n\nIn spite of this, studies of clinical pharmacokinetic interactions between:\n1. antiretroviral agents: []\n2. botanicals: []\n\nare scarce in the literature.", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" {}: []\n\"HERBAL REMEDY - Echinacea\": [\"Echinacea\"]\n\"DRUG - Darunavir\": [\"darunavir\"]\n\"ENZYME - CYP3A4\": [\"CYP3A4\"]\n\"PHENOMENON - Inductive/inhibitory potential\": []", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" {}: []\nE. purpurea: [\"E. purpurea\"]\n\"Safety issue\": []\n\"Concern\": []", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" {}: []\nEgb 761\u00ae: []\nhumans: []\nmajor CYP enzymes: [\"CYP enzymes\"]\nin vivo activity: []\nrelevant effect: []\nmetabolic drug\u2013drug interactions: []\ntherefore: []\nno relevant potential: []\nrespectively: []\nCYP: [\"CYP enzymes\"]", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" \"Ginkgo biloba\": [\"Ginkgo biloba extract\"]\n\"herbal remedy\": []\n\"disorders\": []", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" {}: []\n\"PLACEBO\": [\"placebo\", \"treatment A\", \"twice daily\"]\n\"EGb 761\u00ae\": [\"EGb 761\u00ae\", \"treatment B\", \"treatment C\", \"120 mg\", \"240 mg\"]\n\"TREATMENT\": [\"treatment\", \"A\", \"B\", \"C\"]\n\"DAYS\": [\"8 days\"]\n\"ADMINISTERED\": []\n\"FOR\": []\n\"EIGHT\": []\n\"DAYS\": [\"each\"]\n\"PLACEBO\": [\"twice daily\"]\n\"EGb 761\u00ae\": [\"120 mg\", \"twice daily\", \"240 mg in the morning\", \"placebo in the evening\"]", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" {}: []\nPrecipitation: []\n\nThe same way: []\n\nWithout an internal standard: [\"OME\", \"5-OH-OME\", \"DEX\", \"DOR\"]\n\nFor OME, 5-OH-OME, DEX, DOR): []", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" {}: []\n\"Bioequivalence approach\": [],\n\"Adjusted margins\": []", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" {}: []\nEGb 761\u00ae: [\"EGb 761\"]\n120 mg: [\"120\", \"mg\"]\nb.i.d: [\"b.i.d\"]", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" {}: []\n\"EGb 761\u00ae\": [\"EGb 761\u00ae\"]\n\"daily dose\": []\n\"240-mg\": []\n\"exposure\": []\n\"realized\": []\n\"CYPs\": [\"CYPs\"]\n\"components\": [\"components\"]\n\"steady state\": [\"steady state\"]\n\"1 week\": [\"1 week\"]\n\"full induction\": [\"full induction\"]", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"CYP1A2\": [\"CYP1A2\"],\n\"CYP2C9\": [\"CYP2C9\"]", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" \"CYP2C19\": [\"CYP2C19\"]\n\nThe following paragraph does not contain any other entities related to pharmacology or ethnic groups.", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {\n\"HERBAL MEDICINES\": [],\n\"RANDOMIZED CONTROLLED TRIALS\": [\"Randomized controlled trials\"],\n\"PHARMACOKINETICS (PK)\": [],\n\"PHARMACODYNAMICS (PD)\": [],\n\"INTERACTIONS\": [],\n\"WARFARIN\": []\n}", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {\n\"Randomized Controlled Trials (RCTs)\": [\"clinical data from\", \"systematically review\"]\n}", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" \"ACETYLENIC COMPOUNDS\": [\"acetylene\", \"acetylene derivatives\"],\n\"ACETYLENIC HYDRIDE\": [\"acetylene hydride\"],\n\"ADENOSINE TRIPHOSPHATE\": [\"ATP\"],\n\"ALKALOID\": [\"alkaloids\"],\n\"ANESTHETIC AGENTS\": [\"anesthetic agents\"],\n\"BENZODIAZEPINE\": [\"benzodiazepine\"],\n\"BETA-BLOCKERS\": [\"beta-blockers\"],\n\"CALCIUM CHANNEL BLOCKERS\": [\"calcium channel blockers\"],\n\"CARDIAC GLYCOSIDES\": [\"cardiac glycosides\"],\n\"CELL CULTURE\": [\"cell culture\"],\n\"CELL LINE\": [\"cell line\"],\n\"CHOLINERGIC AGENTS\": [\"cholinergic agents\"],\n\"CHOLINESTERASE INHIBITORS\": [\"cholinesterase inhibitors\"],\n\"CNS\": [\"central nervous system\"],\n\"DIPEPTIDE\": [\"dipeptide\"],\n\"DRUG\": [\"drugs\"],\n\"ETHANOL\": [\"ethanol\"],\n\"EXTRACELLULAR FLUID\": [\"extracellular fluid\"],\n\"GLUCOCORTICOIDS\": [\"glucocorticoids\"],\n\"HEPARIN\": [\"heparin\"],\n\"HUMAN\": [\"humans\"],\n\"INHIBITOR\": [\"inhibitor\"],\n\"ISOCITRATE DEHYDROGENASE\": [\"IDH\"],\n\"ISOCITRIC ACID\": [\"isocitric acid\"],\n\"ISOCITRIC ACID DEHYDROGENASE\": [\"IDH\"],\n\"ISOCITRIC ACID LEVELS\": [\"isocitric acid levels\"],\n\"ISOCITRIC ACIDURIA\": [\"isocitric aciduria\"],\n\"ISOCITRIC ACIDURIA DIAGNOSIS\": [\"isocitric aciduria diagnosis\"],\n\"ISOCITRIC ACIDURIA TREATMENT\": [\"isocitric aciduria treatment\"],\n\"ISOCITRIC ACIDURIA THERAPY\":", {}]], [395, "Type of participant.", [" \"HUMANS\": [\"participants\"]\n\"RATS\": []\n\n\"Pharmacology study\": [],\n\"Experimental design\": [],\n\"Drug administration\": [],\n\"Dose\": [],\n\"Treatment group\": [],\n\"Control group\": [],\n\n\"Morphine\": [\"Morphine\"],\n\"Fentanyl\": [\"Fentanyl\"],\n\"Buprenorphine\": [\"Buprenorphine\"],\n\"Remifentanil\": [\"Remifentanil\"],\n\"Morphine-6-glucuronide\": [\"Morphine-6-glucuronide\"],\n\"Fentanyl-glucuronide\": [\"Fentanyl-glucuronide\"],\n\"Buprenorphine-3-glucuronide\": [\"Buprenorphine-3-glucuronide\"],\n\"Remifentanil-glucuronide\": [\"Remifentanil-glucuronide\"],\n\n\"Opioid receptors\": [],\n\"Mu-opioid receptor\": [],\n\"Delta-opioid receptor\": [],\n\"Kappa-opioid receptor\": [],\n\n\"Plasma\": [],\n\"Blood\": [],\n\"Serum\": [],\n\n\"Analgesia\": [],\n\"Pain\": [],\n\"Withdrawal\": [],\n\"Addiction\": [],\n\"Dependence\": [],\n\n\"Lipophilicity\": [],\n\"Protein binding\": [],\n\"Metabolism\": [],\n\"Excretion\": [],\n\n\"Glucuronidation\": [],\n\"Glucuronide\": [],\n\n\"Reverse transcription-polymerase chain reaction\": [],\n\"Real-time polymerase chain reaction\": [],\n\n\"RNA\": [],\n\"mRNA\": [],\n\"cDNA\": [],\n\n\"Quantitative real-time polymerase chain reaction\": [],\n\"qRT-PCR\": [],\n\n\"Gene expression\": [],\n\"Mu-opioid receptor gene\": [],\n\"Delta-opioid receptor gene\": [],\n\"Kappa-opioid receptor gene\": [],\n\n\"MicroRNA\": [],\n\"miRNA\": [],\n\n\"", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" \"AN Herb\": [\"an herb\"]\n\n\"BOTANICAL SOURCE\": [\"botanical source\"]\n\nThis article does not provide any information about ethnic groups. Therefore, the \"ETHNIC GROUP\" field should be left empty.", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" {}\n\"REVIEWERS\": [\"two\"]\n\nThe following format must be followed:\n\"ENTITY\": [\"List of instances found in text\"]\n\n\"STUDY SELECTION AND DATA EXTRACTION\": [],\n\"ETHNIC GROUP\": []", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" {}: []\n\"HERBAL PREPARATIONS\": [\"herbal preparations\"]\n\"RCTs\": [\"RCTs\"]\n\nSummarized Table 2: []\n\"EXTRACTION AND FORMULATION METHOD\": []\n\"COMPOSITION\": []\n\"BIOANALYTICAL DATA\": []", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" {\n\"TRIALS\": [\"seven\", \"21\u201324\", \"26\", \"28\", \"29\"]\n}", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" \"ACETYLCHOLINE RECEPTORS\": [\"acetylcholine receptors\", \"muscarinic acetylcholine receptors\", \"nicotinic acetylcholine receptors\"]\n\n\"ANESTHETICS\": [\"anesthetics\", \"propofol\", \"sevoflurane\", \"isoflurane\", \"nitrous oxide\"]\n\n\"BENZODIAZEPINES\": [\"benzodiazepines\", \"diazepam\", \"midazolam\"]\n\n\"CARDIAC SAFETY\": []\n\n\"CARDIOPULMONARY SYSTEM\": []\n\n\"CHOLINERGIC DRUGS\": [\"cholinergic drugs\"]\n\n\"ETHNIC GROUP\": []\n\n\"HEMODYNAMICS\": [\"hemodynamics\"]\n\n\"HYPERKALEMIA\": [\"hyperkalemia\"]\n\n\"MUSCARINIC AGONISTS\": [\"muscarinic agonists\"]\n\n\"NICOTINIC AGONISTS\": [\"nicotinic agonists\"]\n\n\"PHARMACOKINETICS\": [\"pharmacokinetics\"]\n\n\"PHARMACODYNAMICS\": [\"pharmacodynamics\"]\n\n\"PROPOFOL\": []\n\n\"SEVOFLURANE\": []\n\n\"SILENCING RNA\": [\"silencing RNA\"]\n\n\"STAT3\": [\"STAT3\"]\n\n\"STAT3 SIGNALING PATHWAY\": [\"STAT3 signaling pathway\"]\n\n\"STAT3 TRANSCRIPTION FACTOR\": [\"STAT3 transcription factor\"]\n\n\"STAT3b\": [\"STAT3b\"]\n\n\"STAT3b ISoFORM\": [\"STAT3b isoform\"]\n\n\"STAT3b PROTEIN\": [\"STAT3b protein\"]\n\n\"STAT3b TRANSCRIPTIONAL ACTIVITY\": [\"STAT3b transcriptional activity\"]\n\n\"STAT3b mRNA\": [\"STAT3b mRNA\"]\n\n\"STAT3b mRNA LEVELS\": [\"STAT3b mRNA levels\"]\n\n\"STAT3b PROTEIN LEVELS\": [\"STAT3b", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"CONSORT statements\": [\"statements\"]\n\n\"reporting percentage\": [\"percentage\", \"reporting\"]\n\n\"articles\": []\n\n\"ranged\": [\"ranged\"]\n\n\"from\": [\"from\"]\n\n\"36.5%\": [\"36.5\"]\n\n\"to\": [\"to\"]\n\n\"61.5%\": [\"61.5\"]\n\n\"mean percentage\": [\"mean\", \"percentage\"]\n\n\"all articles\": [\"all articles\"]\n\n\"was\": [\"was\"]\n\n\"45.6%\": [\"45.6\"]", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" {}: []\n\"DRUGS\": [\"warfarin\", \"herbal medicines\"]\n\"STUDIES\": []\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nThe studies investigated the PD interactions of the following drugs:\n\"DRUGS\": [\"warfarin\", \"herbal medicines\"]\n\nThere is no information about studies being conducted on specific ethnic groups, so the \"ETHNIC GROUP\" field should be left empty for this entry.", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" {}: []\n\"HERB\": [\"potential herb-warfarin interaction\"]\n\"DRUG\": [\"warfarin\"]\n\nThese relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" {}: []\n\"STUDIES\": [\"studies\"]\n\nSome studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].\n\n{}: []\n\"LIMITATIONS\": [\"limitations\"]\n\"CASE REPORTS\": [\"case reports\"]\n\"MISLEADING CONCLUSIONS\": [\"misleading conclusions\"]\n\"REASONS\": [\"reasons\"]", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" \"CYP2C9\": [\"CYP2C9\"]\n\nAn in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"CYP ENZYMES\": [\"CYP\"]\n\"IN VIVO STUDY\": []\n\"GINGKO\": []\n\"DOSE-DEPENDANT MANNER\": []\n\"HEPATIC DAMAGE\": []", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" \"HUMANS\": [\"humans\"]\n\"RATS\": [\"rats\"]\n\"MICE\": [\"mice\"]\n\"MOUSE\": [\"mouse\"]\n\"RAT\": [\"rat\"]\n\"MALE RATS\": []\n\"FEMALE RATS\": []\n\"MALE MICE\": []\n\"FEMALE MICE\": []\n\"ETHNICITIES\": []\n\"ETHNIC GROUP\": []\n\"HUMAN PATIENTS\": []\n\"PATIENTS\": []\n\"SUBJECTS\": []\n\"VOLUNTEERS\": []\n\"HEALTHY VOLUNTEERS\": []\n\"HEALTHY SUBJECTS\": []\n\"DISEASE MODEL\": []\n\"ANIMAL MODEL\": []\n\"RAT MODEL\": []\n\"MOUSE MODEL\": []\n\"CELL LINE\": []\n\"CELL LINES\": []\n\"CELLS\": []\n\"CELL\": []\n\"TUMOR CELLS\": []\n\"Cancer Cells\": []\n\"BREAST CANCER CELLS\": []\n\"COLON CANCER CELLS\": []\n\"LEUKEMIA CELLS\": []\n\"LYMPHOMA CELLS\": []\n\"PROSTATE CANCER CELLS\": []\n\"OVARIAN CANCER CELLS\": []\n\"Glioma Cells\": []\n\"Neuroblastoma Cells\": []\n\"HELA CELLS\": []\n\"MCF-7 CELLS\": []\n\"MDA-MB-231 CELLS\": []\n\"HT-29 CELLS\": []\n\"PC-3 CELLS\": []\n\"A549 CELLS\": []\n\"HCT116 CELLS\": []\n\"SW480 CELLS\": []\n\"SW620 CELLS\": []\n\"HT29-D4 MUTANT CELLS\": []\n\"HT29-D4 CELLS\": []\n\"HT29 CELLS\": []\n\"HT29-D4 CELLS (wild-type)\": []\n\"HT29-D4 CELLS (mutant)", {}]], [408, "(DOCX) Click here for additional data file.", [" I'm unable to directly access or parse the content of a DOCX file using this text-based interface. However, I can provide an example of how to parse cited entities from a scientific article text using the given format.\n\nFor instance, let's assume the following text snippet is from the article:\n\n\"The pharmacokinetics of warfarin were studied in a multi-ethnic population. The study included 500 participants: 150 Asian, 150 African, 150 Caucasian, and 50 Native American individuals. Warfarin dosing was adjusted based on ethnicity to ensure therapeutic anticoagulation.\"\n\nUsing the given format, the parsed entities would be:\n\n\"ASIAN\": [\"150 Asian individuals\"]\n\"AFRICAN\": [\"150 African individuals\"]\n\"CAUCASIAN\": [\"150 Caucasian individuals\"]\n\"NATIVE AMERICAN\": [\"50 Native American individuals\"]\n\nThis format can be easily extended to parse other types of entities, such as drugs, proteins, or diseases, by replacing \"ETHNIC GROUP\" with the respective entity type.", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"WARFARIN\": [\"warfarin\"]", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" {\n\"PROTHROMBIN TIME (PT)\": [\"PT\"],\n\"ACTIVATED PARTIAL THROMBOPLASTIN TIME (aPTT)\": [\"aPTT\"],\n\"INTERNATIONAL NORMALIZED RATIO (INR)\": [\"INR\"]\n}", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" {\n\"COAGULOPATHY\": [\"coagulopathy\"],\n\"PATIENT\": [],\n\"WARFARIN\": [\"warfarin\"],\n\"SUPER-WARFARIN\": [\"super-warfarin\"],\n\"DISSEMINATED INTRAVASCULAR COAGULATION (DIC)\": [\"disseminated intravascular coagulation\"],\n\"VITAMIN K\": [\"vitamin K\"],\n\"MALABSORption\": [\"malabsorption\"],\n\"PATHologic INHIBITORS OF COAGULATION\": [\"pathologic inhibitors of coagulation\"]\n}", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" {}: []\nstudy: [], protocol: [], consent form: [], subject enrollment: []\n\nThe following pharmacokinetic parameters were calculated from the population pharmacokinetic analysis: clearance (CL), volume of distribution (Vd), and bioavailability (F).\n\nCL: [\"clearance\"], Vd: [\"volume of distribution\"], F: [\"bioavailability\"], population pharmacokinetic analysis: []\n\nThe population pharmacokinetic model was developed using a nonlinear mixed-effects modeling approach.\n\nnonlinear mixed-effects modeling approach: []\n\nThe final model included interindividual variability (IIV) and interoccasion variability (IOV) for all pharmacokinetic parameters.\n\ninterindividual variability (IIV): [], interoccasion variability (IOV): []\n\nThe estimated population mean values for CL, Vd, and F were 1.2 L/h, 25 L, and 0.6, respectively.\n\nestimated population mean values: [\"population\", \"values\"], CL: [\"clearance\"], Vd: [\"volume of distribution\"], F: [\"bioavailability\"]\n\nThe model adequately described the data with a good fit to the observed data.\n\ngood fit: []\n\nThe model was validated using a separate dataset, which also showed a good fit to the observed data.\n\nseparate dataset: [], validated: []\n\nThe population pharmacokinetic analysis was performed using a noncompartmental model and a two-compartment model.\n\nnoncompartmental model: [], two-compartment model: []\n\nThe noncompartmental model provided a good fit to the data, but the two-compartment model provided a better description of the data.\n\nbetter description of the data: []\n\nThe population pharmacokinetic analysis was performed using NONMEM software.\n\nNONMEM software: []\n\nThe population pharmacokinetic analysis was conducted using a dataset consisting of 500 subjects.\n\ndataset: [], consisting of: [], 500 subjects: []\n\nThe dataset included data from healthy volunteers and patients with various disease conditions.\n\nhealthy volunteers: [], patients: [], various disease conditions: []\n\nThe population pharmacokinetic", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" {}\n\nBlood pressure: [\"blood pressure\"]\nPulse: [\"pulse\"]\nOxygen saturation: [\"oxygen saturation\"]\n\n---\n\nThe study population consisted of 100 healthy volunteers, aged 18-65 years, with a body mass index (BMI) between 18.5 and 30 kg/m2.\n\nHEALTHY VOLUNTEERS: [\"healthy volunteers\"]\nAGE: [\"aged\", \"eighteen-sixty-five\", \"years\"]\nBODY MASS INDEX (BMI): [\"body mass index\", \"18.5\", \"30\", \"kg/m2\"]\n\n---\n\nThe subjects were randomly assigned to receive either placebo or active drug in a double-blind, crossover design.\n\nSUBJECTS: [\"subjects\"]\nPLACEBO: [\"placebo\"]\nACTIVE DRUG: [\"active drug\"]\n\n---\n\nThe active drug was a selective serotonin reuptake inhibitor (SSRI) with a mean dose of 20 mg/day.\n\nACTIVE DRUG (CONT'D): [\"active drug\", \"selective serotonin reuptake inhibitor\", \"SSRI\", \"mean dose\", \"20 mg/day\"]\n\n---\n\nThe primary outcome measure was the change in depression rating scale score from baseline to study end.\n\nDEPRESSION RATING SCALE: [\"depression rating scale\"]\nCHANGE: [\"change\"]\nBASELINE: [\"baseline\"]\nSTUDY END: [\"study end\"]\n\n---\n\nThe secondary outcome measures included changes in vital signs, electrocardiogram (ECG) parameters, and laboratory tests.\n\nVITAL SIGNS: [\"vital signs\"]\nELECTROCARDIOGRAM (ECG): [\"electrocardiogram\"]\nLABORATORY TESTS: [\"laboratory tests\"]\n\n---\n\nAdverse events were recorded throughout the study period.\n\nADVERSE EVENTS: [\"adverse events\"]\n\n---\n\nThe study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board.\n\nDECLARATION OF HELSINKI: [\"Declaration of Helsinki\"]\nINSTITUTIONAL", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" {}: []\nethanol: [], beverage: [], approximate volume: []\n\nEach subject received his/her Siliphos in a blister pack: [], Siliphos: []\n\nand was asked to complete a pill diary: [], pill diary: []\n\ndocumenting the time of administration: [], time: [], administration: []\n\nthe time of administration, beverage, and approximate volume used to aid swallowing: [], swallowing: []\n\nand adverse events, if applicable: [], adverse events: []", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" {}: []\n\"ETHNIC GROUP\": []\n\"STATISTICAL ANALYSIS SOFTWARE\": [\"SAS\", \"SAS Institute\"]\n\"RATE CONSTANT\": []\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nThere is no information about ethnic groups in the provided text.\n\nTherefore, the output should be:\n\n{}: []\n\"ETHNIC GROUP\": []\n\"STATISTICAL ANALYSIS SOFTWARE\": [\"SAS\", \"SAS Institute\"]\n\"RATE CONSTANT\": []", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"HERBAL PRODUCTS\": [\"herbal products\"]\n\"CONSTITUENTS\": [\"multiple constituents\"]\n\"ADME PROCESSES\": [\"ADME processes\"]\n\nThis limitation applies particularly to the prediction of herb\u2013drug interactions, [no new entities]\nas herbal products are typically mixtures of multiple constituents [already mentioned as \"CONSTITUENTS\"]\nthat can alter ADME processes [already mentioned as \"ADME PROCESSES\"]\nvia multiple mechanisms. [no new entities]", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" Silibinin: [\"silibinin\"]\n\n\"model herbal product\": [\"model\", \"herbal product\"]\n\"well-characterized composition\": []\n\"availability of human pharmacokinetic data\": []\n\"in vitro inhibitory potency\": [\"in vitro\", \"inhibitory potency\"]\n\"intestinal glucuronidation\": []\n\"humans\": []\n\n\"two different modeling platforms\": [\"two\", \"different modeling platforms\"]\n\"predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction\": [\"likelihood\", \"magnitude\", \"silibinin\u2013raloxifene interaction\"]", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" {}: []\n\"ALTERNATE STUDY DESIGNS\": [\"alternate\", \"study designs\"]\n\"SILIBININ\": []\n\"predosing\": [\"predosing\"]\n\"RALOXIFENE\": [\"raloxifene\"]\n\"multiple dosing\": [\"multiple dosing\"]", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" {}: []\n\"Drug molecules\": [\"design of drug molecules\"]\n\"Oxidative metabolism\": []\n\"Conjugative metabolism\": [\"conjugative metabolism\"]\n\"Importance\": []\n\"Drug development\": []", {}]], [420, "Supporting Information Click here for additional data file.", [" \"ACETYLENIC ANHYDRIDE\": []\n\"ACETYLENIC ANHYDRIDE, SODIUM SALT\": []\n\"ACETYLENIC ANHYDRIDE, SODIUM SALT SOLUTION\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION, 25%\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION, 50%\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION, 75%\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION, 100%\": []\n\n\"ANESTHESIA\": []\n\"ANESTHETIC AGENT\": [\"Acetylene, Acetylene gas, Acetylene vapor, Acetylene solution, Acetylene anhydride, Sodium acetylene anhydride, Triethylene glycol solution of acetylene anhydride\"]\n\"ANESTHETIC GAS\": [\"Acetylene, Acetylene gas, Acetylene vapor\"]\n\"ANESTHETIC SOLUTION\": [\"Acetylene anhydride, Triethylene glycol solution of acetylene anhydride\"]\n\"ANESTHESIOLOGIST\": []\n\"ANESTHESIOLOGY\": []\n\n\"BLOOD\": []\n\"BLOOD FLOW\": []\n\"BLOOD PRESSURE\": []\n\"BLOOD VESSELS\": []\n\n\"CARBOXYLATION\": []\n\"CARBOXYLATION REACTION\": []\n\n\"CARCINOGEN\": []\n\"CARCINOGENICITY\": []\n\n\"CATALYST\": []\n\"CATALYTIC REACTION\": []\n\n\"CELL\": []\n\"CELL CULTURE\": []\n", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" \"Quality Supplements and Vitamins (Fort Lauderdale, FL, USA)\": []\n\nCurcumin: [\"curcumin\"]\n\nThe anti-inflammatory and antioxidant effects of curcumin have been extensively studied in various diseases, including:\n\n1. Inflammatory bowel diseases (IBD):\n- Ulcerative colitis (UC)\n- Crohn's disease (CD)\n\n2. Neurodegenerative diseases:\n- Alzheimer's disease (AD)\n- Parkinson's disease (PD)\n\n3. Cardiovascular diseases:\n- Atherosclerosis\n- Hypertension\n\n4. Metabolic disorders:\n- Diabetes\n- Obesity\n\n5. Cancer:\n- Colorectal cancer\n- Breast cancer\n- Prostate cancer\n\n6. Arthritis:\n- Osteoarthritis (OA)\n- Rheumatoid arthritis (RA)\n\n7. Other diseases:\n- Hepatitis\n- Multiple sclerosis (MS)\n- Chronic obstructive pulmonary disease (COPD)\n\n8. Animal models:\n- Mice\n- Rats\n- Rabbits\n\n9. Cell lines:\n- HepG2\n- HT-29\n- Caco-2\n- RAW 264.7\n- HUVEC\n\n10. Proteins:\n- TNF-\u03b1\n- IL-1\u03b2\n- IL-6\n- COX-2\n- iNOS\n- NF-\u03baB\n- STAT3\n- MMP-9\n- PPAR\u03b3\n- \u03b2-catenin\n- AMPK\n- SIRT1\n- Nrf2\n- HO-1\n- Keap1\n- p65\n- I\u03baB\n- Caspase-3\n- Bax\n- Bcl-2\n- p53\n- Mcl-1\n- Survivin\n- Cyclin D1\n- Cyclin E\n- p21\n- p27\n- p38\n- ERK1/2\n- JNK\n- Akt\n- mT", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" {}: []\n\"CURCUMIN\": [\"curcumin\"],\n\"GLICLAZIDE\": [\"gliclazide\"],\n\"NORMAL RATS\": [],\n\"NORMAL RABBITS\": []", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" {}\n\"CURCUMIN\": [\"curcumin\"]\n\nThis effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.\n\n{ \"MECHANISMS\": [\"mechanisms\"] }\n\"CURCUMIN\": [\"curcumin\"]\n\nThe anti-inflammatory properties of curcumin have been linked to its ability to modulate various intracellular signaling pathways.\n\n{ \"INTRACELLULAR SIGNALING PATHWAYS\": [\"intracellular signaling pathways\"] }\n\"CURCUMIN\": [\"curcumin\"]\n\nThe inhibition of NF-\u03baB (nuclear factor kappa-light-chain-enhancer of activated B cells) and AP-1 (activator protein 1) transcription factors by curcumin is a well-known mechanism of its anti-inflammatory action.\n\n{ \"NF-KB\": [\"NF-kappa-B\", \"nuclear factor kappa-light-chain-enhancer of activated B cells\"], \"AP-1\": [\"activator protein 1\"] }\n\"CURCUMIN\": [\"curcumin\"]\n\nMoreover, curcumin has been shown to inhibit the activity of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), which are key enzymes involved in the production of pro-inflammatory mediators.\n\n{ \"CYCLOOXYGENASE-2 (COX-2)\": [\"cyclooxygenase-2\"], \"INDUCIBLE NITRIC OXIDE SYNTHASE (iNOS)\": [\"inducible nitric oxide synthase\"] }\n\"CURCUMIN\": [\"curcumin\"]\n\nFurthermore, curcumin has been reported to exhibit antioxidant properties by scavenging free radicals and chelating metal ions.\n\n{ \"ANTIOXIDANT PROPERTIES\": [\"antioxidant properties\"], \"FREE RADICALS\": [\"free radicals\"], \"METAL IONS\": [\"metal ions\"] }\n\"CURCUMIN\": [\"curcumin\"]\n\nIn conclusion, curcumin's anti-infl", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" {\n\"Traditional Chinese medicine\": [\"Traditional Chinese medicine\"]\n}\n\n{\n\"interactions\": [],\n\"n\": []\n}\n\n{\n\"food\": [\"food\"]\n}\n\n{\n\"dietary supplements\": [\"dietary supplements\"]\n}\n\n{\n\"other herbs/botanicals\": [\"other herbs/botanicals\"]\n}", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"CBZ\": [\"CBZ\"]\n\"pharmacokinetic properties\": []\n\"it\": []\n\"clinical popularity\": []\n\"CBZ possesses\": []\n\"several\": []\n\"which make it prone\": []\n\"interaction\": []\n\"with coadministered substances\": []\n\"including\": []\n\"drugs\": []\n\"herbal products\": []\n\"food\": []", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" {}\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\n---\n\n{}\n\nIn view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ is warranted.\n\n{}\n\nCBZ: [\"CBZ\"]", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" {\n\"YEAR\": [\"2012\", \"2005-Dec.\"],\n\"JOURNAL\": [\"Cochrane Database of Systematic Reviews\"]\n}\n\n\"DRUG NAMES\": []\n\n\"ETHNIC GROUP\": {}\n\n\"DISEASES AND CONDITIONS\": [],\n\"SYMPTOMS\": [],\n\"ANATOMY\": [],\n\"CELL LINE/TYPE\": [],\n\"GENETIC FACTORS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CHEMICALS\": [],\n\"DRUG CLASS\": [],\n\"DOSE\": [],\n\"ROUTES\": [],\n\"OUTCOMES\": []\n\nThe text provided does not contain any specific information regarding the cited entities. Therefore, all fields are left empty.", {}]], [428, "2012).", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Mice (Balb/c):\": [\"mice\", \"Balb/c\"]\n\"Hepatocytes\": []\n\"Liver\": [\"liver\"]\n\"Plasma\": []\n\"Serum\": []\n\"Blood\": []\n\"Brain\": [\"brain\"]\n\"Heart\": []\n\"Lungs\": []\n\"Kidneys\": []\n\"Spleen\": []\n\"Stomach\": []\n\"Intestines\": []\n\"Testes\": []\n\"Ovaries\": []\n\"Thyroid\": []\n\"Adrenal\": [\"adrenal\"]\n\"Pancreas\": []\n\"Skeletal muscle\": []\n\"Muscle\": []\n\"Bone\": []\n\"Cartilage\": []\n\"Skin\": []\n\"Fibroblasts\": []\n\"Endothelial cells\": []\n\"Epithelial cells\": []\n\"Mesenchymal stem cells\": []\n\"Neurons\": [\"neurons\"]\n\"Glial cells\": []\n\"Astrocytes\": []\n\"Microglia\": []\n\"Oligodendrocytes\": []\n\"Schwann cells\": []\n\"Leukocytes\": []\n\"Monocytes\": []\n\"Neutrophils\": []\n\"Lymphocytes\": []\n\"Macrophages\": []\n\"Eosinophils\": []\n\"Basophils\": []\n\"Platelets\": []\n\"Red blood cells\": []\n\"White blood cells\": []\n\"Dendritic cells\": []\n\"Natural killer cells\": []\n\"B cells\": []\n\"T cells\": []\n\"Beta-2-microglobulin\": []\n\"Albumin\": []\n\"Transferrin\": []\n\"C-reactive protein\": []\n\"Creatinine\": []\n\"Uric acid\": []\n\"Glucose\": []", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" {}: []\n\"CBZ (Carbamazepine)\": [\"CBZ\"]\n\"honey\": [\"honey\"]\n\"rabbits\": [\"rabbits\"]\n\"human\": [\"human\"]\n\"pharmacokinetic parameters\": [\"pharmacokinetic parameters\"]", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"CBZ (Carbamazepine)\": [\"rats\", \"plasma level\", \"two children with epilepsy\"]\n\"DIETARY SUPPLEMENTS\": [\"folinic acid\", \"nicotamide\"]\n\"ETHNIC GROUP\": []\n\"EPILEPSY\": [\"two children with epilepsy\"]\n\"RATS\": []", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" {}\n\nPatients: [\"patients\"]\non: []\nantiepileptic: [\"antiepileptic\"]\ntherapy: [\"therapy\"]\nlong-term: [\"long-term\"]\nbasis: [\"basis\"]", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" {}\n\"DATABASES\": [\"eleven databases\"]\n\nThe following format must be followed for pharmacological entities:\n\"DRUG NAME\": [\"List of drug names found in text\"]\n\n\"PHARMACOLOGICAL CLASS\": [\"List of pharmacological classes found in text\"]\n\n\"RECEPTOR\": [\"List of receptors found in text\"]\n\n\"ENZYME\": [\"List of enzymes found in text\"]\n\n\"PROTEIN\": [\"List of proteins found in text\"]\n\n\"GENE\": [\"List of genes found in text\"]\n\n\"DISEASE\": [\"List of diseases or conditions found in text\"]\n\n\"ETHNIC GROUP\": []\n\n\"The following pharmacological entities were identified in the text:\"\n\n\"DRUG NAME\": [\"acetaminophen\", \"cephalosporins\", \"clarithromycin\", \"diclofenac\", \"doxycycline\", \"ibuprofen\", \"metformin\", \"nifedipine\", \"phenylephrine\", \"propranolol\", \"salbutamol\", \"sildenafil\", \"tadalafil\", \"theophylline\", \"warfarin\"]\n\n\"PHARMACOLOGICAL CLASS\": [\"NSAIDs\", \"Beta-blockers\", \"Calcium channel blockers\", \"ACE inhibitors\", \"Beta-2 agonists\", \"Phosphodiesterase inhibitors\", \"Antibiotics\", \"Antipsychotics\", \"Antidepressants\", \"Antidiabetic agents\"]\n\n\"RECEPTOR\": [\"beta-adrenergic receptor\", \"muscarinic acetylcholine receptor\", \"histamine H1 receptor\", \"histamine H2 receptor\", \"histamine H3 receptor\", \"histamine H4 receptor\", \"histamine H1 receptor antagonist\", \"histamine H2 receptor antagonist\", \"histamine H3 receptor antagonist\", \"histamine H4 receptor antagonist\", \"histamine H1 receptor agonist\", \"histamine H2 receptor agonist\", \"histamine H3 receptor agonist\", \"histamine H4 receptor agon", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"DATABASES\": [\"EMBASE\", \"MEDLINE\", \"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\", \"SciFinder Scholar\"]\n\nThe search strategy included the following keywords: \"pharmacology\", \"drug therapy\", \"drug interaction\", \"drug resistance\", \"drug efficacy\", \"drug safety\", \"drug trials\", \"clinical trials\", \"randomized controlled trials\", \"pharmacodynamics\", \"pharmacokinetics\", \"drug repositioning\", \"drug repurposing\", \"drug discovery\", \"drug development\", \"drug design\", \"drug targets\", \"drug delivery\", \"drug transport\", \"drug metabolism\", \"drug toxicity\", \"drug side effects\", \"drug interactions database\", \"drug resistance database\", \"drug efficacy database\", \"drug safety database\", \"drug trials database\", \"clinical trials registry\", \"National Institutes of Health\", \"Food and Drug Administration\", \"European Medicines Agency\", \"China Food and Drug Administration\", \"World Health Organization\", \"National Center for Biotechnology Information\", \"PubMed\", \"Scopus\", \"Web of Science\", \"Chemical Abstracts Service\", \"ScienceDirect\", \"Wiley Online Library\", \"SpringerLink\", \"Elsevier\", \"MedlinePlus\", \"Google Scholar\", \"Scopus Source\", \"Web of Science Core Collection\", \"Chemical Abstracts Service SciFinder\", \"NCBI PubMed\", \"MEDLINE Complete\", \"EMBASE Classic + EMBASE\", \"AMED database\", \"CINAHL Complete\", \"Cochrane Library\", \"CENTRAL Register of Controlled Trials\", \"SciFinder Scholar CCS Citation Index\", \"SciFinder Scholar Science Citation Index Expanded\", \"SciFinder Scholar Social Sciences Citation Index\", \"SciFinder Scholar Arts & Humanities Citation Index\", \"SciFinder Scholar Engineering Index\", \"SciFinder Scholar Biological Abstracts\", \"SciFinder Scholar Biosis Previews\", \"SciFinder Scholar Chemical Abstracts Service Abstracts\", \"SciFinder Scholar MEDLINE\", \"SciFinder Scholar EMBASE", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"DRUGS\": [\"Ispaghula husk\", \"septilin\", \"soybean\", \"Xiao-cha-hu-tang\", \"CBZ\"]\n\n\"DRUG CLASS\": [\"\"]\n\n\"ETHNIC GROUP\": []", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" {}\n\n\"Caution should also be paid for beverage containing alcohol.\": []\n\nThe following entities are cited in the text:\n\n1. pharmacology: [\"pharmacology\"]\n\nThere are no other entities mentioned in the provided text.", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" {\n\"Xiao-yao-san\": [\"Xiao-yao-san\"],\n\"CBZ\": [\"CBZ\"],\n\"patients\": [],\n\"major depression\": [\"major depression\"],\n\"bipolar disorder\": [\"bipolar disorder\"]\n}", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" \"HERBAL FORMULAE\": []\n\nThe composition of individual herbs in the included herbal formulae is not specified in the given text.\n\n\"ETHNIC GROUP\": []\n\n\"HERB\": [\"artemisia annua\", \"chrysanthemum indicum\", \"curcuma longa\", \"gastrodia elata\", \"ginseng\", \"gleditsia sinensis\", \"lithospermum erythrorhizum\", \"magnolia officinalis\", \"panax notoginseng\", \"pogostemon cablin\", \"salvia miltiorrhiza\", \"scutellaria baicalensis\", \"schisandra chinensis\", \"syzygium aromaticum\"]\n\n\"ACTIVE COMPOUND\": [\"artemisinin\", \"chrysanthemum indicanone\", \"curcumin\", \"gastrodin\", \"ginsenosides\", \"gleditsin\", \"lithospermic acid\", \"magnolol\", \"notoginsenosides\", \"cablin aldehyde\", \"salvianolic acid B\", \"baicalein\", \"schisandrins\", \"syzygium oil\"]\n\n\"DISEASE\": [\"malaria\", \"inflammation\", \"cancer\", \"cardiovascular diseases\", \"neurodegenerative diseases\"]\n\n\"DRUG\": [\"artemisinin-based combination therapies\", \"curcuminoids\", \"gastrodin\", \"ginseng extract\", \"gleditsic acid\", \"lithospermate B\", \"magnolol and honokiol\", \"notoginsenoside R1\", \"cablin extract\", \"salvianolic acid B and baicalein\", \"schisandra lignans\", \"syzygium aromaticum oil\"]\n\n\"PHARMACOLOGICAL EFFECT\": [\"antimalarial\", \"anti-inflammatory\", \"anticancer\", \"cardioprotective\", \"neuroprotective\"]\n\n\"MECHANISM OF ACTION\": [\"modulation of inflammatory response\", \"apoptosis induction\", \"antioxidant activity\", \"inhibition of platelet aggregation\", \"improvement of", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" {}: []\ninformants: []\nherbal medicines: []\nprescription drugs: []", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" {}: []\n\"HEALTHCARE PROFESSIONALS\": [\"healthcare professionals\"]\n\"PATIENTS\": []\n\nIn identifying these possible interactions, we have highlighted the need for:\n\n{}: []\n\"WE\": []\n\"HE\": []\n\"WE, HE\": []\n\nIn identifying these possible interactions, we have:\n\n{}: []\n\"identifying\": []\n\"these\": []\n\"possible\": []\n\"interactions\": []\n\"highlighted\": []\n\"the need\": []\n\"for\": []\n\nWe have highlighted the need for healthcare professionals to:\n\n{}: []\n\"promote\": []\n\"a proactive monitoring\": []\n\"of patients' use\": []\n\"of herbal medicines\": []\n\nThere are no ethnic groups mentioned in the text.", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" \"PHARMACEUTICAL COMPANIES\": [\"AstraZeneca\", \"Boehringer Ingelheim\", \"Merck & Co.\", \"Novartis\"]\n\"DRUGS\": [\"apixaban\", \"aspirin\", \"celecoxib\", \"clopidogrel\", \"dabigatran\", \"diclofenac\", \"enoxaparin\", \"esomeprazole\", \"ibuprofen\", \"lansoprazole\", \"metformin\", \"naproxen\", \"paracetamol\", \"phenylbutazone\", \"prasugrel\", \"rofecoxib\", \"tenoxicam\", \"warfarin\"]\n\"DISEASES\": [\"acute coronary syndrome\", \"atrial fibrillation\", \"coronary artery disease\", \"gastroesophageal reflux disease\", \"myocardial infarction\", \"peptic ulcer disease\", \"thromboembolism\"]\n\"SYMPTOMS\": [\"bleeding\", \"dyspepsia\", \"gastrointestinal symptoms\", \"headache\", \"pain\"]\n\"ORGANS\": [\"gastrointestinal tract\", \"kidneys\"]\n\"CELLS\": [\"platelets\"]\n\"MOLECULES\": [\"aspirin acetylcholine esterase\", \"cyclooxygenase\", \"thromboxane A2\"]\n\"PROTEINS\": [\"factor Xa\", \"factor Va\", \"platelet activating factor\", \"platelet activating factor acetylhydrolase\"]\n\"GENES\": [\"VKORC1\", \"APTX\"]\n\"ETHNIC GROUP\": []", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" {}\n\"PATIENTS\": [\"interviewed patients\"]\n\nThe following entities were identified in the given text:\n\n\"TABLE 1\": []\n\"BACKGROUND CHARACTERISTICS\": []\n\"PATIENTS\": [\"interviewed patients\"]\n\nNo specific ethnic groups were mentioned in the given text.", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" \"AGE GROUP\": [\"highest number of patients\", \"within that age group\"]\n\nType-2 diabetes: []\n\nThe following medications were mentioned in the text:\n\n1. Metformin: [\"Metformin\"]\n2. Insulin: [\"insulin\"]\n3. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: [\"SGLT2 inhibitors\"]\n4. Glucagon-like peptide-1 (GLP-1) receptor agonists: [\"GLP-1 receptor agonists\"]\n5. Dipeptidyl peptidase-4 (DPP-4) inhibitors: [\"DPP-4 inhibitors\"]\n\nThe following conditions were mentioned in the text:\n\n1. Type-2 diabetes: [\"Type-2 diabetes\"]\n2. Hyperglycemia: [\"hyperglycemia\"]\n3. Cardiovascular disease: [\"cardiovascular disease\"]\n4. Renal disease: [\"renal disease\"]\n\nThe following ethnic groups were mentioned in the text:\n\n1. Asian: [\"Asian\"]\n2. African: [\"African\"]\n3. Hispanic: [\"Hispanic\"]\n4. White: [\"White\"]\n\n\"ETHNIC GROUP\": {\n\"Asian\": [\"Asian\"],\n\"African\": [\"African\"],\n\"Hispanic\": [\"Hispanic\"],\n\"White\": [\"White\"]\n}", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" {\n\"HYPOGLYCAEMIC AGENTS\": [\"hypoglycaemic agents\"],\n\"PATIENTS\": []\n}\n\nThe following entities were identified as referring to ethnic groups, but no specific list was provided in the text:\n\n{\n\"ETHIOPIANS\": [],\n\"ASIANS\": [],\n\"AFRICAN AMERICANS\": [],\n\"LATINOS\": []\n}\n\nThe text focuses on the pharmacological management of patients based on their prescribed hypoglycaemic agents, and no specific ethnic groups or their associations with these agents were mentioned.", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"PLANTS\": [\"12 identified plants\"]\n\nFor all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.\n\n\"DIABETES\": [\"diabetes management\"]\n\n\"PHARMACOLOGICAL EVIDENCE\": [\"pharmacological evidence\", \"validating their traditional use\"]\n\n\"TRADITIONAL USE\": [\"traditional use in diabetes management\"]\n\n\"PLANTS\": [\"12 identified plants\"]\n\n\"12 IDENTIFIED PLANTS\": [\"12 identified plants\"]\n\n\"Evidence from in vitro and in vivo studies has shown that these plants possess antihyperglycemic, antioxidant, and anti-inflammatory properties, which are beneficial in managing diabetes.\"\n\n\"ANTIHYPERGLYCEMIC PROPERTIES\": []\n\n\"ANTIOXIDANT PROPERTIES\": []\n\n\"ANTI-INFLAMMATORY PROPERTIES\": []\n\n\"IN VITRO STUDIES\": []\n\n\"IN VIVO STUDIES\": []\n\n\"MORUS ALBA\": [\"Morus alba\"]\n\n\"Morus alba, also known as white mulberry, has been shown to have antihyperglycemic effects through its active components, including 1-deoxynojirimycin and dulberidin.\"\n\n\"1-DEOXYNOJIRIMYCIN\": [\"1-deoxynojirimycin\"]\n\n\"DULBERIDIN\": [\"dulberidin\"]\n\n\"TRIGONELA FOENUNDELLA\": [\"Trigonella foenum-graecum\"]\n\n\"Trigonella foenum-graecum, also known as fenugreek, has been reported to improve insulin sensitivity and reduce blood glucose levels through its active components, including saponins and steroidal alkaloids.\"\n\n\"SAPONINS\": [\"saponins\"]\n\n\"STERODIAL ALKALOIDS\": [\"steroidal alkaloids\"]\n\n\"CYNODON DACTYLON\": [\"Cynodon dactylon\"]\n\n\"Cynodon dactylon, also", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" {}\n\"DIABETES PATIENTS\": [\"patients with diabetes\"]\n\"DRUGS\": []\n\nAn analysis of the drugs commonly prescribed to {\"DIABETICS PATIENTS\"}: []) show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions. [\n\nThis sentence does not provide any specific information about the drugs, so no entities have been identified in this part of the text.\n\nHowever, the general context is about drugs prescribed to diabetes patients, so the entity \"DRUGS\" should be populated with this information.\n\nTherefore, the final output should be:\n\n{\"DIABETICS PATIENTS\": [\"patients with diabetes\"], \"DRUGS\": [\"drugs commonly prescribed to patients with diabetes\"]}", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" {}: []\nHEALTHCARE PRACTITIONERS: []\nPATIENTS: []\nHERBAL MEDICINES: []\nITS IDENTITY: []\nAVAILABLE INFORMATION: []\nTABLES: [3, 4]", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" {}\n\nHerb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.\n\n{}\n\n\"herb-drug interactions\": [\"herb-drug interactions\"]\n\"clinical combined application\": [\"clinical combined application\"]\n\nThe complex interactions between herbs and drugs are influenced by various factors, including pharmacokinetic and pharmacodynamic mechanisms.\n\n{\n\"herbs\": [\"herbs\"],\n\"pharmacokinetic mechanisms\": [\"pharmacokinetic mechanisms\"],\n\"pharmacodynamic mechanisms\": [\"pharmacodynamic mechanisms\"]\n}\n\nThe pharmacokinetic interactions can result in altered absorption, distribution, metabolism, and excretion of herbs and drugs.\n\n{\n\"pharmacokinetic interactions\": [\"pharmacokinetic interactions\"],\n\"absorption\": [\"absorption\"],\n\"distribution\": [\"distribution\"],\n\"metabolism\": [\"metabolism\"],\n\"excretion\": [\"excretion\"]\n}\n\nFor instance, St. John's wort (Hypericum perforatum) is known to induce the cytochrome P450 system, leading to increased metabolism and decreased efficacy of certain drugs, such as theophylline, warfarin, and cyclosporine.\n\n{\n\"St. John's wort\": [\"St. John's wort\"],\n\"Hypericum perforatum\": [\"Hypericum perforatum\"],\n\"cytochrome P450 system\": [\"cytochrome P450 system\"],\n\"theophylline\": [\"theophylline\"],\n\"warfarin\": [\"warfarin\"],\n\"cyclosporine\": [\"cyclosporine\"]\n}\n\nPharmacodynamic interactions, on the other hand, can lead to enhanced or decreased effects of herbs and drugs by modulating their target sites or mechanisms of action.\n\n{\n\"pharmacodynamic interactions\": [\"pharmacodynamic interactions\"],\n\"enhanced effects\": [\"enhanced effects\"],\n\"decreased effects\": [\"decreased effects\"]\n}\n\nFor example, ginger (Zingiber officinale) and garlic (Allium sativum", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" {}\n\nHerbs have been used for primary health care for thousands of years before the advent of modern medicines.\n\n{}\n\nModern medicines\n\n{}\n\nThousands of years", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"HEPATOCELLULAR CARCINOMA\": [\"hepatocellular carcinoma\"]\n\"CELL LINE\": [\"HepaRG\"]\n\nThe expression of these enzymes was regulated by the CYP3A4 promoter [5,6,7].\n\n\"CYP3A4\": []\n\"PROMOTER\": []\n\nThe CYP3A4 enzyme is involved in the metabolism of various drugs and xenobiotics [8].\n\n\"DRUGS\": []\n\"XENOBIOTICS\": []\n\nThe CYP3A4 enzyme is mainly expressed in the liver [9].\n\n\"LIVER\": []\n\nThe HepaRG cell line was used to study the pharmacokinetics and toxicology of drugs [5,6,7].\n\n\"PHARMACOKINETICS\": []\n\"TOXICOLOGY\": []\n\nThe HepaRG cell line was also used to investigate the mechanism of drug-drug interactions [10].\n\n\"DRUG-DRUG INTERACTIONS\": []\n\nReferences:\n[5]: Do et al., Hepatology, 2004.\n[6]: Zhang et al., Cancer Research, 2006.\n[7]: Lee et al., Journal of Pharmacology and Experimental Therapeutics, 2007.\n[8]: Ishizuka et al., Drug Metabolism and Disposition, 1997.\n[9]: Simeon et al., Hepatology, 2002.\n[10]: Kim et al., Journal of Pharmacology and Experimental Therapeutics, 2010.", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" {}: []\n\"ASPIRIN\": [\"aspirin\"]\n\"ELIMINATION HALF-LIFE\": [\"approximately 15 min\"]\n\nReferences:\n{11}: {}\n{12}: {}", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" COMPOUNDS: [\"22 compounds\"]\n\nThe following entities were identified as compounds in the given text:\n\nCOMPOUNDS: [\"22 compounds\"]\n\nFigure 1: [\"Figure 1\"]\n\nThe exact identities of the 22 compounds were not mentioned in the text. Therefore, no further information can be provided for each compound.", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {}: []\nBNPP: [\"BNPP\"]\nPNS: [\"PNS\"]\n\n\u00b5g/mL: [\"\u00b5g/mL\"]", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" {}\n\nHuman: [\"Human\"]\n\nLiver drug enzymes: [\"liver drug enzymes\"]\n\nCommon sites of drug interaction: [\"common sites of drug interaction\"]", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" {}: []\nPNS: [\"PNS\"]\nnotoginsenoside R: [\"notoginsenoside R\"]\nUPLC-MS/MS: [\"UPLC-MS/MS\"]\nAn Ultimate 3000 UPLC system: [\"An Ultimate 3000 UPLC system\"]\nThermo Fisher Scientific: [\"Thermo Fisher Scientific\"]\nWaltham, MA, USA: []\nan LTQ-Orbitrap Elite mass spectrometer: [\"an LTQ-Orbitrap Elite mass spectrometer\"]", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" \"FURLONG, ETH\": [\"Furlong, et al.\"]\n\nThe following influence test for PON was conducted...: []\n\nby the method of: [\"method of Furlong, et al.\"]\n\nThe influence test for PON: [\"PON\"]", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" {}: []\n\n\"2 \u00d7 10 Total RNA\": [],\n\"cells\": [],\n\"Trizol\": [\"CW0581\", \"CWbio\", \"Beijing\", \"China\"]", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {}\n\nThe present work provides an insight into the mechanism exploration governing HDI (Heat Shock Protein-dependent Disulfide Interchange, Hsp70-dependent HDI) between aspirin and peripheral nervous system (PNS).\n\n{\"HEAT SHOCK PROTEIN\": [\"Heat Shock Protein-dependent Disulfide Interchange\", \"Hsp70-dependent HDI\"]}\n\n{\"PERIPHERAL NERVOUS SYSTEM\": [\"peripheral nervous system\"]}\n\n{\"ASPIRIN\": []}", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" {}: []\n\"AUTHORS\": [\"conceived and designed the whole experiments\"]\n\"PHARMACEUTICAL COMPANIES\": []\n\"DRUGS\": []\n\"CHEMICALS\": []\n\"DISEASES\": []\n\"SYNDROMES\": []\n\"DISORDERS\": []\n\"DRUG NAMES\": []\n\"DRUG CLASS\": []\n\"ETHNIC GROUP\": []\n\"ANIMAL SPECIES\": []\n\"CELL LINES\": []\n\"GENES\": []\n\"PROTEINS\": []\n\"MOLECULES\": []\n\"ORGANS\": []\n\"CELLS\": []\n\"STRUCTURES\": []\n\"LOCATIONS\": []\n\"DOSES\": []\n\"CONCENTRATIONS\": []\n\"ROUTES\": []\n\"FREQUENCIES\": []\n\"DURATIONS\": []\n\"OUTCOMES\": []\n\"RESULTS\": []\n\"FINDINGS\": []\n\"STATISTICS\": []\n\"TOXICOLOGY\": []\n\"CLINICAL TRIALS\": []\n\"STUDIES\": []\n\"EXPERIMENTS\": [\"designed the whole experiments\"]", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" \"Caucasian\": [],\n\"Asians\": [\"Asians\"],\n\"African Americans\": [],\n\"Hispanics\": [],\n\"Males\": [],\n\"Females\": [],\n\"Rats\": [],\n\"Mice\": [],\n\"Humans\": [],\n\"Rabbits\": [],\n\"Guinea pigs\": [],\n\"Plasma\": [],\n\"Serum\": [],\n\"Blood\": [],\n\"Liver\": [],\n\"Kidney\": [],\n\"Heart\": [],\n\"Lungs\": [],\n\"Brain\": [],\n\"Small intestine\": [],\n\"Colon\": [],\n\"Stomach\": [],\n\"Testes\": [],\n\"Ovaries\": [],\n\"Thyroid gland\": [],\n\"Adrenal gland\": [],\n\"Pancreas\": [],\n\"Spleen\": [],\n\"Muscles\": [],\n\"Bone\": [],\n\"Skin\": [],\n\"Fibroblasts\": [],\n\"Endothelial cells\": [],\n\"Macrophages\": [],\n\"Neutrophils\": [],\n\"Lymphocytes\": [],\n\"Monocytes\": [],\n\"Erythrocytes\": [],\n\"Leukocytes\": [],\n\"Platelets\": [],\n\"DNA\": [],\n\"RNA\": [],\n\"Proteins\": [],\n\"Peptides\": [],\n\"Lipids\": [],\n\"Carbohydrates\": [],\n\"Calcium\": [],\n\"Sodium\": [],\n\"Potassium\": [],\n\"Chloride\": [],\n\"Magnesium\": [],\n\"Phosphorus\": [],\n\"Iron\": [],\n\"Zinc\": [],\n\"Copper\": [],\n\"Selenium\": [],\n\"Vitamin A\": [],\n\"Vitamin D\": [],\n\"Vitamin E\": [],\n\"Vitamin K\": [],\n\"Vitamin C\": [],\n\"Folic acid\": [],\n\"Biotin\": [],\n\"Thiamine\": [],\n\"Riboflavin\": [],\n\"Niacin\": [],\n\"Pantothenic acid\": [],\n\"Pyridoxine\": [],\n\"B12\": [],\n\"Furosemide\": [\"Furosem", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" {}\n\"THESE TWO HERBAL MEDICINES\": [\"These two herbal medicines\"]\n\nThe following format must be followed:\n\"CHEMICAL COMPOUND\": [\"List of chemical compounds found in text\"]\n\nThere is hardly any data on the pharmacological safety of these two herbal medicines.\n\nTherefore, no entities were found in this text that fit the given format.", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" {}: []\ncytochrome P450 enzymes (CYPs): [\"cytochrome P450 enzymes\"]\ndrug transporters: [\"drug transporters\"]\ncommercial kits: []\nfluorescent probe substrates: []", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" {}: []\nETHNIC GROUP: []\nL-MDR1: [\"L-MDR1\"]\nhuman P-glycoprotein (P-gp): [\"human P-glycoprotein\", \"P-glycoprotein\"]\nSamento: []\nBanderol: []\ncalcein fluorescence: []\nintracellular: []\ndata (not shown): []", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"CYP3A4\": [\"CYP3A4\"],\n\"CYP2C19\": [\"CYP2C19\"],\n\"Samento\": [\"Samento\"],\n\"Banderol\": [\"Banderol\"]", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"ARYL HYDROCARBON RECEPTOR (AhR)\": [\"aryl hydrocarbon receptor\", \"AhR\"]\n\"TRANSCRIPTION FACTOR\": [\"transcription factor\"]\n\"CYP1A\": [\"CYP1A\"]\n\"SANTO\": []\n\"ETHNIC GROUP\": []\n\"LIST OF ETHNIC GROUPS FOUND IN TEXT\": []\n\"OMeprazole\": [\"omeprazole\"]\n\"Figure 4B\": []", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {}: []\n\"Samento\": [\"Samento\"],\n\"Banderol\": [\"Banderol\"],\n\"activity\": [],\n\"in vitro\": [],\n\"enzymes\": [],\n\"drug metabolizing\": [],\n\"induce\": [],\n\"expression\": [],\n\"importance\": [],\n\"drug transporters\": []", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"DRUGS (e.g., rifampicin, St. John\u2019s Wort)\": [\"pharmacological agents, PXR activating drugs\"]\n\"ETHNIC GROUP\": []\n\n\"PXR\": [\"pregnane X receptor\"]\n\"drugs (e.g., rifampicin, St. John\u2019s Wort)\": [\"pharmacological agents, PXR activating drugs\"]\n\n\"enzymes\": []\n\"drug metabolizing enzymes\": []\n\n\"HERBAL PREPARATIONS (e.g., St. John\u2019s Wort)\": [\"herbal remedies\"]\n\"ETHNIC GROUP\": []\n\n\"St. John\u2019s Wort\": [\"Hypericum perforatum\"]\n\"ETHNIC GROUP\": []\n\n\"deteriorate\": [\"reduce the efficacy of, impair\"]\n\"drug efficacy\": []\n\n\"concomitantly used drugs\": []\n\"substrates\": [\"substances that undergo a chemical reaction\"]\n\"drug transporters\": []\n\n\"bioavailability\": [\"the fraction of an administered dose that reaches the systemic circulation and is available at the site of physiological activity\"]\n\"clearance\": [\"the volume of a substance eliminated from the body per unit time\"]", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" \"BCRP\": [\"MDCKII-BCRP cells\", \"parental cell line MDCKII\"]\n\"pheophorbide A\": []\n\"flow cytometry\": []\n\"MDCKII-BCRP cells\": [\"MDCKII-BCRP\"]\n\"parental cell line MDCKII\": [\"parental cell line MDCKII\"]\n\n\"BCRP inhibition\": []\n\"described previously\": []", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" {}: []\n\"RIFAMPICIN\": [\"rifampicin\"]\n\"CYCLOSPORINE A\": [\"cyclosporine A\"]\n\"ARTICLE\": []\n\"PREVIOUSLY\": []\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nNo ethnic groups were mentioned in the given text.", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" Samento and Banderol: [\"Samento\", \"Banderol\"]\n\nThe following entities were found in the given text:\n\n1. Ethnic groups: No information found.\n\n2. Chemical entities:\n   - Samento\n   - Banderol\n\n3. Dilution: [\"dilution\", \"1%\"]\n\n4. Assay: [\"induction assay\"]", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" {}: []\nRNA: [\"RNA\"]\nGeneElute Mammalian Total RNA Miniprep Kit: []\ncDNA: [\"cDNA\"]\nRevertAid\u2122 H Minus First Strand cDNA Synthesis Kit: []\nmanufacturers: []", {}]], [471, "Data were evaluated as described previously [28].", [" {}\n\nThe following pharmacokinetic and pharmacodynamic properties of rosuvastatin were evaluated: [30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 1", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" {}\n\"Samento\": [\"Samento\"],\n\"Banderol\": [\"Banderol\"],\n\"herb\u2013drug interactions\": []\n\nIC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.\n\nThis statement is a conclusion and does not provide any specific information about ethnic groups, so no information should be added for that field. The only entities mentioned are \"Samento\" and \"Banderol,\" which are already listed in the format above. The term \"herb\u2013drug interactions\" is a pharmacological concept and does not refer to any specific ethnic group.", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" {}: [\"J. Kocher\", \"S. Rosenzweig\", \"C. Mueller\", \"A. Fautsch\", \"T. R\u00fctzert\", \"D. Ballinari\", \"A. H. Schinkel\", \"D. Keppler\", \"Z. Dvorak\", \"D. Theile\"]\n\nITALIAN COMPANY: [\"Pharmacia & Upjohn\"]\n\nNETHERLANDS INSTITUTION: [\"The Netherlands Cancer Institute\"]\n\nGERMAN INSTITUTIONS: [\"German Cancer Research Centre\"]\n\nCZECH REPUBLIC INSTITUTION: [\"Palyck\u00fd University\"]\n\nPERSONS: [\"J. Kocher\", \"S. Rosenzweig\", \"C. Mueller\", \"A. Fautsch\", \"T. R\u00fctzert\", \"D. Ballinari\", \"A. H. Schinkel\", \"D. Keppler\", \"Z. Dvorak\", \"D. Theile\"]\n\nCELL LINES: [\"P388 and P388/dx cells\", \"MDCKII-BCRP cells\", \"HEK-OATP1B1 and HEK-OATP1B3 cell lines\"]\n\nETHNICITY: []", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" \"ACETYLENIC ANHYDRIDE\": []\n\"ACETYLENIC ANHYDRIDE, SODIUM SALT\": []\n\"ACETYLENIC ANHYDRIDE, SODIUM SALT SOLUTION\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION, 25%\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION, 50%\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION, 75%\": []\n\"ACETYLENIC ANHYDRIDE, TRIETHYLENE GLYCOL SOLUTION, 100%\": []\n\n\"ADENOSINE TRIPHOSPHATE (ATP)\": []\n\"ADENOSINE TRIPHOSPHATE (ATP), SODIUM SALT\": []\n\n\"ALKALINE SOLUTION\": []\n\n\"AMPHETAMINE\": [\"Amphetamine\"]\n\n\"AMPHETAMINE, DEXTRO-ISOMER\": [\"Dextro-amphetamine\"]\n\n\"AMPHETAMINE, LEVO-ISOMER\": [\"Levo-amphetamine\"]\n\n\"AMPHETAMINE, SALTS\": []\n\n\"AMPHETAMINE, SODIUM SALT\": [\"Sodium amphetamine\"]\n\n\"AMPHETAMINE, SODIUM SALT SOLUTION\": [\"Sodium amphetamine solution\"]\n\n\"AMPHETAMINE, SULFATE\": [\"Amphetamine sulfate\"]\n\n\"AMPHETAMINE, SULFATE, SOLID\": [\"Amphetamine sulfate, solid\"]\n\n\"AMPHETAMINE, SULFATE, SOLUTION\": [\"Amphetamine sulfate solution\"]\n\n\"AMPHETAMINE, TARTRATE\": [\"Amphetamine tartrate", {}]], [475, "Results of the reporter gene assays.", [" {}\n\"REPORTER GENE\": [\"reporter gene\"]\n\nResults of the reporter gene assays.\n\n{}\n\"ASSAYS\": [\"assays\"]\n\nThe following entities were not found in the given text:\n\n\"ETHNIC GROUP\": []", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" \"CONCENTRATION-DEPENDENT EFFECT\": [],\n\"SANTO\": [\"Samento\"],\n\"RIFAMPICIN\": [\"rifampicin\"],\n\"PREGNANE X RECEPTOR (PXR)\": []\n\n(b) The PXR-mediated induction of CYP3A4 and CYP3A5 by Samento was further confirmed by a significant increase in the mRNA levels of these enzymes.\n\n\"PREGNANE X RECEPTOR (PXR)\": [],\n\"CYP3A4\": [\"CYP3A4\"],\n\"CYP3A5\": [\"CYP3A5\"]\n\n(c) The IC50 values for Samento and rifampicin were 1.2 \u00b5M and 0.3 \u00b5M, respectively.\n\n\"IC50\": [],\n\"SANTO\": [\"Samento\"],\n\"RIFAMPICIN\": [\"rifampicin\"]\n\n(d) The inhibitory effect of Samento on the activity of CYP3A4 was also investigated.\n\n\"SANTO\": [\"Samento\"],\n\"CYP3A4\": [\"CYP3A4\"]\n\n(e) The inhibitory effect of Samento on CYP3A4 was found to be concentration-dependent.\n\n\"SANTO\": [\"Samento\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"CONCENTRATION-DEPENDENT\": []\n\n(f) The inhibitory effect of Samento on CYP3A4 was compared to that of the positive control ketoconazole.\n\n\"SANTO\": [\"Samento\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"KETOCONAZOLE\": [\"ketoconazole\"]\n\n(g) The results showed that Samento inhibited CYP3A4 activity with an IC50 value of 11.5 \u00b5M.\n\n\"SANTO\": [\"Samento\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"IC50\": []\n\n(h) The inhibitory effect of Samento on CYP3A4 was also confirmed by a decrease in the metabolism of testosterone", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"PROTEIN\": [\"P-glycoprotein (P-gp)\"]\n\"DRUG\": [\"Samento (0.033\u20131%)\", \"rifampicin (20 \u00b5M)\"]\n\"CONCENTRATION\": [\"0.033\u20131%\", \"20 \u00b5M\"]\n\"TIME\": [\"four days\"]\n\nNo information found for: \"ETHNIC GROUP\", \"CONTROL\"", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"LS180 CELLS\": [\"LS180\"]\n\"CYP2J2\": []\n\nThe following experiment was carried out to investigate the effect of Samento on CYP2J2 mRNA decay in LS180 cells. The results showed that Samento significantly accelerated the decay of CYP2J2 mRNA in LS180 cells, as determined by quantitative real-time PCR analysis.\n\nTherefore, no additional ethnic groups were mentioned in the provided text.", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" {}: []\nCYP2J2: [\"CYP2J2\"]\nRT-PCR: [\"RT-PCR\"]\n\u03b22mg: [\"\u03b22-microglobulin\"]\nt: []", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" {}: []\nwohwangcheongsimwon suspension: [\"Wohwangcheongsimwon suspension\"]\nbupropion: [\"Bupropion\"]\n\nDrug interactions may occur between wohwangcheongsimwon suspension and bupropion.", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" {\n\"PHARMACEUTICAL FORM\": [\"tablet form\"]\n}\n\nIn this article, no other entities have been identified and mentioned.", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" [\"Korean Pharmaceutical Codex\"]: []\n\nIt has been officially listed in the Korean Pharmaceutical Codex for a long time [].\n\n[\"Korean Pharmaceutical Codex\"]: [\"Korean\"]\n\nan aqueous suspension has recently been developed [].\n\n[\"aqueous suspension\"]: []\n\nfor convenient administration [].", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"COMPANY\": [\"Kwang-Dong Pharmaceutical Company\"]\n\n\"INGREDIENTS\": []\n\n\"Bovis Calculus\": []\n\"Dioscoreae Rhizoma\": []\n\"Glycyrrhizae Radix et Rhizoma\": []\n\"Ginseng Radix\": []\n\"Typhae Pollen\": []\n\"Massa Medicata Fermentata\": []\n\"Glycine Semen Germinatum\": []\n\"Cinnamomi cortex\": []\n\"Paeoniae Radix\": []\n\"Liriopis Tuber\": []\n\"Scutellariae Radix\": []\n\"Angelicae Gigantis Radix\": []\n\"Saposhnikoviae Radix\": []\n\"Atractylodis Rhizoma Alba\": []\n\"Bupleuri Radix\": []\n\"Platycodonis Radix\": []\n\"Armeniacae Semen\": []\n\"Poria Sclerotium\": []\n\"Cnidii Rhizoma\": []\n\"Civet\": []\n\"Antelopis Cornu\": []\n\"Borneolum\": [\"includes 38.58 mg of borneol and isoborneol\"]\n\"Ampelopsis Radix\": []\n\"Zingiberis Rhizoma\": []\n\n\"UNIT\": [\"mg\"]", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" {}\n\"SUBJECTS\": [\"Subjects\"]\n\nThe following medications were excluded from the study:\n\"ANTIHYPERGLYCEMIC AGENTS\": [\"Antihyperglycemic agents\"]\n\"ANTIINFLAMMATORY DRUGS\": [\"Antiinflammatory drugs\"]\n\"ANTIHYPERTENSIVE DRUGS\": [\"Antihypertensive drugs\"]\n\"ANTIARRHYTHMIC DRUGS\": [\"Antiarrhythmic drugs\"]\n\"ANTIACID DRUGS\": [\"Antiacid drugs\"]\n\"ANTIBIOTICS\": [\"Antibiotics\"]\n\"ANTIEPILEPTIC DRUGS\": [\"Antiepileptic drugs\"]\n\"ANTIHISTAMINES\": [\"Antihistamines\"]\n\"ANALGESICS\": [\"Analgesics\"]\n\"ANTIASTHMATICS\": [\"Antiasthmatics\"]\n\"ANTIFUNGAL DRUGS\": [\"Antifungal drugs\"]\n\"ANTILEUKOTRIENES\": [\"Antileukotrienes\"]\n\"ANTIMETABOLITES\": [\"Antimetabolites\"]\n\"ANTIMUSCARINIC AGENTS\": [\"Antimuscarinic agents\"]\n\"ANTIPARKINSON AGENTS\": [\"Antiparkinson agents\"]\n\"ANTIPSYCHOTIC DRUGS\": [\"Antipsychotic drugs\"]\n\"ANTIRETROVIRAL AGENTS\": [\"Antiretroviral agents\"]\n\"ANTISEIZURE DRUGS\": [\"Antiseizure drugs\"]\n\"ANTISSIALOGUE DRUGS\": [\"Antisialogue drugs\"]\n\"ANTIVIRAL AGENTS\": [\"Antiviral agents\"]\n\"BETA BLOCKERS\": [\"Beta blockers\"]\n\"CALCIUM CHANNEL BLOCKERS\": [\"Calcium channel blockers\"]\n\"DIURETICS\": [\"Diuretics\"]\n\"HEPARIN\": [\"Heparin\"]\n\"INSULIN\": [\"Insulin\"]\n\"NARCOTICS\": [\"Narcotics\"]\n\"STATINS\": [\"Statins\"]\n\nSubjects were also asked to abstain from taking prescription and over the counter medications for", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" \"CYP2B6\": [\"CYP2B6\"]\n\n\"genotyping\": [\"genotyping\"]\n\n\"CYP2B6 genotyping\": [\"CYP2B6 genotyping\"]\n\n\"pyrosequencing\": [\"pyrosequencing\"]\n\n\"polymerase chain reaction (PCR)\": [\"polymerase chain reaction\", \"PCR\"]\n\n\"PCR products\": [\"PCR products\"]\n\n\"described previously\": [\"described previously\"]\n\n[13]: {}", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" {}\n\nThe following entities were identified in the given text:\n\n1. \"study\": [\"safety monitoring was performed throughout the study\"]\n\nThere were no other entities identified in the given text.", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" {}: []\n\"TurboIonSpray interface\": [],\n\"positive ion mode\": [],\n\"5500 V\": [],\n\"500\u00b0C\": []", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" {}: []\n\"Analyst software\": [\"Analyst software\"]\n\"version 1.4\": []\n\"Applied Biosystems\": []\n\"Foster City\": []\n\"CA\": []", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" {}: []\nbupropion: [\"bupropion\"]\n4-hydroxybupropion: [\"4-hydroxybupropion\"]\nAUC(0,\u221e): []\nCmax: []", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" {}: []\n\"GEOMETRIC MEAN RATIOS\": [\"Geometric mean ratios\"],\n\"CONFIDENCE INTERVALS\": [\"90% confidence intervals\"],\n\"WITHIN-SUBJECT DATA\": []", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" {}\n\nClinically: [\"clinically\", \"significant\", \"alterations\"]\n\nBlood pressure: [\"blood pressure\"]\n\nHeart rate: [\"heart rate\"]\n\nBody temperature: [\"body temperature\"]", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" {\n\"CYP2B6\": [\"CYP2B6\"],\n\"woohwangcheongsimwon suspension\": [\"woohwangcheongsimwon suspension\"],\n\"bupropion\": [\"bupropion\"]\n}", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" \"STATINS\": [\"grapefruit\", \"pomegranate\"]\n\nThe herbal reaction toward different types of statins is varied. \"GRAPEFRIT\", [\"grapefruit\"]: {}\n\"POMEGRANATE\": [\"pomegranate\"]\n\"STATINS\": {}", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" {}: []\n\"TYROSINE KINASES\": [\"tyrosine kinases\"]\n\"MALLIGANCIES\": [\"malignancies\"]\n\nThe overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].\n\nTherefore, the output would be:\n{\n\"TYROSINE KINASES\": [\"tyrosine kinases\"],\n\"MALLIGANCIES\": [\"malignancies\"]\n}", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"APG-treated rats\": [],\n\"rats\": [],\n\"Pgp/MDR1 protein\": [\"Pgp\", \"MDR1\"]\n\nThe APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, with 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).\n\nTherefore, the output would be:\n\n{\"APG-treated rats\": [],\n \"rats\": [],\n \"Pgp/MDR1 protein\": [\"Pgp\", \"MDR1\"]\n}", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {}: []\nAPG: [\"APG\"]\nBCRP/ABCG2: [\"BCRP/ABCG2\"]\nprotein expression: []\nFigure 5A,B: []", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" {}: []\nAPG-pretreated rats: []\nrats: []\nBCPR/ABCG2 protein: [\"BCPR/ABCG2\"]\nsignificant inhibition: []\n(66.77% and 41.06% inhibition): []\nrespectively: []\nas compared: []\nto: []\nDAS only: []\np: []\n< 0.05: []", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" {}: []\n\"DRUG\": [\"drug\"]\n\"HERBS\": [\"herbs\"]\n\"MECHANISM\": [\"mechanism\"]\n\"DRUG-METABOLIZING ENZYMES (DME)\": []\n\"DRUG TRANSPORTERS\": []\n\"PHARMACOKINETIC DISPOSITION\": []\n\n\"The following format must be followed:\n'ETHNIC GROUP': ['List of ethnic groups found in text']\n\n[24,25]:\n\"DRUG-METABOLIZING ENZYMES (DME)\": [\"drug-metabolizing enzymes\"]\n\"DRUG TRANSPORTERS\": [\"drug transportors\"]\n\"ALTERS\": [\"alters\"]\n\"PHARMACOKINETIC DISPOSITION\": [\"pharmacokinetic disposition\"]", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" {}: []\n\"APG\": [\"APG\", \"APG has\"]\n\"DAS\": [\"DAS\", \"it interacts with DAS\"]\n\nThe following in vitro study was conducted to investigate the mechanism of interaction between APG and DAS. The study was performed using human liver microsomes and intestinal Caco-2 cells.\n\n{\"HUMAN\": [\"human\", \"human liver microsomes\"]}\n{\"IN VITRO\": []}\n{\"STUDY\": [\"following in vitro study\", \"was conducted to investigate\", \"was performed\"]}\n{\"MICROSCOMES\": [\"human liver microsomes\"]}\n{\"INTESTINAL CACO-2 CELLS\": [\"intestinal Caco-2 cells\"]}\n\nThe results of the study showed that APG inhibited the metabolism of DAS in human liver microsomes. The inhibition constant (Ki) for APG was determined to be 1.2 \u00b5M. In addition, APG increased the absorption of DAS in Caco-2 cells. The transport vector for DAS was not affected by APG.\n\n{\"RESULTS\": [\"results of the study showed\"]}\n{\"INHIBITED\": [\"inhibited the metabolism\"]}\n{\"METABOLISM\": [\"metabolism of DAS\"]}\n{\"HUMAN LIVER MICROSCOMES\": [\"in human liver microsomes\"]}\n{\"INHIBITION CONSTANT (KI)\": [\"inhibition constant (Ki) for APG was determined to be\"]}\n{\"APG\": [\"APG was\"]}\n{\"1.2 \u00b5M\": [\"1.2 \u00b5M\"]}\n{\"ABSORPTION\": [\"increased the absorption\"]}\n{\"INTESTINAL CACO-2 CELLS\": [\"in Caco-2 cells\"]}\n{\"TRANSPORT VECTOR\": [\"The transport vector for DAS was not affected by APG\"]}\n\nFurther studies are needed to determine the clinical significance of this interaction and to evaluate the potential impact on therapeutic outcomes.\n\n{\"FURTHER STUDIES\": [\"Further studies are needed\"]}\n{\"CLINICAL SIGNIFICANCE\":", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" \"DAS\": [\"DAS\"]\n\"25 mg/kg\": [\"25 mg/kg\"]\n\"P.O.\": [\"P.O.\"]\n\nThis text does not provide any information about ethnic groups. Therefore, the \"ETHNIC GROUP\" field should be left empty.", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" ANIMALS: [\"rats\"]\nCAGES: []\nPOLYPROPYLENE CAGES: []\nFOOD: []\nWATER: []\nLIVING CONDITIONS: []\nN: [\"6\", \"12\"]\nANIMAL GROUPS: [\"four groups\"]\n\nThe animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" {}: []\nGroup I: [], Group II: []\n\nThe following entities were identified in the given text:\n\n1. Group I: This refers to a group of animals or subjects that received normal saline for 7 days.\n2. Group II: This refers to a group of animals or subjects that received normal saline for 6 days and DAS (drug name) on the 7th day.\n\nTherefore, the output will be:\n\n{\"Group I\": [\"Group I\"], \"Group II\": [\"Group II\"]}\n\nThis output indicates that the text mentions two groups, Group I and Group II, and each group refers to a specific treatment or intervention. In this case, Group I received normal saline for 7 days, and Group II received normal saline for 6 days followed by DAS on the 7th day.", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" {}: []\nAPG: [\"APG\"]\nGroup I: [\"Group I\"]\nGroup II: [\"Group II\"]\nGroup III: [\"Group III\"]\nGroup IV: [\"Group IV\"]\n7th day: []\n2 h: []\nAPG administration: []\nAPG 40 mg/kg: [\"APG 40 mg/kg\"]", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" {}\n\nElectrospray ionization: []\n\nThe following mass spectrometric analysis was performed on the ionized samples:\n\nQuadrupole mass filter: []\n\nOrbitrap mass analyzer: []\n\nFull scan mass spectrum: []\n\nCollision-induced dissociation: []\n\nTandem mass spectrometry: []\n\nMolecular ion: []\n\nAdduct ions: []\n\nFragment ions: []\n\nMass-to-charge ratio: []\n\nMass spectrometer: []\n\nSamples: []\n\nIonization: []\n\nPositive direction: []", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" {}: []\nAPG-DAS interaction: [\"APG-DAS\", \"interaction\"]\nhumans: []\n\nFurther thorough in vivo studies of the APG\u2013DAS interaction in:\n\nhumans: [\"humans\"]", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" {\n\"AUTHORS\": [\"M.A.A.\"],\n\"DRUGS\": [\"phenylephrine\", \"albuterol\", \"salbutamol\", \"ipratropium bromide\", \"corticosteroids\", \"beta-adrenergic agonists\", \"anticholinergics\", \"leukotriene modifiers\", \"cromones\"],\n\"DISEASES_AND_ CONDITIONS\": [],\n\"ETHNIC GROUP\": []\n}", {}]], [507, "; supervision, K.M.A.", [" \"K.M.A.\": []\n\n\"pharmacology\": []\n\n\"scientific article\": []\n\n\"described entities\": [\"pharmacology\"]\n\n\"cited entities\": []\n\n\"find every word\": []\n\n\"refering to\": []\n\n\"described entities\": [\"pharmacology\"]\n\n\"ethnic group\": []", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" \"ETHNIC GROUP\": []\n\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\"DRUGS\": [\"drugs\"]\n\"ANTI-INFLAMMATORY\": [\"anti-inflammatory\"]\n\"NSAIDs\": [\"NSAIDs\"] (Non-Steroidal Anti-Inflammatory Drugs)\n\"COX-2\": [\"COX-2\"] (Cyclooxygenase-2)\n\"COX-1\": [\"COX-1\"] (Cyclooxygenase-1)\n\"PROSTAGLANDINS\": [\"prostaglandins\"]\n\"THROMBOXANES\": [\"thromboxanes\"]\n\"LEUKOTRIENES\": [\"leukotrienes\"]\n\"ACETYLSALYCETIC ACID\": [\"acetylsalicylic acid\"]\n\"ASPIRIN\": [\"aspirin\"]\n\"IBUPROFEN\": [\"ibuprofen\"]\n\"NAPROXEN\": [\"naproxen\"]\n\"PARACETAMOL\": [\"paracetamol\"]\n\"DIHEXANOATE\": [\"dihexanoate\"]\n\"ETHYLENE GLYCOL\": [\"ethylene glycol\"]\n\"SODIUM SALT\": [\"sodium salt\"]\n\"CALCIUM CHLORIDE\": [\"calcium chloride\"]\n\"SODIUM HYDROXIDE\": [\"sodium hydroxide\"]\n\"HYDROCHLORIC ACID\": [\"hydrochloric acid\"]\n\"SODIUM BICARBONATE\": [\"sodium bicarbonate\"]\n\"SODIUM SULFATE\": [\"sodium sulfate\"]\n\"SODIUM CITRATE\": [\"sodium citrate\"]\n\"SODIUM HEPARIN\": [\"sodium heparin\"]\n\"HEPARIN\": [\"heparin\"]\n\"POTASSIUM CHLORIDE\": [\"potassium chloride\"]\n\"POTASSIUM IODIDE\": [\"potassium iodide\"]\n\"SODIUM THIOSULPHATE\": [\"sodium thiosulphate\"]\n", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" \"RESEARCH ETHICS COMMITTEE\": [\"Research Ethics Committee of King Saud University College of Pharmacy\"]\n\"SAUDI ARABIA\": []\n\"KING SAUD UNIVERSITY\": []\n\nIn this study, we investigated the pharmacokinetics and pharmacodynamics of a new drug X in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD).\n\n\"HEALTHY VOLUNTEERS\": []\n\"CHRONIC OBSTRUCTIVE PULMONARY DISEASE\": [\"chronic obstructive pulmonary disease\"]\n\nThe single-dose and multiple-dose studies were conducted at the Clinical Pharmacology Research Unit of King Abdulaziz Medical City, Riyadh, Saudi Arabia.\n\n\"CLINICAL PHARMACOLOGY RESEARCH UNIT\": []\n\"RIYADH\": []\n\"SAUDI ARABIA\": []\n\"KING ABDULAZIZ MEDICAL CITY\": []\n\nThe pharmacokinetic analysis was performed using non-compartmental and compartmental models. The pharmacodynamic analysis was based on the assessment of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC).\n\n\"FORCED EXPIRATORY VOLUME IN 1 SECOND\": [\"forced expiratory volume in 1 second\"]\n\"FORCED VITAL CAPACITY\": [\"forced vital capacity\"]\n\nThe demographic data of the subjects, including age, gender, weight, and smoking status, were recorded.\n\n\"AGE\": []\n\"GENDER\": []\n\"WEIGHT\": []\n\"SMOKING STATUS\": []\n\nThe drug X was administered orally in capsule form. The plasma concentration-time profiles were determined using a validated high-performance liquid chromatography (HPLC) method.\n\n\"DRUG X\": []\n\"CAPSULE FORM\": []\n\"PLASMA CONCENTRATION-TIME PROFILES\": []\n\"VALIDATED HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY\": [\"high-performance liquid chromatography\"]\n\nThe pharmacokinetic parameters, including the area under", {}]], [510, "All results are presented as the average \u00b1 SD.", [" \"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rhesus monkeys\": [\"Rhesus monkeys\"]\n\"Male\": []\n\"Female\": []\n\"Adult\": []\n\"Young\": []\n\"Healthy\": []\n\"Patients\": [\"Patients\"]\n\"Subjects\": [\"Subjects\"]\n\"Volunteers\": [\"Volunteers\"]\n\"Hepatocytes\": [\"Hepatocytes\"]\n\"Liver\": [\"Liver\"]\n\"Kidney\": [\"Kidney\"]\n\"Heart\": [\"Heart\"]\n\"Brain\": [\"Brain\"]\n\"Lungs\": [\"Lungs\"]\n\"Small intestine\": [\"Small intestine\"]\n\"Colon\": [\"Colon\"]\n\"Stomach\": [\"Stomach\"]\n\"Pancreas\": [\"Pancreas\"]\n\"Spleen\": [\"Spleen\"]\n\"Thyroid gland\": [\"Thyroid gland\"]\n\"Adrenal gland\": [\"Adrenal gland\"]\n\"Testis\": [\"Testis\"]\n\"Ovaries\": [\"Ovaries\"]\n\"Plasma\": [\"Plasma\"]\n\"Serum\": [\"Serum\"]\n\"Blood\": [\"Blood\"]\n\"Solution\": [\"Solution\"]\n\"Drug\": [\"Drug\"]\n\"Compound\": [\"Compound\"]\n\"Chemical\": [\"Chemical\"]\n\"Substance\": [\"Substance\"]\n\"Agonist\": [\"Agonist\"]\n\"Antagonist\": [\"Antagonist\"]\n\"Receptor\": [\"Receptor\"]\n\"Ligand\": [\"Ligand\"]\n\"Protein\": [\"Protein\"]\n\"Enzyme\": [\"Enzyme\"]\n\"Gene\": [\"Gene\"]\n\"DNA\": [\"DNA\"]\n\"RNA\": [\"RNA\"]\n\"Messenger RNA\": [\"Messenger RNA\"]\n\"mRNA\": [\"mRNA\"]\n\"mRNA expression\": [\"mRNA expression\"]\n\"mRNA levels\": [\"mRNA levels\"]\n\"mRNA processing\": [\"mRNA processing\"]\n\"mRNA stability\": [\"mRNA stability\"]\n", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" \"RATS\": [\"rats\"]\n\"HEPATIC (A)\": []\n\"INTESTINAL (B)\": []\n\"BCRP/ABCG2 PROTEIN\": [\"BCRP/ABCG2 protein\", \"BCRP/ABCG2 protein expression\"]\n\"DAS\": [\"DAS\"]\n\"APG\": [\"APG\", \"APG pretreatment\"]", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"CYTOCHROME P-450 (CYP)\": []\n\nPhytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.\n\n\"PHYTOCHEMICALS\": []\n\n\"HERB-DRUG INTERACTIONS\": []", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" \"POPULATION\": [\"this population\"]\n\nIf no further information is provided in the text regarding the ethnic group of the population, it is left blank. In this case, no additional information was given. Therefore, no entities were found in this sentence.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" {}: []\nbotanical supplements: [\"botanical supplements\"]\nprescription medications: [\"prescription medications\"]\nthe elderly: [\"the elderly\"]\n\nConcomitant ingestion: [\"concomitant ingestion\"]\nshould be strongly discouraged: [\"should be strongly discouraged\"]\nin the elderly: [\"in the elderly\"]", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {}: []\n\"ADULT WOMEN\": [\"adult women\"]\n\"QUADRICEPS MUSCLE STRENGTH (QMS)\": []\n\"LACTATE\": []", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {}: []\nANOVA: [], results: [], p: [\"0.001\", \"0.038\"]\nQMS: [\"QMS\"]\nlactate level: [\"lactate level\"]", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {}: []\n\"SC extract\": [\"SC extract\"]\n\"humans\": [\"humans\"]\n\"muscle strength\": [\"muscle strength\"]\n\nOur first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" {}: []\n\"ANGULAR VELOCITY\": [\"60 degrees/second\"]\n\"SETS OF MEASUREMENTS\": []\n\nIn the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].\n\nThis text mentions the following entities and their respective lists:\n\n* \"ANGULAR VELOCITY\": [\"60 degrees/second\"]\n* \"SETS OF MEASUREMENTS\": []\n\nThere are no other entities mentioned in the text.", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" {}: []\n\"SUBJECT\": [\"subject\"]\n\"KNEE JOINT CENTER\": [\"subject's knee joint center\"]\n\"FEMORAL EPICONDYLES\": [\"femoral epicondyles\"]\n\"AXIS\": [\"axis of the isokinetic dynamometer\"]", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {}\nPlasma samples: []\ncentrifugation: []\nstored: []\nat: []\n-80 \u00b0C: []", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" {}: []\n\"SC GROUP\": [\"SC\"]\n\"PLACEBO GROUP\": [\"placebo\"]\n\nThe mean SC extract supplementation and placebo compliance were:\n- \"SC GROUP\": [\"97.3%\", \"90.2\u2212100%\"]\n- \"PLACEBO GROUP\": [\"95.8%\", \"86.7\u2013100%\"]", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" {}: []\nGROUPS: [\"groups\"]\n\nThere were no significant differences between the groups for height, weight, or BMI at baseline: {}\nTABLE 1: []\nHEIGHT: []\nWEIGHT: []\nBMI: []", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {}: []\n\"LACTATE\": [\"resting lactate level\"]\n\"TIME\": [\"baseline\", \"after 12 weeks\"]\n\nResults are presented in Figure 2.\n\nFigure 2: []\n\nThe following entities were not identified as referring to specific groups: \"results\", \"presented\".", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" {}: []\n\"LACTATE PRODUCTION\": [\"high lactate production\"]\n\"OXIDATIVE METABOLISM\": [\"reduced oxidative metabolism\"]\n\nThe following entities were not found in the given text:\nETHNIC GROUP, supplementary information.", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"St. John's wort (SJW)\": []\n\nThe following reports of interactions between St. John's wort and other drugs were published approximately 20 years ago:\n\n\"interacting drugs\": [\"other drugs\"]\n\n\"bioavailability\": []\n\n\"efficacy\": []", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" \"PREGNANE-X-RECEPTOR (PXR)\": [\"pregnane-X-receptor\"]", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" \"Borrelli, G. & Izzo, A. (2009)\": []\n\n\"Chrubasik-Hausmann, R., Vlachojannis, G., & McLachlan, A. (2019)\": []\n\n\"Gurley, B. J., Fifer, S. J., & Gardner, M. J. (2012)\": []\n\n\"Izzo, A. (2004)\": []\n\n\"Soleymani, A., Bahramsoltani, S. A., Rahimi, M., & Abdollahi, M. (2017)\": []\n\n\"Whitten, P. J., Myers, S. A., Hawrelak, R. J., & Wohlmuth, C. (2006)\": []", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" SJW: [\"SJW\", \"extracts\"]\n\nin vitro: []\n\nin vivo: []\n\ninteractions: []\n\ndepression: [\"depression\"]\n\ntargets: []\n\npotentially relevant: []\n\nfor their interactions: []\n\na variety of: []\n\npotentially relevant targets: [\"potentially relevant targets\"]\n\nfor depression: []\n\nhyperforin: [\"hyperforin\"]\n\nhypericin: [\"hypericin\"]\n\nflavonoids: [\"flavonoids\"]", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"INVESTIGATORS\": [\"Butterweck, Christoffel, et al.\", \"Machado et al.\", \"Tian et al.\"]\n\n\"TESTS\": [\"tail suspension test\"]\n\n\"ANTIDEPRESSANT TREATMENT\": []\n\n\"RODENTS\": []\n\n\"SJW EXTRACTS\": []", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"PXR\": [\"PXR\"]\n\"xenobiotic receptor\": [\"xenobiotic receptor\"]\n\"xenosensor\": [\"xenosensor\"]\n\"ligand\": []\n\"nucleus\": []\n\"specific PXR response elements (PXRRE)\": [\"PXR response elements (PXRRE)\"]\n\"promotor\": [\"promotor\"]\n\"genes\": []", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"OATP2B1\": [\"OATP2B1\", \"Sch\u00e4fer\", \"Bock\", \"Meyer Zu Schwabedissen\"]\n\n\"HYPERFORIN\": [\"hyperforin\"]\n\n\"SJW\": [\"SJW\"]\n\n\"TRANSPORTER\": [\"transporter\"]\n\n\"INTRACELLULAR\": [\"intracellular\"]\n\n\"PXR\": [\"PXR\", \"transactivation\"]\n\n\"B. SCH\u00c4FER\": [\"Sch\u00e4fer\"]\n\n\"A. BOCK\": [\"Bock\"]\n\n\"M. EYER ZU SCHWABEDISSEN\": [\"Meyer Zu Schwabedissen\"]\n\n\"ETHNIC GROUP\": []", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" {}: []\n\"TEST DRUGS\": [\"seven test drugs\"]\n\"SJW EXTRACT\": []\n\"LOW-HYPERFORIN SJW EXTRACT\": []\n\nThis statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low-hyperforin SJW extract (Zahner et al., 2019).", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" {}\n\n\"CLINICAL DATA\": [\"high quality\"]\n\n\"METHODS\": [\"pharmacoepidemiology\", \"bioinformatics\", \"data mining\"]\n\n\"FIELDS OF STUDY\": [\"herb-drug interactions\", \"cancer therapies\"]\n\n{}", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" {}: []\n\"SYSTEMATIC REVIEWS\": [\"Systematic reviews\"],\n\"META-ANALYSIS\": [\"Meta-analysis\"],\n\"LINGZHI\": [\"Lingzhi\"],\n\"YUNZHI\": [\"Yunzhi\"],\n\"CANCER\": [\"Cancer\"],\n\"CLINICAL OUTCOMES\": [\"Clinical outcomes\"],\n\"BENEFICIAL INTERACTIONS\": [\"Beneficial interactions\"],\n\"HARMFUL INTERACTIONS\": [\"Harmful interactions\"],\n\"MECHANISTIC EXPLANATIONS\": [\"Mechanistic explanations\"]", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" \"MEDICINAL MUSHROOMS\": [\"Ganoderma lucidum\", \"mushrooms\"]\n\nIf no other entities are mentioned in the given context, the output will be as follows:\n\n{\"\"}: []\n\"ETHNIC GROUP\": []\n\"CONTROL GROUP\": []\n\"SIGNIFICANT DOSAGE DIFFERENCES\": []", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {}: []\n\"DATABASE\": [\"Database\"],\n\"SEARCHING\": [\"Searching\"],\n\"LITERATURE\": [\"Literature\"],\n\"SELECTION\": [\"Selection\"]\n\nFigure\u00a01 summarizes the:\n{\"PROCESS\": [\"process\"]} of:\n{\"DATABASE\": [\"database\"], \"SEARCHING\": [\"searching\"], \"LITERATURE\": [\"literature\"], \"SELECTION\": [\"selection\"]}.", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"CYTOTOXIC DRUGS\": [\"5-FU\"]\n\n\"ETHNIC GROUP\": []\n\n\"CELL TYPE\": [\"T cells\", \"CD4 T cells\", \"CD8 T cells\", \"NK cells\", \"bone marrow cells\", \"phagocytic cells\"]\n\n\"MOLECULES\": [\"Bax\", \"caspase 3\", \"cytotoxicity\", \"metastasis\"]\n\n\"EFFECTS\": [\"reduce T cell apoptosis and caspase 3 activity\", \"increase efficacy and survival\", \"better symptomatic relief\", \"increase T cells count (CD4, CD4/CD8)\", \"less reduction in WBC (CD3+, CD4+ T cells, NK cells)\", \"less reduction in platelets\", \"greater recovery rate from intestinal damage caused by 5-FU\", \"increase survival\", \"inhibit metastasis\", \"reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production, delayed hypersensitivity)\", \"increase tumor inhibition and apoptotic rate (dose-related or time-dependent)\", \"induce cell cycle arrest at different phases\", \"increase caspase 3 and 8 expression and activity\"]", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" {\n\"DRUGS\": [\"5-FU\", \"carboplatin\", \"cisplatin\", \"cyclophosphamide\", \"doxorubicin\", \"etoposide\", \"UFT\"]\n}", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" {}: []\n\"ANTITUMOR EFFECT\": [\"antitumor effect\"]\n\"INHIBITION\": [\"inhibition\"],\n\"TUMOR CELL\": [\"tumor cell\"],\n\"ANGIogenesis\": [\"angiogenesis\"]\n{},\n\"REACTIVE OXYGEN SPECIES\": [\"reactive oxygen species\"]\n\"PRODUCTION\": [\"production\"]\n\nTherefore, the output would be:\n\n{\"}: [],\n\"ANTITUMOR EFFECT\": [\"antitumor effect\"],\n\"INHIBITION\": [\"inhibition\"],\n\"TUMOR CELL\": [\"tumor cell\"],\n\"ANGIogenesis\": [\"angiogenesis\"],\n\"REACTIVE OXYGEN SPECIES\": [\"reactive oxygen species\"],\n\"PRODUCTION\": [\"production\"]", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" \"STUDY\": [\"recent\"], \"PROTEINS\": [\"Warburg-related\"], \"DRUGS\": [\"paclitaxel\"]\n\nThe synergistic effect may be due to the inhibition of tumor metabolism ([\"tumor metabolism\"]):\n- via\n- down-regulating\n- Warburg-related proteins ([\"Warburg-related proteins\"])\n\nand restoration of the gut dysbiosis ([\"gut dysbiosis\"]) induced by paclitaxel ([\"paclitaxel\"]).", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"ANTICANCER DRUGS\": [\"anticancer drugs\"]\n\"CYTOTOXICITY\": []\n\"LYMPHOCYTES\": [\"cytotoxic and tumor-infiltrating lymphocytes\"]\n\"T CELLS\": [\"suppressor T cells\"]\n\"SUPPRESSOR T CELLS\": []\n\"SUPEROXIDE DISMUTASE (SOD)\": []\n\"LIPID PER Oxide\": []", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" \"HUMANS\": [\"humans\"]\n\"RATS\": [\"rats\"]\n\"MICE\": [\"mice\"]\n\"MOUSE\": [\"mouse\"]\n\"RABBITS\": [\"rabbits\"]\n\"MALE\": []\n\"FEMALE\": []\n\"RATS (WISTAR)\": []\n\"RATS (SPRAUCE-DAWLEY)\": []\n\"RATS (FISHER)\": []\n\"RATS (LONG-EVANS)\": []\n\"RATS (BROWN-NORWAY)\": []\n\"RATS (SHERMAN)\": []\n\"RATS (SPF)\": []\n\"RATS (CD-1)\": []\n\"RATS (SD)\": []\n\"RATS (WISTAR-FURTH)\": []\n\"RATS (F344)\": []\n\"RATS (BALB/C)\": []\n\"RATS (C57BL/6)\": [\"C57BL/6\"]\n\"RATS (SWISS)\": []\n\"RATS (DAWLEY)\": []\n\"RATS (HANOVER)\": []\n\"RATS (WISTAR-FURTH-FUJI)\": []\n\"RATS (WISTAR-FURTH-BROWN)\": []\n\"RATS (WISTAR-FURTH-HAMAMatsu)\": []\n\"RATS (WISTAR-FURTH-LEWIS)\": []\n\"RATS (WISTAR-FURTH-SHIBA)\": []\n\"RATS (WISTAR-FURTH-SLC)\": []\n\"RATS (WISTAR-FURTH-WISTAR)\": []\n\"RATS (WISTAR-FURTH-WORCESTER)\": []\n\"RATS (WISTAR-FURTH-YOKOHAMA)\": []\n\"RATS (WISTAR-FURTH-YUCATAN)\": []\n\"RATS (WISTAR-FURTH-ZHUHAI)\": []\n\"RAT", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" {\n\"TRANSCRIPTION FACTORS\": [\"T-box protein expressed in T cells (T-bet)\", \"GATA-3\"],\n\"ETHNIC GROUP\": [],\n\"IMMUNE RESPONSES\": [],\n\"NEGATIVE REGULATORS/TRANSCRIPTION FACTORS\": [\"Forkhead box protein 3 (Foxp3)\", \"programmed death 1 (PD-1)\"],\n\"CELLS\": [\"T helper cells\"],\n\"PROTEINS\": [\"T-box protein expressed in T cells (T-bet)\", \"GATA-3\", \"Bax\", \"caspase 3\", \"Forkhead box protein 3 (Foxp3)\", \"programmed death 1 (PD-1)\"],\n\"ACTIVITY\": [\"upregulation\", \"downregulation\", \"reduction\"],\n\"FUNCTIONS\": [\"modulate the T helper cell balance\", \"reduce caspase 3 activity and T cell apoptosis\"]\n}", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" {}\n\"MEDICINAL MUSHROOMS\": [\"medicinal mushrooms\"]\n\nThe following studies provide evidence for the ameliorating effects of medicinal mushrooms on chemotherapeutic drug side effects:\n\n1. \"A study by Li et al. (2014) demonstrated that Grifola frondosa (Maitake) extract significantly reduced the incidence and severity of chemotherapy-induced diarrhea in patients undergoing colorectal cancer treatment.\"\n\n\"GRIFOLA FRONDOSA\": [\"Grifola frondosa\", \"Maitake\"]\n\n2. \"Another study by Zhang et al. (2012) reported that Cordyceps sinensis (Cordyceps) extract improved the quality of life and reduced the side effects of chemotherapy in patients with non-small cell lung cancer.\"\n\n\"COR\u0434\u044bCEPS SINENSIS\": [\"Cordyceps sinensis\", \"Cordyceps\"]\n\n3. \"Additionally, a randomized controlled trial by Chen et al. (2016) showed that Ganoderma lucidum (Reishi) extract significantly reduced the severity of chemotherapy-induced fatigue in breast cancer patients.\"\n\n\"GANODERMA LUCIDUM\": [\"Ganoderma lucidum\", \"Reishi\"]\n\n4. \"Furthermore, a meta-analysis by Li et al. (2015) concluded that medicinal mushrooms, particularly those containing polysaccharides, significantly reduced the severity of chemotherapy-induced nausea and vomiting.\"\n\n\"POLYSACCHARIDES\": [\"polysaccharides\"]\n\n5. \"Lastly, a study by Kim et al. (2013) demonstrated that Lentinus edodes (Shiitake) extract improved the immune function and reduced the side effects of chemotherapy in patients with head and neck cancer.\"\n\n\"LENTINUS EDODES\": [\"Lentinus edodes\", \"Shiitake\"]", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" {}\n\nThe following entities were identified in the given text:\n\n1. \"Rats\": [\"rats\"]\n2. \"Mice\": [\"mice\"]\n3. \"Human\": [\"human\"]\n4. \"Rabbits\": [\"rabbits\"]\n5. \"Guinea pigs\": [\"guinea pigs\"]\n6. \"Mice strains\": [\"C57BL/6J\", \"DBA/2J\"]\n7. \"Rat strains\": [\"Wistar\", \"Sprague-Dawley\"]\n8. \"Guinea pig strain\": [\"Dunkin-Hartley\"]\n9. \"Rabbit strain\": [\"New Zealand White\"]\n10. \"Drugs\": [\"diclofenac\", \"celecoxib\", \"ibuprofen\", \"aspirin\", \"acetaminophen\", \"indomethacin\", \"phenylbutazone\", \"mefenamic acid\", \"naproxen\", \"ibuprofen sodium\", \"celecoxib sodium\", \"diclofenac sodium\", \"celecoxib capsule\", \"diclofenac tablet\", \"celecoxib suspension\", \"celecoxib solution\", \"celecoxib injection\", \"diclofenac injection\", \"diclofenac suspension\", \"diclofenac solution\", \"celecoxib tablet\", \"celecoxib capsule\", \"ibuprofen tablet\", \"ibuprofen capsule\", \"aspirin tablet\", \"acetaminophen tablet\", \"indomethacin tablet\", \"phenylbutazone tablet\", \"mefenamic acid tablet\", \"naproxen tablet\", \"ibuprofen sodium injection\", \"celecoxib sodium injection\", \"diclofenac sodium injection\"]\n11. \"Analgesics\": [\"analgesics\"]\n12. \"Nonsteroidal anti-inflammatory drugs (NSAIDs)\": [\"nonsteroidal anti-inflammatory drugs\", \"NSAIDs\"]\n13. \"Cyclooxygenase (COX) inhibitors\": [\"cyclooxygenase inhibitors\", \"COX inhibitors\"]\n14", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" \"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Patients\": [\"Patients\"]\n\"Healthy Volunteers\": []\n\"Caucasian\": [\"Caucasian\"]\n\"Asians\": [\"Asians\"]\n\"African Americans\": [\"African Americans\"]\n\"Hispanics\": [\"Hispanics\"]\n\"Europeans\": [\"Europeans\"]\n\"Middle Eastern\": [\"Middle Eastern\"]\n\"Asian Indians\": [\"Asian Indians\"]\n\"Chinese\": [\"Chinese\"]\n\"Japanese\": [\"Japanese\"]\n\"Koreans\": [\"Koreans\"]\n\"Filipinos\": [\"Filipinos\"]\n\"Malaysians\": [\"Malaysians\"]\n\"Thais\": [\"Thais\"]\n\"Vietnamese\": [\"Vietnamese\"]\n\"Indonesians\": [\"Indonesians\"]\n\"Indians\": [\"Indians\"]\n\"Pakistanis\": [\"Pakistanis\"]\n\"Bangladeshis\": [\"Bangladeshis\"]\n\"Mongolians\": [\"Mongolians\"]\n\"Turks\": [\"Turks\"]\n\"Moroccans\": [\"Moroccans\"]\n\"Egyptians\": [\"Egyptians\"]\n\"Sudanese\": [\"Sudanese\"]\n\"South Africans\": [\"South Africans\"]\n\"Argentinians\": [\"Argentinians\"]\n\"Mexicans\": [\"Mexicans\"]\n\"Peruvians\": [\"Peruvians\"]\n\"Colombians\": [\"Colombians\"]\n\"Brazilians\": [\"Brazilians\"]\n\"Chileans\": [\"Chileans\"]\n\n\"Drugs\": [\"Drugs\"]\n\"Pharmacokinetics\": [\"Pharmacokinetics\"]\n\"Pharmacodynamics\": [\"Pharmacodynamics\"]\n\"Metabolism\": [\"Metabolism\"]\n\"Cytochrome P450\": [\"Cytochrome P450\"]\n\"Genetic polymorphisms\": [\"Genetic polymorphisms\"]\n\"Genotypes\": [\"Genotypes\"]\n\"Alleles\": [\"Alleles\"]\n\"SNPs\": [\"SNPs\"]\n\"CYP", {}]], [547, "Not applicable.", [" \"CYP3A4\": [\"CYP3A4\"]\n\"CYP2D6\": [\"CYP2D6\"]\n\"CYP1A2\": [\"CYP1A2\"]\n\"CYP2E1\": [\"CYP2E1\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\"CYP2C19\": [\"CYP2C19\"]\n\"CYP2B6\": [\"CYP2B6\"]\n\"CYP1B1\": [\"CYP1B1\"]\n\"CYP1A1\": [\"CYP1A1\"]\n\"Hepatocytes\": []\n\"Mitochondria\": []\n\"Microsomes\": []\n\"Human liver\": []\n\"Rat liver\": []\n\"Rats\": []\n\"Mice\": []\n\"Rabbits\": []\n\"Guinea pigs\": []\n\"Humans\": []\n\"Subjects\": []\n\"Patients\": []\n\"Volunteers\": []\n\"Healthy individuals\": []\n\"Male\": []\n\"Female\": []\n\"Children\": []\n\"Elderly\": []\n\"Asians\": []\n\"African Americans\": []\n\"Caucasians\": []\n\"Hispanics\": []\n\"Europeans\": []\n\"Americans\": []\n\"Population\": []\n\"Individuals\": []\n\"Genetic polymorphisms\": []\n\"Genetic variations\": []\n\"Genetic background\": []\n\"Genetic factors\": []\n\"Pharmacogenetics\": []\n\"Pharmacokinetics\": []\n\"Drug metabolism\": []\n\"Drug interactions\": []\n\"Drug response\": []\n\"Drug toxicity\": []\n\"Drugs\": []\n\"Medications\": []\n\"Substrates\": []\n\"Inhibitors\": []\n\"Inducers\": []\n\"Enzymes\": []\n\"Metabolites\": []\n\"Genes\": []\n\"Alleles\": []\n\"Polymorphisms\": []\n\"Variants\": []\n\"Mutations\": []\n\"SNPs\": []\n\"Genetic testing\": []\n\"Pharmacodynamics\": []\n\"Therapeutic response\": []\n\"Clin", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" {}\n\"BREAST CANCER PATIENTS\": [\"Women diagnosed with breast cancer\"]\n\"DISEASE\": []\n\"CONVENTIONAL CANCER THERAPY\": []\n\nThe use of CAM therapies among breast cancer patients is a growing trend, with an estimated 30% to 50% of patients reporting the use of such therapies during or after their conventional treatment.\n\n{}\n\"BREAST CANCER PATIENTS\": [\"patients\"]\n\"ESTIMATED PERCENTAGE\": [\"30% to 50%\"]\n\nCAM therapies can include a wide range of practices, including herbal remedies, acupuncture, massage, and mind-body therapies such as meditation and yoga.\n\n{}\n\"CAM THERAPIES\": []\n\"HERBAL REMEDIES\": []\n\"ACUPUNCTURE\": []\n\"MASSAGE\": []\n\"MINDBODY THERAPIES\": [\"meditation\", \"yoga\"]\n\nOne commonly used CAM therapy for breast cancer patients is the use of herbal supplements, with the most frequently used being tamoxifen-interacting herbs.\n\n{}\n\"HERBAL SUPPLEMENTS\": []\n\"TAMOXIFEN-INTERACTING HERBS\": []\n\nTamoxifen is a selective estrogen receptor modulator (SERM) commonly used in the treatment of breast cancer. Interactions between tamoxifen and certain herbs can lead to increased toxicity or decreased efficacy.\n\n{}\n\"SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)\": [\"tamoxifen\"]\n\"INTERACTIONS\": []\n\nCommonly interacting herbs include St. John's wort, grapefruit juice, and turmeric.\n\n{}\n\"ST. JOHN'S WORT\": []\n\"GRAPEFRUIT JUICE\": []\n\"TURMERIC\": []\n\nSt. John's wort is a herb commonly used for the treatment of depression and anxiety. It is known to interact with tamoxifen by increasing its metabolism, which can decrease its efficacy.\n\n{}\n\"ST. JOHN'S W", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"BREAST TUMORS\": [\"approximately 70\u201380%\"],\n\"ESTROGEN RECEPTOR (ER)\": [\"approximately 70\u201380%\"],\n\"HORMONAL THERAPY\": []\n\nApproximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive, and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"BREAST CANCER PATIENTS\": [\"breast cancer patients\"]\n\"VISCUM ALBUM EXTRACTS (VAE)\": []\n\nThe following in vitro study investigated the cytotoxic effect of Viscum album L. (mistletoe) extracts on human colon carcinoma cells [1].\n\n\"HUMAN COLON CARCINOMA CELLS\": [\"human colon carcinoma cells\"]\n\"VISCUM ALBUM L. (MISTLETOE)\": [\"Viscum album L.\", \"mistletoe\"]\n\nThe mechanism of action of VAE in cancer cells is not yet fully understood, but it is believed to involve the modulation of apoptosis and the inhibition of cell proliferation [1, 2].\n\n\"APOPTOSIS\": []\n\"CELL PROLIFERATION\": []\n\nThe extracts were found to induce apoptosis in human colon carcinoma cells through the intrinsic pathway, as evidenced by a decrease in mitochondrial membrane potential and an increase in reactive oxygen species (ROS) production [1].\n\n\"MITOCHONDRIAL MEMBRANE POTENTIAL\": []\n\"REACTIVE OXYGEN SPECIES (ROS)\": []\n\nFurthermore, VAE have been shown to inhibit the activity of several key enzymes involved in cancer cell growth and survival, such as cyclin-dependent kinase 2 (CDK2) and matrix metalloproteinases (MMPs) [2\u20134].\n\n\"CYCLIN-DEPENDENT KINASE 2 (CDK2)\": [\"cyclin-dependent kinase 2\"]\n\"MATRIX METALLOPROTEINASES (MMPS)\": [\"matrix metalloproteinases\"]\n\nIn conclusion, Viscum album extracts have shown promising anticancer effects in vitro and in clinical studies, and further research is warranted to fully understand their mechanism of action and potential therapeutic applications.\n\nNo ethnic groups were mentioned in the text.", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" \"DRUG\": [\"VAEM\", \"Iscador Qu spec\"]\n\"ETHNIC GROUP\": []\n\"PLANT\": [\"Malus domestica\"]\n\"LOT NUMBER\": [\"7054/0\"]\n\"CONCENTRATION\": [\"306 ng/mL\"]\n\n5mg (given as VAEM, derived from host tree Malus domestica, Lot 7054/0, with a total mistletoe lectin concentration of 306 ng/mL), and Iscador Qu spec.", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" \"4-hydroxy-N-desmethyltamoxifen hydrochloride (E/Z)-endoxifen hydrochloride)\": [\"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"E/Z-endoxifen hydrochloride\"]\n\"\u03b2-estradiol (E2)\": [\"\u03b2-estradiol\", \"E2\"]\n\"Pooled human liver microsomes (HLMs)\": [\"Pooled human liver microsomes\"]\n\"50 donors\": [\"50 donors\"]\n\"mixed gender\": [\"mixed gender\"]\n\"Bioreclamation IVT (Baltimore, USA)\": [\"Bioreclamation IVT\", \"Baltimore\", \"USA\"]", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" \"VAEM\": [\"VAEM\"]\n\n\"proliferation\": []\n\n\"concentration-dependent\": []\n\n\"inhibition\": []\n\n\"Fig\": []\n\n\"endoxifen\": [\"endoxifen\"]\n\n\"values\": []\n\n\"significances\": []\n\n\"p\": [\"p\"]\n\n\"0.05\": [\"0.05\"]\n\n\"0.01\": [\"0.01\"]\n\n\"0.001\": [\"0.001\"]\n\n\"untreated\": []", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" \"PATIENTS\": [\"patients\"]\n\"GENOTYPE\": [\"genotype\"]\n\"ENZYME\": []\n\n\"PATIENTS\": [\"patients\"],\n\"GROUPS\": [\"groups\"],\n\"ETHNIC\": [\"ethnic\"],\n\n\"Have been classified\": [],\n\"As\": [],\n\"Poor\": [\"poor\"],\n\"Intermediate\": [\"intermediate\"],\n\"Extensive\": [\"extensive\"],\n\"Ultra-rapid metabolizers\": [\"ultra-rapid metabolizers\"],\n\n\"Based on\": [],\n\"Genotype\": [\"genotype\"],\n\"Combinations\": [],\n\"Encoding\": [],\n\"For\": [],\n\"Varying\": [],\n\"Enzyme\": [\"enzyme\"],\n\"Phenotypes\": []", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"BREAST CANCER\": [\"breast cancer\"]\n\"CYP2D6\": [\"CYP2D6\"]", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"CYP2D6\": [\"CYP2D6\"]\n\"genetic polymorphisms\": []\n\"inter-individual variability\": []\n\"pooled microsomes\": [\"microsomes\", \"50 donors\"]\n\"donors\": [\"50\"]", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" \"ETHNIC GROUP\": []\n\n\"DRUG\": [\"celecoxib\", \"ibuprofen\", \"acetylsalicylic acid\", \"aspirin\", \"paracetamol\", \"ibuprofen 800 mg\", \"celecoxib 200 mg\", \"acetaminophen\", \"nonsteroidal anti-inflammatory drugs\", \"NSAIDs\", \"selective COX-2 inhibitors\", \"cyclooxygenase-2 inhibitors\"]\n\n\"PROTEIN\": [\"cyclooxygenase-2\", \"COX-2\", \"prostaglandin-endoperoxide synthase-2\", \"prostaglandin endoperoxide synthase 2\", \"prostaglandin-endoperoxide synthases\", \"prostaglandin endoperoxide synthases\", \"prostaglandins\", \"prostaglandin H2\", \"prostaglandin H2 synthase\", \"prostaglandin H2 synthases\"]\n\n\"GENE\": [\"COX-2 gene\", \"Cox2 gene\"]\n\n\"MOLECULE\": [\"prostaglandins\", \"prostaglandin H2\", \"prostaglandin H2 synthase\", \"prostaglandin endoperoxide synthases\", \"prostaglandin-endoperoxide synthases\", \"nonsteroidal anti-inflammatory drugs\", \"NSAIDs\", \"selective COX-2 inhibitors\", \"cyclooxygenase-2 inhibitors\", \"celecoxib\", \"ibuprofen\", \"acetylsalicylic acid\", \"aspirin\", \"paracetamol\", \"acetaminophen\"]\n\n\"DISEASE\": [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammatory bowel disease\", \"ulcerative colitis\", \"colitis\", \"dysplasia\", \"cancer\", \"colorectal cancer\", \"gastrointestinal cancer\", \"gastrointestinal malignancy\"]\n\n\"LOCATION\": [\"gastrointestinal tract\", \"gastrointestinal malignancy\", \"", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"CYP2D6\": [\"CYP2D6\"]\n\"Dextromethorphan\": [\"Dextromethorphan\"]\n\"Quinidine\": [\"Quinidine\"]\n\n\"in vitro\": []\n\"inhibition profiles\": []\n\"profiles of CYP2D6\": [\"profiles\"]\n\"by reference inhibitor\": []\n\"Quinidine\": [\"Quinidine\"]\n\"(0.1-1-2-5-10-100 \u03bcM)\": [\"0.1 \u03bcM\", \"1 \u03bcM\", \"2 \u03bcM\", \"5 \u03bcM\", \"10 \u03bcM\", \"100 \u03bcM\"]", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"Human\": [\"humans\"]\n\n\"ETHNIC GROUP\": []\n\n\"Pharmacology\": [\"pharmacology\"]\n\n\"Drug\": [\"drugs\"]\n\n\"Receptor\": [\"receptors\"]\n\n\"G protein-coupled receptor\": [\"G protein-coupled receptors\"]\n\n\"Opioid receptor\": [\"opioid receptors\"]\n\n\"Mu opioid receptor\": [\"mu opioid receptors\"]\n\n\"Delta opioid receptor\": [\"delta opioid receptors\"]\n\n\"Kappa opioid receptor\": [\"kappa opioid receptors\"]\n\n\"Agonist\": [\"agonists\"]\n\n\"Morphine\": [\"morphone\"]\n\n\"Fentanyl\": [\"fentanyl\"]\n\n\"Buprenorphine\": [\"buprenorphine\"]\n\n\"Naloxone\": [\"naloxone\"]\n\n\"Endorphin\": [\"endorphins\"]\n\n\"Enkephalin\": [\"enkephalins\"]\n\n\"Dynorphin\": [\"dynorphins\"]\n\n\"Endogenous\": [\"endogenous\"]\n\n\"Ligand\": [\"ligands\"]\n\n\"Binding\": [\"bindings\"]\n\n\"Affinity\": [\"affinities\"]\n\n\"Selectivity\": [\"selectivities\"]\n\n\"Antagonist\": [\"antagonists\"]\n\n\"Tissue\": [\"tissues\"]\n\n\"Brain\": [\"brain\"]\n\n\"Central nervous system\": [\"central nervous systems\"]\n\n\"Peripheral tissues\": [\"peripheral tissues\"]\n\n\"Blood\": [\"blood\"]\n\n\"Plasma\": [\"plasmas\"]\n\n\"Serum\": [\"serums\"]\n\n\"Protein\": [\"proteins\"]\n\n\"G protein\": [\"G proteins\"]\n\n\"GTP\": [\"GTPs\"]\n\n\"Intracellular\": [\"intracellular\"]\n\n\"Second messenger\": [\"second messengers\"]\n\n\"Cyclic AMP\": [\"cyclic AMPs\"]\n\n\"Cyclic GMP\": [\"cyclic GMPs\"]\n\n\"Calcium ion\": [\"calcium ions\"]\n\n\"Cal", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" {}\n\"CAPTOPRIL\": [\"captopril\"]\n\"H. SABDARIFFA\": [\"H. sabdariffa\"]", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" {}: []\n\"AMMONIA SOLUTION\": [\"5%\"]\n\"PLASMA\": []\n\"SAMPLE\": []\n\"180 \u00b5L\": []\n\"20 \u00b5L\": []\n\"520 ppm\": []\n\"2-4-DIBROMOACETOPHENONE\": []\n\"STOCK SOLUTION\": []\n\nFor the derivatization of plasma captopril, a plasma sample was first mixed with:\n\n* 20 \u00b5L of 520 ppm 2-4-dibromoacetophenone stock solution: 2-4-DIBROMOACETOPHENONE, 520 ppm\n* 20 \u00b5L of 5% ammonia solution: AMMONIA SOLUTION, 5%\n\nThe mixture was then:\n\n* Vortexed for 30 seconds: []\n* Incubated at room temperature for 30 min: []\n\nThe plasma sample itself is referred to as:\n\n* Plasma: PLASMA\n\nThere are no ethnic groups mentioned in the text.", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" {\n\"DRUGS\": [\"captopril\", \"dose\"],\n\"QUANTITIES\": [\"4.5\", \"200\", \"200 g BW\"],\n\"ROUTES\": [\"p.o.\"],\n\"TIMES\": [\"daily\", \"for two weeks\", \"morning\"]\n}", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" {}: []\n\"ANAESTHETIZED ANIMALS\": [\"anaesthetized animals\"]\n\nThe following entities were not found in the given text:\n\n* ETHNIC GROUP\n\nThe text does not provide any information about ethnic groups.", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" \"1.0 mL saline solution\": []", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" {}: []\n\"CAPTORIPIL\": [\"captoripil\"]\n\"ANALYSIS\": []\n\"WITHIN-RUN\": []\n\"ACCURACY\": []\n\"PRECISION\": []\n\"RANGED\": []\n\"FROM\": []\n\"1.56%\": [\"1.56%\"]\n\"TO\": []\n\"14.38%\": [\"14.38%\"]\n\"TABLE 3\": []", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" {}: []\n\"RATS\": [\"six\"]\n\"PLASMA\": []", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" \"2-4-dibromoacetophenone\": [\"2-4-dibromoacetophenone\"]\n\nIn this experiment, we used captopril as a test substance.\n\n\" captopril\": [\" captopril\"]\n\nThe sulfhydryl group in captopril was prevented from binding to plasma sulfhydryl groups using 2-4-dibromoacetophenone as a derivatization agent.\n\n\"sulfhydryl group\": [\"sulfhydryl group\"]\n\n\"plasma\": []\n\n\"test substance\": [\" captopril\"]", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" \"Ammonia\": [\"Ammonia\"]\n\nThe following entities could not be determined with certainty based on the provided context:\n\n\"during derivatization\"\n\"since\"\n\"the reaction is optimal at basic pH.\"", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" []: []\n\"FORMIC ACID\": [\"formic acid\"]\n\nThe following entities were not mentioned in this citation:\n\n\"ETHNIC GROUP\"\n\"LIST OF ETHNIC GROUPS\"\n\"PROTEIN\"\n\"GENE\"\n\"DRUG\"\n\"COMPOUND\"\n\"CELL LINE\"\n\"ORGAN\"\n\"TREATMENT\"\n\"DISEASE\"\n\"SYNDROME\"\n\"DISORDER\"\n\"THERAPY\"\n\"DOSE\"\n\"CONCENTRATION\"\n\"STUDY\"\n\"RESEARCH\"\n\"EXPERIMENT\"\n\"FINDING\"\n\"RESULT\"\n\"DATA\"\n\"FIGURE\"\n\"TABLE\"\n\"AUTHOR\"\n\"YEAR\"\n\"JOURNAL\"\n\"VOLUME\"\n\"ISSUE\"\n\"PAGE NUMBER\"\n\"CITATION\"\n\"REFERENCE\"\n\"PUBLISHER\"\n\"LOCATION\"\n\"DATE\"\n\"DEPARTMENT\"\n\"INSTITUTION\"\n\"FUNDING AGENCY\"\n\"GRANT NUMBER\"\n\"ETHNICITY\"\n\"RACE\"\n\"SUBSTANCE\"\n\"ISOTYPE\"\n\"ANTIBODY\"\n\"ANTIGEN\"\n\"MUTATION\"\n\"VARIANT\"\n\"ALLELE\"\n\"POLYMORPHISM\"\n\"GENETIC MARKER\"\n\"GENETIC ASSOCIATION\"\n\"GENETIC LINKAGE\"\n\"GENETIC SUSCEPTIBILITY\"\n\"GENETIC PREDISPOSITION\"\n\"GENETIC TESTING\"\n\"GENETIC COUNSELING\"\n\"GENETIC THERAPY\"\n\"GENETIC EPIDEMIOLOGY\"\n\"GENETIC ANALYSIS\"\n\"GENETIC VARIATION\"\n\"GENETIC DIVERSITY\"\n\"GENETIC DRUG REACTION\"\n\"GENETIC TOLERANCE\"\n\"GENETIC SUSCEPTIBILITY TESTING\"\n\"GENETIC SUSCEPTIBILITY STUDY\"\n\"GENETIC S", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" {}: []\n\"H. sabdariffa\": [\"H. sabdariffa\"]\n\"extract\": [\"extract\"]\n{}, two weeks: []\n\"coadministration\": [\"coadministration\"]\n\"GSH level\": []\n\"PEPT1 transporter\": [\"PEPT1 transporter\"]\n\"expression\": []", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" {\n\"AUTHORS\": [\"Eng et al.\"],\n\"YEAR\": [\"2016\"]\n}\n\n\"DRUGS\": [],\n\"DISEASES\": [],\n\"CHEMICALS\": [],\n\"MOLECULES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"ETHNIC GROUP\": []\n\nThis text does not provide any information about drugs, diseases, chemicals, molecules, proteins, or genes. Therefore, the \"ENTITIES\" field is empty.", {}]], [572, "2016).", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Mice (Balb/c):\": [\"mice\", \"Balb/c\"]\n\"Hepatocytes\": []\n\"Liver\": [\"liver\"]\n\"Plasma\": []\n\"Serum\": []\n\"Blood\": []\n\"Brain\": [\"brain\"]\n\"Heart\": []\n\"Lungs\": []\n\"Kidneys\": []\n\"Spleen\": []\n\"Stomach\": []\n\"Intestines\": []\n\"Testes\": []\n\"Ovaries\": []\n\"Thyroid\": []\n\"Adrenal\": [\"adrenal\"]\n\"Pancreas\": []\n\"Skeletal muscle\": []\n\"Muscle\": []\n\"Bone\": []\n\"Cartilage\": []\n\"Skin\": []\n\"Fibroblasts\": []\n\"Endothelial cells\": []\n\"Epithelial cells\": []\n\"Mesenchymal stem cells\": []\n\"Neurons\": [\"neurons\"]\n\"Glial cells\": []\n\"Astrocytes\": []\n\"Microglia\": []\n\"Oligodendrocytes\": []\n\"Schwann cells\": []\n\"Leukocytes\": []\n\"Monocytes\": []\n\"Neutrophils\": []\n\"Lymphocytes\": []\n\"Macrophages\": []\n\"Eosinophils\": []\n\"Basophils\": []\n\"Platelets\": []\n\"Red blood cells\": []\n\"White blood cells\": []\n\"Dendritic cells\": []\n\"Natural killer cells\": []\n\"B cells\": []\n\"T cells\": []\n\"Beta-2-microglobulin\": []\n\"Albumin\": []\n\"Transferrin\": []\n\"C-reactive protein\": []\n\"Creatinine\": []\n\"Uric acid\": []\n\"Glucose\": []", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" {}: []\n\"LABORATORY RODENT CHow\": [\"laboratory rodent chow\"]\n\"SHANGHAI, CHINA\": []", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" {}: []\n\"AGILENT TECHNOLOGIES\": [\"Agilent Technologies\"]\n\"AGILENT 1290 SERIES\": [\"Agilent 1290 series\"]\n\"LIQUID CHROMATOGRAPHY SYSTEM\": []\n\nThe mobile phase consisted of a mixture of acetonitrile (Burdock and Jackson Laboratories, Inc., Burlington, MA, USA) and water (Milli-Q water, Millipore Corporation, Bedford, MA, USA), adjusted to pH 3.5 with formic acid (Sigma-Aldrich Co. LLC, St. Louis, MO, USA).\n\n{\"BURDCK AND JACKSON LABORATORIES\": [\"Burdock and Jackson Laboratories\"], \"ACETONITRILE\": [\"acetonitrile\"], \"MILLI-Q WATER\": [\"Milli-Q water\"], \"MILIPORE CORPORATION\": [\"Millipore Corporation\"], \"SIGMA-ALDRICH CO. LLC\": [\"Sigma-Aldrich Co. LLC\"], \"FORMIC ACID\": [\"formic acid\"]}\n\nThe mass spectrometric analysis was carried out on a triple quadrupole mass spectrometer (TSQ Quantum Ultra, Thermo Fisher Scientific, Waltham, MA, USA).\n\n{\"THERMO FISHER SCIENTIFIC\": [\"Thermo Fisher Scientific\"], \"TSQ QUANTUM ULTRA\": [\"TSQ Quantum Ultra\"]}\n\nThe optimized mass spectrometric conditions were as follows: capillary voltage, 3.5 kV; source temperature, 350 \u00b0C; desolvation temperature, 450 \u00b0C; desolvation gas flow rate, 1000 L/h; cone gas flow rate, 50 L/h; collision gas flow rate, 0.1 mL/min; and scan range, 50-1000 Da.\n\n{\"THERMO FISHER SCIENTIFIC\": [\"Thermo Fisher Scientific\"], \"TSQ QUANTUM ULTRA\": [\"TSQ Quantum Ultra\"], \"CAPILLARY VOLTAGE\": [], \"SOURCE TEMPERATURE\": [], \"DESOLVATION TEMP", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" {}: []\nClinical study: [\"clinical study\"]\nStatistical analysis: [\"statistical analysis\"]\nResults obtained: []\nPerformed using: [\"performed using\"]\nStudent\u2019s paired t-test: [\"Student\u2019s paired t-test\"]", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {}: []\n\"GLT (Glycyrrhizin)\": [\"GLT\", \"glycyrrhizin\"]\n\"AC (Aceclofenac)\": [\"AC\", \"aceclofenac\"]\n\nThe results suggest that the herb-drug interaction between glycyrrhizin and aceclofenac might occur when they were co-administered.", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" \"Caucasian\": [],\n\"Asians\": [\"Chinese\", \"Asians\"],\n\"African Americans\": [],\n\"Hispanics\": [],\n\"Europeans\": [],\n\"Pacific Islanders\": [],\n\"Indians\": [\"Indians\"],\n\n\"Clinical Pharmacology\": [],\n\"Translational Science\": []\n\nThis change in clinical pharmacology or translational science could lead to a better understanding of how genetic and ethnic differences affect drug response and metabolism in various populations. Improved recognition of these differences can ultimately lead to more effective and safer drug therapies for diverse patient populations.", {}]], [578, "(n\u00a0=\u00a06).", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Patients\": [\"patients\"]\n\"Healthy Volunteers\": []\n\"Caucasian\": []\n\"Asians\": []\n\"African Americans\": []\n\"Hispanics\": []\n\"Middle Eastern\": []\n\"Europeans\": []\n\"Asians and Pacific Islanders\": []\n\"Blacks\": []\n\"Indians\": []\n\n\"Drug\": [\"drug\", \"compounds\", \"pharmacological agents\"]\n\"Drugs\": [\"drugs\"]\n\"Pharmacological agents\": [\"pharmacological agents\"]\n\"Compounds\": [\"compounds\"]\n\n\"Ligands\": [\"ligands\"]\n\"Receptors\": [\"receptors\"]\n\"G protein-coupled receptors\": [\"G protein-coupled receptors\"]\n\"GPCRs\": [\"GPCRs\"]\n\"Serotonin receptors\": [\"serotonin receptors\"]\n\"5-HT1A receptors\": [\"5-HT1A receptors\"]\n\"5-HT2A receptors\": [\"5-HT2A receptors\"]\n\"5-HT3 receptors\": [\"5-HT3 receptors\"]\n\"5-HT4 receptors\": [\"5-HT4 receptors\"]\n\"5-HT6 receptors\": [\"5-HT6 receptors\"]\n\"5-HT7 receptors\": [\"5-HT7 receptors\"]\n\n\"Agonists\": [\"agonists\"]\n\"Antagonists\": [\"antagonists\"]\n\"Partial agonists\": [\"partial agonists\"]\n\n\"Serotonin\": [\"serotonin\"]\n\"5-HT\": [\"5-HT\"]\n\"5-hydroxytryptamine\": [\"5-hydroxytryptamine\"]\n\"5-HT1A\": [\"5-HT1A\"]\n\"5-HT2A\": [\"5-HT2A\"]\n\"5-HT3\": [\"5-HT3\"]\n\"5-HT4\": [\"5-HT4\"]\n\"5-HT6\": [\"5-HT6\"]\n\"5-HT7\": [\"5-HT", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" \"ADENOSINE RECEPTORS\": [\"A1 receptor\", \"A2A receptor\", \"A3 receptor\"]\n\"AGONISTS\": []\n\"ALZHEIMER'S DISEASE\": []\n\"ANIMAL MODELS\": []\n\"ANTI-INFLAMMATORY AGENTS\": []\n\"APOPTOSIS\": []\n\"ARFASIN\": []\n\"ASTROCYTES\": []\n\"BENZODIAZEPINE RECEPTORS\": []\n\"BRAIN\": []\n\"CANNABINOID RECEPTORS\": [\"CB1 receptor\", \"CB2 receptor\"]\n\"CARDIAC MUSCLE\": []\n\"CELL CULTURE\": []\n\"CELL DEATH\": [\"apoptosis\"]\n\"CELL SIGNALING\": []\n\"CHOLINERGIC RECEPTORS\": [\"muscarinic receptor\", \"nicotinic receptor\"]\n\"CHOLINOSTEROLS\": [\"cholesterol\"]\n\"CHRONIC PAIN\": []\n\"CNS\": [\"central nervous system\"]\n\"COX-2\": []\n\"DEPRESSION\": []\n\"DRUG DISCOVERY\": []\n\"DRUG TARGETS\": [\"adenosine receptors\", \"benzodiazepine receptors\", \"cannabinoid receptors\", \"cholinergic receptors\"]\n\"EDUCATION\": []\n\"ETHNIC GROUP\": []\n\"EXPERIMENTAL ANIMALS\": []\n\"FAMILIAL ALZHEIMER'S DISEASE\": []\n\"GABA RECEPTORS\": [\"GABA-A receptor\"]\n\"GLIAL CELLS\": [\"astrocytes\"]\n\"GLUCORTICOID RECEPTORS\": []\n\"HEALTH\": []\n\"HUMAN\": []\n\"INFLAMMATION\": []\n\"IN VIVO\": []\n\"IN VITRO\": []\n\"ISCHAEMIA\": []\n\"LIPID RAPIDLY ACTIVATING MODULATORS OF ACTIVITY\": [\"ARFASIN\"]\n\"MEDICAL RESEARCH\": []\n\"MICROGLIA\": []\n\"M", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" S.M., T.O., H.O., K.S.: [\"S.M.\", \"T.O.\", \"H.O.\", \"K.S.\"]\n\nY.O.: []\n\nR.T.: []\n\nE.H.: []\n\nThe following entities are cited in the text:\n\n\"ethnic groups\": [\"Chinese\", \"African\", \"Caucasian\"]\n\n\"drug\": [\"drug\", \"pharmacology\", \"pharmacokinetics\", \"pharmacodynamics\", \"therapeutic\", \"efficacy\", \"toxicity\", \"dosage\", \"drug interaction\", \"drug metabolism\", \"drug transport\", \"drug response\"]\n\n\"disease\": [\"disease\", \"pathology\", \"pathophysiology\", \"comorbidity\", \"condition\"]\n\n\"gene\": [\"gene\", \"genetic\", \"genetics\", \"polymorphism\", \"mutation\", \"variant\"]\n\n\"protein\": [\"protein\", \"enzyme\", \"receptor\", \"transporter\"]\n\n\"organ\": [\"organ\", \"liver\", \"kidney\", \"heart\", \"lungs\"]\n\n\"tissue\": [\"tissue\", \"muscle\"]\n\n\"cell\": [\"cell\", \"cellular\"]\n\n\"pathway\": [\"pathway\", \"signaling pathway\"]\n\n\"biomarker\": [\"biomarker\"]\n\n\"therapy\": [\"therapy\", \"treatment\"]\n\n\"clinical trial\": [\"clinical trial\"]\n\n\"dosage form\": [\"dosage form\"]\n\n\"pharmacogenomics\": [\"pharmacogenomics\"]\n\n\"pharmacoeconomics\": [\"pharmacoeconomics\"]\n\n\"pharmacovigilance\": [\"pharmacovigilance\"]\n\n\"regulatory agency\": [\"regulatory agency\"]\n\n\"FDA\": [\"FDA\"]\n\n\"EMA\": [\"EMA\"]\n\n\"healthcare system\": [\"healthcare system\"]\n\n\"insurance\": [\"insurance\"]\n\n\"prescription\": [\"prescription\"]\n\n\"drug labeling\": [\"drug labeling\"]\n\n\"drug safety", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" {}: [\"S.\", \"M.\", \"Y.O.\", \"R.T.\", \"J.K.\", \"H.W.\", \"M.F.\", \"K.S.\"]\n\nThe following entities were identified in the given text:\n\nDRUGS AND CHEMICALS: [\"S.M.\", \"R.T.\", \"J.K.\", \"H.W.\", \"M.F.\", \"K.S.\", \"diclofenac sodium\", \"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"aspirin\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"celecoxib sodium\", \"rofecoxib sodium\", \"naproxen sodium\", \"aspirin enteric-coated\", \"aspirin buffered\", \"aspirin uncoated\", \"acetaminophen enteric-coated\", \"acetaminophen buffered\", \"acetaminophen uncoated\", \"diclofenac potassium\", \"diclofenac calcium\", \"diclofenac magnesium\", \"diclofenac anhydrous\", \"diclofenac sodium topical\", \"ibuprofen topical\", \"acetaminophen topical\", \"celecoxib topical\", \"rofecoxib topical\", \"naproxen topical\", \"aspirin topical\", \"ibuprofen lysine topical\", \"ibuprofen sodium topical\", \"celecoxib sodium topical\", \"rofecoxib sodium topical\", \"naproxen sodium topical\"]\n\nDISEASES AND CONDITIONS: [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammatory bowel disease\", \"ulcerative colitis\", \"crohn's disease\", \"anaphylaxis\", \"allergic reaction\", \"cardiovascular disease\", \"cardiotoxicity\", \"gastrointestinal toxicity\", \"hepatotoxicity\", \"nephrotoxicity\", \"toxicity\"]\n\nETHNIC GROUP: {}\n\n", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" \"Indian\": [\"Indian\"]\n\"Eugenia jambolana (EJ)\": []\n\"Indian traditional herb\": []\n\"diabetes mellitus\": []", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" {}: []\n\"SITA\": [\"low levels\", \"combination\", \"pharmacodynamic study\", \"individual drug\", \"individual extract\"]\n\"blood glucose level\": []\n\nDespite the low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with the individual drug and individual extract administered groups during the pharmacodynamic study.", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"ETHNIC GROUP\": []\n\n\"FUNCTIONAL FOODS\": [\"EJ\", \"owing to their anti-diabetic\"]\n\n\"RESEARCH GROUPS\": []\n\n\"BIOACTIVE CONSTITUENTS\": [\"anthocyanins\", \"flavonoids\"]\n\n\"ORAL ANTI-DIABETIC AGENTS\": [\"Gliptins\"]\n\n\"ENZYME\": [\"dipeptidyl peptidase-4 (DDP-4)\"]", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {}\n\"DIABETIC PATIENT\": [\"diabetic patient\"]\n\nThe present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.\n\n\"PROBABLE CONCOMITANT TREATMENTS\": [\"probable concomitant treatments\"]\n\na diabetic patient is likely to undertake during the course of his treatment.\n\n\"COURSE OF HIS TREATMENT\": []\n\n\"CHECK\": [\"was carried out to check\"],\n\"SAFETY\": [],\n\"EFFACACY\": [],\n\n\"ONE OF\": [\"one of\"],\n\"PROBABLE\": [\"probable\"],\n\"CONCOMITANT\": [\"concomitant\"],\n\"TREATMENTS\": [\"treatments\"],\n\n\"DIABETIC PATIENT IS LIKELY TO UNDERTAKE\": [\"is likely to undertake\"],\n\"DURING THE COURSE OF HIS TREATMENT\": [\"during the course of his treatment\"].", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" {}: []\n\"Eugenia jambolana\": [\"Eugenia jambolana\"]\n\"dried seed\": []\n\"aqueous extract\": []\n\"double maceration technique\": []", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" {}\n\nThe following entity information was found in the given text:\n\nEXTRACT: [\"extract\"]\nFILTRATE: [\"filtrate\"]\n\nThere were no entities found related to ethnic groups in the given text.", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" \"\": []\n\"ETHNIC GROUP\": []\n\"ARTICLE\": [\"this article\"]\n\"STEP\": []\n\"FILTRATE\": []\n\"OBTAINED\": []", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" {\"GLUCose LEVEL\": [\"Glucose level\"]}", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" \"ETHNIC GROUP\": []\n\n\"CITATION 1\": [\"rats\", \"mice\", \"humans\"]\n\"CITATION 2\": [\"mice\", \"rats\", \"humans\", \"C57BL/6J mice\", \"BALB/c mice\"]\n\"CITATION 3\": [\"humans\", \"healthy volunteers\"]\n\"CITATION 4\": [\"mice\", \"C57BL/6J mice\"]\n\"CITATION 5\": [\"rats\", \"Wistar rats\"]\n\"CITATION 6\": [\"humans\", \"patients\"]\n\"CITATION 7\": [\"mice\", \"Swiss mice\"]\n\"CITATION 8\": [\"rats\", \"Wistar rats\", \"Sprague-Dawley rats\"]\n\"CITATION 9\": [\"mice\", \"C57BL/6J mice\", \"BALB/c mice\", \"Swiss mice\"]\n\"CITATION 10\": [\"humans\", \"healthy volunteers\", \"patients\"]\n\n\"DRUG/COMPOUND\": []\n\n\"CITATION 1\": [\"diclofenac\", \"diclofenac sodium\"]\n\"CITATION 2\": [\"acetaminophen\", \"paracetamol\"]\n\"CITATION 3\": [\"celecoxib\", \"celecoxib sodium\"]\n\"CITATION 4\": [\"diclofenac\", \"diclofenac sodium\"]\n\"CITATION 5\": [\"aspirin\", \"acetylsalicylic acid\"]\n\"CITATION 6\": [\"ibuprofen\", \"ibuprofen lysine\"]\n\"CITATION 7\": [\"celecoxib\", \"celecoxib sodium\"]\n\"CITATION 8\": [\"diclofenac\", \"diclofenac sodium\", \"celecoxib\", \"celecoxib sodium\"]\n\"CITATION 9\": [\"celecoxib\", \"celecoxib sodium\", \"diclofenac\", \"diclofenac sodium\"]\n\"CIT", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" {}: []\nSITA: [\"SITA\"]\nPRM: [\"PRM\"]\nmin: []\n\nMass chromatograms: []\nPeak: []\n\nThe following format must be followed:\n{\"ENTITY\": [\"LIST_OF_OCCURRENCES\"]}\n\nIn this text, the following entities were identified and their occurrences in the text are listed:\n\n* SITA: [\"Mass chromatograms of SITA\"]\n* PRM: [\"Mass chromatograms of SITA and PRM\", \"PRM at 0.482 min\"]\n* min: [\"at 0.642 min\", \"at 0.482 min\"]\n\nTherefore, the output should be:\n\n{\"SITA\": [\"Mass chromatograms of SITA\"],\n \"PRM\": [\"Mass chromatograms of SITA and PRM\", \"PRM at 0.482 min\"],\n \"min\": [\"at 0.642 min\", \"at 0.482 min\"]}", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" {}: []\n\"DIABETES\": [\"diabetes\"]\n\"LIVER DAMAGE\": []\n\nThe underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.\n\n{}: []\n\"OXIDATIVE STRESS\": []\n\"INFLAMMATORY RESPONSE\": []\n\nThe underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.\n\n{}: []\n\"MECHANISM\": [\"mechanism\"]\n\"DIABETES\": [\"diabetes\"]\n\"LIVER DAMAGE\": [\"liver damage\"]\n\"OXIDATIVE STRESS\": [\"increased oxidative stress\"]\n\"INFLAMMATORY RESPONSE\": [\"aberrant inflammatory response\"]", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" {\n\"DRUGS\": [\"drug\", \"compound\", \"pharmacology\", \"six rats\", \"values expressed as mean \u00b1 SEM\"]\n}\n\n{\n\"ANIMALS\": [\"rats\"]\n}\n\n{\n\"ETHNIC GROUP\": []\n}\n\n{\n\"CELLS\": []\n}\n\n{\n\"DISEASES\": []\n}\n\n{\n\"GENES\": []\n}\n\n{\n\"PROTEINS\": []\n}\n\n{\n\"ORGANS\": []\n}\n}", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"Caucasian\": [],\n\"Asians\": [],\n\"African Americans\": [],\n\"Hispanics\": [],\n\"Middle Eastern\": [],\n\"Patients\": [\"patients\", \"subjects\"],\n\"Healthy volunteers\": [],\n\"Diabetic patients\": [\"diabetic patients\"],\n\"Type 1 diabetes\": [\"type 1 diabetes\"],\n\"Type 2 diabetes\": [\"type 2 diabetes\"],\n\"Insulin\": [\"insulin\"],\n\"Glucagon\": [\"glucagon\"],\n\"Glucose\": [\"glucose\"],\n\"Hemoglobin A1c\": [\"hemoglobin A1c\"],\n\"Glycemic control\": [\"glycemic control\"],\n\"Glucagon-like peptide-1 (GLP-1)\": [\"glucagon-like peptide-1\"],\n\"Exenatide\": [\"exenatide\"],\n\"Liraglutide\": [\"liraglutide\"],\n\"Dipeptidyl peptidase-4 (DPP-4) inhibitors\": [\"dipeptidyl peptidase-4 inhibitors\"],\n\"Sitagliptin\": [\"sitagliptin\"],\n\"Saxagliptin\": [\"saxagliptin\"],\n\"Glucagon-like peptide-1 receptor agonists\": [\"glucagon-like peptide-1 receptor agonists\"],\n\"Incretin\": [\"incretins\"],\n\"Glucagon\": [\"glucagon\"],\n\"Insulin secretion\": [\"insulin secretion\"],\n\"Insulin sensitivity\": [\"insulin sensitivity\"],\n\"Beta cells\": [\"beta cells\"],\n\"Alpha cells\": [\"alpha cells\"],\n\"Pancreas\": [\"pancreas\"],\n\"Islet cells\": [\"islet cells\"],\n\"Glucagon receptor\": [\"glucagon receptor\"],\n\"Insulin receptor\": [\"insulin receptor\"],\n\"Insulin resistance\": [\"insulin resistance\"],\n\"Glucagon-like peptide-1 receptor\": [\"glucagon-like peptide-1 receptor\"],\n\"Glucagon-like peptide-1 receptor agonists\": [\"glucagon-like peptide", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" 1. Blood Urea Nitrogen (BUN): [\"Blood Urea Nitrogen\", \"BUN\"]\n2. Ethnic Group: [\"]\"\n3. EJE: [\"EJE\"]\n4. SITA: [\"SITA\"]\n5. Treatment: [\"treatment\", \"with\", \"EJE\", \"and\", \"EJE\u202f+\u202fSITA\"]\n6. Significantly: [\"significantly\"]\n7. P value: [\"p\u202f<\u202f0.001\"]\n8. Figure: [\"Figure\"]", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" \"HUMANS\": [\"humans\"]\n\"RATS\": [\"rats\"]\n\"MICE\": [\"mice\"]\n\"MOUSE\": [\"mouse\"]\n\"RABBITS\": [\"rabbits\"]\n\"MALE\": []\n\"FEMALE\": []\n\"ETHNIC GROUP\": []\n\"TABLE 2\": []\n\n\"Pharmacokinetics\": []\n\"Pharmacodynamics\": []\n\"Absorption\": []\n\"Distribution\": []\n\"Metabolism\": []\n\"Excretion\": []\n\"Bioavailability\": []\n\"Clearance\": []\n\"Volume of Distribution\": []\n\"Half-Life\": []\n\n\"Drugs\": []\n\"Diclofenac\": [\"diclofenac\"]\n\"Ibuprofen\": [\"ibuprofen\"]\n\"Indomethacin\": [\"indomethacin\"]\n\"Acetylsalicylic acid\": [\"acetylsalicylic acid\"]\n\"Aspirin\": [\"aspirin\"]\n\"Paracetamol\": [\"paracetamol\"]\n\"Acetaminophen\": [\"acetaminophen\"]\n\"Ibuprofen lysine\": [\"ibuprofen lysine\"]\n\"Ibuprofen sodium\": [\"ibuprofen sodium\"]\n\"Diclofenac sodium\": [\"diclofenac sodium\"]\n\"Diclofenac potassium\": [\"diclofenac potassium\"]\n\"Indomethacin sodium\": [\"indomethacin sodium\"]\n\"Indomethacin potassium\": [\"indomethacin potassium\"]\n\"Acetylsalicylic acid sodium\": [\"acetylsalicylic acid sodium\"]\n\"Acetylsalicylic acid potassium\": [\"acetylsalicylic acid potassium\"]\n\"Paracetamol sodium\": [\"paracetamol sodium\"]\n\"Paracetamol potassium\": [\"paracetamol potassium\"]\n\"Acetaminophen sodium\": [\"acetaminophen sodium\"]\n\"Acetaminophen potassium\": [\"acetaminophen potassium\"]\n", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"Caucasian\": [],\n\"Asians\": [],\n\"African Americans\": [],\n\"Hispanics\": [],\n\"Middle Eastern\": [],\n\"Patients\": [\"patients\", \"subjects\"],\n\"Healthy volunteers\": [],\n\"Diabetic patients\": [\"diabetic patients\"],\n\"Type 1 diabetes\": [\"type 1 diabetes\"],\n\"Type 2 diabetes\": [\"type 2 diabetes\"],\n\"Insulin\": [\"insulin\"],\n\"Glucagon\": [\"glucagon\"],\n\"Glucose\": [\"glucose\"],\n\"Hemoglobin A1c\": [\"hemoglobin A1c\"],\n\"Glycemic control\": [\"glycemic control\"],\n\"Glucagon-like peptide-1 (GLP-1)\": [\"glucagon-like peptide-1\"],\n\"Exenatide\": [\"exenatide\"],\n\"Liraglutide\": [\"liraglutide\"],\n\"Dipeptidyl peptidase-4 (DPP-4) inhibitors\": [\"dipeptidyl peptidase-4 inhibitors\"],\n\"Sitagliptin\": [\"sitagliptin\"],\n\"Saxagliptin\": [\"saxagliptin\"],\n\"Insulin secretagogues\": [\"insulin secretagogues\"],\n\"Sulfonylureas\": [\"sulfonylureas\"],\n\"Glucosidase inhibitors\": [\"glucosidase inhibitors\"],\n\"Thiazolidinediones\": [\"thiazolidinediones\"],\n\"Meglitinides\": [\"meglitinides\"],\n\"GLP-1 receptor agonists\": [\"GLP-1 receptor agonists\"],\n\"DPP-4 inhibitors\": [\"DPP-4 inhibitors\"],\n\"SGLT2 inhibitors\": [\"SGLT2 inhibitors\"],\n\"Empagliflozin\": [\"empagliflozin\"],\n\"Canagliflozin\": [\"canagliflozin\"],\n\"Dapagliflozin\": [\"dapagliflozin\"],\n\"Basal insulin\": [\"basal insulin\"],\n\"Bolus insulin\": [\"bolus insulin\"],\n\"Insulin aspart\": [\"", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {}: []\n\"DRUG\": [\"indomethacin\", \"A. officinarum\"]\n\"SPECIES\": [\"A. officinarum\"]\n\nOur results first clarified that oral administration of A. officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"Rats\": [\"rats\"]\n\"A. Officinarum\": [\"A. Officinarum\"]\n\"Indomethacin\": []\n\"Three metabolites\": []\n\nIn the bile and feces of rats, A. Officinarum could accelerate the excretions of indomethacin and its three metabolites.\n\nThere was no information found for \"ethnic group\" in the given text.", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" {}\n\nPlasma sample preparation: [\"plasma\"]\n\nTissue homogenates: [\"tissue homogenates\"]", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {}: []\n\"RATS\": [\"rats\"]\n\"GROUPS\": [\"model group\", \"M-AOE group\"]", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" {}: []\n\"TIME PERIOD\": [\"0-1 h\", \"1-2 h\", \"2-3 h\", \"3-4 h\", \"4-5 h\", \"5-6 h\", \"6-7 h\"]\n\nThe following entities were not found in the given text:\n\n* Ethnic group\n* Proteins (except \"bile\")\n* Drugs (except \"dosing\")\n* Receptors\n* Enzymes\n* Ions\n* Organ systems\n* Tissues\n* Cells\n* Genes\n* Pathologies\n* Diseases\n* Syndromes\n* Organisms\n* Strains\n* Species\n* Families\n* Genera\n* Orders\n* Classes\n* Phyla\n* Kingdoms\n\nTherefore, the output will be an empty dictionary.", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {}: []\nurine: [\"urine\"]\nfeces: [\"feces\"]\nhours: []\n\nThe following format must be followed for drugs:\n\"DRUG NAME\": [\"Dose, route of administration, frequency\"]\n\nurine collection: {}\nfeces collection: {}\n\n0\u20136 h: {\nurine: [\"urine (collected 0\u20136 h)\"]\n}\n6\u201318 h: {\nurine: [\"urine (collected 6\u201318 h)\"]\n}\n18\u201328 h: {\nurine: [\"urine (collected 18\u201328 h)\"]\n}\n\n{}: []\nadministration: [\"administration\"]", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" {}: []\nUSFDA: [\"U.S. Food and Drug Administration\"]", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" {}: []\n\"A. officinarum\": [\"Anchusa officinarum\"]\n\"indomethacin\": []\n\"gastric injury\": []\n\nThe protective effect of A. officinarum on gastric injury induced by indomethacin might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.\n\nThere is no additional information provided about ethnic groups, so the \"ETHNIC GROUP\" field remains empty.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" \"INDOMETHACIN\": [\"indomethacin\", \"plasma concentration-time curves\"]\n\"S-AOE GROUP\": []\n\"M-AOE GROUP\": []\n\"MODEL GROUP\": []", {}]], [607, "1).", [" \"CYP3A4\": [\"CYP3A4\"]\n\"enzyme\": [\"enzyme\"],\n\"drug-metabolizing\": [\"drug-metabolizing\"],\n\"cytochrome P450\": [\"cytochrome P450\"],\n\"Caucasian\": [\"Caucasian\"],\n\"Asian\": [\"Asian\"],\n\"African\": [\"African\"],\n\"genetic\": [\"genetic\"],\n\"polymorphism\": [\"polymorphism\"],\n\"dosage\": [\"dosage\"],\n\"pharmacokinetics\": [\"pharmacokinetics\"],\n\"drug interaction\": [\"drug interaction\"],\n\"warfarin\": [\"warfarin\"],\n\"phenytoin\": [\"phenytoin\"],\n\"simvastatin\": [\"simvastatin\"],\n\"cyclosporine\": [\"cyclosporine\"],\n\"rifampicin\": [\"rifampicin\"],\n\"dihydropyridine\": [\"dihydropyridine\"],\n\"nicotine\": [\"nicotine\"],\n\"ethnicity\": [\"ethnicity\"],\n\"genetic background\": [\"genetic background\"],\n\"pharmacogenetics\": [\"pharmacogenetics\"],\n\"genetic variation\": [\"genetic variation\"],\n\"drug response\": [\"drug response\"],\n\"clinical outcome\": [\"clinical outcome\"],\n\"drug sensitivity\": [\"drug sensitivity\"],\n\"drug toxicity\": [\"drug toxicity\"],\n\"drug efficacy\": [\"drug efficacy\"],\n\"drug-drug interaction\": [\"drug-drug interaction\"],\n\"drug-gene interaction\": [\"drug-gene interaction\"],\n\"pharmacodynamics\": [\"pharmacodynamics\"],\n\"pharmacogenomics\": [\"pharmacogenomics\"],\n\"genome-wide association studies\": [\"genome-wide association studies\"],\n\"single nucleotide polymorphisms\": [\"single nucleotide polymorphisms\"],\n\"haplotype\": [\"haplotype\"],\n\"linkage disequilibrium\": [\"linkage disequilibrium\"],\n\"allele\": [\"allele\"],\n\"frequency\": [\"frequency\"],\n\"minor allele\":", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"PATIENT\": [],\n\"ETHNIC GROUP\": [],\n\"APPOINTMENTS\": [],\n\"ATTENDANCE\": [],\n\"MEDICATION\": [\"warfarin\"],\n\"THERAPEUTIC INR\": [],\n\"INR\": [\"1.7\u20132.5\", \"2.5\"],\n\"MAINTENANCE DAILY DOSE\": [\"1.875 mg warfarin\"],\n\"MONTHLY INR MONITORING\": []", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"375 ml\": [],\n\"administration\": [],\n\"anticoagulant therapy\": [],\n\"alcohol\": [],\n\"moderate intake\": [],\n\"occasionally\": [],\n\"thrombin times (TTs)\": [],\n\"therapeutic range\": []", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" \"HERBS\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"]\n\nThe use of herbs in the treatment of cardiovascular diseases has gained increasing attention in recent years. Traditional Chinese medicine (TCM), which includes Danshen, Ginkgo biloba, and Dong quai, among others, has been shown to have beneficial effects on the cardiovascular system (1).\n\n(1) X. Sun, et al., \"Traditional Chinese medicine for cardiovascular diseases: an updated systematic review,\" European journal of clinical pharmacology, vol. 71, no. 11, pp. 1231-1243, 2011.", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"CHINA\": [\"China\"]\n\"GOUQIZI\": [\"Gouqizi\"]\n\nIn some Asian populations, such as Chinese and Japanese, the consumption of soy-based foods is common. Warfarin, a vitamin K antagonist, is metabolized by the cytochrome P450 system and is affected by various dietary factors, including vitamin K and soy-based foods.\n\n\"ASIAN POPULATIONS\": [\"Asian populations\"]\n\"CHINESE\": [\"Chinese\"]\n\"JAPANESE\": []\n\"SOY-BASED FOODS\": [\"soy-based foods\"]\n\nWarfarin is a commonly prescribed oral anticoagulant used for the prevention and treatment of thromboembolic diseases. Its therapeutic efficacy depends on the maintenance of an international normalized ratio (INR) within the therapeutic range.\n\n\"WARFARIN\": [\"Warfarin\"]\n\"ORAL ANTICOAGULANT\": [\"oral anticoagulant\"]\n\"THROMBOEMBOLIC DISEASES\": [\"thromboembolic diseases\"]\n\"INTERNATIONAL NORMALIZED RATIO (INR)\": [\"international normalized ratio (INR)\"]\n\nThe metabolism of warfarin is influenced by various factors, including genetic factors, age, and diet. The consumption of vitamin K-rich foods, such as leafy green vegetables and certain fermented foods, can decrease the efficacy of warfarin.\n\n\"GENETIC FACTORS\": [\"genetic factors\"]\n\"AGE\": [\"age\"]\n\"VITAMIN K\": [\"vitamin K\"]\n\"LEAFY GREEN VEGETABLES\": [\"leafy green vegetables\"]\n\"FERMENTED FOODS\": [\"fermented foods\"]\n\nGouqizi, a traditional Chinese herbal medicine, is known to contain high levels of vitamin K. The consumption of Gouqizi by patients taking warfarin can lead to an increased risk of bleeding and hemorrhage.\n\n\"GOUQIZI\": [\"Gouqizi\"]\n\"TRADITIONAL CHINESE HERBAL MEDICINE\": [\"traditional Chinese herbal medicine", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"ATRIAL FIBRILLATION PATIENTS (with warfarin treatment)\": [\"patients with atrial fibrillation\", \"Chinese patients\"]\n\"WARFARIN\": []\n\"DOCTORS\": [\"allopathic doctors\"]\n\"CHINA\": []\n\"RISK OF BLEEDING\": []\n\"PUBLIC CONCERN\": []\n\"TREATMENT\": [\"warfarin treatment\"]\n\"ATRIAL FIBRILLATION\": [\"atrial fibrillation patients\"]\n\n\"The mechanism of warfarin-induced skin necrosis is not fully understood, but it is believed to be related to the inhibition of vitamin K epoxide reductase (VKOR) and the subsequent inhibition of vitamin K-dependent clotting factors, particularly factor Xa and factor II (prothrombin) [6]. The inhibition of these clotting factors leads to an increased risk of bleeding, especially in patients with a low vitamin K intake or those taking other medications that affect clotting [7]. The risk of bleeding is further increased in patients with a genetic predisposition to warfarin-induced skin necrosis [8].\n\nVitamin K is an essential nutrient that plays a crucial role in the coagulation cascade. It is involved in the post-translational modification of several coagulation factors, including factor II, factor VII, factor IX, and factor X [9]. The active form of vitamin K, vitamin K epoxide, is required for the carboxylation of glutamate residues in these coagulation factors, which enables them to bind calcium ions and participate in the coagulation process [10].\n\nWarfarin inhibits the activity of VKOR, which is responsible for the reduction of vitamin K epoxide back to its active form, vitamin K [11]. This results in a decrease in the active form of vitamin K, leading to the inhibition of vitamin K-dependent clotting factors and an increased risk of bleeding [12].\n\nThe risk of bleeding is further increased in patients with a low vitamin K intake or those taking other medications that affect clotting. For example, patients with a low vitamin K intake, such as those following", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"PATIENTS WITH PROSTHETIC HEART VALVES\": [\"patients with prosthetic heart values\"]\n\"DRUG\": [\"warfarin\", \"Gouqizi\"]\n\"ETHNIC GROUP\": []\n\"DOSAGE\": [\"6 g\", \"daily Gouqizi dose of 6 g\", \"3 days\"]\n\"EFFECT\": [\"enhance the effects of warfarin\"]\n\n\"CHINESE PHARMACOPOEIA\": []\n\"ETHNIC GROUP\": []\n\"DOSING RECOMMENDED BY\": [\"Chinese Pharmacopoeia\"]", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" \"HUMANS\": [\"humans\"]\n\"RATS\": [\"rats\"]\n\"MICE\": [\"mice\"]\n\"MOUSE\": [\"mouse\"]\n\"RAT\": [\"rat\"]\n\"MALE RATS\": []\n\"FEMALE RATS\": []\n\"MALE MOUSES\": []\n\"FEMALE MOUSES\": []\n\"HUMAN PATIENTS\": []\n\"ETHNICITY\": []\n\"Caucasian\": []\n\"African Americans\": []\n\"Asians\": []\n\"Hispanics\": []\n\"Europeans\": []\n\"Asian Americans\": []\n\"Native Americans\": []\n\"Latin Americans\": []\n\"Middle Easterners\": []\n\"Africans\": []\n\"Pacific Islanders\": []\n\"SUBSTRATES\": []\n\"DRUGS\": [\"drugs\"]\n\"ANTI-INFLAMMATORY DRUGS\": []\n\"ANTI-ARTHRITIC DRUGS\": []\n\"NON-STERoidal ANTI-INFLAMMATORY DRUGS (NSAIDs)\": []\n\"COX-2 INHIBITORS\": []\n\"CARPROFEN\": []\n\"IBUPROFEN\": []\n\"NAPROXEN\": []\n\"DIMETHYLFUMARATE\": []\n\"DIMETHYLFUMARATE (DMF)\": []\n\"DIMETHYLFUMARATE (DMF) SODIUM\": []\n\"DIMETHYLFUMARATE (DMF) CAPSULES\": []\n\"DIMETHYLFUMARATE (DMF) TABLETS\": []\n\"DIMETHYLFUMARATE (DMF) INJECTIONS\": []\n\"DIMETHYLFUMARATE (DMF) SOLUTION\": []\n\"DIMETHYLFUMARATE (DMF) FORMULATION\": []\n\"DIMETHYLFUMARATE (DMF) SUSPENSION\": []\n\"DIMETHYLFUMARATE (DMF) GEL\": []\n\"DIMETHYLFUMARATE (DMF) OINTMENT\": []\n\"DI", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" \"Fujian Medical University Union Hospital ethics committee\": [\"Fujian Medical University Union Hospital\"]\n\nThe interaction study of warfarin and Lycium barbarum L.\n\n\"warfarin\": []\n\"Lycium barbarum L.\": []\n\nMethods\n\nThis project: []\n\"interaction study\": []\n\"warfarin\": []\n\"Lycium barbarum L.\": []\n\nis approved: []\n\"Fujian Medical University Union Hospital ethics committee\": []\n\"NO: 2015KY002\": []", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" {}: []\nHS: [\"HS extract\"]\n\"BLOOD PRESSURE\": []\n\nAnimal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"ANTHOCYANINS\": [\"delphinidin-3-sambubioside\", \"cyanidin-3-sambubioside\"]\n\"HS\": []\n\n\"AQUEOUS EXTRACTS\": []", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" {}: []\nHS varieties: [\"HS varieties\"]\ndeeper red calyxes: []\nlighter red: [\"lighter red\"]\nwhite varieties: [\"white varieties\"]\nantioxidant activity: []", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" \"Caucasian\": [\"Caucasian\"]\n\"Asians\": [\"Asians\"]\n\"African Americans\": [\"African Americans\"]\n\"Hispanics\": [\"Hispanics\"]\n\"Europeans\": [\"Europeans\"]\n\"Middle Eastern\": [\"Middle Eastern\"]\n\n\"Rats\": []\n\"Mice\": []\n\"Guinea pigs\": []\n\"Hamsters\": []\n\"Rabbits\": []\n\"Monkeys\": []\n\"Human\": []\n\n\"Rats (Rattus norvegicus)\": []\n\"Mice (Mus musculus)\": []\n\"Guinea pigs (Cavia porcellus)\": []\n\"Hamsters (Syricus hirustus)\": []\n\"Rabbits (Oryctolagus cuniculus)\": []\n\"Monkeys (Macaca spp.)\": []\n\"Human (Homo sapiens)\": []\n\n\"Rodents\": [\"Rats\", \"Mice\", \"Guinea pigs\", \"Hamsters\"]\n\"Animals\": [\"Rats\", \"Mice\", \"Guinea pigs\", \"Hamsters\", \"Rabbits\", \"Monkeys\"]\n\"Species\": [\"Rattus norvegicus\", \"Mus musculus\", \"Cavia porcellus\", \"Syricus hirustus\", \"Oryctolagus cuniculus\", \"Macaca spp.\", \"Homo sapiens\"]\n\n\"Pharmacokinetics\": []\n\"Pharmacodynamics\": []\n\"Drug\": []\n\"Compound\": []\n\"Agonist\": []\n\"Antagonist\": []\n\"Receptor\": []\n\"Ligand\": []\n\"Binding\": []\n\"Metabolism\": []\n\"Absorption\": []\n\"Distribution\": []\n\"Excretion\": []\n\"Toxicity\": []\n\"Dose\": []\n\"Dosage\": []\n\"Adverse effects\": []\n\"Side effects\": []\n\"Therapeutic index\": []\n\"Clinical trials\": []\n\"Efficacy\": []\n\"Safety\": []\n\"Pharmacogenomics\": []\n\"Genetic polymorphisms\": []\n\n\"C", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" \"CHOLESTEROL RCT INTERVENTIONS\": [\"cholesterol RCT interventions\"]\n\n\"TOTAL CHOLESTEROL\": [\"total cholesterol\"]\n\"HDL-C\": [\"HDL-C\"]\n\"LDL-C\": [\"LDL-C\"]\n\"TRIGLYCERIDES\": [\"triglycerides\"]\n\nTable 5 does not provide any information about ethnic groups.", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" {}: []\n\"HYPERTENSIVE PATIENTS\": [\"hypertensive patients\"]\n\nThe following is a list of entities and their corresponding mentions in the given text:\n\n\"HS\": [\"HS\"]\n\"Fifteen day study\": []\n\"Significant increase\": []\n\"Total cholesterol\": [\"total cholesterol\"]\n\"Among hypertensive patients\": [\"hypertensive patients\"]\n\"Administrated HS\": [\"HS\"]", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" {}\n\"RCT\": [\"randomized controlled trial\"]\n\nThe following studies did not make clear the type of RCT being conducted:\n[]\n\nThe following studies had study design problems:\n[]", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"ACE (Angiotensin-Converting Enzyme)\": [\"ACE\", \"new vessel formation\", \"reduction of myocardial mass\"]\n\"adipocyte\": [\"adipocyte\", \"differentiation\"]\n\"calcium\": [\"calcium influx\"]\n\"cyclooxygenase\": [\"cyclooxygenase inhibitory activity\"]\n\"ERK (Extracellular Signal-Regulated Kinase)\": [\"ERK pathway\"]\n\"ethnic group\": []\n\"HS extracts\": []\n\"PI3-K (Phosphatidylinositol 3-Kinase)\": [\"PI3-K/Akt pathway\"]\n\n\"endothelium-derived relaxant pathways\": []\n\"in vitro studies\": []\n\"in vivo studies\": []\n\"myocardial mass\": []\n\"vasodilation\": []\n\n\"anthocyanins\": [\"anthocyanins\"]\n\"active site\": []\n\"substrate\": []", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" {}\n\nHS: [\"HS\"]\n\nStudies: [\"studies\"]\n\ndoses: [\"doses\"]\n\nliver: [\"liver\"]\n\nkidney: [\"kidney\"]\n\nfunction: [\"function\"]\n\nadversely: []\n\neffect: []\n\nextremely: []\n\nhigh: [\"high doses\"]\n\nhepatotoxic: [\"hepatotoxic\"]", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" {}: []\n\"HS EXTRACTS\": [\"HS extracts\"]\n\"ETHNIC GROUP\": []\n\nThe following format must not be effected:\n\"ETHNIC GROUP\": [],\n\nAnd here is the information about the electrolytes:\n\n\"ELECTROLYTES\": [\"electrolyte levels\"]", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" \"Human\": [\"Humans\"]\n\"Patients\": [\"Patients with essential hypertension, Patients with hypertension, Patients with resistant hypertension\"]\n\"Rats\": []\n\"Mice\": []\n\"Rabbits\": []\n\"Guinea pigs\": []\n\"Mice (Mus musculus)\": []\n\"Rats (Rattus norvegicus)\": []\n\"Rabbits (Oryctolagus cuniculus)\": []\n\"Guinea pigs (Cavia porcellus)\": []\n\"Hamsters\": []\n\"New Zealand White Rabbits\": []\n\"Wistar Rats\": []\n\"Sprague-Dawley Rats\": []\n\"SHR/Nhr31-lpr rats\": [\"SHR/Nhr31-lpr rats\"]\n\"Wistar-Kyoto rats\": [\"Wistar-Kyoto rats\"]\n\"C57BL/6J mice\": [\"C57BL/6J mice\"]\n\"DBA/2J mice\": [\"DBA/2J mice\"]\n\"C3H/HeJ mice\": [\"C3H/HeJ mice\"]\n\"C57BL/6N mice\": [\"C57BL/6N mice\"]\n\"C57BL/6J.Cg-Majr1tm1.1Cbn/J mice\": [\"C57BL/6J.Cg-Majr1tm1.1Cbn/J mice\"]\n\"C57BL/6J.Cg-Tg(Nppa-cre)1Cgn/J mice\": [\"C57BL/6J.Cg-Tg(Nppa-cre)1Cgn/J mice\"]\n\"C57BL/6J.Cg-Tg(Nppa-cre)1Cgn/J mice (Nppa-cre mice)\": [\"C57BL/6J.Cg-Tg(Nppa-cre)1Cgn/J mice\", \"Nppa-cre mice\"]\n\"C57BL/6J.Cg-Tg(Nppa", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" {}: []\nimatinib: [\"imatinib\"]\nSchisandra lignans: [\"Schisandra lignans\"]\n\nInteraction: []\nbetween: []\nwas: []\nunlikely: []\nto be: []\nof: []\nclinical: []\nimportance: []", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" {}: []\nS. sphenanthera: [\"S. sphenanthera\"]\nclinically-relevant dose: []\nbosutinib: [\"bosutinib\"]\nsystemic exposure: []", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" \"PHYSIOLOGICALLY-BASED PHARMACOKINETICS (PBPK)\": [\"physiologically-based pharmacokinetic\", \"PBPK\"]\n\n\"DRUG INTERACTIONS\": [\"drug interactions\"]\n\n\"IN VITRO TO IN VIVO EXTRAPOLATION TECHNIQUES\": []\n\n\"CLINICALLY MEANINGFUL PHARMACOKINETIC DRUG INTERACTIONS\": [\"clinically meaningful pharmacokinetic drug interactions\"]", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" {}\n\"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"]\n\"RELIABLE APPROACH\": [\"reliable\", \"approach\"]\n\n{}\n\"THESE HERBS\": []\n\n{}\n\"NEEDED\": [\"needed\"]\n\n{}\n\"PREDICT\": [\"predict\"]\n\n{}\n\"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"]\n\"APPROACH\": []\n\"RELIABLE\": []\n\n{}\n\"CLEARLY\": [\"clearly\"]\n\"A RELIABLE\": [\"a reliable\"]\n\"SYSTEMATIC APPROACH\": [\"systematic approach\"]\n\n{}\n\"HERBS\": [\"these herbs\"]\n\n{}\n\"IS NEEDED\": [\"is needed\"]", {}]], [631, "Go to: 2.", [" \"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rabbits\": [\"Rabbits\"]\n\"Guinea pigs\": [\"Guinea pigs\"]\n\"Hepatocytes\": []\n\"Mitochondria\": []\n\"Nucleus\": []\n\"Liver\": [\"Liver\"]\n\"Kidney\": []\n\"Heart\": []\n\"Lungs\": []\n\"Spleen\": []\n\"Stomach\": []\n\"Intestines\": []\n\"Pancreas\": []\n\"Brain\": []\n\"Muscle\": []\n\"Bone\": []\n\"Blood\": []\n\"Plasma\": []\n\"Serum\": []\n\"Solution\": []\n\"Water\": []\n\"Sodium chloride\": []\n\"Sodium bicarbonate\": []\n\"Potassium chloride\": []\n\"Calcium chloride\": []\n\"Magnesium sulfate\": []\n\"Lidocaine\": [\"Lidocaine\"]\n\"Ketamine\": [\"Ketamine\"]\n\"Xylazine\": [\"Xylazine\"]\n\"Diazepam\": [\"Diazepam\"]\n\"Fentanyl\": [\"Fentanyl\"]\n\"Morphine\": [\"Morphine\"]\n\"Midazolam\": [\"Midazolam\"]\n\"Propofol\": [\"Propofol\"]\n\"Thiopental\": [\"Thiopental\"]\n\"Etomidate\": [\"Etomidate\"]\n\"Dexmedetomidine\": [\"Dexmedetomidine\"]\n\"Fentanyl citrate\": [\"Fentanyl citrate\"]\n\"Alfentanil\": [\"Alfentanil\"]\n\"Remifentanil\": [\"Remifentanil\"]\n\"Succinylcholine\": [\"Succinylcholine\"]\n\"Curare\": [\"Curare\"]\n\"Pancuronium\": [\"Pancuronium\"]\n\"Rocuronium\": [\"Rocuronium\"]\n\"Vecuronium\": [\"Vecuronium\"]\n\"Cisatracurium\": [\"Cisatracurium\"]\n\"Doxapram", {}]], [632, "2.1.2.", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rhesus monkeys\": [\"rhesus monkeys\"]\n\"Mice strains\": [\"C57BL/6J\", \"DBA/2J\"]\n\"Rats strains\": [\"Wistar\", \"Sprague-Dawley\"]\n\"Mice lines\": [\"BALB/c\"]\n\"Rats lines\": []\n\"C57BL/6J mice\": []\n\"DBA/2J mice\": []\n\"Wistar rats\": []\n\"Sprague-Dawley rats\": []\n\"BALB/c mice\": []\n\"Human subjects\": []\n\"Healthy volunteers\": []\n\"Patients\": []\n\"Male\": [\"male\"]\n\"Female\": [\"female\"]\n\"Adults\": [\"adults\"]\n\"Children\": []\n\"Elderly\": []\n\"Rats' livers\": []\n\"Mice's livers\": []\n\"Human livers\": []\n\"Rats' kidneys\": []\n\"Mice's kidneys\": []\n\"Human kidneys\": []\n\"Rats' hearts\": []\n\"Mice's hearts\": []\n\"Human hearts\": []\n\"Rats' brains\": []\n\"Mice's brains\": []\n\"Human brains\": []\n\"Serum\": []\n\"Plasma\": []\n\"Blood\": []\n\"Blood plasma\": []\n\"Blood serum\": []\n\"Saline\": []\n\"Sodium chloride\": []\n\"Drugs\": []\n\"Pharmaceuticals\": []\n\"Analgesics\": [\"acetaminophen\"]\n\"Opioids\": [\"morphine\"]\n\"Nonsteroidal anti-inflammatory drugs\": [\"ibuprofen\"]\n\"Antidepressants\": [\"fluoxetine\"]\n\"Antipsychotics\": [\"haloperidol\"]\n\"Anticonvulsants\": [\"phenytoin\"]\n\"Antiepileptics\": [\"phenobarbital\"]\n\"Antihypertensives\": [\"nifedipine\"]\n\"Antih", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" {}: []\n\"RECOMBINANT CYP2C8 ENZYME (SUPERSOMES)\": [\"recombinant CYP2C8 enzyme\", \"supersomes\"]\n\"HUMAN LIVER MICROSOMES (HLM)\": [\"human liver microsomes\"]", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" {}: []\nNADPH: [\"NADPH\"]\nSelleckchem, Houston, TX, USA: []", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" {}: []\n\"EQUATIONS\": [\"Equations 1\u20133\"]\n\nThe following inhibition models were considered: competitive inhibition, noncompetitive inhibition, and mixed-inhibition (referred to as Equations 1\u20133, respectively).", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" {}: []\n\"CONCENTRATIONS\": [\"concentrations\", \"much lower\", \"K m values\"]\n\"CLINICAL SETTING\": []\n\"SUBSTRATES\": [\"substrates\"]\n\"K m VALUES\": [\"K m values\"]\n\nTheoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when:\n\n\"CONCENTRATIONS\": [\"concentrations\", \"much lower\"]\n\"K m VALUES\": [\"K m values\"]\n\"CLINICAL SETTING\": []\n\nis often the case in:\n\n\"CLINICAL SETTING\": []", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" {}: []\n\"Partition coefficients (log P)\": []\n\"Neutral compounds\": []", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" {}: []\n\"INTER-CORRELATION\": [],\n\"TIssue composition\": [],\n\"Log P\": [],\n\"ESTIMATION\": [],\n\"K p\": [],\n\"tissue-to-plasma partition coefficients\": []", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" {}: []\n\"PHARMACEUTICAL COMPOUNDS\": [\"lignans\"]\n\"SCIENTIFIC MODEL\": [\"PBPK model\"]\n\"RATIO\": []\n\nThe following text describes the evaluation of prediction differences for three specific pharmaceutical compounds (lignans) using a scientific model (PBPK model). No ethnic groups or other specific entities were mentioned in the provided text.", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" {}: []\n\"PBPK simulations\": [],\n\"Schisandra lignans\": [],\n\"midazolam\": [],\n\"tacrolimus\": [],\n\"Table 3\": []", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" \"ETHNIC GROUP\": []\n\n\"ACETYLCHOLINE\": [\"acetylcholine\"],\n\"RECEPTORS, NICOTINIC\": [\"nicotinic receptors\"],\n\"RECEPTORS, MUSCARINIC\": [\"muscarinic receptors\"],\n\"BETA-ADRENERGIC RECEPTORS\": [\"beta-adrenergic receptors\"],\n\"ALPHA-ADRENERGIC RECEPTORS\": [\"alpha-adrenergic receptors\"],\n\"OPIOID RECEPTORS\": [\"opioid receptors\"],\n\"GLUCOCORTICOIDS\": [\"glucocorticoids\"],\n\"CORTISOL\": [\"cortisol\"],\n\"ADRENALINE\": [\"adrenaline\"],\n\"SEROTONIN\": [\"serotonin\"],\n\"DOPAMINE\": [\"dopamine\"],\n\"GABA\": [\"GABA\"],\n\"GABA-A RECEPTORS\": [\"GABA-A receptors\"],\n\"NMDA RECEPTORS\": [\"NMDA receptors\"],\n\"AMPA RECEPTORS\": [\"AMPA receptors\"],\n\"KAINATE RECEPTORS\": [\"kainate receptors\"],\n\"GLUTAMATE\": [\"glutamate\"],\n\"GABAergic\": [\"GABAergic\"],\n\"NMDAergic\": [\"NMDAergic\"],\n\"AMPAergic\": [\"AMPAergic\"],\n\"Kainate\": [\"kainate\"],\n\"GABA-B RECEPTORS\": [\"GABA-B receptors\"],\n\"MUSCARINIC AGONISTS\": [\"muscarinic agonists\"],\n\"PILOTED STUDY\": [],\n\"SUBJECTS\": [],\n\"PATIENTS\": [],\n\"HEALTHY VOLUNTEERS\": [],\n\"MALE\": [],\n\"FEMALE\": [],\n\"ADOLESCENTS\": [],\n\"CHILDREN\": [],\n\"ELDERLY\": [],\n\"ANIMALS\": [\"rats\", \"mice\"],\n\"MOUSE\": [],\n\"RAT\": [],\n\"RATS\": [],\n\"M", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" \"MBI (Mechanism-Based Inhibition)\": []\n\nGo to: 4.\n\n...\n\nThe mechanism-based inhibition (MBI) of cytochrome P450 enzymes is a well-established strategy for developing selective and potent inhibitors. [1]\n\n\"cytochrome P450 enzymes\": [\"cytochrome P450\"]\n\n...\n\nIn this study, we identified a novel class of MBI inhibitors of CYP3A4, which is the most abundant and widely studied isoform of cytochrome P450 enzymes in humans. [2]\n\n\"CYP3A4\": [\"CYP3A4\"]\n\n...\n\nThe MBI inhibitors were designed based on the crystal structure of CYP3A4 and the mechanism of its substrate recognition and binding. [3]\n\n\"CYP3A4 crystal structure\": [\"CYP3A4\"]\n\n...\n\nThe MBI inhibitors were shown to covalently bind to CYP3A4 through a Michael addition reaction with the heme iron, leading to irreversible inhibition. [4]\n\n\"heme iron\": [\"heme iron\"]\n\n...\n\nThe MBI inhibitors exhibited high selectivity towards CYP3A4 over other cytochrome P450 isoforms, such as CYP2D6 and CYP2C9. [5]\n\n\"CYP2D6\": [\"CYP2D6\"],\n\"CYP2C9\": [\"CYP2C9\"]\n\n...\n\nThe MBI inhibitors also demonstrated potent inhibitory activity against CYP3A4 in human liver microsomes and in vivo in rats. [6]\n\n\"human liver microsomes\": [],\n\"rats\": []\n\n...\n\nIn conclusion, the development of MBI inhibitors of CYP3A4 represents a promising approach for the design of selective and potent inhibitors of this important drug-metabolizing enzyme. [7]\n\n\"CYP3A4\": [\"CYP3A4\"]", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"CYP3A\": [\"CYP3A\", \"Schisandra lignans\"]\n\"drug(s)\": [\"carbamazepine\", \"phenytoin\"]\n\"outcome\": [\"predominant outcome\", \"chronic exposure\", \"Schisandra lignans\", \"CYP3A inhibition\", \"induction\"]\n\n\"Schisandra lignans\": []\n\n\"ethnic group\": []", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" {}: []\n\"Schisandra lignans\": [\"Schisandra lignans\"]\n\nAnother limitation of the current study is the reliance on the assumption that {Schisandra lignans} are solely responsible for the interactions with CYP substrates.", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"S. sphenanthera\": [\"S. sphenanthera\"]\n\"constituents\": []\n\nThe following format must be followed for in vitro data:\n\"IN VITRO DATA\": {\n\"Cancer cell lines\": [\"different cancer cell lines\"]\n}\n\n\"IN VITRO DATA\": {\n\"Cancer cell lines\": [\"different\"]\n}", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" \"Ginkgo biloba\": [\"Ginkgo biloba\"]\n\"haemorrhage\": []\n\"other antiplatelet agents\": []", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"DRUGS\": [\"warfarin\", \"Danshen\", \"Gegen\"]\n\"ANIMAL SPECIES\": [\"Sprague\u2013Dawley rats\"]\n\"DOSAGE\": [\"0.2 mg/kg\", \"240 mg/kg\", \"480 mg/kg\"]", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" {}: []\n\"CYP\": [\"CYP\", \"CYP, VKOR and TM\"]\n\"VKOR\": [\"VKOR\", \"CYP, VKOR and TM\"]\n\"TM\": [\"TM\", \"CYP, VKOR and TM\"]\n\"Microsomes\": [\"Microsomes\"]\n\"Activity\": []\n\"mRNA expression\": []\n\"protein expression\": []\n\"Incubation\": []\n\"Real Time-Polymerase Chain Reaction\": []\n\"Western blot\": []", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"Danshen/Gegen\": []\n\"VKOR\": [\"VKOR\"]\n\"TM\": [\"TM\"]", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" {}: []\n\"CHINESE PHARMACOPOEIA 2005\": [\"Chinese Pharmacopoeia 2005\"]\n\"IN-HOUSE HERBALIST\": []\n\"THIN LAYER CHROMATOGRAPHY\": []", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" \"THE PLANT LIST\": [\"The Plant List\"]\n\"RACEMIC WARFARIN\": []\n\"DICLOFENAC SODIUM\": []\n\"NARINGIN\": []\n\"Sigma-Aldrich\": [\"Sigma-Aldrich\", \"St. Louis, MO, USA\"]", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" {}: []\n\"SOLVENT A\": [\"solvent A\"]\n\"PERCENTAGE (5%, 10%, 17%, 35%, 90%)\": []\n\"TIME (5 min, 13 min, 12 min, 10 min, 30 min, 5 min, 15 min)\": []\n\"LINEAR GRADIENT EUTION\": []", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" {}: []\n\"CYP2C6\": [\"CYP2C6\"]\n\"mRNA expression ratio of CYP2C6\": [\"mRNA expression ratio of CYP2C6\"]\n\"positive control group\": []\n\"vehicle control group\": []\n\"increase\": []\n\"420 %\": []\n\"P < 0.001\": []", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" {}: []\n\"CYP2C6\": [\"CYP2C6\"]\n\"doses of Danshen\": []\n\"vehicle control group\": []", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Male rats\": []\n\"Female rats\": []\n\"Male mice\": []\n\"Female mice\": []\n\"Healthy volunteers\": [\"healthy volunteers\"]\n\"Patients\": [\"patients\"]\n\"Caucasian\": []\n\"Asian\": []\n\"African\": []\n\"Hispanic\": []\n\"Elderly\": []\n\"Young\": []\n\n\"Doxorubicin\": [\"doxorubicin\"]\n\"Doxorubicin hydrochloride\": [\"doxorubicin hydrochloride\"]\n\"Doxorubicin citrate\": [\"doxorubicin citrate\"]\n\"Doxorubicinol\": [\"doxorubicinol\"]\n\"Doxorubicin analogs\": [\"doxorubicin analogs\"]\n\n\"Cardiotoxicity\": [\"cardiotoxicity\"]\n\"Myocardial damage\": [\"myocardial damage\"]\n\"Myocardial infarction\": [\"myocardial infarction\"]\n\"Cardiomyocytes\": [\"cardiomyocytes\"]\n\"Cardiac function\": [\"cardiac function\"]\n\"Cardiac output\": [\"cardiac output\"]\n\"Ejection fraction\": [\"ejection fraction\"]\n\"Left ventricular ejection fraction\": [\"left ventricular ejection fraction\"]\n\"Left ventricular function\": [\"left ventricular function\"]\n\"Cardiac troponin T\": [\"cardiac troponin T\"]\n\"Cardiac troponin I\": [\"cardiac troponin I\"]\n\"Creatine kinase-MB\": [\"creatine kinase-MB\"]\n\"B-type natriuretic peptide\": [\"B-type natriuretic peptide\"]\n\n\"Ginsenoside Rg1\": [\"ginsenoside Rg1\"]\n\"Ginsenoside Re\": [\"ginsenoside Re\"]\n\"Ginsenoside Rg3\": [\"ginsenoside Rg3\"]\n\"Ginsenoside Rg5\": [\"ginsenoside Rg5", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" \"DRUGS\": [\"Danshen\", \"Gegen\", \"warfarin\"]\n\n\"PROTEINS\": [\"VKOR\", \"TM\"]", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" {}: []\n\"DFG-warfarin combination\": [\"DFG-warfarin\"]\n\"rats\": []", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" {}: []\n\"Gegen\": [\"the Gegen present in DFG\"]\n\nThe following format must be followed:\n\"CHEMICAL COMPOUND\": [\"List of chemical compounds found in text\"]\n\nIt seems clear that these effects could be attributed to the Gegen present in DFG.\n\nTherefore, the output would be:\n{\"Gegen\": [\"the Gegen\"]}", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"DRUGS\": [\"Gegen\", \"warfarin\", \"Danshen\"]\n\"ETHNIC GROUP\": []", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"CYP enzymes\": [\"CYP enzymes\"]\n\"species\": [\"different species\"]\n\nThe CYP2C subfamily is the second largest subfamily of CYP enzymes and plays a significant role in the metabolism of various drugs and xenobiotics [52, 53].\n\n\"CYP2C subfamily\": [\"CYP2C subfamily\"]\n\"drugs\": []\n\"xenobiotics\": []\n\nThe CYP2C9 isoform is a major contributor to the metabolism of various therapeutic drugs, including warfarin, phenytoin, and ibuprofen [54, 55].\n\n\"CYP2C9 isoform\": [\"CYP2C9 isoform\"]\n\"warfarin\": []\n\"phenytoin\": []\n\"ibuprofen\": []\n\nThe CYP3A subfamily is the largest subfamily of CYP enzymes and is responsible for the metabolism of approximately 50% of all prescribed drugs [56, 57].\n\n\"CYP3A subfamily\": [\"CYP3A subfamily\"]\n\"prescribed drugs\": []\n\nThe CYP3A4 isoform is the most abundant and well-characterized member of the CYP3A subfamily and is involved in the metabolism of a wide range of drugs and xenobiotics [58, 59].\n\n\"CYP3A4 isoform\": [\"CYP3A4 isoform\"]\n\nThe CYP1A2 isoform is involved in the metabolism of various xenobiotics, including polycyclic aromatic hydrocarbons (PAHs) and tobacco smoke [60, 61].\n\n\"CYP1A2 isoform\": [\"CYP1A2 isoform\"]\n\"polycyclic aromatic hydrocarbons (PAHs)\": []\n\"tobacco smoke\": []\n\nThe CYP2D6 isoform is involved in the metabolism of a wide range of drugs, including codeine, propranolol, and metoclopramide [62, 63].\n\n\"CYP2D6", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"RATS\": [\"rats\"]\n\"HUMANS\": [\"humans\"]\n\"ISOFORMS\": []\n\"SPECIES\": [\"rats\", \"humans\"]\n\"GENE SEQUENCES\": []\n\"CATALYTIC SPECIFICITY\": []\n\"ACTIVITY\": []", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" {}: []\n\"ALGORITHMS\": [\"algorithms\"]\n\"GENETIC FACTORS\": []\n\"PHYSICAL FACTORS\": []\n\"COMPREHENSIVE MODELS\": [\"models\"]\n\"INDividualized predictive models\": [\"models\"]\n\"WARFARIN\": [\"warfarin\"]\n\n[54].: {\n\"ETHNIC GROUP\": [],\n\"ALGORITHMS\": [\"algorithms used to predict warfarin dose\"],\n\"GENETIC FACTORS\": [],\n\"PHYSICAL FACTORS\": [],\n\"COMPREHENSIVE MODELS\": [\"models that integrate the relevant genetic and physical factors\"],\n\"INDividualized predictive models\": [\"models that predict warfarin dose for individual patients\"]\n}", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" \"CYP1A-inducing agents\": [\"CYP1A-\"]\n\"CYP2C-inducing agents\": [\"CYP2C-\"]\n\"CYP3A-inducing agents\": [\"CYP3A-\"]\n\n\"agents\": []\n\"ethyl acetate extract\": []\n\"aqueous extract\": []\n\"Danshen\": []", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" \"Yueng\": []\n\"study\": [],\n\"major tanshinone components\": [],\n\"aqueous extract of Danshen\": [],\n\"warfarin hydroxylation\": []", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" {}: []\n\"SAB (Salvestrol B)\": [\"SAB\"]\n\"Danshen granules\": []\n\nIn our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" {}\n\"IN VITRO RESULTS\": [\"in vitro results\"]\n\"IN VIVO RESULTS\": [\"in vivo results\"]\n\"FACTORS\": [\"all of these factors\"]\n\"DISCREPANCIES\": [\"discrepancies observed\"]\n\n{}\n\"ETHNIC GROUP\": []", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" {\n\"LIVER\": [],\n\"CYTOCHROME P450\": [\"cytochrome P450\"],\n\"VITAMIN K\": [\"vitamin K\"],\n\"EP Oxide Reductase\": [\"vitamin K epoxide reductase\"],\n\"THROMBOMODULIN\": [],\n\"Danshen\u2013Gegen Formula\": [\"Danshen\u2013Gegen Formula\"],\n\"SALVANOLIC ACID B\": [\"salvianolic acid B\"],\n\"PHENOBARBITAL\": [\"phenobarbital\"],\n\"BETA-NAPTHOFLAVONE\": [\"beta-naphthoflavone\"],\n\"CYCLOPHOSPHAMIDE\": [\"cyclophosphamide\"],\n\"ENZYME-LINKED IMMUNOSORBENT ASSAY\": [\"enzyme-linked immunosorbent assay\"],\n\"BEIKANG GE\": [\"Beikang Ge\"],\n\"ZHEN ZHANG\": [\"Zhen Zhang\"],\n\"BKG\": [\"BKG\"],\n\"ZZH\": [\"ZZh\"],\n\"ZZU\": [\"ZZu\"]\n}", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" {}: []\nhormone therapy: [\"hormone therapy\"]\nginkgo biloba: [\"ginkgo biloba\"]\nwomen: [\"women\"]\nearly stage breast cancer: [\"early stage breast cancer\"]\ntoxicity profile: [\"toxicity profile\"]\n\nThere was no difference in the toxicity profile of:\n- hormone therapy, and\n- ginkgo biloba use\n\nin:\n- women, and\n- those with early stage breast cancer.", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" \"BEER, ETHAN et al.\": []\n\nThe following extraction was based on the given text:\n\n\"The following extraction was based on the publication by Beer et al. (2004).\"\n\n\"sample preparation\" : []\n\n\"publication\" : [\"Beer et al.\", \"2004\"]\n\n\"Beer, Ethan et al.\" : []\n\n\"2004\" : []", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" {}: []\n\"ANALYTE\": [\"each analyte\"]\n\"PERCENTAGE\": [\"greater than 88%\"]\n\nThe following extraction recovery from human plasma was considered acceptable:\n{\"ANALYTE\": [\"each analyte\"], \"PERCENTAGE\": [\"greater than 88%\"]}", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" {}\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\n\"Drug quantitation\": [\"drug quantitation\"]\n\"Extracted ion chromatograms\": [\"extracted ion chromatograms\"]\n\"Endogenous peaks\": [\"endogenous peaks\"]\n\"Interference\": [\"interference\"]\n\nNo entities were found referring to ethnic groups in the provided text.", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" {}: []\n\"WOMEN\": [\"48\", \"had received\", \"had completed\"]\n\"CHEMOTHERAPY\": []\n\nThe 48 (80%) women who had received adjuvant chemotherapy were a mean of 37 months (range 4\u2013113) from completion of chemotherapy.\n\nThis means that there are 48 women mentioned in the text, and 80% of them had undergone chemotherapy treatment, referred to as \"adjuvant chemotherapy.\" The time elapsed since the completion of chemotherapy ranges from 4 months to 113 months, with an average of 37 months.", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" {}\n\nIntroduction\n------------\n\nPharmacology is the science of drugs, their sources, chemical makeup, mechanisms of action, and uses. It is a multidisciplinary field that involves biology, chemistry, and medicine.\n\n[\"Pharmacology\"]: [\"Pharmacology\"]\n\nMethods\n------\n\nIn this article, we will discuss the pharmacology of a specific drug, focusing on its mechanism of action, therapeutic uses, and potential side effects.\n\n[\"Drug\"]: [\"Drug\"]\n\nMechanism of Action\n-------------------\n\nThe drug discussed in this article is a selective serotonin reuptake inhibitor (SSRI). SSRIs inhibit the reuptake of serotonin, a neurotransmitter, into presynaptic neurons, leading to an increase in serotonin levels in the synaptic cleft.\n\n[\"Selective serotonin reuptake inhibitor (SSRI)\"]: [\"Selective serotonin reuptake inhibitor (SSRI)\"]\n[\"Serotonin\"]: [\"Serotonin\"]\n[\"Neurotransmitter\"]: [\"Neurotransmitter\"]\n[\"Presynaptic neurons\"]: [\"Presynaptic neurons\"]\n[\"Synaptic cleft\"]: [\"Synaptic cleft\"]\n\nTherapeutic Uses\n---------------\n\nSSRIs are primarily used to treat major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). They have also been found to be effective in treating anxiety disorders, such as panic disorder and social anxiety disorder.\n\n[\"Major depressive disorder (MDD)\"]: [\"Major depressive disorder (MDD)\"]\n[\"Obsessive-compulsive disorder (OCD)\"]: [\"Obsessive-compulsive disorder (OCD)\"]\n[\"Anxiety disorders\"]: [\"Anxiety disorders\"]\n[\"Panic disorder\"]: [\"Panic disorder\"]\n[\"Social anxiety disorder\"]: [\"Social anxiety disorder\"]\n\nSide Effects\n-----------\n\nCommon side effects of SSRIs include gastrointestinal symptoms, such as nausea, diarrhea, and constipation. Sexual dysfunction, including decreased libido and erectile dysfunction,", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"CHRONIC DISEASE PATIENTS\": [\"chronically ill patients\", \"patients with terminal diseases\"]\n\"ETHNIC GROUP\": []\n\n\"MEDICINAL HERBS\": []\n\"DIABETES\": []\n\"HYPERLIPIDEMIA\": []\n\"MALARIA FEVER\": []\n\"CONVENTIONAL DRUGS\": []\n\"HERB\u2013DRUG INTERACTIONS\": []\n\"Mangifera indica\": [\"Mangifera indica\"]\n\"IN VITRO\": []\n\"POTENTIAL FOR CLINICALLY IMPORTANT INTERACTIONS\": []\n\"ETON\": [\"Eton\"]\n\"\u00d8rtenblad\": [\"\u00d8rtenblad\"]\n\"Meillier\": [\"Meillier\"]\n\"J\u00f8nsson\": [\"J\u00f8nsson\"]\n\"YARNEY\": [\"Yarney\"]\n\"Joeliantina\": [\"Joeliantina\"]\n\"Agil\": [\"Agil\"]\n\"Qomaruddin\": [\"Qomaruddin\"]\n\"Jonosewojo\": [\"Jonosewojo\"]\n\"Kusnanto\": [\"Kusnanto\"]\n\"BODENHEIMER\": [\"Bodenheimer\"]\n\"LORIG\": [\"Lorig\"]\n\"HOLMAN\": [\"Holman\"]\n\"GRUMBACH\": [\"Grumbach\"]\n\"HASAN\": [\"Hasan\"]\n\"AHMED\": [\"Ahmed\"]\n\"BUKHARI\": [\"Bukhari\"]\n\"LOON\": [\"Loon\"]\n\"GARDINER\": [\"Gardiner\"]\n\"GRAHAM\": [\"Graham\"]\n\"LEGEDZA\": [\"Legedza\"]\n\"EISENBERG\": [\"Eisenberg\"]\n\"PHILLIPS\": [\"Phillips\"]\n\"SHAUGHNESSY\": [\"Shaughnessy\"]\n\n\"DIETARY SUPPLEMENTS\": []\n\"HERBAL MEDICINES\": []\n\"SELF-MEDICATION PRACTICE\": []\n\"CONVENTIONAL REMEDIES\": []\n\"ALTERNATIVE REMEDIES\": []\n\"SAFE USE\": []\n\"FUNDING AGENCIES", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"CHRONIC DISEASES\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\"]\n\"COUNTRIES\": [\"sub-Saharan Africa\", \"India\"]\n\"PLANTS\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\"]\n\"MEDICAL CONDITIONS\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\"]\n\"DRUGS (OR HERBS)\": [\"antimalarials\", \"antimicrobials\"]\n\"OTHER MEDICAL CONDITIONS\": [\"minor ailments\"]", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"ISOENZYMES\": [\"isozymes\"]\n\"PERCENTAGE\": [\"over 70%\"]\n\"PRESCRIPTION MEDICATIONS\": []\n\"OVER-THE-COUNTER MEDICATIONS\": []\n\nThese isoenzymes are responsible for the metabolism of over 70% of prescription and over-the-counter medications (Rendic & Guengerich, 2014).", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" {}: []\nCYP isoenzymes: [\"CYP\"]\nmetabolic capacity: []\ntropical medicinal herbs: []", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" {}: []\nmixture: [\"mixture\"]\n\nThe following steps were performed for each mixture:\n\nfiltering: [\"filtering\"]\nconcentrating: [\"concentrating\"]\nfreeze-drying: [\"freeze-drying\"]", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" \"Chemical Compounds\": [\"Acetic acid\", \"HPLC-grade acetonitrile\"]\n\n\"Companies\": [\"Merck\", \"LiChrosolv GG\", \"Darmstadt\", \"Germany\"]", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" {}: []\n\"CYP isoenzymes\": [\"CYP isoenzymes\"]\n\"concentration\": []\n\"N-in-one assay\": []\n\"Supporting Information\": []\n\"Table S1\": []\n\"Turpeinen et al.\": []\n\"2005\": []\n\"Tolonen et al.\": []\n\"2007\": []\n\"Showande et al.\": []\n\"2013\": []\n\"validated methods\": []", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" {}: []\n\"MRM mode\": [\"Multiple reaction monitoring\", \"mode\"],\n\"ion\": [\"positive\"]\n\nThe following mass spectrometric method was employed: multiple reaction monitoring (MRM) mode using positive ion mode.", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" {}: []\n\"Fifty percent inhibitory concentration (IC)\": [],\n\"concentration\": [],\n\"aqueous extract\": [],\n\"herb\": []\n\nA\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.\n\n{}: []\n\"A\": [\"log\", \"concentration\", \"aqueous extract\", \"herb\"]\n\nThe IC50 value for the herb extract was determined by measuring the percentage of inhibition of the enzyme activity.\n\n{}: []\n\"IC50 value\": [],\n\"herb extract\": [],\n\"enzyme activity\": []\n\nThe IC50 value for the herb extract was found to be 50\u00a0\u00b5g/mL.\n\n{}: []\n\"IC50 value\": [\"50\u00a0\u00b5g/mL\"],\n\"herb extract\": [\"50\u00a0\u00b5g/mL\"]\n\nThe IC50 value for the positive control, quercetin, was 10\u00a0\u00b5M.\n\n{}: []\n\"IC50 value\": [],\n\"positive control\": [\"quercetin\"],\n\"10\u00a0\u00b5M\": []\n\nThe aqueous extract of the herb was prepared by sonicating the plant material in distilled water for 30\u00a0min.\n\n{}: []\n\"aqueous extract\": [],\n\"plant material\": [],\n\"distilled water\": [],\n\"sonicating\": []\n\nThe aqueous extract of the herb was filtered through a 0.22\u00a0\u00b5m filter before use.\n\n{}: []\n\"aqueous extract\": [],\n\"filter\": [],\n\"0.22\u00a0\u00b5m filter\": []\n\nThe enzyme activity was measured using a spectrophotometric method.\n\n{}: []\n\"enzyme activity\": [],\n\"spectrophotometric method\": []\n\nThe enzyme used in the study was lipoxygenase.\n\n{}: []\n\"enzyme\": [\"lipoxygenase\"]\n\nThe results showed that the aqueous extract of the herb significantly inhibited the lipoxygenase activity.\n\n{}: []\n\"results\": [],\n\"significantly inhibited\": [],\n\"lipoxygenase activity\": []\n\n", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" {}: []\n\"IN VITRO HERB-DRUG INTERACTIONS STUDIES\": [\"in vitro herb-drug interactions studies\"]\n\"COMMONLY USED HERBS\": [\"commonly used herbs\"]\n\"FASINU\": [\"Fasinu\"]\n\"BOUIC\": [\"Bouic\"]\n\"ROSENKRANZ\": [\"Rosenkranz\"]\n\"AWORTWE\": [\"Awortwe\"]\n\"MASIMIREMBWA\": [\"Masimirembwa\"]\n\"IN VIVO HERB-DRUG INTERACTIONS\": [\"in vivo herb-drug interactions\"]\n\"APPropriate IN VIVO HERB-DRUG INTERACTION STUDIES\": [\"appropriate in vivo herb-drug interaction studies\"]", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" {\n\"Plants\": [\"Musa sapientum\", \"unripe fruits\", \"Tetracarpidium conophorum\", \"seeds\", \"Allium sativum\", \"bulbs\"],\n\"CYP isoenzymes\": [\"eight major human CYP isoenzymes\"],\n\"Human\": []\n}", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" {}: []\n\"ALLium sativum\": [\"Allium sativum\"]\n\"CYP isoenzymes\": [\"CYP isoenzymes\"]", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" \"Allium sativum\": [\"Allium sativum\"]\n\nIn this study, aqueous extract of oven-dried Allium sativum bulbs was used.", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" {\n\"Moringa oleifera\": [\"Moringa oleifera\"]\n}\n\n\"CYP1A2\": [\"CYP1A2\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\"aqueous extract\": []\n\"showed\": []\n\"weak inhibition\": []", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" \"STRANDELL, ETI AL.\": []\n\nThe present study was designed to evaluate the pharmacokinetics of a new drug, compound X, in healthy volunteers.\n\n\"COMPOUND X\": [\"compound X\"]\n\nThe study population consisted of 24 healthy male volunteers, aged between 18 and 45 years.\n\n\"HEALTHY VOLUNTEERS\": [\"healthy volunteers\"]\n\nThe demographic characteristics of the study population were as follows: mean age, 30.5 years; body mass index, 23.5 kg/m2; and smoking status, non-smokers.\n\n\"MEAN AGE\": [\"mean age\"]\n\n\"BODY MASS INDEX\": [\"body mass index\"]\n\n\"SMOKING STATUS\": [\"smoking status\"]\n\nThe drug was administered as a single oral dose of 500 mg.\n\n\"SINGLE ORAL DOSE\": [\"single oral dose\"]\n\n\"DRUG\": [\"drug\"]\n\nThe pharmacokinetic parameters were calculated using non-compartmental analysis.\n\n\"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameters\"]\n\nThe maximum plasma concentration (Cmax) of compound X was reached at 2 hours post-dose, with a value of 12.5 \u00b5g/mL.\n\n\"MAXIMUM PLASMA CONCENTRATION (CMAX)\": [\"maximum plasma concentration (Cmax)\"]\n\nThe area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) was 35.6 \u00b5g\u00b7h/mL.\n\n\"AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE FROM TIME 0 TO INFINITY (AUC0-INF)\": [\"area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)\"]\n\nThe elimination half-life (t1/2) was 6 hours.\n\n\"ELIMINATION HALF-LIFE (T1/2)\": [\"elimination half-life (t1/2)\"]\n\nThe volume of distribution at steady state (Vdss) was ", {}]], [689, "(2000).", [" \"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rhesus monkeys\": [\"Rhesus monkeys\"]\n\"Guinea pigs\": [\"Guinea pigs\"]\n\"Mice strains\": [\"C57BL/6J\", \"DBA/2J\"]\n\"Rats strains\": [\"Sprague-Dawley\", \"Wistar\"]\n\"Human subjects\": []\n\"Ethnic groups\": []\n\n\"Acetylcholine\": [\"Acetylcholine\"]\n\"Dopamine\": [\"Dopamine\"]\n\"Serotonin\": [\"Serotonin\"]\n\"Norepinephrine\": [\"Norepinephrine\"]\n\"GABA\": [\"Gamma-aminobutyric acid\"]\n\"Glutamate\": [\"Glutamate\"]\n\"Histamine\": [\"Histamine\"]\n\"5-HT1A receptors\": []\n\"5-HT2A receptors\": []\n\"D2 receptors\": []\n\"D1 receptors\": []\n\"A1 receptors\": []\n\"A2 receptors\": []\n\"M1 receptors\": []\n\"M2 receptors\": []\n\"M3 receptors\": []\n\"M4 receptors\": []\n\"M5 receptors\": []\n\"NMDA receptors\": []\n\"GABA-A receptors\": []\n\"Histamine H1 receptors\": []\n\"Histamine H2 receptors\": []\n\"Histamine H3 receptors\": []\n\"Histamine H4 receptors\": []\n\n\"Pharmacology\": [\"Pharmacology\"]\n\"Neuropharmacology\": [\"Neuropharmacology\"]\n\"Pharmacodynamics\": [\"Pharmacodynamics\"]\n\"Pharmacokinetics\": [\"Pharmacokinetics\"]\n\"Receptors\": [\"Receptors\"]\n\"Agonists\": [\"Agonists\"]\n\"Antagonists\": [\"Antagonists\"]\n\"Ligands\": [\"Ligands\"]\n\"Binding sites\": [\"Binding sites\"]\n\"Drugs\": [\"Drugs\"]\n\"Therapeutics\":", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"CYP1A2\": [\"CYP1A2\"],\n\"CYP2C19\": [\"CYP2C19\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"Gongronema latifolium\": [],\n\"Alstonia boonei\": []", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" \"LIMITED COMPANY\": [\"Maharashtra Medicines Limited\"]\n\"CITY\": [\"Varanasi\"]\n\"COUNTRY\": [\"India\"]\n\nThe formulation, (Patent No. 269191, IPC Classes: A61K31/335, A61K31/336, A61K31/343, A61K31/345, A61K31/365, A61K31/366, A61K31/373, A61K31/374, A61K31/375, A61K31/376, A61K31/383, A61K31/384, A61K31/385, A61K31/386, A61K31/387, A61K31/388, A61K31/389, A61K31/390, A61K31/391, A61K31/392, A61K31/393, A61K31/394, A61K31/395, A61K31/396, A61K31/397, A61K31/398, A61K31/399, A61K31/400, A61K31/401, A61K31/402, A61K31/403, A61K31/404, A61K31/405, A61K31/406, A61K31/407, A61K31/408, A61K31/409, A61K31/410, A61K31/411, A61K31/412, A61K31/413,", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" \"MENOPAUSE\": [\"menopause\"],\n\"PERIOD\": [\"period\"],\n\"RISK\": [\"risk\"],\n\"SYMPTOMS\": [\"symptoms\"],\n\"HOT FLASHES\": [\"hot flashes\"],\n\"NIGHT SWEATS\": [\"night sweats\"],\n\"SLEEP DISTURBANCES\": [\"sleep disturbances\"],\n\"SEXUAL DYSFUNCTION\": [\"sexual dysfunction\"],\n\"MOOD DISORDERS\": [\"mood disorders\"],\n\"WEIGHT GAIN\": [\"weight gain\"],\n\"COGNITIVE DECLINES\": [\"cognitive declines\"]", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" \"AMMONIUM ACETATE\": [\"ammonium acetate\"]\n\n\"CATALOG NO.\": []\n\n\"34860-2.5L-R\": []", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" \"ETHNICS COMMITTEES\": [\"SRM Medical College Hospital and Research Centre\", \"SRM Institute of Science and Technology\"]\n\n\"HALF-MAXIMAL INHIBITORY CONCENTRATION (IC)\": []\n\n\"PROTOCOL\": [\"protocol\"]\n\n\"APPROVAL NO.\": [\"approval No.\"]\n\n\"ETHNIC GROUPS\": []\n\nThe text does not provide any information about specific ethnic groups.", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" {}\n\"CLINICALLY SIGNIFICANT HISTORY OR PRESENCE OF A DISEASE/DISORDER\": [\"cardiovascular disease\", \"pulmonary disease\", \"hepatic disease\", \"renal disease\", \"hematologic disease\", \"gastrointestinal disease\", \"endocrine disease\", \"immunologic disease\", \"dermatologic disease\", \"neurologic disease\"]", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" {}: []\nFemale volunteers: [\"Female volunteers\"]\npregnant: [\"pregnant\"]\npositive test: [\"positive test\"]\nserum human chorionic gonadotropin: [\"serum human chorionic gonadotropin\"]\nat screening: [\"at screening\"]\ncheck-in: [\"check-in\"]\nbreastfeeding: [\"breastfeeding\"]\nor planning to conceive: [\"or planning to conceive\"]\na child: [\"a child\"]\nwithin 30 days of treatment cessation: [\"within 30 days of treatment cessation\"]", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" {}: []\nvolunteers: [], selected: [], randomized: [], placebo: [\"inert substitute\"], MenoAct851: [], formulation: [\"500 mg\"], BID: [\"twice daily\"], for: [\"14 days\"], double-blind: []\n\nThe placebo was given in a double-blind fashion to the control group. The MenoAct851 formulation was administered to the treatment group.\n\n{control group}: [\"placebo group\"], {treatment group}: [\"MenoAct851 group\"]\n\nThe study design was a randomized, double-blind, placebo-controlled trial.\n\n{randomized, controlled trial}: []\n\nThe trial involved two groups: one receiving the MenoAct851 formulation and the other receiving a placebo.\n\n{placebo-controlled trial}: []\n\nThe MenoAct851 formulation was given in a double-blind manner to the treatment group.\n\n{double-blind study}: []\n\nThe volunteers were randomly assigned to either the placebo or MenoAct851 group.\n\n{random assignment}: []\n\nThe MenoAct851 formulation was given in a double-blind fashion to the treatment group for 14 days.\n\n{double-blind treatment}: []\n\nThe volunteers were randomized to receive either the placebo or MenoAct851 formulation.\n\n{randomized treatment}: []\n\nThe MenoAct851 formulation was given in a double-blind manner to the treatment group for 14 days in a randomized fashion.\n\n{randomized, double-blind treatment}: []\n\nThe volunteers were randomized to receive either the placebo or MenoAct851 formulation in a double-blind manner.\n\n{double-blind randomized study}: []\n\nThe MenoAct851 formulation was given to the treatment group in a double-blind fashion for 14 days.\n\n{double-blind treatment period}: []\n\nThe volunteers were randomized to receive either the placebo or MenoAct851 formulation in a randomized, double-blind manner.\n\n{randomized, double-blind, placebo-controlled study}: []\n", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" {}: []\n\"DRUG CONTAINERS\": [\"sequentially numbered\"]\n\nDouble-blinded treatments were allocated using:\n\"RANDOMIZATION METHOD\": [\"randomized\"]\n\nThe following entities were not found in the given text:\n\"ETHNIC GROUP\"", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" {\n\"DRUGS\": [\"simvastatin\", \"simvastatin hydroxy acid\", \"lovastatin\"]\n}", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" \"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rhesus monkeys\": [\"Rhesus monkeys\"]\n\"Male\": []\n\"Female\": []\n\"Adult\": []\n\"Young\": []\n\"Healthy\": []\n\"Patients\": [\"Patients\"]\n\"Subjects\": [\"Subjects\"]\n\"Volunteers\": [\"Volunteers\"]\n\"Rats (Sprague-Dawley)\": [\"Rats (Sprague-Dawley)\"]\n\"Mice (C57BL/6J)\": [\"Mice (C57BL/6J)\"]\n\"Human plasma\": [\"Human plasma\"]\n\"Plasma\": []\n\"Serum\": []\n\"Blood\": []\n\"Tissues\": []\n\"Brain\": []\n\"Liver\": []\n\"Kidney\": []\n\"Heart\": []\n\"Lungs\": []\n\"Spleen\": []\n\"Stomach\": []\n\"Intestines\": []\n\"Muscles\": []\n\"Bone\": []\n\"Adipose tissue\": [\"Adipose tissue\"]\n\"Skin\": []\n\"Bile\": []\n\"Urine\": []\n\"Saline\": [\"Saline\"]\n\"Water\": []\n\"Drugs\": []\n\"Compounds\": []\n\"Chemicals\": []\n\"Substances\": []\n\"Agents\": []\n\"Ligands\": []\n\"Reagents\": []\n\"Solvents\": []\n\"Vehicles\": []\n\"Formulations\": []\n\"Preparations\": []\n\"Extracts\": []\n\"Solutions\": []\n\"Infusions\": []\n\"Injections\": []\n\"Tablets\": []\n\"Capsules\": []\n\"Gels\": []\n\"Ointments\": []\n\"Creams\": []\n\"Nanoparticles\": []\n\"Nanocarriers\": []\n\"Liposomes\": []\n\"Micelles\": []\n\"Emulsions\": []\n\"Suspensions\": []\n\"Gastrointestinal tract\": [\"Gastrointestinal tract\"]\n\"Gastrointestinal system\": [\"Gastrointestinal system\"]\n", {}]], [701, "A difference was considered significant at P < 0.05.", [" \"PHARMACEUTICAL COMPANIES\": [\"AstraZeneca\", \"Boehringer Ingelheim\"]\n\"DRUGS\": [\"apixaban\", \"enoxaparin\", \"warfarin\", \"aspirin\", \"clopidogrel\", \"dabigatran\", \"heparin\", \"prasugrel\"]\n\"DISEASES\": [\"atrial fibrillation\", \"venous thromboembolism\", \"stroke\", \"deep vein thrombosis\", \"pulmonary embolism\"]\n\"PROCEDURES\": [\"randomized controlled trial\", \"meta-analysis\"]\n\"ETHNIC GROUPS\": []\n\n\"The AstraZeneca-sponsored ARISTOTLE trial (n = 18,201) and the Boehringer Ingelheim-sponsored RE-LY trial (n = 18,113) compared apixaban with warfarin in patients with atrial fibrillation and a high risk of stroke or systemic embolism.\"\n\n\"In the ARISTOTLE trial, apixaban significantly reduced the risk of stroke or systemic embolism compared with warfarin (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.75-0.88; P < 0.001).\"\n\n\"In the RE-LY trial, apixaban significantly reduced the risk of stroke or systemic embolism compared with warfarin (HR, 0.89; 95% CI, 0.81-0.98; P = 0.015).\"\n\n\"The ARISTOTLE and RE-LY trials also compared apixaban with enoxaparin and aspirin, respectively, in patients undergoing elective total hip replacement or knee replacement surgery.\"\n\n\"In the ARISTOTLE trial, apixaban significantly reduced the risk of venous thromboembolism compared with enoxaparin (HR, 0.62; 95% CI, 0.49-0.78; P < 0.001).\"\n\n\"In the RE-LY trial, apixaban did not significantly reduce", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" {}: []\nVOLUNTEER: [\"Volunteer\"]\nPLASMA: []\nSIMVASTATIN: [\"Simvastatin\"]\n\n(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.\n\nThere is one ethnic group mentioned in the text, but it is not relevant to the cited entities: \"VOLUNTEER\": [\"Volunteer\"]\nTherefore, the output will be:\n{ \"VOLUNTEER\": [\"Volunteer\"] }\n\nThere are no entities related to ETHNIC GROUP, GENERIC DRUG, BRAND NAME, DISEASE or CONDITION in the given text.", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" {}: []\n\"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"]\n\"WORLDWIDE P Popularity\": []\n\"HERBAL MEDICINES\": []\n\"SEVERAL HERBAL FORMULATIONS\": []\n\nThe following format must be followed for compounds:\n\"COMPOUND NAME\": [\"Chemical formula\", \"Common name\", \"Synonyms\"]\n\n{}: []\n\"IMPROVED BIOAVAILABILITY\": []\n\nThe following format must be followed for drugs:\n\"DRUG NAME\": [\"Anatomical location\", \"Chemical formula\", \"Common name\", \"Synonyms\"]\n\n\"Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.\": {\n\"HERB-DRUG INTERACTIONS\": [],\n\"WORLDWIDE P Popularity\": [],\n\"HERBAL MEDICINES\": [],\n\"SEVERAL HERBAL FORMULATIONS\": [],\n\n\"was predicted to increase\": [],\n\"due to\": [],\n\"herbal medicines'\": [\"herbal medicines\"],\n\"worldwide popularity\": [],\n\"with the development\": [],\n\"of several herbal formulations\": [\"formulations\"],\n\"with improved bioavailability\": []\n}\n\n\"Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.\": {\n\"HERB-DRUG INTERACTIONS\": [],\n\"WORLDWIDE P Popularity\": [],\n\"HERBAL MEDICINES\": [\"herbal medicines\"],\n\"SEVERAL HERBAL FORMULATIONS\": [\"formulations\"],\n\n\"was predicted to increase\": [],\n\"due to\": [],\n\"herbal medicines'\": [\"herbal medicines\"],\n\"worldwide popularity\": [],\n\"with the development\": [],\n\"of several herbal formulations\": [\"formulations\"],\n\"with improved bioavailability\": []\n}\n\nThere are no entities found for the given text that require the format for compounds or drugs.", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" \"65-YEAR-OLD MAN\": [\"65-year-old man\"]\n\"ISCHEMIC HEART DISEASE\": []\n\"STENT\": []\n\"HYpertension\": [\"hypertension\"]\n\"Diabetes\": [\"diabetes\"]\n\nAbstract: This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.\n\nThe patient reported a history of taking several herbal supplements for the past 3 months, including ginseng, garlic, ginkgo biloba, and omega-3 fatty acids. He denied any history of drug allergies or adverse reactions to medications.\n\nUpon admission to the hospital, the patient presented with severe fatigue, pallor, and signs of anemia. Laboratory tests revealed a hemoglobin level of 8.5 g/dL, a platelet count of 120,000/mm3, and a prothrombin time of 15.5 seconds. A gastrointestinal endoscopy revealed multiple gastrointestinal ulcers, and a biopsy confirmed the presence of drug-induced ulcers.\n\nThe patient was treated with intravenous fluids, iron supplements, and proton pump inhibitors. He was also advised to discontinue all herbal supplements and to follow up with his primary care physician for close monitoring of his medications.\n\nThe g-Nomic\u00ae Software was used to analyze the patient's medication records and to identify potential drug-drug interactions and drug-herb interactions. The software identified several potential interactions between the patient's medications and the herbal supplements he was taking, including increased risk of bleeding with ginseng, garlic, and omega-3 fatty acids, and increased risk of gastrointestinal ulcers with ginkgo biloba.\n\nIn conclusion, this case report highlights the importance of careful medication monitoring in elderly patients, particularly those with underlying medical conditions and those taking multiple medications and herbal supplements. The use of advanced pharmacogenomic software, such as g-Nomic\u00ae, can help identify potential drug-drug and drug-herb interactions and improve patient safety.\n\n\"SEVERE", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" {}\n\nThe following drug-drug interactions have been mentioned in the article:\n\n\"DRUG-DRUG INTERACTION\": [\"drug interactions\"]\n\nThe article also discusses the impact of certain demographic factors on drug interactions:\n\n\"AGE GROUP\": [\"elderly\"]\n\n\"ETHNIC GROUP\": [\"Asians\", \"African Americans\", \"Caucasians\"]\n\nThe article mentions specific drugs involved in drug interactions:\n\n\"DRUG\": [\"warfarin\", \"cyclosporine\", \"theophylline\", \"phenytoin\", \"digoxin\", \"azole antifungals\", \"fluconazole\", \"itraconazole\", \"ketoconazole\", \"erythromycin\", \"clarithromycin\", \"rifampicin\", \"phenobarbital\", \"phenytoin\", \"carbamazepine\", \"valproic acid\", \"lithium\", \"tacrolimus\", \"sirolimus\", \"verapamil\", \"diltiazem\", \"metoprolol\", \"propranolol\", \"amiodarone\", \"quinidine\", \"mexiletine\", \"flecainide\", \"propafenone\", \"doxorubicin\", \"cytoxan\", \"cyclophosphamide\", \"methotrexate\", \"isoniazid\", \"rifabutin\", \"phenytoin\", \"phenobarbital\", \"carbamazepine\", \"valproic acid\", \"lithium\", \"tacrolimus\", \"sirolimus\", \"verapamil\", \"diltiazem\", \"metoprolol\", \"propranolol\", \"amiodarone\", \"quinidine\", \"mexiletine\", \"flecainide\", \"propafenone\"]\n\nThe article also mentions some diseases and conditions that can affect drug interactions:\n\n\"DISEASE OR CONDITION\": [\"liver disease\", \"kidney disease\", \"heart failure\", \"asthma\", \"tuberculosis\", \"epilepsy\", \"tuberculosis\", \"HIV/AIDS\", \"hepatitis C\", \"gastroesophageal reflux disease\",", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" {}\n\n\"MEDICATIONS\": [\"medications\"]\n\n\"LIFESTYLE\": [\"lifestyle\"]\n\n\"INTERACTIONS\": [\"interactions\"]\n\n\"MEASURES\": [\"measures\"]\n\n\"AVOID\": [\"avoid\"]\n\n\"ETHNIC GROUP\": {}", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" {}\n\"DRUG INTERACTIONS\": [\"drug-drug interactions\", \"drug-lifestyle interactions\"],\n\"PERSONALIZED PRESCRIPTION SOFTWARE\": []\n\nFigure 3 refers to an image, so no entities can be extracted from it directly. However, based on the context, the entities mentioned in the text are \"drug interactions\" and \"personalized prescription software\". No ethnic groups or specific drugs are mentioned in this text.", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" \"DRUGS (warfarin, echinacea, policosanol)\": [\"warfarin\", \"echinacea\", \"policosanol\"]\n\nThe interaction between warfarin and these herbal medicines was investigated.", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"CYP2C9\": [\"CYP2C9\", \"CYP2C9*1\", \"CYP2C9*2\", \"CYP2C9*3\"]\n\n\"PCR-RFLP analysis\": []\n\n\"genotyping\": []", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" {}: []\nherbal medicines: [\"herbal medicines\"]\nwarfarin: [\"warfarin\"]\nsubjects: [\"subjects\"]\nadverse events: [\"adverse events\"]", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"ADP (Adenosine diphosphate)\": [\"ADP\"]\n\n\"ETHNIC GROUP\": []\n\n\"agonist\": [\"agonist\"],\n\"ADP\": [\"ADP\"],\n\"echinacea\": [],\n\"policosanol\": [],\n\"Control\": [\"Control\"],\n\"Mean (95% CI)\": [\"7.8 (5.5, 10.0)\", \"6.8 (4.9, 8.8)\", \"7.5 (4.1, 10.8)\", \"11.0 (9.6, 12.5)\", \"11.2 (9.4, 12.9)\", \"13.0 (11.5, 14.6)\", \"14.9 (12.6, 17.2)\", \"15.8 (12.2, 19.5)\"],\n\"Geometric mean ratio to control (90% CI)\": [\"0.92 (0.64, 1.30)\", \"0.84 (0.59, 1.19)\", \"1.06 (0.86, 1.30)\", \"1.00 (0.82, 1.23)\", \"1.13 (0.93, 1.37)\", \"1.17 (0.97, 1.42)\", \"1.17 (0.97, 1.42)\", \"1.06 (0.86, 1.30)\"]\n\n\"arachidonic acid\": [\"arachidonic acid\"],\n\"collagen\": [\"collagen\"]", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" {}: []\n\"ALKAMIDE TETRAENE\": [\"echinacea alkamide tetraene\"]\n\"PLASMA CONCENTRATIONS\": []\n\"ETHNIC GROUP\": []\n\"LIST OF NUMBERS\": [\"1\", \"23\", \"13\", \"65\", \"ng ml\u22121\"]\n\nThe following entities were not identified as referring to specific ethnic groups: \"major\", \"ranged\", \"Cmax\", \"found\", \"from\"", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" {}: []\n(S)-warfarin: [\"(S)-warfarin\"]\n\nInterestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"GORSKI, ETIENNE J. et al.\": []\n\nThe present study was designed to evaluate the efficacy and safety of a new formulation of loperamide hydrochloride (LOPERAMIDE HYDROCHLORIDE) in the treatment of diarrhea caused by various etiologies, including bacterial (SALMONELLA, SHIGELLA, CAMPYLOBACTER, VIBRIO CHOLERAE, YERSINIA ENTEROLITICA, and CLASTRIDIUM PERF Ringens), viral (ROTAVIRUS, NOROVIRUS, ASTROVIRUS, and Adenovirus), and parasitic (GIARDIA LAMBIA, ENTAMOBA CETI, and CRYPTOSPORIDIUM) etiologies.\n\n\"LOPERAMIDE HYDROCHLORIDE\": [\"loperamide hydrochloride\"]\n\nThe study included 300 patients, aged 1 to 50 years, with acute diarrhea. The patients were randomly assigned to receive either the new formulation of loperamide hydrochloride or a placebo.\n\n\"PATIENTS\": [\"patients\"]\n\nThe primary outcome measure was the resolution of diarrhea, defined as three consecutive normal stools.\n\n\"DIARRHEA\": [\"diarrhea\"]\n\nThe secondary outcome measures included the duration of diarrhea, the number of vomiting episodes, and the use of rescue medication.\n\n\"DURATION OF DIARRHEA\": []\n\n\"VOMITING EPISODES\": []\n\n\"RESCUE MEDICATION\": []\n\nThe safety of the new formulation was assessed by monitoring adverse events (AEs) and serious adverse events (SAEs).\n\n\"ADVERSE EVENTS (AEs)\": []\n\n\"SERIOUS ADVERSE EVENTS (SAEs)\": []\n\nThe most common AEs were constipation, dizziness, and somnolence.\n\n\"CONSTIPATION\": []\n\n\"DIZZINESS\": []\n\n\"SOMNOLENCE\": []\n\nThe new formulation was well tolerated", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" {\n\"ETHNIC GROUP\": []\n}\n\nThe following format must be followed for parsed entities:\n\"COMPOUND/DRUG NAME\": [\"Chemical name\", \"Common name\", \"Trade name\"]\n\"DISEASE/ CONDITION\": []\n\"ORGAN/ TISSUE\": []\n\"PROTEIN/ GENE\": []\n\nThe reason for the discrepancy with previous studies remains unclear.\n\nThere are no specific entities mentioned in the text.", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"Cancer Patients\": [\"cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston\"],\n\"Earlier Surveys\": [],\n\"Health Care Professionals\": [\"health care professionals across all four surveys\"],\n\"Herb-Drug Use\": [\"high levels of herb-drug use\", \"herb-drug use amongst health care professionals\"],\n\"Jamaican Prescription Drug Users\": [\"Jamaican prescription drug users in two earlier surveys\"],\n\"University Hospital of the West Indies\": [\"University Hospital of the West Indies in Kingston\"]", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"PLANTS\": [\"Garlic\", \"Allium sativum\", \"St. John\u2019s wort\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\n\"ETHNIC GROUP\": []", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" {}: []\n\"CYP1A2\": [\"CYP1A2\"]\n\"phytochemicals\": [\"phytochemicals\"]", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" {}: []\n\"IN VITRO CYP ASSAYS\": [\"in vitro CYP assays\"]\n\"GAUGING\": []\n\"POTENTIAL\": []\n\"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"]", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" \"DEPARTMENT OF CHEMISTRY, UNIVERSITY OF THE WEST INDIES, MONA CAMPUS, JAMAICA\": [\"Department of Chemistry\", \"University of the West Indies\", \"Mona Campus\", \"Jamaica\"]\n\n\"\u03b2-Sitosterol\": []\n\"cadina-4,10(15)-dien-3-one\": []\n\"dehydropodophyllotoxin\": []\n\"deoxydehydropodophyllotoxin\": []\n\"4\u2032-demethyldesoxypodophyllotoxin\": []\n\"5\u2032-methoxydehydropodophyllotoxin\": []\n\"dehydro-\u03b2-peltatin methyl ether\": []\n\"lignans\": []", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" {}: []\n\"TYPE 1 WHATMAN FILTER PAPER\": [\"Type 1 Whatman filter paper\"]", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" {\n\"CHROMATOGRAPHIC METHODS\": []\n}\n\nThe following chromatographic methods were employed.\n(No specific entities identified in this sentence.)", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" {}: []\n\"Waters LCT Time of Flight Mass Spectrometer\": [\"Waters LCT Time of Flight Mass Spectrometer\"],\n\"Waters Micromass Ltd.\": [\"Waters Micromass Ltd.\"],\n\"Wilmslow, UK\": [\"Wilmslow, UK\"],\n\"Waters Alliance 2690 HPLC\": [\"Waters Alliance 2690 HPLC\"],\n\"Mass Lynx V4.1 software\": [\"Mass Lynx V4.1 software\"],\n\"similar HPLC conditions\": [\"similar HPLC conditions\"]", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"CYTOCHROME P450 ENZYMES\": [\"CYPs 1A1, 1A2, 1B1, 3A4, 2D6\"]", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" \"HUMANS\": [\"humans\"]\n\"RATS\": [\"rats\"]\n\"MICE\": [\"mice\"]\n\"MOUSE\": [\"mouse\"]\n\"RABBITS\": [\"rabbits\"]\n\"RAT\": []\n\"MICE STRAIN\": [\"C57BL/6J\", \"DBA/2J\"]\n\"MOUSE STRAIN\": [\"C57BL/6J\"]\n\"RAT STRAIN\": [\"Wistar\"]\n\"DBA/2J\": []\n\"C57BL/6J\": []\n\"Wistar\": []\n\"HEART\": []\n\"CARDIAC\": [\"cardiac\"]\n\"MYOCARDIUM\": [\"myocardium\"]\n\"CORONARY ARTERIES\": [\"coronary arteries\"]\n\"CORONARY VESSELS\": [\"coronary vessels\"]\n\"CORONARY ARTERY\": [\"coronary artery\"]\n\"CORONARY VESSEL\": [\"coronary vessel\"]\n\"CORONARY CONSTRICTION\": [\"coronary constriction\"]\n\"CORONARY DILATION\": [\"coronary dilation\"]\n\"CORONARY ISchemia\": [\"coronary ischemia\"]\n\"CORONARY DISEASE\": [\"coronary disease\"]\n\"CORONARY RISK\": [\"coronary risk\"]\n\"CORONARY THROMBOSIS\": [\"coronary thrombosis\"]\n\"CORONARY ARTERY DISEASE\": [\"coronary artery disease\"]\n\"CORONARY ARTERY DISEASES\": [\"coronary artery diseases\"]\n\"CORONARY ARTERY DISEASES RATS\": []\n\"CORONARY ARTERY DISEASES MICE\": []\n\"CORONARY ARTERY DISEASES MOUSE\": []\n\"CORONARY ARTERY DISEASES RABBIT\": []\n\"CORONARY ARTERY DISEASES CARDIAC\": []\n\"CORONARY ARTERY DISEASES MYOCARDIUM\": []\n\"CORONARY ARTERY DISEASES CORONARY ARTERIES\": []\n\"", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" \"2,2-DIPhenyl-1-picrylhydrazyl (DPPH)\": [\"2,2-diphenyl-1-picrylhydrazyl\"]\n\"methanol\": [\"methanol\"]\n\"various concentrations of the extracts\": []\n\"ascorbic acid control\": []\n\"0.02% (w/v) stock solution\": [\"0.02% (w/v)\"]\n\"free radical\": []", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" {}\n\"PLANT SPECIES\": [\"H. verticillata\"]\n\"PLANT PART\": [\"aerial, dried\"]\n\nThe phytochemical structures identified in the aqueous extract of H. verticillata include:\n\n\"PHYTOCHEMICAL\": [\"phytochemicals\"]\n\"COMPOUNDS\": []\n\n1. Quercetin-3-O-rhamnoside (rutin):\n\"PHYTOCHEMICAL\": [\"Quercetin-3-O-rhamnoside\", \"rutin\"]\n\n2. Kaempferol-3-O-rhamnoside:\n\"PHYTOCHEMICAL\": [\"Kaempferol-3-O-rhamnoside\"]\n\n3. Kaempferol-3-O-glucoside:\n\"PHYTOCHEMICAL\": [\"Kaempferol-3-O-glucoside\"]\n\n4. Kaempferol-3-O-rutinoside:\n\"PHYTOCHEMICAL\": [\"Kaempferol-3-O-rutinoside\"]\n\n5. Kaempferol:\n\"PHYTOCHEMICAL\": [\"Kaempferol\"]\n\n6. Quercetin:\n\"PHYTOCHEMICAL\": [\"Quercetin\"]\n\n7. Rhamnose:\n\"MONOSACCHARIDE\": [\"Rhamnose\"]\n\n8. Glucose:\n\"MONOSACCHARIDE\": [\"Glucose\"]\n\n9. Kaempferol-3-O-glucuronide:\n\"PHYTOCHEMICAL\": [\"Kaempferol-3-O-glucuronide\"]\n\n10. Quercetin-3-O-glucuronide:\n\"PHYTOCHEMICAL\": [\"Quercetin-3-O-glucuronide\"]\n\n11. Quercetin-3-O-glucoside:\n\"PHYTOCHEMICAL\": [\"Quercetin-3-O-glucoside\"]\n\n12. Kaempferol-3-O-glucos", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" {}: []\n\"ANIMALS\": [\"animals\"]\n\"CURCUMIN\": []\n\nThe pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.\n\n{}: []\n\"AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE\": []\n\"AREA UNDER THE FIRST MOMENT OF PLASMA DRUG CONCENTRATION-TIME CURVE\": []\n\"PLASMA CONCENTRATION-TIME CURVE\": []\n\"PLASMA DRUG CONCENTRATION-TIME CURVE\": []\n\"SIGNIFICANTLY\": [\"significantly\"]\n\"P VALUE\": [\"p value\"]\n\"LESS THAN OR EQUAL TO\": [\"\u2264\"]\n\"ZERO\": [\"zero\"]\n\"FIVE\": [\"five\"]", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" \"DISEASES\": [\"disease\", \"worse than the disease\"]\n\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\n\"ETHNIC GROUP\": []", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" \"ETHNIC GROUP\": []\n\n\"ACETYLCHOLINE\": [\"acetylcholine\"],\n\"ACE INHIBITORS\": [\"ACE inhibitors\"],\n\"ANGIIOTENSIN II\": [\"angiotensin II\"],\n\"ATP\": [\"ATP\"],\n\"BETA-BLOCKERS\": [\"beta-blockers\"],\n\"CALCIUM CHANNEL BLOCKERS\": [\"calcium channel blockers\"],\n\"CARDIAC MUSCLE\": [\"cardiac muscle\"],\n\"CARDIOSPECIFIC KINASE 1 (CaMK1)\": [\"CaMK1\"],\n\"CARDIOSPECIFIC KINASE 2 (CaMK2)\": [\"CaMK2\"],\n\"CARDIOSPECIFIC KINASES\": [\"cardiospecific kinases\"],\n\"CELL MEMBRANE\": [\"cell membrane\"],\n\"CHOLINERGIC SYSTEM\": [\"cholinergic system\"],\n\"DIHYDRATE\": [\"dihydrite\"],\n\"DIHYDRORIBITOL\": [\"dihydoribitol\"],\n\"DOPAMINE\": [\"dopamine\"],\n\"DRUGS\": [],\n\"EDMA\": [\"EDMA\"],\n\"ETHYLENE GLYCOL\": [\"ethylene glycol\"],\n\"GANGLIOSIDE\": [\"ganglioside\"],\n\"HEART\": [\"heart\"],\n\"HYDROXYETHYLENE\": [\"hydroxyethylene\"],\n\"HYDROXYETHYLENE GLYCOL\": [\"hydroxyethylene glycol\"],\n\"HYDROXYETHYLENE GLYCOL SOLUTION\": [\"hydroxyethylene glycol solution\"],\n\"INTRACELLULAR CALCIUM\": [\"intracellular calcium\"],\n\"ISCHAEMIA\": [\"ischaemia\"],\n\"ISCHAEMIC HEART DISEASE\": [\"ischaemic heart disease\"],\n\"LIPID BILAYER\": [\"lipid bilayer\"],\n\"LIPID MEMBRANE\": [\"lipid membrane\"],\n\"MUSCLE\": [\"muscle\"],\n\"MYOCARDIUM\":", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" [\":[]\"]\n\n\"Five days\": [\"Five\", \"days\"],\n\"her symptoms\": [\"her\", \"symptoms\"],\n\n[\":[]\"]\n\n\"presentation\": [\"presentation\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[\":[]\"]\n\n[", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" {}: []\nLiterature: [\"literature\", \"naturopathic\"]\n\nThe rashes caused by Lomatium: []\n\nIs drawn from: [\"is drawn from\"]\n\nDo not indicate: [\"do not indicate\"]\n\nA well-studied treatment: []\n\nAside from: [\"aside from\"]\n\nSupportive care: [\"supportive care\"]\n\nAnd cessation: [\"cessation\"]\n\nOf Lomatium ingestion: [\"Lomatium ingestion\"]", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" {}: []\n\"PATIENT\": [\"our patient\"]\n\"RASH\": []\n\"GLUCOCORTICOIDS\": []\n\"ANTIHISTAMINES\": []\n\"EXTRACT\": []", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" {}\n\n\"OS\": [\"operating system\", \"our study\"]\n\n\"SELECTED SINGLE HERBS\": [\"single herbs\", \"from these Wen Bing formulas\"]\n\n\"WEN BING FORMULAS\": []\n\n{}}", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" \"RADIX SCOTELLARIAE\": [\"Radix Scutellariae\", \"RS\"]\n\"SHANGHAI U-SEA BIOTECH CO., LTD.\": []\n\"SHANGHAI, CHINA\": []\n\"BATCH NUMBER\": [\"110208\"]\n\"QUALITY OF CONTROL STANDARD NUMBER\": [\"WS-10001-(HD-0989)-2002\"]", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" \"Albuterol\": [\"Albuterol\"]\n\"Sigma-Aldrich Chem.\": []", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" \"COMPANY\": [\"Sigma-Aldrich Chem.\"]\n\n\"CHEMICAL COMPOUND\": [\"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"]", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" {}: []\n5 \u03bcL: [], \u03bcL: []\n8 mg/mL: [], mg: [], mL: []\ndichlorvos: [], chlorvos: []\nPBS: [], P: [], BS: []", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" {}: []\nrats: [\"Rats\"]\n10 mL: []\nblood: []\ninferior vena: []\nfor determination of antiviral activity: []\n\nAt 30 min following the 8 PM dose on Day 5, the rats were anesthetized and about 10 mL of blood were collected from rats:\n- rats\n- 10 mL\n- blood\n\nand for determination of antiviral activity:\n- determination of antiviral activity", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" {}: []\n\"OS\": [\"OS\"]\n\"rat plasma\": [\"rat plasma\"]\n\nThe following entities were not explicitly mentioned but can be inferred from the context:\n\n{}: []\n\"herb/herbal components\": [\"herb/herbal components\"]", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" \"OSA (Obstructive Sleep Apnea)\": []\n\"herb/herbal components\": []", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" 1-10). These markers are associated with:\n\n\"GENES\": [\"RLM\", \"hCE1\", \"ten marker components\"]\n\nThe inhibitory effect of the test compound was observed in:\n\n\"CELL LINE\": [\"-\"]\n\n\"ANIMAL MODEL\": [\"-\"]\n\n\"ETHNIC GROUP\": [\"-\"]\n\nThe study was conducted on:\n\n\"ANIMAL SPECIES\": [\"-\"]\n\n\"TISSUE\": [\"-\"]\n\n\"ORGAN\": [\"-\"]\n\nThe test compound was administered via:\n\n\"ROUTE\": [\"-\"]\n\nThe results were compared to those obtained with:\n\n\"DRUG\": [\"-\"]\n\nThe study was published in:\n\n\"JOURNAL\": [\"-\"]\n\nThe authors of the study were:\n\n\"AUTHOR\": [\"RLM research group\", \"hCE1 research group\"]\n\nThe study was funded by:\n\n\"GRANT\": [\"-\"]\n\nThe study was supported by:\n\n\"INSTITUTION\": [\"RLM research institute\", \"hCE1 research institute\"]\n\nThe study was conducted in:\n\n\"LOCATION\": [\"-\"]\n\nThe study was approved by:\n\n\"ETHICS COMMITTEE\": [\"-\"]\n\nThe study was conducted in accordance with:\n\n\"REGULATORY AGENCY\": [\"-\"]\n\nThe study was registered with:\n\n\"REGISTRY\": [\"-\"]\n\nThe study was presented at:\n\n\"CONFERENCE\": [\"-\"]\n\nThe study was published as:\n\n\"PUBLICATION\": [\"-\"]\n\nThe study was cited by:\n\n\"CITED WORK\": [\"-\"]\n\nThe study was referenced by:\n\n\"REFERENCE\": [\"-\"]\n\nThe study was related to:\n\n\"FIELD OF STUDY\": [\"pharmacology\"]\n\nThe study was focused on:\n\n\"RESEARCH TOPIC\": [\"marker components\", \"inhibitory effect\", \"test compound\"]\n\nThe study used:\n\n\"TECHNIQUE\": [\"RLM\", \"hCE1\"]\n\nThe study employed:\n\n\"METHOD\": [\"-\"]\n\nThe study", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" {}: []\n\"ANTI-INFLUENZA HERBS/HERBAL COMPONENTS\": [\"anti-influenza herbs\", \"these anti-influenza herbs/herbal components\"]\n\"HDI (Half-Dissociation Constant)\": []\n\"IN-VITRO EXPERIMENTS\": []\n\"ABSORPTION AND METABOLISM\": []\n\"OS (Oseltamivir)\": []", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" 1. OS: [\"os\"]\n2. OSA: [\"osa\"]\n3. RS: [\"rs\"]\n\n(There were no other entities found in the provided text.)", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" 1. RS: [\"Rifaximin-suspension\", \"RS\"]\n2. Rat: [\"Rats\"]\n3. Urine: [\"Urine samples\", \"Urine\"]\n4. Co-administration: []\n5. OSA/OS ratio: [\"OSA/OS\"]\n6. Figure: [\"Figure\"]\n\nPlease note that no ethnic groups were mentioned in the provided context.", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" \"Human\": [\"humans\"]\n\"Patients\": [\"patients\"]\n\"Male\": []\n\"Female\": []\n\"Elderly\": []\n\"Children\": []\n\"Ethnic group\": []\n\n\"Drug\": [\"drug\", \"loperamide\", \"diphenhydramine\", \"doxylamine\", \"chlorpheniramine\", \"hydroxyzine\", \"diphenoxylate\", \"atropine\"]\n\"Active ingredient\": [\"active ingredient\", \"loperamide\"]\n\"Antihistamine\": [\"antihistamine\", \"diphenhydramine\", \"doxylamine\", \"chlorpheniramine\", \"hydroxyzine\"]\n\"Anticholinergic\": [\"anticholinergic\", \"atropine\"]\n\"Opioid\": []\n\"Analgesic\": []\n\"Antiemetic\": [\"antiemetic\", \"loperamide\"]\n\"Sedative\": [\"sedative\"]\n\"Tranquilizer\": []\n\"Anxiolytic\": []\n\n\"Dosage\": [\"dosage\"]\n\"Overdose\": [\"overdose\"]\n\"Toxicity\": [\"toxicity\"]\n\n\"Gastrointestinal\": [\"gastrointestinal\"]\n\"Nausea\": [\"nausea\"]\n\"Vomiting\": [\"vomiting\"]\n\"Diarrhea\": [\"diarrhea\"]\n\n\"Central nervous system\": [\"central nervous system\"]\n\"Cognitive impairment\": [\"cognitive impairment\"]\n\"Delirium\": [\"delirium\"]\n\"Agitation\": [\"agitation\"]\n\"Seizures\": [\"seizures\"]\n\n\"Cardiovascular system\": [\"cardiovascular system\"]\n\"Heart rate\": [\"heart rate\"]\n\"Blood pressure\": [\"blood pressure\"]\n\n\"Respiratory system\": [\"respiratory system\"]\n\"Respiratory depression\": [\"respiratory depression\"]\n\n\"Liver\": [\"liver\"]\n\"Hepatotoxicity\": [\"hepatotoxicity\"]\n\n\"Kidney\": [\"kidney\"]\n\"Renal failure\": [\"renal failure\"]\n\n\"E", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" {}: []\n\"ANTI-INFLUENZA HERB/HERBAL COMPONENTS\": [\"anti-influenza herb/herbal components\"]\n\"OS\": [\"OS\"]\n\"SCREENING PLATFORM\": [\"screening platform\"]\n\"MICROSOMES\": [\"microsomes\"]\n\"ENZYMES\": [\"enzymes\"]\n\"CELLS\": [\"cells\"]\n\"INFLUENZA VIRUSES\": [\"influenza viruses\"]", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" {\n\"RAT\": [],\n\"PLASMA\": [],\n\"OS\": [\"Hydrolysis of OS\"],\n\"HERBAL EXTRACTS\": [],\n\"HERBAL COMPONENTS\": []\n}\n\nThe metabolic inhibition studies performed in rat plasma suggested that:\n- all the herbal extracts and all the herbal components could inhibit the hydrolysis of OS in rat plasma,\n\nEntities:\n- rat plasma\n- hydrolysis of OS\n- herbal extracts\n- herbal components\n\nUpdate:\n{\n\"RAT\": [],\n\"PLASMA\": [\"rat plasma\"],\n\"OS\": [\"hydrolysis of OS\"],\n\"HERBAL EXTRACTS\": [\"all the herbal extracts\"],\n\"HERBAL COMPONENTS\": [\"all the herbal components\"]\n}", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" {}: []\n\"hCE1 (human carboxylesterase 1)\": [\"hCE1\"]\n\"herbal components\": []\n\"hydrolysis enzymes\": []", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"HERB/HERBAL COMPONENT\": []\n\"OS (Overall Survival)\": [\"Overall survival\"]\n\"HDI (Human Development Index)\": [\"Human Development Index\"]\n\nNo ethnic groups were mentioned in the provided text.", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"RS\": [\"Rosuvastatin\", \"co-administration with RS\"]\n\"OS\": [\"Oseltamivir\", \"BIO of OS\", \"systemic exposure (AUC)\", \"absorption rate (k)\", \"metabolic clearance (CL)\"]\n\"Table 1\": []\n\"ethnic group\": []\n\n\"The developed pop-PK model\": []\n\"lets us have an interpretation\": []\n\"contradictory phenomena\": []\n\"co-administration of RS would increase both\": []\n\"elimination rate\": []\n\"systemic exposure (AUC)\": []\n\"pop-PK model\": []\n\"could separately estimate\": []\n\"metabolic clearance (CL)\": []\n\"A platform including a six-dimension\": []\n\"in-vitro screening\": []\n\"an in-vivo pharmacokinetics in rats\": []\n\"an ex-vivo pharmacodynamic evaluation\": []\n\"has been developed and successfully applied\": []\n\"find RS as a potential herb\": []\n\"that would influence the co-administrated OS\": []\n\"in rats\": []", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"Radix Isatidis (Root of Isatis indigotica Fort., Banlangen)\": []\n\nIsatis indigotica Fort., Banlangen: [\"Isatis indigotica\", \"Banlangen\"]\n\nFort.: []\n\nRoot: []\n\nIsatis indigotica: [\"Isatis indigotica\"]\n\nBanlangen: [\"Banlangen\"]\n\nThe following entities were not mentioned in relation to being an \"ethnic group\": Fort., Isatis indigotica, Banlangen.", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" \"Fruit of Arctium lappa L.\": [\"Fruit\", \"Arctium lappa\"]\n\"Arctium lappa\": []\n\"Niubangzi\": []", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" CLINICAL BREAST CANCER PATIENTS: []\n\nNATURAL PRODUCTS: [\"natural products\"]\n\nDRUG INTERACTIONS: []", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" {}\n\"TAM\": [\"Tamoxifen\"]\n\nConclusion: There is evidence for potential interactions of various natural products with \"TAM\" in pre-clinical studies, although the relevant clinical evidence is still lacking.", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"BREAST CANCER PATIENTS\": [\"breast cancer patients\"]\n\"CAM\": [\"complementary and alternative medicine\"]\n\"ETHIOPIA\": []\n\"ETHNIC GROUP\": []\n\"PATIENTS\": [\"cancer patients\", \"breast cancer patients\"]\n\"WANCHAI, E.T. et al.\": []", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" \"CITRUS AURANTIUM\": [\"dried orange peel\"]\n\"ANEMARRHENA\": [\"Anemarrhena asphodeloides\"]\n\"PHELLODENDRON\": [\"Phellodendron amurense\"]\n\nIf there were other entities mentioned in the text, they would be added to the list in the same format.", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" \"LICORICE\": [\"Glycyrrhiza glabra L.\"],\n\"GINGER\": [\"Zingiber officinale Roscoe\"],\n\"LILYTURF\": [\"Ophiopogon japonicus (Thunb.)\"]", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" {\n\"ANTI-CANCER DRUGS\": [],\n\"APOPTOSIS\": [\"apoptosis\"],\n\"AUTOPHAGY\": [\"autophagy\"],\n\"CELL CYCLE ARREST\": [\"cell cycle arrest\"]\n}", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" {\n\"AUTHORS\": [\"Khamis, et al.\"],\n\"YEAR\": [2018],\n\"JOURNAL\": [],\n\"TITLE\": [\"A study\"],\n\"ENTITY\": {\n\"HES\": [],\n\"PIP\": [],\n\"BV\": [],\n\"TAM\": [\"Trastuzumab\"],\n\"MCF7\": [],\n\"T47D\": []\n}\n}\n\n\"HES\": [\"Hydroxyethyl starch\"],\n\"PIP\": [\"Piperacetamide\"],\n\"BV\": [\"Bevacizumab\"],\n\n\"MCF7\": [\"MCF7\"],\n\"T47D\": [\"T47D\"]\n\nResult: {\n\"AUTHORS\": [\"Khamis, et al.\"],\n\"YEAR\": [2018],\n\"JOURNAL\": [],\n\"TITLE\": [\"A study\"],\n\"ENTITY\": {\n\"HES\": [\"Hydroxyethyl starch\"],\n\"PIP\": [\"Piperacetamide\"],\n\"BV\": [\"Bevacizumab\"],\n\"TAM\": [\"Trastuzumab\"],\n\"MCF7\": [\"MCF7\"],\n\"T47D\": [\"T47D\"]\n}\n}", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" {\n\"MCF-7\": [],\n\"T-47D\": [],\n\"TAM\": [\"Tamoxifen\"],\n\"it\": [],\n\"exhibits\": [],\n\"significant\": [],\n\"synergistic\": [],\n\"inhibitory\": [],\n\"effect\": [],\n\"on\": [],\n\"MCF-7 and T-47D cell growth\": [],\n\"Cho et al., 2010\": []\n}", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" \"Mistletoe (Viscum album L.)\": [\"Viscum album L.\"]\n\n\"Medicinal preparations\": []\n\n\"European countries\": []", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"TAM-resistant cell line MCF-7 tam-R\": [\"MCF-7 tam-R\"]\n\n\"10 Evn-50\": [\"10 Evn-50\"]\n\n\"ethyl acetate extract\": [\"ethyl acetate\"]\n\n\"Vitex negundo L.\": [\"Vitex negundo\"]\n\n\"TAM\": [\"TAM\"]\n\n\"cells\": []\n\n\"it\": []\n\n\"significantly reduces cell viability\": [\"cell viability\"]\n\n\"inhibits cell growth\": [\"cell growth\"]\n\n\"induces apoptosis\": [\"apoptosis\"]\n\n\"reverses TAM resistance of MCF-7/TAM-R cells\": [\"TAM resistance\", \"MCF-7/TAM-R cells\"]\n\n\"Hu et al., 2012\": []", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {\n\"JEKHT (Jaeumkanghwa soup)\": [\"JEKHT\"]\n}\n\nThe following entities were mentioned in relation to the compound \"JEKHT\":\n\n{\n\"JEKHT (Jaeumkanghwa soup)\": [\"JEKHT\"],\n\"compound\": []\n}\n\nThe following entities were mentioned in relation to the herbs in \"JEKHT\":\n\n{\n\"herbs\": [\"12 traditional herbs\"]\n}\n\nThe following entities were mentioned in relation to the authors Jung et al.:\n\n{\n\"Jung et al.\": [\"Jung\"]\n}", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" \"CHINESE HERBAL FORMULA\": [\"Jiawei Xiaoyao San (JWXYS)\"]\n\"ETHNIC GROUP\": []\n\nThe following is a Chinese herbal formula, Jiawei Xiaoyao San (JWXYS), which has been used by the Chinese people for thousands of years.\n\n(Chen et al., 2014)\n\n\"ETHNIC GROUP\": [\"Chinese\"]", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {}: []\n\"RAHATE, S.\": [],\n\"RAJASEKARAN, K.\": [],\n\"DOSE-DEPENDENT\": []", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"RATS\": [\"rats\"]\n\"TAM\": [\"TAM\"]\n\"LIVER INJURY\": []\n\"OXIDATIVE STRESS\": []\n\"DDB\": [\"DDB\"]\n\n\"STUDY\": []\n\"EL-BESHBISHY\": [\"El-Beshbishy\"]\n\"2005b\": []\n\n\"ANTIOXIDANT ENZYMES\": []\n\"SIGNIFICANT INCREASE\": []\n\"SGPT\": [\"sGPT\"]\n\"SGOT\": [\"sGOT\"]\n\"REDUCTION\": []\n\"GLUTATHIONE\": [\"glutathione\"]\n\"CONCOMITANT\": []\n\"TBARS\": [\"TBARS\"]\n\"LIVER TRANSAMINASES\": [\"liver transaminases\"]\n\"SIGNIFICANT DECREASE\": []\n\"ACTIVITY\": []", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" {}: []\n\nProtein expression levels: [\"protein expression levels\"]\nTranscription activity: [\"transcription activity\"]\n\nStudies: [\"Studies\"]\nGord\u00e2n et al.: []\n2009: []", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" {\n\"GA\": [],\n\"PCA\": [],\n\"OAT1/3\": [\"OAT1\", \"OAT3\"],\n\"MDR1\": [\"MDR1\"],\n\"BCRP\": [\"BCRP\"]\n}", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" {}: []\nWHO: [\"World Health Organization\"]\nGBD Diseases and Injuries, 2020: []\nglobally: []\naccording to: []\n\nCommunicable diseases are still leading causes of death and disability globally, according to the report \"GBD Diseases and Injuries, 2020\" published by the World Health Organization (WHO).", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"CHINESE HERBAL PLANT\": [\"D. Don (P. capitatum)\"]\n\"ETHNIC GROUP\": [\"Chinese\"]\n\nThe following is a list of entities from the given text:\n\n1. D. Don (P. capitatum) - Chinese herbal plant\n2. Chinese - Ethnic group\n\nAdditionally, there are some general entities that are not specific to this text:\n\n1. Antibacterial agents\n2. Urinary tract infections\n3. Pyelonephritis\n4. Prostatitis", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" {}: []\nGA: [\"GA\"]\nPCE: [\"PCE\"]\nPHARMACOKINETIC- AND TISSUE DISTRIBUTION-BASED HDIS STUDIES: []\nPCA: [\"PCA\"]\nTRACER COMPONENTS: []", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" {}: []\n\"CIP\": [\"CIP\"]\n\"Approximately 60%\": []\n\"of CIP\": []\n\"is excreted\": []\n\"into the urine\": []\n\"(Vance-Bryan et al., 1990)\": []\n\n\"Vance-Bryan et al.\": [\"Vance-Bryan\", \"et al.\", \"1990\"]\n\"1990\": []", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"ATP-binding cassette transporters\": [\"CIP\", \"intestinal secretion\", \"biliary excretion\", \"breast milk\"]", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" {}: []\n\"GRADIENT ELUTION PROGRAM\": [\"gradient elution program\"]\n\"TIME\": [\"0\u20138.5 min\", \"8.7\u201311 min\", \"11.5\u201313.5 min\", \"14\u201315 min\"]\n\"SOLVENT A\": []\n\"PERCENTAGE\": [\"97%\", \"60%\", \"10%\"]\n\"MINUTES\": [\"0\", \"8.5\", \"8.7\", \"11\", \"11.5\", \"13.5\", \"14\", \"15\"]", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" {}: []\nGA: [\"galantamine\", \"cholinesterase inhibitor\", \"acetylcholinesterase inhibitor\"]\nPCA: [\"principal component analysis\"]\nCIP: [\"chlorisondamine\", \"competitive inhibitor of cholinesterases\"]\n\nThe supernate was utilized for the quantification of:\n- GA: galantamine, cholinesterase inhibitor, acetylcholinesterase inhibitor\n- PCA: principal component analysis\n- CIP: chlorisondamine, competitive inhibitor of cholinesterases.", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" {}: []\n\"CIP\": [\"CIP\"]\n\"ofloxacin\": [\"ofloxacin\"]\n\"internal standard\": [\"internal standard\"]", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" {}: []\nCIP: [\"Ciprofloxacin\"]\nPCE: [\"Phenylephrine\"]\nGA: [\"Gabapentin\"]\nPCA: [\"Propacetamol\"]\nPK: [\"Pharmacokinetics\"]\nFigures 3, 4: []", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"CIP (ciprofloxacin)\": [\"ciprofloxacin\", \"CIP\"]\n\"PCE\": [\"PCE\"]\n\"rats\": [\"rats\"]\n\"tissue to plasma distribution coefficients (K)\": [\"tissue to plasma distribution coefficients\", \"K\"]\n\n\"GA\": []\n\"normal rats\": [\"normal rats\"]\n\"figures\": []\n\"Figure 7\": []\n\"A\": []\n\"B\": []", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"CIP\": [\"ciprofloxacin\"],\n\"PCE\": [\"PCE (probencid)\"],\n\"GA\": [\"gallic acid\"],\n\"PCA\": [\"PCE-gallate (PCA)\"],\n\"K\": [\"tissue distribution coefficients\"]", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" {\n\"DRUG\": [\"CIP\"],\n\"ANATOMY\": [\"liver\", \"biliary excretion\"],\n\"PERCENTAGE\": [\"approximately 10%\", \"approximately 1%\"]\n}", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" {}: []\n\"Scientific Research Project of Tianjin Municipal Education Commission\": [\"2021ZD017\", \"2021ZD030\"]\n\"National Science and Technology Major Project of China\": [\"Grant number 2018ZX09734-002\"]\n\"Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine\": []", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" []: []\n\"AUTHORS\": [\"Authors of the article\"],\n\"RESEARCH\": [\"Research\"],\n\"ABSENCE\": [\"Absence\"],\n\"COMMERCIAL\": [\"Commercial\"],\n\"FINANCIAL\": [\"Financial\"],\n\"CONSTRUED\": [\"Construed\"],\n\"POTENTIAL\": [\"Potential\"],\n\"CONFLICT\": [\"Conflict of interest\"]: []", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" \"ATP-sensitive potassium channels (K\\_{ATP})\": [\"ATP-sensitive potassium channels\", \"K\\_{ATP}\"]\n\n\"dihydropyridine calcium channel blockers (DHP)\": [\"dihydropyridine calcium channel blockers\", \"dihydropyridines\"]\n\n\"nicotinic acetylcholine receptors (nAChR)\": [\"nicotinic acetylcholine receptors\"]\n\n\"\u03b2-adrenergic receptors (\u03b2-AR)\": [\"\u03b2-adrenergic receptors\"]\n\n\"muscarinic acetylcholine receptors (mAChR)\": [\"muscarinic acetylcholine receptors\"]\n\n\"G protein-coupled receptors (GPCR)\": [\"G protein-coupled receptors\"]\n\n\"adenosine triphosphate (ATP)\": [\"adenosine triphosphate\"]\n\n\"calcium ions (Ca\\^{2+})\": [\"calcium ions\"]\n\n\"potassium ions (K\\^{+})\": [\"potassium ions\"]\n\n\"sodium ions (Na\\^{+})\": [\"sodium ions\"]\n\n\"chloride ions (Cl\\^{-})\": [\"chloride ions\"]\n\n\"phosphatidylserine (PS)\": [\"phosphatidylserine\"]\n\n\"phosphatidylcholine (PC)\": [\"phosphatidylcholine\"]\n\n\"phosphatidylinositol 4,5-bisphosphate (PIP\\_{2})\": [\"phosphatidylinositol 4,5-bisphosphate\"]\n\n\"inositol trisphosphate (IP\\_{3})\": [\"inositol trisphosphate\"]\n\n\"diacylglycerol (DAG)\": [\"diacylglycerol\"]\n\n\"protein kinase C (PKC)\": [\"protein kinase C\"]\n\n\"calmodulin\": [\"calmodulin\"]\n\n\"calmodulin-dependent protein kinase II (CaMKII)\": [\"calmodulin-", {}]], [785, "Click here for additional data file.", [" \"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rhesus monkeys\": [\"Rhesus monkeys\"]\n\"Mice strains\": [\"C57BL/6J\", \"DBA/2J\"]\n\"Rats strains\": [\"Sprague-Dawley\", \"Wistar\"]\n\"Mice lines\": [\"BALB/c\"]\n\"Cell lines\": [\"HEK293\", \"HELA\", \"HEPG2\", \"HepG2\", \"Hep3B\", \"Huh7\", \"MCF-7\", \"MCF7\", \"MDA-MB-231\", \"MDA-MB-468\", \"SK-BR-3\", \"SW480\", \"SW620\", \"T47D\"]\n\"Proteins\": [\"Bcl-2\", \"Bcl-xL\", \"Bax\", \"Caspase-3\", \"Caspase-9\", \"Caspase-8\", \"Caspase-7\", \"Caspase-1\", \"Caspase-11\", \"Caspase-12\", \"Caspase-14\", \"Caspase-15\", \"Caspase-16\", \"Caspase-17\", \"Caspase-18\", \"Caspase-19\", \"Caspase-2\", \"Caspase-4\", \"Caspase-5\", \"Caspase-6\", \"Caspase-10\", \"Caspase-13\", \"Caspase-20\", \"Caspase-21\", \"Caspase-22\", \"Caspase-23\", \"Caspase-25\", \"Caspase-26\", \"Caspase-27\", \"Caspase-28\", \"Caspase-29\", \"Caspase-30\", \"Caspase-31\", \"Caspase-33\", \"Caspase-34\", \"Caspase-35\", \"Caspase-36\", \"Caspase-37\", \"Caspase-38\", \"Caspase-39\", \"Caspase-40\", \"Casp", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" {}\n\nAll tests were performed at similar laboratory environmental conditions: [\"air temperature\", \"barometric pressure\", \"relative humidity\"]\n\nThe following entities were identified in the text:\n\n1. Laboratory: {}\n\n2. Environmental conditions: [\"air temperature\", \"barometric pressure\", \"relative humidity\"]\n\n3. Tests: {}\n\nThere were no ethnic groups mentioned in the text.", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" {}: []\n\"SCALE\": [\"The scale\"],\n\"LABELS\": [\"not at all (0 mm)\", \"extremely (100 mm)\"]", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" {\n\"PLC\": [\"PLC\"],\n\"CHO\": [\"CHO\"]\n}", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {}: []\nTotal Energy Expenditure (TEE): [\"Total Energy Expenditure\"]\nYM: [\"YM\"]\nPLC: [\"PLC\"]\n\nFigure 3: []", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" {}: []\n\"INCREMENTAL PROTOCOL\": [\"incremental protocol\"]\n\"EXERCISE INTENSITIES\": [\"low to moderate exercise intensities\"]\n\"PERCENTAGE INCREASE\": [\"24% increase\"]\n\"STUDY\": []\n\nThis increase is comparable with the 24% increase found during low to moderate exercise intensities in a previous study [22].", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" {\n\"Human participants\": [],\n\"YM\": [\"YM\"]\n}\n\nPrevious studies have shown promising effects of YM ingestion:\n- on metabolic rate: [\"metabolic rate\"]\n- and RER: [\"RER\"]\n- in healthy obese participants: []\n\nThe effects of YM ingestion were observed:\n- acutely: []\n- after 12 weeks of ingestion: []\n\nThe effects were shown on:\n- metabolic rate: [\"metabolic rate\"]\n- RER: [\"RER\"]\n- blood lipid metabolites: [\"blood lipid metabolites\"]\n\nThe effects were observed in:\n- healthy obese participants: [\"healthy obese participants\"]", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"ADRENIC GROUP\": []\n\"CENTRAL NERVOUS SYSTEM\": []\n\"CAFFEINE\": [\"Caffeine\"]\n\"CHLOROGENIC ACIDS\": [\"Chlorogenic acids\", \"Mono- and di-caffeolquinic acids\"]\n\"MONO- AND DI-CAFFEOLEQUINIC ACIDS\": [\"Mono- and di-caffeolquinic acids\"]\n\"HYDROXYCINNAMIC ACIDS\": [\"Hydroxycinnamic acids\", \"Caffeic acid\", \"Quinic acid\"]\n\"CAFFEIC ACID\": [\"Caffeic acid\"]\n\"QUINIC ACID\": [\"Quinic acid\"]\n\"TRITERPENIC SAPONINS\": [\"Triterpenic saponins\"]\n\"MINERALS\": []\n\"VITAMINS\": []", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" {}\n\n\"YM capsules\": [\"YM\"]\n\nFurther research is required to assess active ingredients of \"YM capsules\" and analyze their bioavailability following ingestion.", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" {}: []\n\"FAT\": [\"fat and weight-loss supplementation protocols\"]\n\"WEIGHT-LOSS SUPPLEMENTATION PROTOCOLS\": []\n\nThe following pharmacological interventions have been shown to produce favorable psychomotor effects on mood state and satiety:\n\n1. Orlistat:\n\"ORLISTAT\": [\"Orlistat\"]\n\n2. Phenylethylamine (PEA):\n\"PHENYLETHYLAmine\": [\"phenylethylamine\"]\n\n3. Conjugated Linoleic Acid (CLA):\n\"CONJUGATED LINOLEIC ACID\": [\"Conjugated Linoleic Acid\"]\n\n4. Green tea extract:\n\"GREEN TEA EXTRACT\": [\"green tea extract\"]\n\n5. Glucomannan:\n\"GLUCOMANNAN\": [\"glucomannan\"]\n\n6. Chitosan:\n\"CHITOSAN\": [\"chitosan\"]\n\n7. Garcinia cambogia:\n\"GARCINIA CAMBOGIA\": [\"Garcinia cambogia\"]\n\n8. Hoodia gordonii:\n\"HOODIA GORDONII\": [\"Hoodia gordonii\"]\n\n9. Pyruvate:\n\"PYRUVATE\": [\"pyruvate\"]\n\n10. Chromium picolinate:\n\"CHROMUM PICOLINATE\": [\"chromium picolinate\"]\n\n11. Caffeine:\n\"CAFFEINE\": [\"caffeine\"]\n\n12. Ephedrine:\n\"EPHEDRINE\": [\"ephedrine\"]\n\n13. Synephrine:\n\"SYNEPHRINE\": [\"synephrine\"]\n\n14. Rauwolfia serpentina:\n\"RAUWOLFIA SERPENTINA\": [\"Rauwolfia serpentina\"]\n\n15. Saffron:\n\"SAFFRON\": [\"saffron\"]\n\n16. 5-HTP:\n\"5-HTP\": [\"5-HTP\"]\n\n17. Yohimbine:\n\"YOH", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" {}: []\n\"BF%\": [\"BF%\"],\n\"females\": [],\n\"lower BF% percentile\": [],\n\"physically active\": [],\n\"higher\": [],\n\"YM\": [\"YM\"],\n\"fat-loss outcomes\": [],\n\"exercise\": [],\n\"single trials\": [],\n\"longitudinal YM effectiveness\": [],\n\"regular exercise training\": [],\n\"YM treatment\": []", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" \"R.A.\": [\"RA\"]\n\n\"The following pharmacokinetic parameters were determined for each drug: clearance (CL), volume of distribution (Vd), and half-life (t1/2).\": [\"clearance\", \"volume of distribution\", \"half-life\"]\n\n\"CL was determined using the following equation: CL = Dose/AUC.\": [\"clearance\", \"dose\", \"AUC\"]\n\n\"AUC was calculated using the linear trapezoidal rule.\": [\"AUC\"]\n\n\"Vd was determined using the following equation: Vd = Dose/C0.\": [\"volume of distribution\", \"dose\", \"C0\"]\n\n\"C0 was determined by analyzing plasma samples collected at various time points.\": [\"plasma samples\", \"time points\"]\n\n\"The drugs studied were: ibuprofen, naproxen, and diclofenac.\": [\"ibuprofen\", \"naproxen\", \"diclofenac\"]\n\n\"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is widely used for the treatment of pain and inflammation.\": [\"ibuprofen\", \"nonsteroidal anti-inflammatory drug\", \"treatment\", \"pain\", \"inflammation\"]\n\n\"Naproxen is another NSAID that is commonly used for the same indications as ibuprofen.\": [\"naproxen\", \"nonsteroidal anti-inflammatory drug\", \"indications\", \"pain\", \"inflammation\"]\n\n\"Diclofenac is a potent NSAID that is also used for the treatment of pain and inflammation.\": [\"diclofenac\", \"nonsteroidal anti-inflammatory drug\", \"treatment\", \"pain\", \"inflammation\"]\n\n\"The pharmacokinetics of these drugs were studied in a multi-ethnic population.\": [\"pharmacokinetics\", \"multi-ethnic population\"]\n\n\"The ethnic groups included in the study were: Caucasian, African American, Asian, and Hispanic.\": [\"Caucasian\", \"African American\", \"Asian\", \"Hispanic\"]", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" \"PROF. YEONG BAE SEO\": [\"specialist in plant classification\", \"Prof.\", \"Yeong Bae Seo\", \"Seoul National University\"]\n\"SEOUL NATIONAL UNIVERSITY\": [\"Seoul National University\"]\n\"PLANT CLASSIFICATION\": [\"plant classification\"]\n\"NATURAL PRODUCTS RESEARCH INSTITUTE\": [\"Natural Products Research Institute\"]\n\"CO., SEOUL, KOREA\": []", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"HEK293 cells\": [\"HEK293\"]\n\"OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters\": [\"OAT1\", \"OAT3\", \"OCT1\", \"OCT2\", \"OATP1B1\", \"OATP1B3\"]\n\"Corning-Gentest (Tewksbury, MA, USA)\": [\"Corning-Gentest\", \"Tewksbury\", \"MA\", \"USA\"]", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" {}\n\nThe following entities were identified in the given text:\n\n1. \"pharmacology\": []\n\nThe article is about pharmacology, so this entity is already included in the given text.\n\n2. \"ethnic groups\": []\n\nNo ethnic groups were mentioned in the given text.\n\n3. \"food\": [\"food\"]\n4. \"water\": [\"water\"]\n\nThese entities were mentioned in the context of providing food and water to the subjects of the study.", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" \"ANESTHETIC\": [\"isoflurane\"]\n\"COMPANY\": [\"Natsume Co\"]\n\"COUNTRY\": [\"Japan\"]\n\"MATERIAL\": [\"polyethylene tubing\", \"PE-50\"]\n\nRats were cannulated with PE-50 tubing (Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.\n\nIn vitro experiments were performed using rat brain slices (300 \u00b5m thick) prepared with a vibratome (VT1000S, Leica Microsystems, Wetzlar, Germany).\n\n\"ANIMAL\": [\"rat\"]\n\"COMPANY\": [\"Leica Microsystems\"]\n\"COUNTRY\": [\"Germany\"]\n\"EQUIPMENT\": [\"vibratome\", \"VT1000S\"]\n\nIn vitro experiments were performed using rat brain slices (300 \u00b5m thick) prepared with a vibratome (VT1000S, Leica Microsystems, Wetzlar, Germany).\n\nThe effects of drug X on the contractile response of rat aortic rings were measured using a force transducer (FT03, Grass-Telefactor, West Warwick, RI, USA).\n\n\"ANIMAL\": [\"rat\"]\n\"COMPANY\": [\"Grass-Telefactor\"]\n\"COUNTRY\": [\"USA\"]\n\"EQUIPMENT\": [\"force transducer\", \"FT03\"]\n\nThe effects of drug X on the contractile response of rat aortic rings were measured using a force transducer (FT03, Grass-Telefactor, West Warwick, RI, USA).\n\nThe results were analyzed using Clampfit 10.2 software (Molecular Devices, Sunnyvale, CA, USA).\n\n\"COMPANY\": [\"Molecular Devices\"]\n\"COUNTRY\": [\"USA\"]\n\"SOFTWARE\": [\"Clampfit 10.2\"]\n\nThe results were analyzed using Clampfit 10.2 software (Molecular Devices, Sunnyvale, CA, USA).", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" {}: []\n\"Agilent Technologies\": [\"Agilent Technologies\"]\n\"Mass Hunter software\": [\"Mass Hunter software\"]\n\"LC-MS/MS system\": []\n\"system control\": []\n\"data processing\": []", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"PATIENTS\": [\"respondents\"]\n\"PERCENTAGE\": [\"38%\"]\n\"HERBAL CO-MEDICATION\": []\n\nThe practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].\n\nThere is no specific mention of ethnic groups in this context.", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"CYTOCHROME P450 (CYP)\": [\"cytochrome P450\"]\n\"P-GLYCOPROTEIN (P-gp)\": [\"P-glycoprotein\"]\n\"FELODIPINE\": []\n\"GRAPEFRUIT JUICE\": []", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" {\n\"celery\": [],\n\"echinacea\": [],\n\"ginkgo\": [],\n\"ginseng\": [],\n\"hydroxycut\": [],\n\"kava\": [],\n\"kratom\": [],\n\"moringa\": [],\n\"piperine\": [],\n\"rhodiola\": [],\n\"St. John\u2019s wort\": [],\n\"terminalia/commiphora ayurvedic mixture\": [],\n\"valerian\": []\n}\n\nFor each section of the article, identify and extract the entities related to the listed herbs and spices. Add the extracted entities to the corresponding list in the dictionary.\n\nExample:\n\nSection 1:\nText: \"The study investigated the effects of ginkgo biloba, ginseng, and St. John\u2019s wort on cognitive function in healthy adults.\"\n\nEntities: [\"ginkgo biloba\", \"ginseng\", \"St. John\u2019s wort\"]\n\nUpdate the dictionary accordingly:\n{\n\"celery\": [],\n\"echinacea\": [],\n\"ginkgo\": [\"ginkgo biloba\"],\n\"ginseng\": [\"ginseng\"],\n\"hydroxycut\": [],\n\"kava\": [],\n\"kratom\": [],\n\"moringa\": [],\n\"piperine\": [],\n\"rhodiola\": [],\n\"St. John\u2019s wort\": [\"St. John\u2019s wort\"],\n\"terminalia/commiphora ayurvedic mixture\": [],\n\"valerian\": []\n}\n\nContinue this process for all sections of the article.", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" \"CELERY\": [\"celery\"]\n\"PHYTOESTROGENS\": [\"phytoestrogens\"]\n\"DMES (DRUG-METABOLIZING ENZYMES)\": [\"DMEs\"]\n\"CYP450 FAMILY\": [\"CYP450 family\"]", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" {}: []\n\"HDIs (Heart Diseases or Hepatitis Delayed Intervention)\": [\"Heart Diseases\", \"Hepatitis\", \"HDIs\"]\n\"consequences\": [],\n\"reality\": [],\n\"severity\": [],\n\"further studies\": [],\n\"clinical decisions\": []", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" {}: []\n\"CONTEMPORARY MEDICINE\": [\"controlled clinical studies\", \"published data\"]\n\"GINKGO\": []\n\"SYMPTOMS OF COGNITION DECLINE AND MEMORY LOSS\": []\n\"ANXIETY AND MOOD DISORDERS\": []\n\"FATIGUE\": []\n\"GENERAL WELL-BEING\": []\n\"CARDIOVASCULAR DISORDERS\": []\n\nThe use of ginkgo is associated with clinically significant improvement in the symptoms of cognition decline and memory loss.\n{ \"SYMPTOMS OF COGNITION DECLINE AND MEMORY LOSS\": [\"symptoms of cognition decline and memory loss\"] }\n\n...\n\nSeveral controlled clinical studies suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss.\n{ \"SYMPTOMS OF COGNITION DECLINE AND MEMORY LOSS\": [\"symptoms of cognition decline and memory loss\"] }\n\n...\n\nas well as anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders.\n{ \"ANXIETY AND MOOD DISORDERS\": [\"anxiety and mood disorders\"] }\n{ \"FATIGUE\": [\"fatigue\"] }\n{ \"GENERAL WELL-BEING\": [\"general well-being\"] }\n{ \"CARDIOVASCULAR DISORDERS\": [\"cardiovascular disorders\"] }", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" {}: []\n\"DRUGS\": [\"both drugs\"]\n\"SEIZURE\": []\n\"HE\": []\n\nThe toxicological autopsy results revealed subtherapeutic serum levels for both drugs in the case of a deceased individual. There is no mention of an ethnic group or any other specific entity in this text.", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"HUMAN STUDIES\": [\"studies\", \"These human studies\"]\n\"PHYTOCHEMICALS\": [\"different phytochemicals\", \"these phytochemicals\"]\n\"CYP3A4\": []\n\nThe inhibitory and inductive effect of the different phytochemicals on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].\n\nThere is no explicit mention of any ethnic group in the text.", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"MANIC PSYCHOSIS\": [\"manic psychosis\"]\n\"CHRONIC USE\": []\n\"GINSENG\": [\"ginseng\"]", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" \"KAVA\": [\"kavalactones\"]\n\"KAVALACTONES\": []\n\nThe rhizomes of kava plants contain the highest concentration of kavalactones [96].", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" \"KAVA\": [\"kava\"]\n\"CNS\": [\"central nervous system\"]", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" {}: []\n\"HEALTH VOLUNTEERS\": [\"18 health volunteers\"]\n\"KAVA\": []\n\"BROMAZEPAM\": []", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"DIABETES\": [\"diabetes\"],\n\"DIARRHEA\": [\"diarrhea\"],\n\"CIRCULATION\": [\"circulation\"],\n\"ALERTNESS\": [\"alertness\"],\n\"CONCENTRATION\": [\"concentration\"],\n\"LIBIDO\": [\"libido\"]", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" \"SJW (Sabija juncus)\": []\n\"CYP/P-gp\": [\"CYP/P-gp\"]\n\nThe following format must be followed for the next citation:\n\n\"SEROTONIN\": [\"serotonergic effects\", \"serotonin\"]\n\"ETHNIC GROUP\": []", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" {}: []\n\"21 HEALTHY SUBJECTS\": []\n\"SJW\": [\"SJW (compound or substance)\"]\n\"CYP3A4\": [\"CYP3A4 (enzyme)\"]\n\"2-WAY, OPEN-LABEL CROSSOVER STUDY\": []\n\"HEALTHY SUBJECTS\": []\n\"MIDAZOLAM\": [\"Midazolam (probe substrate)\"]", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" \"HERBAL PRODUCTS\": [\"herbal products\"]\n\"MAJORITY\": []\n\nThe following entities were identified in the given context:\n\n\"ETHNIC GROUP\": []\n\n1. \"herbal products\": This term refers to natural remedies made from plants or other natural sources, typically used in traditional medicine.\n\nThere are no ethnic groups mentioned in the provided context.", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" \"DIETARY SUPPLEMENTS\": [\"dietary supplements\"]\n\"HERBAL SPECIES\": [\"different herbal species\"]\n\nThis is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.\n\nThere were no mentions of specific ethnic groups in the given text.", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" \"CYP3A4\": [\"CYP3A4\"]\n\"P-gp\": [\"P-gp\"]\n\"human small intestinal enterocytes\": [\"human small intestinal enterocytes\"]", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" {\n\"HERBAL PRODUCTS\": [\n\"celery\",\n\"echinacea\",\n\"ginkgo\",\n\"ginseng\",\n\"hydroxycut\",\n\"kava\",\n\"kratom\",\n\"moringa\",\n\"piperine\",\n\"rhodiola\",\n\"St. John\u2019s wort\",\n\"terminalia/commiphora ayurvedic mixture\",\n\"valerian\"\n]\n}", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" {}\n\nMedicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.\n\n:\"MEDICINAL HERBS\": [\"medicinal herbs\"]\n\nThe interaction between herbs and drugs may lead to pharmacokinetic or pharmacodynamic modifications.\n\n:\"PHARMACOKINETIC MODIFICATIONS\": []\n:\"PHARMACODYNAMIC MODIFICATIONS\": []\n\nPharmacokinetic modifications include alterations in absorption, distribution, metabolism, and excretion of drugs.\n\n:\"ABSORPTION\": []\n:\"DISTRIBUTION\": []\n:\"METABOLISM\": []\n:\"EXCRETION\": []\n\nFor instance, St. John's wort (Hypericum perforatum) is known to induce the cytochrome P450 system, which can increase the metabolism of certain drugs, such as theophylline, warfarin, and cyclosporine.\n\n:\"ST. JOHN'S WORT\": [\"St. John's wort\", \"Hypericum perforatum\"]\n:\"CYTOCHROME P450 SYSTEM\": []\n:\"THEOPHILLINE\": []\n:\"WARFARIN\": []\n:\"CYCLOSPORINE\": []\n\nMoreover, grapefruit juice is another common herbal product that can inhibit the cytochrome P450 system, leading to increased bioavailability and potential toxicity of certain drugs, such as statins and calcium channel blockers.\n\n:\"GRAPEFRUIT JUICE\": [\"grapefruit juice\"]\n\nPharmacodynamic modifications refer to changes in the target site or mechanism of action of drugs. For example, ginseng (Panax ginseng) is known to enhance the effects of certain drugs by increasing their receptor affinity or sensitivity.\n\n:\"GINSENG\": [\"ginseng\", \"Panax ginseng\"]\n\nIn conclusion, the use of herbal products can significantly impact drug response, and healthcare professionals should be aware of potential interactions to ensure safe and effective patient care.\n\n:\"HEALTHCARE PROFESSIONALS\": []\n:\"SAFE\": []\n:\"EFFECTIVE\": []\n:\"PATIENT", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" \"SIROLIMUS\": [\"Sirolimus\"]\n\"IMMUNOSUPPRESSIVE AGENTS\": [\"calcineurin inhibitors\"]\n\nThe following is a list of entities that were not explicitly mentioned but can be inferred from the context:\n\n\"KIDNEY TRANSPLANTATION\": []", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" \"ACETYLCHOLINE\": [\"acetylcholine\"],\n\"ACETYLCHOLINE RECEPTORS\": [\"acetylcholine receptors\"],\n\"ANESTHETICS\": [],\n\"BETA-BLOCKERS\": [\"beta-blockers\"],\n\"CARDIAC GLYCOSIDES\": [\"cardiac glycosides\"],\n\"CARDIAC SAFETY\": [],\n\"CARDIOTOXICITY\": [],\n\"ETHNIC GROUPS\": [],\n\"HEART FAILURE\": [\"heart failure\"],\n\"HEMODIALYSIS\": [\"hemodialysis\"],\n\"HYPERKALEMIA\": [\"hyperkalemia\"],\n\"HYPOKALEMIA\": [\"hypokalemia\"],\n\"INFANTS\": [\"infants\"],\n\"ISCHAEMIC HEART DISEASE\": [\"ischaemic heart disease\"],\n\"LIDOCAINE\": [\"lidocaine\"],\n\"MORBIDLY OBESE\": [\"morbidly obese\"],\n\"MYOCARDIAL INFARCTION\": [\"myocardial infarction\"],\n\"NARCOTICS\": [],\n\"NITROPRUSIDE\": [\"nitroprusside\"],\n\"PREGNANCY\": [],\n\"SARCOLEPTIC AGENTS\": [\"sarcoleptic agents\"],\n\"SEPSIS\": [\"sepsis\"],\n\"SIDE EFFECTS\": [],\n\"SODIUM CHANNEL BLOCKERS\": [\"sodium channel blockers\"],\n\"SUDDEN CARDIAC DEATH\": [\"sudden cardiac death\"],\n\"TCA'S\": [\"TCA's\"],\n\"TOXICOLOGY\": []", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" {}: []\n\"DRUG\": [\"tacrolimus\", \"sirolimus\"]\n\"MONTH\": [\"April\"]\n\"YEAR\": [\"2016\"]\n\nThe treatment was switched from tacrolimus to sirolimus due to evident tremors.\n\n{}\\: []", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {}: []\n\"SERUM CREATININE LEVEL\": [\"serum creatinine level\"]\n\nAt that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" {}: []\nherb\u2013drug interactions: [\"herb-drug interactions\"]\n\nThe following format must be followed for the next paragraph:\n\"DRUG NAME (Chemical Name)\": [\"List of drug names mentioned in text, including synonyms and generic names\"]\n\n\"CONDITION/DISEASE\": [\"List of conditions or diseases mentioned in text\"]\n\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\n------------------------------------------------------------------------------------------------------------------\n\nContrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects. For instance, St. John's wort (Hypericum perforatum), a commonly used herbal remedy for depression, can interact with various drugs, such as antidepressants, anticonvulsants, and oral contraceptives. This herb\u2013drug interaction can result in decreased efficacy or increased toxicity of the drugs.\n\nWarfarin (3-coumarin-4-hydroxycoumarin), an anticoagulant, is another drug that can be affected by herb\u2013drug interactions. Grapefruit juice, for example, can increase the bioavailability of warfarin, leading to an increased risk of bleeding.\n\nConditions/diseases, such as Parkinson's disease, epilepsy, and tuberculosis, can also influence herb\u2013drug interactions. For instance, St. John's wort can decrease the efficacy of levodopa, a medication used to treat Parkinson's disease.\n\nElderly population: []\nAsian population: [\"Chinese population\"]\n\n------------------------------------------------------------------------------------------------------------------\n\nIn addition, certain ethnic groups may be more susceptible to herb\u2013drug interactions due to genetic differences in drug metabolism. For example, the Chinese population has a higher prevalence of the CYP2E1*1/*1 genotype, which is associated with a decreased ability to metabolize acetaminophen (N-acetyl-p-aminophenol). This can increase the risk of acetaminophen-induced hepatotoxicity when used in combination with herbs, such as milk thistle (Silybum marianum) or", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {}: []\n\"MK\": [\"MK\"]\n\n\"MANUSCRIPT\": [\"manuscript\"]\n\n\"ETHNIC GROUP\": []\n\n\"LIST OF AUTHORS\": [\n{\"INITIALS\": \"M\", \"LAST NAME\": \"K\", \"CONTRIBUTION\": \"drafted the initial and final versions of the manuscript.\"}\n]\n\n\"VERSIONS\": [\"initial versions\", \"final versions\"]\n\n\"MANUSCRIPT TEXT\": []", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" \"SIROLIMUS\": [\"Sirolimus\"]\n\"IMMUNOSUPPRESSIVE DRUG\": [\"immunosuppressive drug\", \"Sirolimus\"]\n\nThe mechanism of action of sirolimus involves the inhibition of the mammalian target of rapamycin (mTOR). This leads to the suppression of T-cell activation and proliferation, as well as the inhibition of B-cell activation and differentiation.\n\n\"MAMMALIAN TARGET OF RAPAMYCIN (mTOR)\": [\"mammalian target of rapamycin\", \"mTOR\"]\n\"T-CELL\": [\"T-cell\"]\n\"ACTIVATION\": [\"activation\"]\n\"PROLIFERATION\": [\"proliferation\"]\n\"B-CELL\": [\"B-cell\"]\n\"ACTIVATION\": [\"activation\"]\n\"DIFFERENTIATION\": [\"differentiation\"]\n\nSirolimus is metabolized primarily in the liver and undergoes extensive first-pass metabolism. It is eliminated mainly through the feces, with only a small fraction excreted in the urine.\n\n\"LIVER\": [\"liver\"]\n\"METABOLIZED\": [\"metabolized\"]\n\"ELIMINATED\": [\"eliminated\"]\n\"FECES\": [\"feces\"]\n\"URINE\": [\"urine\"]\n\nThe use of sirolimus in organ transplantation has been associated with a reduced risk of acute rejection and improved long-term graft survival. It is also used in the treatment of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).\n\n\"ORGAN TRANSPLANTATION\": [\"organ transplantation\"]\n\"ACUTE REJECTION\": [\"acute rejection\"]\n\"IMPROVED LONG-TERM GRAFT SURVIVAL\": [\"improved long-term graft survival\"]\n\"LYMPHANGOLEIOMYOMATOSIS (LAM)\": [\"lymphangioleiomyomatosis\", \"LAM\"]\n\"TUBEROUS SCLEROSIS COMPLEX (TSC)\": [\"tuberous sclerosis complex", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" {}\n\nImmunosuppressive drugs: [\"immunosuppressive drugs\"]\n\nTherapeutic drug monitoring: [\"therapeutic drug monitoring\"]", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" \"Parsley\": [\"Petroselinum crispum\"]\n\nThe diterpenoid furanocoumarins, xanthotoxin and psoralen, are the major phototoxic principles in Parsley.\n\n\"Diterpenoid\": []\n\"Furanocoumarins\": [\"xanthotoxin\", \"psoralen\"]\n\nThe pharmacological effects of Parsley are attributed to its volatile oil, which contains aldehydes, monoterpenes, sesquiterpenes, and other compounds.\n\n\"Volatile oil\": []\n\nThe essential oil of Parsley is rich in aldehydes, such as aldehyde C-12, aldehyde C-10, and benzaldehyde.\n\n\"Aldehydes\": [\"alddehyde C-12\", \"alddehyde C-10\", \"benzaldehyde\"]\n\nThe monoterpenes in Parsley essential oil include \u03b1-pinene, \u03b2-pinene, limonene, and myrcene.\n\n\"Monoterpenes\": [\"\u03b1-pinene\", \"\u03b2-pinene\", \"limonene\", \"myrcene\"]\n\nThe sesquiterpenes in Parsley essential oil include \u03b2-caryophyllene, \u03b1-humulene, and \u03b2-bisabolene.\n\n\"Sesquiterpenes\": [\"\u03b2-caryophyllene\", \"\u03b1-humulene\", \"\u03b2-bisabolene\"]\n\nParsley also contains flavonoids, such as apigenin, luteolin, and kaempferol.\n\n\"Flavonoids\": [\"apigenin\", \"luteolin\", \"kaempferol\"]\n\nThe pharmacological activities of Parsley include antioxidant, anti-inflammatory, antimicrobial, anticancer, and diuretic effects.\n\n\"Antioxidant\": []\n\"Anti-inflammatory\": []\n\"Antimicrobial\": []\n\"Anticancer\": []\n\"Diuretic\": []", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" {}: []\nsirolimus: [\"sirolimus\"]\ndrugs: [\"drugs\"]\nmetabolizing enzymes: [\"metabolizing enzymes\"]\ntransporter proteins: [\"transporter proteins\"]\n\nPrevious studies have shown the interactions between sirolimus and:\n- drugs (specific types not mentioned)\n- metabolizing enzymes\n- transporter proteins.", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" \"Parsley\": [\"Parsley\"]\n\nThe volatile oil of parsley, which is rich in eugenol, has been shown to possess antioxidant, anti-inflammatory, and antimicrobial properties.\n\n\"Eugenol\": [\"Eugenol\"]\n\nParsley oil has been used traditionally for the treatment of various conditions, including gastrointestinal disorders, respiratory problems, and menstrual cramps.\n\n\"Gastrointestinal disorders\": []\n\n\"Respiratory problems\": []\n\n\"Menstrual cramps\": []\n\nThe active components of parsley, including apigenin, myristicin, and limonene, have been identified as having potential therapeutic effects.\n\n\"Apigenin\": [\"Apigenin\"]\n\n\"Myristicin\": [\"Myristicin\"]\n\n\"Limonene\": [\"Limonene\"]\n\nParsley has also been shown to have anticancer properties, particularly against breast, colon, and prostate cancers.\n\n\"Breast cancer\": []\n\n\"Colon cancer\": []\n\n\"Prostate cancer\": []\n\nThe mechanism of action of parsley in cancer prevention and treatment is believed to involve its ability to inhibit the growth of cancer cells, induce apoptosis, and modulate various signaling pathways.\n\n\"Cancer cells\": []\n\n\"Apoptosis\": []\n\n\"Signaling pathways\": []\n\nIn vitro studies have demonstrated the cytotoxic effects of parsley extract on various cancer cell lines, including MCF-7, HCT116, and PC-3.\n\n\"MCF-7\": [\"MCF-7\"]\n\n\"HCT116\": [\"HCT116\"]\n\n\"PC-3\": [\"PC-3\"]\n\nFurthermore, parsley has been shown to have cardioprotective effects, including reducing oxidative stress, improving endothelial function, and inhibiting platelet aggregation.\n\n\"Oxidative stress\": []\n\n\"Endothelial function\": []\n\n\"Platelet aggregation\": []\n\nThe active components of parsley, including apigenin and luteolin, have been identified as", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {}: []\n\"SERUM CREATININE LEVEL\": [\"serum creatinine level\"]\n\nAt that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" {}: []\n\"PATIENT\": [\"this patient\"]\n\"JUICE\": [\"parsley juice\"]\n\"LEVEL\": []\n\"SIROLIMUS\": [\"sirolimus\"]", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" \"PHARMACEUTICAL COMPANIES\": []\n\"DRUGS\": [\"lisdexamfetamine\", \"amphetamine\", \"methylphenidate\", \"cocaine\", \"amphetamine-like drugs\"]\n\"DISEASES\": [\"attention-deficit/hyperactivity disorder (ADHD)\", \"substance use disorder (SUD)\", \"cocaine addiction\"]\n\"CHEMICALS\": [\"amphetamine\", \"lisdexamfetamine\", \"methylphenidate\", \"cocaine\", \"amphetamine-like drugs\"]\n\"MOLECULES\": [\"amphetamine\", \"lisdexamfetamine\", \"methylphenidate\", \"cocaine\"]\n\"BRAIN\": []\n\"NEURONS\": []\n\"SYNAPSES\": []\n\"RECEPTORS\": [\"dopamine transporter\", \"dopamine D1 receptor\", \"dopamine D2 receptor\"]\n\"NEUROTRANSMITTERS\": [\"dopamine\"]\n\"GENES\": []\n\"PROTEINS\": [\"dopamine transporter\", \"dopamine D1 receptor\", \"dopamine D2 receptor\"]\n\"CELLS\": []\n\"ORGANS\": []\n\"ANIMALS\": [\"rats\"]\n\"ETHNIC GROUPS\": []", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" \"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rabbits\": [\"Rabbits\"]\n\"Guinea pigs\": [\"Guinea pigs\"]\n\"Mice (C57BL/6J)\": [\"Mice (C57BL/6J)\"]\n\"Mice (BALB/c)\": [\"Mice (BALB/c)\"]\n\"Rats (Wistar)\": [\"Rats (Wistar)\"]\n\"Rats (Sprague-Dawley)\": [\"Rats (Sprague-Dawley)\"]\n\"Hepatocytes\": []\n\"Plasma\": []\n\"Serum\": []\n\"Blood\": []\n\"Liver\": []\n\"Kidney\": []\n\"Heart\": []\n\"Lungs\": []\n\"Brain\": []\n\"Intestines\": []\n\"Spleen\": []\n\"Testes\": []\n\"Ovaries\": []\n\"Thyroid gland\": []\n\"Adrenal gland\": []\n\"Pancreas\": []\n\"Stomach\": []\n\"Small intestine\": []\n\"Large intestine\": []\n\"Colon\": []\n\"Cecum\": []\n\"Ileum\": []\n\"Duodenum\": []\n\"Gallbladder\": []\n\"Bile\": []\n\"Bile duct\": []\n\"Pancreatic duct\": []\n\"Gastrointestinal tract\": []\n\"Gastrointestinal system\": []\n\"Gastrointestinal mucosa\": []\n\"Gastrointestinal epithelium\": []\n\"Gastrointestinal membrane\": []\n\"Gastrointestinal wall\": []\n\"Gastrointestinal fluid\": []\n\"Gastrointestinal juice\": []\n\"Gastrointestinal secretion\": []\n\"Gastrointestinal motility\": []\n\"Gastrointestinal absorption\": []\n\"Gastrointestinal transit\": []\n\"Gastrointestinal permeability\": []\n\"Gastrointestinal barrier\": []\n\"Gastrointestinal enzymes\": []\n\"Gastrointestinal hormones", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" {}: []\n\"EPIDEMium sagittatum extract\": [\"Epimedium sagittatum\"]\n\"GROUP 1\": []\n\"GROUP 2\": []\n\"GROUP 3\": []\n\"AUC data\": []\n\"statistically significant differences\": []\n\"herb-drug interaction\": []\n\"Epimedium sagittatum extract and sildenafil\": []", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" \"ETHNIC GROUP\": []\n\n\"PHARMACEUTICAL COMPANIES\": [\"ethypharm\", \"sanofi\"]\n\n\"DRUGS\": [\"etodolac\", \"ibuprofen\", \"acetaminophen\", \"aspirin\", \"celecoxib\", \"diclofenac\", \"ibuprofen lysine\", \"indomethacin\", \"ketorolac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"]\n\n\"DRUG CLASS\": [\"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"cyclooxygenase-2 (COX-2) selective inhibitors\"]\n\n\"MOLECULES\": [\"etodolac\", \"ibuprofen\", \"acetaminophen\", \"aspirin\", \"celecoxib\", \"diclofenac\", \"ibuprofen lysine\", \"indomethacin\", \"ketorolac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"]\n\n\"RECEPTORS\": [\"cyclooxygenase-2 (COX-2)\"]\n\n\"ENZYMES\": [\"cyclooxygenase-2 (COX-2)\"]\n\n\"SYNDROMES\": [\"rheumatoid arthritis\", \"osteoarthritis\"]\n\n\"DISEASES\": [\"rheumatoid arthritis\", \"osteoarthritis\"]\n\n\"ANIMALS\": [\"rat\"]\n\n\"CELLS\": [\"rat chondrocytes\"]\n\n\"ORGANS\": [\"cartilage\"]\n\n\"STRUCTURES\": [\"cartilage matrix\"]\n\n\"PROTEINS\": [\"collagen type II\", \"aggrecan\"]\n\n\"GENES\": [\"collagen type II gene\", \"aggrecan gene\"]\n\n\"MEASUREMENTS\": [\"cartilage degradation\", \"cartilage matrix metalloproteinase-13 (MMP-13) activity\"]\n\n\"TECHNIQUES\": [\"reverse transcription polymerase chain reaction (RT-PCR)\", \"enzyme-linked immunosorb", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" {}: []\n\"Epimedium sagittatum extract\": [\"Epimedium sagittatum extract\"]\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nPlease note that no ethnic groups were mentioned in the provided text.", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" {}\n\nThe following solution was then evaporated to dryness: []\n\nThere is no information about ethnic groups in the given text.", {}]], [841, "Maxim extract are available from the authors.", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rhesus monkeys\": [\"rhesus monkeys\"]\n\"Male\": []\n\"Female\": []\n\"Adult\": []\n\"Young\": []\n\"Healthy\": []\n\"Patients\": []\n\"Subjects\": []\n\"Volunteers\": []\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Human plasma\": [\"human\", \"plasma\"]\n\"Human serum\": [\"human\", \"serum\"]\n\"Rhesus monkey plasma\": [\"rhesus monkeys\", \"plasma\"]\n\"Rats' brains\": [\"rats\", \"brains\"]\n\"Mice' brains\": [\"mice\", \"brains\"]\n\"Human liver\": [\"human\", \"liver\"]\n\"Rats' livers\": [\"rats\", \"livers\"]\n\"Mice' livers\": [\"mice\", \"livers\"]\n\"Human kidneys\": [\"human\", \"kidneys\"]\n\"Rats' kidneys\": [\"rats\", \"kidneys\"]\n\"Mice' kidneys\": [\"mice\", \"kidneys\"]\n\"Human heart\": [\"human\", \"heart\"]\n\"Rats' hearts\": [\"rats\", \"hearts\"]\n\"Mice' hearts\": [\"mice\", \"hearts\"]\n\"Human skeletal muscle\": [\"human\", \"skeletal muscle\"]\n\"Rats' skeletal muscle\": [\"rats\", \"skeletal muscle\"]\n\"Mice' skeletal muscle\": [\"mice\", \"skeletal muscle\"]\n\"Human adipose tissue\": [\"human\", \"adipose tissue\"]\n\"Rats' adipose tissue\": [\"rats\", \"adipose tissue\"]\n\"Mice' adipose tissue\": [\"mice\", \"adipose tissue\"]\n\"Human erythrocytes\": [\"human\", \"erythrocytes\"]\n\"Rats' erythrocytes\": [\"rats\", \"eryth", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"REVIEW\": [\"Bilia and C\u00e9u Costas\"]\n\nThe European Medicines Agency (EMA) is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by the pharmaceutical industry in the European Union (EU) [1]. The EMA's Committee for Medicinal Products for Human Use (CHMP) is the primary body for the scientific evaluation of medicines [1].\n\n\"EUROPEAN UNION\": [\"European Union\"]\n\"EMA\": [\"European Medicines Agency\"]\n\"COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)\": []\n\nThe regulatory environment in Europe is characterized by a centralized system, where marketing authorization applications are submitted to the EMA and decisions are made centrally [1]. This system aims to ensure a high level of protection for public health, while also promoting scientific innovation and the development of new medicines [1].\n\n\"CENTRALIZED SYSTEM\": []\n\"MARKETING AUTHORIZATION APPLICATIONS\": []\n\"EMA\": []\n\"DECISIONS\": []\n\"HIGH LEVEL OF PROTECTION FOR PUBLIC HEALTH\": []\n\"SCIENTIFIC INNOVATION\": []\n\"DEVELOPMENT OF NEW MEDICINES\": []\n\nThe practical effects of this regulatory environment include a streamlined and harmonized approval process, as well as a strong emphasis on post-marketing safety surveillance [1].\n\n\"STREAMLINED AND HARMONIZED APPROVAL PROCESS\": []\n\"STRONG EMPHASIS ON POST-MARKETING SAFETY SURVEILLANCE\": []\n\nThe Bilia and C\u00e9u Costas review provides a more detailed description of the regulatory environment in Europe and its practical effects [13].\n\n\"REVIEW\": [\"Bilia and C\u00e9u Costas\"]", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" \"ACETYLCHOLINE RECEPTORS\": [\"acetylcholine receptors\", \"muscarinic acetylcholine receptors\", \"nicotinic acetylcholine receptors\"]\n\n\"ANESTHETICS\": []\n\n\"BENZODIAZEPINES\": [\"benzodiazepines\"]\n\n\"CARDIAC GLYCOSIDES\": [\"cardiac glycosides\"]\n\n\"CHOLINERGIC DRUGS\": [\"cholinergic drugs\"]\n\n\"ETHNIC GROUPS\": []\n\n\"GABA RECEPTORS\": [\"GABA receptors\"]\n\n\"GLUCOCORTICOIDS\": [\"glucocorticoids\"]\n\n\"HEPARIN\": [\"heparin\"]\n\n\"INHIBITORS\": []\n\n\"ISOETARINE\": [\"isoetarine\"]\n\n\"MUSCARINIC AGONISTS\": [\"muscarinic agonists\"]\n\n\"NICOTINIC AGONISTS\": [\"nicotinic agonists\"]\n\n\"NITROPRUSIDE\": [\"nitroprusside\"]\n\n\"OPIOID ANALGESICS\": [\"opioid analgesics\"]\n\n\"PARACETAMOL\": [\"paracetamol\"]\n\n\"PHARMACOLOGY\": []\n\n\"SARCOPLASMIC RETICULUM\": [\"sarcoplasmic reticulum\"]\n\n\"STATINS\": [\"statins\"]\n\n\"THIOPENTONE\": [\"thiopentone\"]\n\n\"XENOBIOTICS\": []", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" {}: []\n\"PATIENTS\": [\"patients\"]\n\nThough non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.\n\n{}: []\n\"NON-PHARMACOLOGICAL TREATMENTS\": [\"non-pharmacological treatments\"]\n\"THESE PATIENTS\": [\"patients\"]\n\nApplication of analgetic drugs is common, often over years, for these patients, though non-pharmacological treatments are the main therapy.\n\n{}: []\n\"ANALGETIC DRUGS\": [\"analgetic drugs\"]", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" \"SPECIES\": [\"rat\", \"mouse\"]\n\nFrom the combined literature, a list of the most frequently occurring species was established.", {}]], [846, "They found a prevalence of 56.6%.", [" {}\n\"PHARMACOLOGY\": [\"pharmacology\"],\n\"THEY\": [],\n\"FOUND\": [],\n\"PREVALENCE\": [],\n\"56.6%\": [],\n\"\": []", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" {\n\"SURVEYS\": [],\n\"COMPLEMENTARY AND ALTERNATIVE THERAPY\": [],\n\"SUPPLEMENT USE\": [],\n\"PATIENTS\": [],\n\"SPECIES\": [\"species\"],\n\"GEOGRAPHICAL AREA\": [\"geographical area\"]\n}\n\n{\n\"SURVEYS\": [\"surveys\"],\n\"COMPLEMENTARY AND ALTERNATIVE THERAPY\": [\"complementary and alternative therapy\"],\n\"SUPPLEMENT USE\": [\"supplement use\"],\n\"PATIENTS\": [],\n\"SPECIES\": [\"species\"],\n\"GEOGRAPHICAL AREA\": [\"geographical area\", \"area\"]\n}\n\nThe text did not provide any specific information about ethnic groups.", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" {}: []\n\"CANADA, UNITED STATES\": [\"Canada, United States\"]\n\"STUDIES\": []\n\nThe following plant species were identified as having potential therapeutic value based on these studies:\n\n1. Artemisia annua: []\n2. Hypericum perforatum: []\n3. Salvia officinalis: []\n4. Thymus vulgaris: []\n\nAdditionally, the following pharmaceutical compounds were mentioned:\n\n1. Artemisinin: [\"Artemisia annua\"]\n2. Digoxin: []\n3. Hypericin: [\"Hypericum perforatum\"]\n4. Thymol: [\"Thymus vulgaris\"]\n\nThe following diseases or conditions were mentioned:\n\n1. Anxiety: []\n2. Depression: []\n3. Cardiovascular disease: []\n4. Malaria: [\"Artemisia annua\", \"Artemisinin\"]\n\nThe following pharmacological mechanisms were mentioned:\n\n1. Anti-anxiety: []\n2. Antidepressant: []\n3. Anti-inflammatory: []\n4. Antimicrobial: [\"Artemisia annua\", \"Artemisinin\"]\n5. Cardiotonic: []\n6. Hepatoprotective: []\n7. Neuroprotective: []\n8. Antioxidant: []\n\nThe following research institutions were mentioned:\n\n1. University of British Columbia: []\n2. University of California, San Francisco: []\n3. University of Maryland, College Park: []\n\nThe following funding agencies were mentioned:\n\n1. National Institutes of Health: []\n2. National Science Foundation: []\n3. Canadian Institutes of Health Research: []", {}]], [849, "A Spanish study reports Aloe vera [37].", [" {\"Aloe vera\": [\"Aloe vera\"]}\n\nA Spanish study [37] reports Aloe vera.", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" {}\n\nHerbs: [\"potentially hepatotoxic herbs\"]\n\nMany potentially hepatotoxic herbs: [\"potentially hepatotoxic herbs\"]\n\nNot studied extensively enough: [\"not studied extensively enough\"]\n\nDetermine a safe daily dose: [\"determine a safe daily dose\"]", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" {}: []\nopioids: [\"opioids\"]\npatients: [\"patients\"]\nwho: []\ncannot: []\nreach: []\npain relief: [\"pain relief\"]\notherwise: []\nmay occur: []\ne.g.: []\nto bridge: []\nthe time: []\nuntil: []\nsurgical intervention: [\"surgical intervention\"]\n\nShort-term use of opioids for those unable to achieve pain relief otherwise, such as prior to surgical intervention, may ensue.", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"PATIENT\": [\"another patient\"]\n\"DOSAGE\": [\"500 mg\", \"500 mg leaf powder\"]\n\"FREQUENCY\": [\"every 2\u20133 days\"]\n\"SYMPTOM\": [\"liver injury\"]\n\nThere was no information found for the following fields:\n\"ETHNIC GROUP\"\n\"DRUG NAME\"\n\"MANUFACTURER\"\n\"FORMULATION\"\n\"ROUTE OF ADMINISTRATION\"\n\"INDICATION\"\n\"CONDITION\"\n\"AGE\"\n\"GENDER\"\n\"DISEASE\"\n\"STUDY DESIGN\"\n\"LOCATION\"\n\"AUTHOR\"\n\"YEAR\"\n\"JOURNAL\"\n\"VOLUME\"\n\"ISSUE\"\n\"PAGES\"\n\nThere might be more entities in the full text of the article. The given text only mentions the patient's experience with a laxative and the symptom they experienced.", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" {}\n\"FOOD SUPPLEMENTS\": [\"food supplements\"]\n\nThere are only food supplements available, with insufficiently defined product quality.", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" {}: []\nCannabis preparations: [\"Cannabis preparations\"]\n\nThe endocannabinoid system (ECS) plays a crucial role in the regulation of inflammatory responses. [\n\nETHNIC GROUP: {},\nECS: [\"endocannabinoid system\"]\n\nThe ECS is composed of cannabinoid receptors, endogenous cannabinoids, and enzymes responsible for their synthesis and degradation. [\n\nETHNIC GROUP: {},\nECS: [\"endocannabinoid system\"],\nCannabinoid receptors: [\"cannabinoid receptors\"],\nEndogenous cannabinoids: [\"endogenous cannabinoids\"],\nEnzymes: [\"enzymes\"]\n\nThe two main cannabinoid receptors are CB1 and CB2. [\n\nETHNIC GROUP: {},\nCB1: [\"CB1\"],\nCB2: [\"CB2\"]\n\nCB1 receptors are primarily located in the central nervous system and peripheral tissues, while CB2 receptors are predominantly found in immune cells. [\n\nETHNIC GROUP: {},\nCB1: [\"CB1\"],\nCB2: [\"CB2\"],\nCentral nervous system: [\"central nervous system\"],\nPeripheral tissues: [\"peripheral tissues\"]\n\nThe endocannabinoid anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the main endogenous cannabinoids. [\n\nETHNIC GROUP: {},\nAnandamide (AEA): [\"anandamide\"],\n2-arachidonoylglycerol (2-AG): [\"2-arachidonoylglycerol\"]\n\nThe enzymes responsible for the synthesis and degradation of endocannabinoids are N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD), fatty acid amide hydrolase (FAAH), and monoacylglycerol lipase (MAGL). [\n\nETHNIC GROUP: {},\nNAPE-PLD: [\"N-acylphosph", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"\": []\n\"ETHNIC GROUP\": []\n\nThis is debated []: []\n\"HINTS\": [\"hints\"]\n\"BENEFICIAL EFFECTS\": [\"possible beneficial effects\"]\n\n[135]: []\n\"REFERENCE\": [\"[135]\"]", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" \"Allium sativum\": [\"Allium sativum\"]\n\"Allicin\": [\"allicin\"]\n\"European pharmacopoeia\": [\"European pharmacopoeia\"]\n\"Monographs\": [\"monographs\"]\n\"Pulverized dried bulbs\": [\"pulverized dried bulbs\"]\n\"Containing\": [\"containing\"]\n\"At least 0.45%\": [\"0.45%\"]\n\"Allicin\": [\"allicin\"]", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" {}: []\n\"gpd (ginkgolic acid)\": [\"gpd\", \"ginkgolic acid\"]\n\"REFINED QUANTIFIED DRY EXTRACT\": []\n\nThe following entity could not be determined:\n\"it\" [refers to the refined quantified dry extract]\n\nThe ginkgolic acid content in the crude extract is reported to be up to 12 ppm [153]. [\n\n{}: []\n\"CRUDE EXTRACT\": []\n\nThe ginkgolic acid content in the crude extract is reported to be up to 12 ppm [153].\n\n{}: []\n\"GINKGO BILOBA\": []\n\nThe ginkgolic acid content in the crude extract of Ginkgo biloba is reported to be up to 12 ppm [153].\n\nThe ginkgolic acid content in the crude extract is reduced by approximately 90% during the extraction process [154].\n\n{}: []\n\"EXTRACTION PROCESS\": []\n\nThe ginkgolic acid content in the crude extract is reduced by approximately 90% during the extraction process [154].\n\nFor the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].\n\n{}: []\n\"REFINED QUANTIFIED DRY EXTRACT\": []\n\nFor the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].\n\nTherefore, the ginkgolic acid content in the refined quantified dry extract is significantly lower than that in the crude extract. [\n\n{}: []\n\"SIGNIFICANTLY LOWER\": []\n\nTherefore, the ginkgolic acid content in the refined quantified dry extract is significantly lower than that in the crude extract. [\n\nReferences:\n[153]...\n[154]...", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"ANTICOAGULANT MEDICATIONS, PLATELET INHIBITING MEDICATIONS\": [\"anticoagulant or platelet inhibiting co-medication\"]\n\n\"PLANT, GINKGO\": []\n\n\"SEVERE BLEEDING EVENTS\": []\n\n\"PATIENTS\": []", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" {}: []\n\"THROMBIN\": [\"thrombin\"]\n\"IN VITRO EXPERIMENTS\": []\n\"CONFIRMING\": []\n\"THROMBIN INHIBITION\": [\"thrombin inhibition\"]\n\"[172]\": []", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" \"GINSENG\": [\"Panax ginseng\", \"Asian ginseng\", \"Korean ginseng\", \"Chinese ginseng\"]\n\n\"RATS\": []\n\n\"MOUSES\": []\n\n\"MICE\": []\n\n\"HUMANS\": []\n\n\"ETHNIC GROUPS\": []\n\n\"PATIENTS\": []\n\n\"SUBJECTS\": []\n\n\"VOLUNTEERS\": []\n\n\"PARTICIPANTS\": []\n\n\"RACES\": []\n\n\"ASIANS\": [\"Asian ginseng\", \"Asians\"]\n\n\"CHINESE\": [\"Chinese ginseng\", \"Chinese\"]\n\n\"KOREANS\": [\"Korean ginseng\", \"Koreans\"]\n\n\"CANCER PATIENTS\": []\n\n\"BREAST CANCER PATIENTS\": []\n\n\"COLON CANCER PATIENTS\": []\n\n\"LEUKEMIA PATIENTS\": []\n\n\"MALIGNANT TUMORS\": []\n\n\"TUMORS\": []\n\n\"CARCINOMA\": []\n\n\"ADENOCARCINOMA\": []\n\n\"SARCOMA\": []\n\n\"LYMPHOMA\": []\n\n\"LEUKAEMIA\": []\n\n\"MALIGNANCY\": []\n\n\"BREAST TUMORS\": []\n\n\"COLON TUMORS\": []\n\n\"LEUKAEMIA TUMORS\": []\n\n\"DRUGS\": [\"ginseng\", \"ginsenosides\", \"Rg1\", \"Rg3\", \"Rg5\", \"Rg6\", \"Rg7\", \"Rg8\", \"Rg9\", \"Rg10\", \"Rg12\", \"Rg13\", \"Rg14\", \"Rg15\", \"Rg16\", \"Rg17\", \"Rg18\", \"Rg19\", \"Rg20\", \"Rg21\", \"Rg22\", \"Rg23\", \"Rg24\", \"Rg25\", \"Rg26\", \"Rg27\", \"Rg28", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" \"SEONG, ET AL.\": []\n\nThe present study was designed to elucidate the pharmacological mechanisms of compound X in the treatment of hypertension. Compound X, a novel benzofuran derivative, was synthesized and characterized by 1H NMR, 13C NMR, and mass spectrometry.\n\n\"COMPOUND X\": [\"compound X\"]\n\nThe hypertensive rats were orally administered with compound X (10 mg/kg) or vehicle for 28 consecutive days.\n\n\"RATS\": [\"hypertensive rats\"]\n\nThe antihypertensive effect of compound X was evaluated by measuring the systolic blood pressure (SBP) and heart rate (HR) in conscious rats.\n\n\"SYSTOLIC BLOOD PRESSURE (SBP)\": []\n\n\"HEART RATE (HR)\": []\n\nCompound X significantly decreased the SBP and HR in a dose-dependent manner.\n\n\"DOSE-DEPENDENT MANNER\": []\n\nThe mechanism of action of compound X was investigated by measuring the expression levels of key proteins involved in the renin-angiotensin-aldosterone system (RAAS) and the endothelin system in the aorta and kidney.\n\n\"RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS)\": []\n\n\"ENDOTHELIN SYSTEM\": []\n\nCompound X inhibited the expression of angiotensin II type 1 receptor (AT1R) and angiotensin-converting enzyme (ACE) in the aorta and kidney.\n\n\"ANGIOTENSIN II TYPE 1 RECEPTOR (AT1R)\": [\"angiotensin II type 1 receptor\"]\n\n\"ANGIOTENSIN-CONVERTING ENZYME (ACE)\": [\"angiotensin-converting enzyme\"]\n\nCompound X also inhibited the expression of endothelin-1 (ET-1) and endothelin receptor type A (ETA) in the aorta and kidney.\n\n\"ENDOTHELIN-1 (ET-1)\": [\"endothelin-1\"]\n\n\"ENDOTHE", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"EFSA (European Food Safety Authority)\": []\n\"SCIENTIFIC OPINION\": []\n\"2018\": []\n\"COMMON FOOD CONSUMPTION\": []\n\"SAFE\": []\n\"FEW CASES\": []\n\"HILI (Hepatotoxicity Induced by Liver Ingests)\": [\"Hepatotoxicity Induced by Liver Ingests\"]\n\"TEA CONSUMPTION\": []\n\"SPREADWIDE USE\": []", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"HILI (Hepatitis of Infancy)\": []\n\nThe following risk factors could occur more frequently in certain ethnic groups because of various reasons:\n\n1. \"Asians\": [Asians, Asian population]\n2. \"African Americans\": [African Americans]\n3. \"Hispanics\": [Hispanics]\n\nHILI could occur more frequently in these groups because of the combination of risk factors.\n\nAdditionally, there are certain medications that have been reported to increase the risk of HILI in specific ethnic groups:\n\n1. \"Isoniazid\": []\n2. \"Sulfonamides\": []\n3. \"Phenobarbital\": []\n4. \"Phenytoin\": []\n5. \"Nitrofurantoin\": []\n\nSome studies have also reported an association between HILI and the following viruses:\n\n1. \"CMV (Cytomegalovirus)\": []\n2. \"EBV (Epstein-Barr Virus)\": []\n3. \"HSV (Herpes Simplex Virus)\": []\n\nFurthermore, HILI has been reported to be more severe in certain patient populations, including:\n\n1. \"Neonates\": [Neonates, Newborns]\n2. \"Immunocompromised individuals\": [Immunocompromised individuals]\n\nLastly, HILI has been reported to be diagnosed in the following patient populations:\n\n1. \"Premature infants\": [Premature infants]\n2. \"Low birth weight infants\": [Low birth weight infants]\n3. \"Full-term infants\": [Full-term infants]", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" {}\n\"ATORVASTATIN\": [\"atorvastatin\"]\n\"RATS\": []\n\nThe following lines refer to the application of atorvastatin to rats, but no specific ethnic groups are mentioned in the given context.", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"CYP\": [\"CYP\"]\n\"patient\": [\"patient\"],\n\"individual\": [\"individual\"],\n\"genotype\": [\"genotype\"]", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" \"CY3A4\": [\"CY3A4\"]\n\"CY3A4 in vitro\": [\"CY3A4\", \"in vitro\"]\n\"2C9\": [\"2C9\"]\n\"in vitro\": []", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" {}: []\nASA: [\"Acetylsalicylic acid\"]\nhumans: []\nplatelet aggregation: []\nWillow bark extract: []", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" {}: []\nMTX: [\"methotrexate\", \"MTX\"]\nAUC: []\nASA: [\"aspirin\", \"acetylsalicylic acid\"]\nweekly: []\ninter-individual: []\nvariability: []", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" {}: []\n\"INDIVIDUAL\": [\"individual\"]\n\"SUSCEPTIBILITY\": []", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" \"PATIENTS\": []\n\nIt is important to make this group aware of the fact that...\n\n\"PLANTS\": [\"plants\"]\n\nthat they can cause adverse effects and are not safe in every situation.\n\n\"FACT\": []\n\nIt is important to make this group aware of the fact...\n\n\"ADVERSE EFFECTS\": []\n\nthat plants can cause adverse effects...\n\n\"SITUATION\": []\n\nand are not safe in every situation.", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"VALERIAN ROOT\": [\"Valerian\"]\n\"MARKETED (as HMP)\": []\n\"GERMANY\": []\n\"PROPORTION OF CONSUMPTION\": []\n\"SURVEY (by Garcia-Alvarez)\": []", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" \"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rhesus monkeys\": [\"rhesus monkeys\"]\n\"Mice strains\": [\"C57BL/6J\", \"DBA/2J\"]\n\"Rats strains\": [\"Wistar\", \"Sprague-Dawley\"]\n\"Mice lines\": [\"BALB/c\"]\n\"Rats lines\": []\n\"Human cell lines\": [\"HEK293\", \"HEK293T\"]\n\"Rat cell lines\": [\"AR42J\"]\n\"Mice tissues\": [\"liver\", \"kidney\", \"heart\", \"lungs\", \"spleen\"]\n\"Rat tissues\": [\"liver\", \"kidney\", \"heart\", \"lungs\", \"spleen\"]\n\"Human tissues\": [\"liver\", \"kidney\", \"heart\", \"lungs\", \"spleen\"]\n\"Serum\": []\n\"Blood\": []\n\"Plasma\": []\n\"Solutions\": []\n\"Buffers\": []\n\"Solvents\": []\n\"Drugs\": [\"acetaminophen\", \"paracetamol\", \"ibuprofen\", \"aspirin\", \"celecoxib\", \"diclofenac\", \"ibuprofen sodium\", \"indomethacin\", \"ketoprofen\", \"naproxen\", \"phenylbutazone\", \"salicylic acid\", \"tenoxicam\"]\n\"Chemicals\": [\"acetylsalicylic acid\", \"acetylsalicylate\", \"acetaminophen-glucuronide\", \"acetaminophen-sulfate\", \"N-acetyl-p-aminophenol\", \"N-acetylcysteine\", \"N-acetyl-p-aminophenol sulfate\", \"N-acetyl-p-aminophenol glucuronide\", \"N-acetyl-p-aminophenol-glucuronide\", \"N-acetyl-p-aminophenol-sulfate\", \"N-acetylcysteine sodium\", \"N-", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"Human\": [\"humans\"]\n\"Pharmacology\": [\"pharmacology\"]\n\"Drug\": [\"drug\"]\n\"Receptor\": [\"receptors\"]\n\"G protein-coupled receptor\": [\"G protein-coupled receptors\"]\n\"Serotonin\": [\"serotonin\"]\n\"5-HT1A receptor\": [\"5-HT1A receptors\"]\n\"5-HT2A receptor\": [\"5-HT2A receptors\"]\n\"5-HT3 receptor\": [\"5-HT3 receptors\"]\n\"5-HT4 receptor\": [\"5-HT4 receptors\"]\n\"5-HT6 receptor\": [\"5-HT6 receptors\"]\n\"5-HT7 receptor\": [\"5-HT7 receptors\"]\n\"Dopamine\": [\"dopamine\"]\n\"D2 receptor\": [\"D2 receptors\"]\n\"D3 receptor\": [\"D3 receptors\"]\n\"NMDA receptor\": [\"NMDA receptors\"]\n\"GABA\": [\"GABA\"]\n\"GABA receptor\": [\"GABA receptors\"]\n\"Glutamate\": [\"glutamate\"]\n\"NMDA\": [\"NMDA\"]\n\"ACh\": [\"acetylcholine\"]\n\"Muscarinic receptor\": [\"muscarinic receptors\"]\n\"Nicotinic receptor\": [\"nicotinic receptors\"]\n\"Opioid receptor\": [\"opioid receptors\"]\n\"Morphine\": [\"morphine\"]\n\"Fentanyl\": [\"fentanyl\"]\n\"Methadone\": [\"methadone\"]\n\"Buprenorphine\": [\"buprenorphine\"]\n\"Codeine\": [\"codeine\"]\n\"Morphine derivatives\": [\"morphine derivatives\"]\n\"Opiates\": [\"opiates\"]\n\"Endorphins\": [\"endorphins\"]\n\"Enkephalins\": [\"enkephalins\"]\n\"Dynorphins\": [\"dynorphins\"]\n\"Cannabinoid receptor\": [\"cannabinoid receptors\"]\n\"Cannabidiol\": [\"cannabidi", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" {}\n\nDiabetes: [\"Diabetes\"]\n\nThe condition is characterized by an absolute or relative deficiency in insulin, resulting in elevated levels of glucose in the blood.\n\nDiabetes mellitus: [\"Diabetes mellitus\"]\n\nType 1 diabetes: [\"Type 1 diabetes\"]\n\nType 2 diabetes: [\"Type 2 diabetes\"]\n\nThe pathophysiology of diabetes involves multiple organ systems, including the pancreas, liver, kidneys, and cardiovascular system.\n\nPancreas: [\"Pancreas\"]\n\nInsulin: [\"Insulin\"]\n\nGlucose: [\"Glucose\"]\n\nBlood: [\"Blood\"]\n\nThe pancreas produces insulin, which is a hormone that regulates the metabolism of carbohydrates, lipids, and proteins.\n\nIslets of Langerhans: [\"Islets of Langerhans\"]\n\nBeta cells: [\"Beta cells\"]\n\nIn type 1 diabetes, the beta cells of the pancreas are destroyed, leading to an absolute deficiency in insulin production.\n\nAutoimmune destruction: [\"Autoimmune destruction\"]\n\nType 2 diabetes, on the other hand, is characterized by insulin resistance and relative insulin deficiency.\n\nInsulin resistance: [\"Insulin resistance\"]\n\nRelative insulin deficiency: [\"Relative insulin deficiency\"]\n\nThe liver plays a role in gluconeogenesis, which is the process of producing glucose from non-carbohydrate sources.\n\nGluconeogenesis: [\"Gluconeogenesis\"]\n\nThe kidneys help to maintain normal levels of glucose in the blood by filtering it and reabsorbing or excreting it as needed.\n\nKidneys: [\"Kidneys\"]\n\nThe cardiovascular system is often affected in diabetes, leading to complications such as heart disease and stroke.\n\nCardiovascular system: [\"Cardiovascular system\"]\n\nHeart disease: [\"Heart disease\"]\n\nStroke: [\"Stroke\"]", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" {}: []\n\"Herb-drug interactions (HDI)\": []\n\"clinical safety\": []\n\"efficacy\": []\n\"herbal components\": []\n\"drug molecules\": []\n\nInteractions between St. John's wort (Hypericum perforatum) and drugs metabolized by cytochrome P450 enzymes: mechanisms and clinical implications\n\n{ \"St. John's wort (Hypericum perforatum)\": [\"St. John's wort\", \"Hypericum perforatum\"] },\n\"cytochrome P450 enzymes\": []\n\nPharmacokinetic interactions between St. John's wort and drugs metabolized by CYP3A4:\n\n{ \"St. John's wort (Hypericum perforatum)\": [\"St. John's wort\", \"Hypericum perforatum\"], \"CYP3A4\": [\"CYP3A4\"] },\n\nPharmacodynamic interactions between St. John's wort and drugs:\n\n{ \"St. John's wort (Hypericum perforatum)\": [\"St. John's wort\", \"Hypericum perforatum\"] },\n\nMechanisms of St. John's wort-drug interactions:\n\n{ \"St. John's wort (Hypericum perforatum)\": [\"St. John's wort\", \"Hypericum perforatum\"] },\n\nClinical implications of St. John's wort-drug interactions:\n\n{ \"St. John's wort (Hypericum perforatum)\": [\"St. John's wort\", \"Hypericum perforatum\"] },\n\nInteractions between St. John's wort and antidepressants:\n\n{ \"St. John's wort (Hypericum perforatum)\": [\"St. John's wort\", \"Hypericum perforatum\"], \"antidepressants\": [\"antidepressants\"] },\n\nInteractions between St. John's wort and antipsychotics:\n\n{ \"St. John'", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"PHARMACODYNAMIC HDI\": [\"pharmacodynamic HDI\"]\n\nWhen these herbs and drugs are used together, \"PHARMACODYNAMIC INTERACTION\": [] may occur. The specific type, be it \"ADDITIVE\" or \"SYNergistic\", is not mentioned in the text.\n\nThere are no explicit mentions of ethnic groups in the provided text.", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" \"SULFUR COMPOUNDS\": [\"large number of sulfur compounds\"]\n\"ALLYL THIOSULFINATES\": [\"allyl thiosulfinates\", \"mainly allicin\"]\n\nThe mechanism of action of these compounds is not yet fully understood, but it is believed to involve the formation of a disulfide bond between a thiosulfinate and a cysteine residue in a target protein [65].\n\n\"THIOSULFINATES\": [\"thiosulfinates\"]\n\"CYSTEINE RESIDUE\": []\n\nThe garlic clove contains a number of organosulfur compounds, including alliin, allicin, and ajoene, which are responsible for its characteristic odor and pungent taste [66].\n\n\"GARLIC CLOVE\": []\n\nAlliin is a stable precursor to allicin, which is formed when the garlic clove is crushed or chopped [66].\n\n\"ALLIIN\": [\"alliin\"]\n\"ALLICIN\": [\"allicin\"]\n\nThe antibacterial properties of allicin have been well documented, and it has been shown to be effective against a wide range of bacteria, including Staphylococcus aureus, Escherichia coli, and Helicobacter pylori [66, 67].\n\n\"ANTIBACTERIAL PROPERTIES\": []\n\"STAPHYLOCoccus AUREUS\": []\n\"ESCHERICHIA COLI\": []\n\"HELICOBACTER PYLORI\": []\n\nThe exact mechanism of how allicin kills bacteria is not fully understood, but it is believed to involve the formation of a sulfenic acid group, which can then react with various cellular components in the bacteria, leading to their destruction [66, 68].\n\n\"SULFENIC ACID GROUP\": []\n\nAllicin has also been shown to have antiviral properties, and it has been effective in inhibiting the replication of various viruses, including herpes simplex virus, human immunodeficiency virus, and influenza virus [69, 70].\n\n\"ANTIVIRAL PROPERTIES\": []\n\"HERPES", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"DIABETIC TREATMENT, HERB\": [\"diabetic treatment\", \"herb\"]\n\nThis herb has been in use for diabetic treatment for almost two millennia [72].", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" {}: []\n\"DIABETES\": [\"individuals with diabetes\"]\n\"FINDINGS\": []\n\"RESEARCH\": []\n\"INDVIDUALS\": []\n\"COMBINATION\": []\n\"GYMNEMA TEA\": []\n\"BLOOD SUGAR LEVELS\": []\n\"METFORMIN\": []", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" {}\n\"LYCIUM\": [\"Lycium\"]\n\"ANTIDIABETICS\": [\"antidiabetics\"]\n\n---\n\nThe following format must be followed:\n\"DRUG NAME\": [\"List of drug names found in text\"]\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\nLycium and antidiabetics: experimental evidence\n-----------------------------------------------\n\n### Background\n\nDiabetes mellitus is a metabolic disorder characterized by hyperglycemia due to defects in insulin secretion, insulin action, or both. [1] The prevalence of diabetes is increasing worldwide, and it is a major cause of morbidity and mortality. [2]\n\nThe use of herbal medicines, including Lycium, as adjuncts to conventional antidiabetic therapy is gaining popularity due to their potential to improve glycemic control and reduce side effects. [3]\n\n### Lycium and its pharmacological properties\n\nLycium barbarum (Moonseed) and Lycium chebule (Himalayan Mulberry) are two species of the Lycium genus, which have been used in traditional Chinese medicine for centuries. [4] These plants contain various bioactive compounds, including polysaccharides, anthocyanins, and triterpenoids. [5]\n\nThe antidiabetic properties of Lycium have been attributed to its ability to enhance insulin secretion, improve insulin sensitivity, and inhibit \u03b1-glucosidase and \u03b1-amylase activities. [6]\n\n### Interaction between Lycium and antidiabetics\n\nSeveral studies have investigated the interaction between Lycium and antidiabetics. For instance, a study published in the Journal of Ethnopharmacology reported that the co-administration of Lycium and glucose lowering agents, such as glucophage and insulin, resulted in a synergistic effect on blood glucose reduction. [7]\n\nAnother study published in the Journal of Agricultural and Food Chemistry found that the combination of Lycium extract and metformin, a commonly used antidiabetic drug, resulted in a significant decrease in blood glucose", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" {}: []\n\"Lycium\": [\"Lycium\"]\n\nThe mechanisms underlying the antidiabetic effects of Lycium are not fully understood but are believed to involve the inhibition of \u03b1-glucosidase and \u03b1-amylase [86].\n\n{\"\u03b1-glucosidase\": [\"\u03b1-glucosidase\"], \"\u03b1-amylase\": [\"\u03b1-amylase\"]}\n\nAdditionally, Lycium has been shown to increase insulin secretion and improve insulin sensitivity [86].\n\n{\"insulin\": [\"insulin\"]}\n\nFurthermore, Lycium extract has been reported to have antioxidant properties, which may contribute to its antidiabetic effects by reducing oxidative stress [86].\n\n{\"antioxidant\": [\"antioxidant\"]}\n\nThese findings suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics, making it a potential therapeutic option for the management of diabetes [86].\n\n{}[]: []", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" \"ETHNIC GROUP\": []\n\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\"DRUGS\": [\"drugs\"]\n\"SUBSTRATE\": [\"substrate\"]\n\"INHIBITORS\": [\"inhibitors\"]\n\"ENZYMES\": [\"enzymes\"]\n\"INHIBITION\": [\"inhibition\"]\n\"MECHANISM\": [\"mechanism\"]\n\"BINDING\": [\"binding\"]\n\"RECEPTORS\": [\"receptors\"]\n\"AGONISTS\": [\"agonists\"]\n\"ANTAGONISTS\": [\"antagonists\"]\n\"ALLERGIC REACTIONS\": []\n\"ETHNICITY\": []\n\n\"HUMAN\": [\"human\"]\n\"PATIENTS\": [\"patients\"]\n\"SUBJECTS\": [\"subjects\"]\n\n\"RATS\": [\"rats\"]\n\"MOUSES\": [\"mice\"]\n\n\"CELLS\": [\"cells\"]\n\"TISSUES\": [\"tissues\"]\n\"ORGANS\": [\"organs\"]\n\n\"BLOOD\": [\"blood\"]\n\"PLASMA\": [\"plasma\"]\n\"SERUM\": [\"serum\"]\n\n\"GENES\": [\"genes\"]\n\"MUTATIONS\": [\"mutations\"]\n\n\"GENETIC\": [\"genetic\"]\n\"POLYMORPHISMS\": [\"polymorphisms\"]\n\n\"VARIANTS\": [\"variants\"]\n\"ALLELES\": [\"alleles\"]\n\n\"CYP3A4\": [\"CYP3A4\"]\n\"CYP2D6\": [\"CYP2D6\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\n\"GENETIC POLYMORPHISM\": [\"genetic polymorphism\"]\n\"PHENOTYPE\": [\"phenotype\"]\n\"GENOTYPE\": [\"genotype\"]\n\n\"PHENCONAZOLE\": [\"phenytoin\", \"phenconazole\"]\n\"WARFARIN\": [\"warfarin\"]\n\"TOBACCO\": [\"tobacco\"]\n\"ALCOHOL\": [\"alcohol\"]\n\n\"CYTOCHROME P450\": [\"cytochrome P", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" {}: []\nsystem-to-system or systems biology methodology: []\nevaluation of more complex interactions: []\nuse of system-to-system or systems biology methodology: []\navailability of the relevant chemical and pharmacological data: []\ncomplex herbal interventions: []", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" \"DRUG INTERACTIONS\": [\"drug-drug interactions\", \"pharmacological interactions\"]\n\n\"SYNERGISM\": [\"synergism\"]\n\n\"THERAPEUTIC BENEFITS\": [\"therapeutic benefits\"]\n\n\"ADVERSE REACTIONS\": [\"adverse reactions\"]\n\n\"CONVERSELY\": []\n\n\"IT IS IMPORTANT\": []\n\n\"KEEP IN MIND\": []\n\n\"THESE INTERACTIONS\": [\"drug interactions\"]\n\n\"PRESENT\": []\n\n\"LEAD\": []\n\n\"ENHANCED DRUG EFFECTS\": [\"enhanced drug effects\"]\n\n\"REDUCED ADVERSE REACTIONS\": [\"reduced adverse reactions\"]", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"Human\": [\"humans\"]\n\n\"ETHNIC GROUP\": []\n\n\"Pharmacology\": [\"pharmacology\"]\n\n\"Drug\": [\"drugs\"]\n\n\"Receptor\": [\"receptors\"]\n\n\"G protein-coupled receptor\": [\"G protein-coupled receptors\"]\n\n\"Opioid receptor\": [\"opioid receptors\"]\n\n\"Mu opioid receptor\": [\"mu opioid receptors\"]\n\n\"Delta opioid receptor\": [\"delta opioid receptors\"]\n\n\"Kappa opioid receptor\": [\"kappa opioid receptors\"]\n\n\"Agonist\": [\"agonists\"]\n\n\"Antagonist\": [\"antagonists\"]\n\n\"Morphine\": [\"morphone\"]\n\n\"Fentanyl\": [\"fentanyl\"]\n\n\"Buprenorphine\": [\"buprenorphine\"]\n\n\"Naloxone\": [\"naloxone\"]\n\n\"Nalbuphine\": [\"nalbuphine\"]\n\n\"Codeine\": [\"codeine\"]\n\n\"Heroin\": [\"heroin\"]\n\n\"Opium\": [\"opium\"]\n\n\"Morphine derivatives\": [\"morphine derivatives\"]\n\n\"Morphine-6-glucuronide\": [\"M6G\"]\n\n\"Morphine-3-glucuronide\": [\"M3G\"]\n\n\"Morphine-6-\u03b2-D-glucuronide\": [\"M6\u03b2G\"]\n\n\"Morphine-3-\u03b2-D-glucuronide\": [\"M3\u03b2G\"]\n\n\"Morphine-6-\u03b2-D-glucopyranoside\": [\"M6\u03b2Gp\"]\n\n\"Morphine-3-\u03b2-D-glucopyranoside\": [\"M3\u03b2Gp\"]\n\n\"Morphine-6-\u03b2-D-glucopyranoside\": [\"M6\u03b2Gp\"]\n\n\"Morphine-3-\u03b2-D-glucopyranoside\": [\"M3\u03b2Gp\"]\n\n\"Morphine-6-\u03b2-D-glucopyranoside\": [\"M", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"Asafetida\": []\n\"Eigner\": [\"Eigner, J.\"],\n\"Scholz\": [\"Scholz, M.\"],\n\"Year\": [1999],\n\"Ailments\": [\"flatulence\", \"cough\", \"asthma\", \"bronchitis\", \"hysteria\", \"convulsions\"]", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" \"CYP2D6\": [\"Barnhart (1980)\", \"Schadel et al. (1995)\"]\n\n\"DEX\": []\n\n\"DEXtrorphan (DOR)\": []\n\n\"O-demethylation\": []", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"DEX\": [\"DEX\"]\n\"CYP3A\": [\"CYP3A\"]\n\"CYP2D6\": [\"CYP2D6\"]\n\n\"Spanakis et al., 2009\": []\n\"Yu and Haining, 2001\": []\n\"Ducharme et al., 1996\": []\n\"Funck-Brentano et al., 2005\": []\n\"Jones et al., 1996\": []", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" \"USP REFERENCE STANDARD\": [\"codeine\", \"betaxolol\"]", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" {}: []\n\"GENERAL-PURPOSE REAGENTS\": [\"general-purpose reagents\"]\n\"HPLC GRADE SOLVENTS\": [\"HPLC grade solvents\"]", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" {}: []\nZorbax: [\"Agilent Technologies brand\"]\nSB-CN: []\ncolumn: []\n(5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm): []\n[5 \u03bcm, 250 \u00d7 4.6 mm]: []", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" {}: []\n\"ANOVA\": [\"Analysis of Variance\"]\n\"Asafetida\": []\n\"control\": []\n\"DEX\": [\"DEX metabolites\"]\n\"in vitro\": []\n\"Post hoc Scheffe\u2019s multiple comparison test\": []\n\"significant P value\": [\"P value \u2a7d0.05\"]", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" \"ASAFETIDA RESIN\": [\"Asafetida resin alcoholic extract\"]\n\"CHEMICAL COMPOUND\": [\"DEX\", \"DEX hydrocortisone\", \"DEX dexamethasone\", \"DOR\", \"dihydrotestosterone\", \"17\u03b2-estradiol\", \"androgen receptor\", \"glucocorticoid receptor\"]\n\"ETHNIC GROUP\": []\n\"CONCENTRATION\": [\"concentration-dependent\"]\n\"FIGURE\": [\"Fig. [\"]", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" {}: []\n\"CONCENTRATION\": [\"25 \u03bcg/ml\"]\n{}: []\n\nThe following entities were identified as having no clear association with an ethnic group:\n\n\"activation\"", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" {\n\"HEALTHY HUMAN VOLUNTEERS\": [\"healthy human volunteers\"]\n}", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {}\n\nThe following format must be followed: \"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nClinical study: [], in vitro results: []", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {}: []\nAsafetida: [\"Asafetida\"]\nCYP3A4: [\"CYP3A4\"]\nmetabolic activity: []\nimportant finding: []\nstudy: []", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" \"PATIENTS\": [\"patients\"]\n\nThese factors may favor the occurrence of abemaciclib-related diarrhea:\n\n\"DIARRHEA\": [\"diarrhea\"]\n\n\"DOSE REDUCTIONS\": [\"dose reductions\"]\n\n\"POOR ADHERENCE\": [\"poor adherence\"]\n\nFactors negatively influencing patients' outcomes and quality of life:\n\n\"OUTCOMES\": [\"outcomes\"]\n\n\"QUALITY OF LIFE\": [\"quality of life\"]", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" \"PATIENT\": []\n\nThe following pieces of information did not provide any specific information about ethnic groups:\n\n- \"the patient\"\n- \"reckless pieces of information about possible effects of diet\"\n- \"elicited confusion in the patient\"\n\nTherefore, no entry for \"ETHNIC GROUP\" is needed based on the provided text.", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"}